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Abstract 
i 
Abstract 
Recent genome-wide studies have identified novel loci associated with cardiovascular 
diseases, but the mechanisms mediating these associations are unknown.  
Investigation of intermediate phenotypes can identify the pathways involved and 
potential targets for therapeutic intervention.  This study investigated the relationship 
with intermediate phenotypes at risk loci on chromosome 9p21 and 2q24.  
Chromosome 9p21 polymorphisms are associated with coronary artery disease and 
congenital intracranial aneurysms.  In the present study risk variants were not 
associated with traditional risk factors, inflammatory mediators, carotid artery intima-
media thickness, echocardiographic measures of cardiac structure and function, or 
congenital heart defects.  There was no evidence of copy number variation using 
MLPA.   
To identify genes involved in mediating disease susceptibility this study examined the 
association of chromosome 9p21 variants with peripheral blood expression in healthy 
subjects of three neighbouring genes: two cyclin-dependent kinase inhibitors, 
CDKN2A and CDKN2B, and a non-coding RNA of unknown function, ANRIL.  Novel 
methodology combining allelic expression data from multiple transcribed markers 
was more powerful than total expression analysis for mapping cis-acting effects.  
Multiple loci were independently associated with expression of each gene, suggesting 
that several sites may modulate disease susceptibility.  Disease-associated variants 
were all associated with allelic expression of ANRIL, while association with the other 
two genes was only detectable for some risk variants.  Variants had an inverse effect 
on ANRIL and CDKN2B expression, supporting a role of antisense transcription in 
CDKN2B regulation.  This study suggests that modulation of ANRIL expression 
mediates susceptibility to several important human diseases.  
Chromosome 2q24 polymorphisms were associated with hypertension in a study 
involving an Amish population; in vitro experiments suggested that influences on 
STK39 expression might mediate these effects.  In the present study allelic expression 
analysis confirmed that reported SNPs were associated with STK39 expression in 
vivo, but were not associated with blood pressure in a large British cohort. 
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1 Introduction 
1.1 Genetics of coronary artery disease 
Coronary artery disease (CAD) is the leading cause of death and morbidity worldwide 
and is rapidly increasing in incidence in nations undergoing industrial development1, 2.  
Understanding the genetic basis of CAD will increase our knowledge of the 
pathophysiological processes involved, with the ultimate clinical goals of improving 
risk-stratification of individuals and offering novel targets for therapeutic and 
preventative interventions3. 
1.1.1 Evidence for genetic susceptibility to CAD 
CAD is a complex phenotype which arises from the interaction of genetic and 
environmental risk factors including smoking, hyperlipidemia, hypertension, obesity, 
and diabetes4.  However, evidence from a range of epidemiological studies has 
consistently identified a family history of CAD as an independent risk factor for 
disease.  The 1994 report from the longitudinal Swedish Twin Study included 21,004 
individuals, of whom 2,810 had fatal CAD5.  Among male twin pairs in which the 
first twin had died of CAD before the age of 55, the relative risk of fatal CAD in the 
second twin was 8.1 (95% CI 2.7 – 24.5) for monozygotic (i.e. genetically identical) 
twins and 3.8 (95% CI 1.4 – 10.5) for dizygotic twins.  Among female twin pairs in 
which the first twin had died of CAD before the age of 65, the relative risk of fatal 
CAD in the second twin was 15.0 (95% CI 7.1 – 31.9) for monozygotic twins and 2.6 
(95% CI 1.0 – 7.1) for dizygotic twins.  These results indicate a significant genetic 
contribution to the risk of CAD death.  A 2002 analysis of the same cohort, which 
included 4,007 CAD deaths and a follow-up time of up to 36 years, used more 
sophisticated statistical modelling approaches to conclude that the heritability of fatal 
CAD events was 57% for males and 38% for females, and that the genetic risk of 
CAD death persisted even into old age6.  A similar analysis among 7,955 Danish twin 
pairs including 2,476 CAD deaths was broadly concordant with this data, reporting a 
heritability of fatal CAD events of 53% for males and 58% for females7.   
Although genetic factors are clearly associated with CAD risk, twin and family 
genetic studies selecting for populations with premature-onset CAD tend to over-
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estimate the risk applicable to a more general population with atherosclerosis.  Studies 
in the offspring of the original Framingham Heart Study participants have shown that 
a family history of cardiovascular disease remains a significant independent predictor 
of disease after multivariable adjustment for other measured risk factors8, 9.  In these 
studies, the relative risk associated with parental or sibling cardiovascular disease was 
between 1.45 and 2.0.  A similar estimate was provided by the INTERHEART genetic 
case-control study4.  This included 15,152 cases with MI and 14,820 controls from 52 
countries in populations derived from every inhabited continent, and identified nine 
modifiable risk factors (smoking, dyslipidemia, hypertension, diabetes, abdominal 
obesity, psychosocial factors, daily consumption of fruit and vegetables, regular 
alcohol consumption, and regular physical activity) that were all significantly related 
to the risk of myocardial infarction (MI).  A family history of CAD also showed an 
independent association with MI, conferring a relative risk of 1.45 (95% CI 1.31 – 
1.60) after adjustment for the nine other risk factors described above.  The population 
attributable risk associated with a family history of CAD was 9.8%, but when family 
history was added to the information from the other risk factors, the overall 
population attributable risk rose from 90.4% to only 91.4%, suggesting that most of 
the associated risk burden can be accounted for through other risk factors.  Many of 
these risk factors, such as hypertension and hypercholesterolaemia, are themselves 
under a similarly moderate degree of genetic control and investigations have been 
unable to find evidence for single ‘major genes’ with appreciable population 
frequency exerting individual large effects10. 
Some studies have examined the heritability of quantitative phenotypes related to 
atherosclerotic disease, such as carotid artery intima-media thickness (CIMT) and 
arterial calcification11-13.  These phenotypes have also been shown to have substantial 
heritabilities, in the order of 30-60%, which provides further evidence that genetic 
factors are important in conferring susceptibility to atherosclerosis and its 
consequences. 
1.1.2 Genetic architecture of CAD susceptibility 
Although CAD susceptibility does appear to have a substantial genetic component, 
identifying the genetic elements involved in causation is complicated by its 
multifactorial nature, involving a complex interplay between multiple genetic loci and 
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multiple environmental modifiers.  Many genes have been implicated in conferring 
CAD susceptibility14, but even with the newly-discovered loci from recent genome-
wide association (GWA) studies that are discussed in detail below, there remains a 
substantial ‘missing heritability’– that is, the fraction of the heritability of CAD that is 
accounted for by confirmed loci to date is much lower than the total calculated 
heritability of the condition3, 15.  Furthermore, the exact architecture of that 
component, in terms of the number of genetic effects and the size of each, remains 
uncertain at present.  Population genetic theory predicts that common alleles are likely 
to have small biological effects, while large effects are confined to rare alleles (as 
illustrated in Figure 1.1).  As discussed below, a small number of Mendelian (single 
gene) disorders with high penetrance have been recognised for CAD.  Although such 
mutations confer very markedly increased risks for affected individuals, they are rare 
and their individual contribution to the population burden of disease is modest.  There 
has been considerable debate about the nature of the genetic effects conferring most 
of the susceptibility to CAD and other complex diseases at the population level.  The 
‘common disease common variant’ (CDCV) hypothesis argues that common 
polymorphisms each with relatively low penetrance are the major contributors to 
genetic susceptibility, whereas the ‘common disease rare variant’ (CDRV) hypothesis 
argues that many individually rare variants, each of relatively high penetrance, are the 
major contributors16.  Common variants tend to be evolutionarily ancient, but it has 
been argued that since CAD is a late onset disease and is unlikely to have influenced 
reproductive fitness, CAD risk variants may not have been subject to negative 
selection pressure and may therefore persist with relatively high population 
frequencies16.   
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Figure 1.1. Effect size and allele frequency in populations. 
Both population genetic theory and empirical evidence suggest that the frequency of an allele will vary 
in the opposite direction to the size of its biological effect (blue curve).  Three general classes of 
detectable variants (red boxes) can be distinguished; different approaches are needed to detect members 
of the different classes. Figure reproduced from Cunnington and Keavney17. 
 
 
 
 
 
 
 
 
 
 
Recent findings of multiple common variants associated with CAD and other complex 
diseases in GWA studies lend support the CDCV hypothesis, with common risk 
alleles associated with 20-30% increases in CAD risk18-25.  Perhaps the best support 
for the CDRV hypothesis with respect to CAD comes from studies investigating 
mutations in the PCSK9 gene.  PCSK9 regulates the availability of LDL receptors on 
the cell surface; activating mutations reduce the number of receptors and give rise to 
autosomal dominant hypercholesterolaemia26, whilst nonsense mutations present in 
2.6% of African Americans increase the number of receptors, resulting in a 28% 
reduction in plasma LDL and 88% reduction in CAD risk27.  The effects on risk 
associated with the low frequency intermediate penetrance variants in PCSK9 are 
much larger than those associated with the common variants identified in GWA 
studies, but the variants are much less prevalent in the population. 
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Far from being an academic debate, the degree to which CAD susceptibility is 
determined by common low penetrance variants (as proposed by the CDCV 
hypothesis) and low frequency intermediate penetrance variants (as proposed by the 
CDRV hypothesis) is important since different experimental strategies are required 
for the identification of each.  Common variants may be detected in association 
studies involving genotyping of polymorphisms throughout the genome in very large 
numbers of cases and controls, exploiting the fact that associations can be detected for 
polymorphisms that are in linkage disequilibrium (LD) with the functionally-
important variants28.  However, because of their low frequency and individually small 
contribution to overall genetic susceptibility, rare variants may not be detectable by 
association studies based on the use of linked polymorphic markers, even in very 
large studies.  These rare variants are usually discovered by extensive resequencing of 
carefully selected candidate genes in relatively large numbers of carefully selected 
cases28, although other methods for screening for such effects have been proposed29.   
It is likely that multiple common and rare variants of varying effects together account 
for the overall heritability of CAD that has been observed at population levels, 
meaning that an integrated approach will be required to identify the majority of the 
variants and pathways involved in conferring disease susceptibility.  Recent studies 
have largely focused on the identification of common variants, not least because this 
was technologically feasible with the development of ultra high-throughput 
genotyping platforms at a time when next generation sequencing technologies were 
not widely available30, 31.  Traditional Sanger sequencing was too slow and costly to 
permit large-scale screening of very large numbers of genes32, but recent 
technological innovations that have dramatically increased the speed and cost 
effectiveness of genome sequencing will enable systematic genome-wide evaluation 
of rare variants in the near future33.   
The discussion below will focus on the approaches used to try and identify genetic 
loci conferring susceptibility to CAD to date, and highlight the major findings from 
such studies.  Before doing this, however, a number of insights from population 
genetic studies which laid the foundations for the framework which has ultimately 
resulted in the recently published GWA studies, and which are important for the 
subsequent work presented in this thesis, will be reviewed. 
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1.1.3 Concepts and tools in population genetics 
1.1.3.1 Single nucleotide polymorphisms and the human haplotype map 
In 1990 the ambitious Human Genome Project set out to sequence the entire human 
genome, and a draft of the complete sequence was reported in 200134, 35.  The large-
scale sequencing studies conducted to achieve this established that much of the 
sequence variation among individuals was accounted for by common variants such as 
single nucleotide polymorphisms (SNPs)34, 36, 37, although the frequency and 
importance of copy number variants (CNVs) had not been fully appreciated at that 
time38, 39.  SNPs are due to a single base difference between chromosomes at a 
particular site, as illustrated in Figure 1.2.  There are estimated to be at least 10 
million SNPs in the human genome with minor allele frequencies of at least 1% – that 
is, on average, one SNP roughly every 300 bases37.  Proponents of the CDCV 
hypothesis argued that common variants with modest effects were likely to contribute 
to many common diseases, and models demonstrated that the statistical power to 
detect disease associations was greater for population based association testing than 
family based linkage studies40.  It was therefore argued that common genetic variants 
in the human genome should be identified to enable their use as markers for 
association testing40, 41.   
The genome sequence characterised by the Human Genome Project provided the 
reference framework necessary for the identification and accurate cataloguing of 
human polymorphisms.  A systematic discovery programme for SNPs was 
implemented by The SNP Consortium, a public-private partnership, which was 
formed in 1999.  The consortium released 1.4 million SNPs into the public domain by 
2001, and there are presently more than 7 million SNPs in public databases42-44.  This 
constitutes a fairly complete picture of human common SNP variation.  However, 
simple knowledge of the SNPs did not make the task of assessing variation across the 
genome possible, since no platform exists that could type 7 million SNPs in each of a 
large number of cases and controls in a cost-effective manner.  It was therefore 
necessary to additionally determine the relationships between the SNPs that had been 
discovered, in order to establish which SNPs gave redundant or substantially 
overlapping information about genetic variation in different regions of the genome, 
and establish a minimal set of SNPs that could be feasibly typed in case-control 
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studies while retaining relatively full information.  Such data was provided by the 
collaborative International Haplotype Map (HapMap) Project, formed in 2002, which 
aimed to obtain detailed genomewide information on patterns of common genetic 
variation in multiple world populations, that could be used for association studies36, 45, 
46
.   
Figure 1.2. SNPs, haplotypes and tag SNPs. 
A, SNPs. Shown is a short stretch of DNA from four versions of the same chromosome region in 
different people. Most of the DNA sequence is identical in these chromosomes, but three bases are 
shown where variation occurs. Each SNP has two possible alleles; the first SNP in panel A has the 
alleles C and T. B, Haplotypes. A haplotype is made up of a particular combination of alleles at nearby 
SNPs. Shown here are the observed genotypes for 20 SNPs that extend across 6,000 bases of DNA. 
Only the variable bases are shown, including the three SNPs that are shown in panel A. For this region, 
most of the chromosomes in a population survey turn out to have haplotypes 1–4. C, Tag SNPs. 
Genotyping just the three tag SNPs out of the 20 SNPs is sufficient to identify these four haplotypes 
uniquely. For instance, if a particular chromosome has the pattern A–T–C at these three tag SNPs, this 
pattern matches the pattern determined for haplotype 1. Note that many chromosomes carry the 
common haplotypes in the population. Figure reproduced from The International HapMap Project36. 
 
 
 
 
 
 
 
 
HapMap characterised 270 individuals from four geographically diverse populations: 
30 mother-father-adult child trios of the Yoruba people in Ibadan Nigeria (YRI); 30 
trios of northern and western European ancestry living in Utah USA (CEU); 45 
unrelated Han Chinese individuals in Beijing China (CHB); 45 unrelated Japanese 
individuals in Tokyo Japan (JPT) – with CHB and JPT populations pooled to form an 
A
B
C
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Asian analysis panel36, 46.  This allowed genetic diversity between these world-wide 
populations to be captured and compared in detail.  Phase I of the HapMap project 
published in 2005 genotyped approximately 1.3 million SNPs45, and Phase II which 
was published in October 2007 characterised over 3.1 million SNPs46.  An online 
database provides free access to this data47.  The HapMap data has been instrumental 
in the development of methods for the design and analysis of GWA studies.  The 
fundamental concepts of LD and haplotype structure which underpin the HapMap 
project and the design of GWA studies are reviewed below. 
1.1.3.2 Linkage disequilibrium and haplotype diversity 
Most SNPs arose from single historical mutation events, and are therefore associated 
with nearby variants that were present on the ancestral chromosome on which the 
mutation occurred36.  These variants which are inherited together on a single 
chromosome are known as a haplotype, as illustrated in Figure 1.2.  The co-
inheritance of these alleles produces statistical associations between these alleles in a 
population, which is known as linkage disequilibrium (LD).  SNPs which are more 
strongly associated with each other are referred to as having higher LD.  For the 
purposes of association mapping, LD is most usefully measured by the correlation 
coefficient r2 which varies between 0 in the case of two SNPs whose genotypes have 
no predictive value for each other, and 1 in the case of two SNPs that are perfect 
proxies for each other (and therefore one of which is redundant for the purposes of 
association studies). 
The association between such alleles can be disrupted by new mutations or 
recombination events occurring during meiosis, which in general is more likely to 
occur the greater the distance is between the two alleles (as illustrated in Figure 1.3).  
On average, therefore, LD between SNPs tends to decrease the further apart they are.  
However, recombination events do not occur with equal frequency throughout the 
genome, but tend to occur repeatedly around certain recombination ‘hotspots’48, 49.  
The overall result is that the human genome is structured in ‘LD blocks’, each of 
which contains alleles in high LD with one another, with adjacent blocks separated by 
recombination hotspots resulting in lower LD between different blocks.  The situation 
is more complex than this simple model implies since population history influences 
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the number, size and frequency of such blocks in human populations.  However, the 
practical value of LD blocks is that genotyping only certain SNPs in a region is 
sufficient to predict information about the other SNPs nearby, thus the common 
variation can be captured by genotyping a limited number of ‘tag’ SNPs50, 51, as 
illustrated in Figure 1.2.   
Figure 1.3. Changes in haplotype structure and LD between alleles over 
generations. 
Consider a new disease susceptibility allele D arising on an ancestral chromosome (blue bar). In that 
generation, all the markers in the region including markers M1 and M2 will be correlated with D. 
Genetic recombination will break down the region of association over time, introducing new 
haplotypes into the region. If the mosaic is ‘coarse’ (which is the case with the human genome) fewer 
markers are needed to tag each piece (‘haplotype block’) of the mosaic: thus, M1 and M2 are both still 
good markers for D when the mosaic is coarse, but only M2 is a good marker after further time has 
elapsed and the mosaic is finer. However, the situation is complicated by population history, since 
founder populations and population bottlenecks reduce haplotype diversity.  Populations of African 
ancestry therefore have a finer mosaic than Caucasian populations. Figure reproduced from Cunnington 
and Keavney17. 
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These associations between SNPs mean that an ‘indirect’ approach can be used for 
performing association studies, since tag SNP markers can detect association between 
a locus and disease irrespective of whether the tag SNP itself has a functional effect36, 
52
.  The length of haplotype blocks varies, but the mean size is estimated to be 
approximately 22kb in populations of European or Asian ancestry, and 11kb in 
populations of African ancestry (defining a haplotype block as a region over which 
<5% of comparisons between SNP pairs showed evidence of historical 
recombination)53.  Based on these data, it has been estimated that fully powered 
haplotype association studies could require up to 300,000 to 1,000,000 tag SNPs (in 
non-African and African samples, respectively), although these are upper limits since 
LD between blocks permits fewer markers to be used without loss of power53. 
The HapMap project has characterised in great detail the location and associations 
between SNPs, providing novel data about the haplotype block structure in different 
human populations.  This enables tag SNPs to be selected for genotyping studies, aids 
in phasing of genotype data, and provides the potential to infer missing genotypes, 
which may improve the design and analysis of GWA studies46.  Some authors have 
criticised the HapMap approach of using indirect assessment of SNPs markers for 
GWA testing, arguing that assumptions may not hold in practice, such that under 
some circumstances this approach could fail to detect associations with disease even 
with infinite sample sizes54.  However, the associations and novel insights provided 
by even the first round of GWA studies are regarded by many as a testament to the 
success of this approach25.  
Such studies have been made possible by the conceptual insights and collaborative 
frameworks outlined above, but also by the technological advances that have enabled 
such high-throughput genotyping to be reliably performed. 
1.1.3.3 Genotyping technologies 
The theoretical advantages of GWA studies for detecting common variants 
influencing disease susceptibility had been recognised for some time40, but the 
limiting factor to achieving them in reality was the availability of high-throughput, 
accurate, cost-effective genotyping platforms.  Many methods were investigated for 
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suitability, but until recently none had proven capable of the massive parallel 
throughput required31.  Developments in high-density oligonucleotide microarrays 
succeeded in achieving these goals and have demonstrated success in identifying risk 
loci in the first wave of genome-wide association analyses in complex diseases 
including CAD.  The Affymetrix GeneChip Human Mapping 500K Array 
simultaneously types approximately 500,000 SNPs and was used in some of the first 
reported GWA studies for CAD18, 21.  The Illumina human Hap300 array, which types 
318,000 SNPs, was also used in early GWA studies for CAD19.  In contrast to the 
Affymetrix GeneChip 500K, the choice of SNPs was selected using an LD-based 
selection strategy, in an attempt to capture the maximum amount of variation across 
the genome with fewer SNPs.  The details of these technologies are beyond the scope 
of this chapter, but have been recently reviewed in detail31.  Newer products from 
these major manufacturers type even greater numbers of SNPs and tag up to 90% of 
genome-wide SNPs in non-African populations and also allow assessment of other 
forms of common genetic variation such as copy number variation (CNV)55, which is 
discussed in more detail in 1.3.3.3. 
1.1.4 Approaches to studying genetic susceptibility to CAD 
A number of approaches have been used to assess the relationship between genetic 
factors and CAD susceptibility.  Many studies look for direct evidence of association 
between genetic markers and presence of the CAD phenotype itself.  The 
methodologies used for this are described below.  However, studies may also 
investigate the association of genetic markers with intermediate CAD phenotypes.  
The main disadvantage of such an approach is that intermediate phenotypes are 
usually not perfect proxies for disease, and must be selected with great care to avoid 
creating spurious associations or missing true associations.   However, the advantages 
of this approach are that intermediate phenotypes are often easier to ascertain, and 
they may give important insights into the mechanisms and pathways involved in 
conferring susceptibility to disease.  Pathways identified in this way may provide 
targets for therapeutic modulation aimed at reducing disease risk.  
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1.1.4.1 Mendelian disorders 
A number of Mendelian disorders associated with premature CAD have been 
recognised, as summarised in Table 1.1.  Such disorders explain only a very small 
proportion of CAD cases, but knowledge of them is important for a number of 
reasons.  First, it allows the development of effective strategies for the detection, 
treatment and prevention of disease in affected individuals and families, which is 
particularly important as disease in these individuals often presents at a young age and 
follows an aggressive clinical course.  Second, certain genes causing Mendelian forms 
of CAD have also been implicated in the risk of non-Mendelian CAD in the general 
population (highlighted in Table 1.1).  Third, novel insights into the 
pathophysiological mechanisms of disease gained through the study of Mendelian 
disorders may allow the identification of new biomarkers or targets for therapeutic 
intervention, as illustrated in the examples below. 
Familial hypercholesterolemia (FH) is the commonest Mendelian disorder conferring 
CAD risk.  It is an autosomal dominant condition caused by mutations in the low-
density lipoprotein receptor (LDLR) gene, which disrupt the ability of the receptor to 
bind LDL at the cell membrane.  Cellular uptake of LDL cholesterol is impaired, 
resulting in increased circulating levels of LDL cholesterol and stimulation of 
intracellular cholesterol synthesis56-59.  FH heterozygotes have elevated circulating 
LDL cholesterol levels and develop tendon xanthomata, corneal arcus and premature 
coronary artery disease often before the age of 50 years.  Affected homozygotes are 
more severely affected, often with LDL cholesterol above 8.5mmol/L, cutaneous 
xanthomata, and coronary disease which may present below the age of 30 years.  
Untreated, the risk of CAD in affected heterozygotes by age 60 years is approximately 
50-85% for men and 30-55% for women60, 61.  Over 1000 mutations in the LDLR gene 
have been reported to be associated with the syndrome.  Point mutations account for 
91% of mutations and 9% are major rearrangements62.  The heterozygote frequency of 
familial forms of hypercholesterolemia is around 1 in 500 in Western populations.   
 
  
Table 1.1. Mendelian disorders involving CAD. 
Disorder Inheritance Affected 
genes 
Consequences of gene mutation Prevalence & clinical features 
Familial 
hypercholesterolemia 
(OMIM# 143890) 
Autosomal 
dominant 
LDLR* LDLR encodes the cell membrane LDL receptor. More than 
1000 mutations have been reported in the LDLR gene, 
which disrupt the ability of the LDL receptor to bind and 
endocytose LDL.62 This results in accumulation of LDL 
cholesterol in the circulation. 
Heterozygote frequency 1/500. Heterozygotes 
have elevated circulating LDL levels, tendon 
xanthomata, corneal arcus, and premature CAD. 
Homozygotes more severely affected with higher 
LDL levels, cutaneous xanthomata, and CAD 
may present below the age of 30 years. 
Familial defective Apo B 
(OMIM# 144010) 
Autosomal 
dominant 
APOB* APOB encodes apolipoprotein B-100, which is the protein 
component of LDL. Apo B-100 is the major ligand for the 
LDL receptor and mediates binding of LDL to the receptor. 
10 mutations reported in APOB, which reduce the binding 
affinity of Apo B-100 to the LDL receptor, resulting in 
impaired cellular uptake and processing of LDL. 
Heterozygote frequency 1/1000. Elevated 
circulating LDL with phenotype very similar to 
FH, but slightly milder in some studies. Risk of 
premature CAD is lower than with FH, but 
remains substantially elevated. 
Autosomal dominant 
hypercholesterolemia 3 
(OMIM# 603776) 
Autosomal 
dominant 
PCSK9* PCSK9 encodes proprotein convertase subtilisin/kexin type 
9. The exact function of this glycoprotein is not well 
understood, but several gain-of-function mutations seem to 
be associated with a reduction in the number of LDL 
receptors at the cell surface. 
Studied in several pedigrees. Phenotype similar to 
FH, but prevalence and variations in phenotype 
not yet well defined. 
Autosomal recessive 
hypercholesterolemia 
(OMIM# 603813) 
Autosomal 
recessive 
ARH ARH encodes LDL receptor adaptor protein 1 
(LDLRRAP1). This interacts with the cytoplasmic domain 
of the LDL receptor and components of the clathrin 
endocytic machinery. Mutations lead to defective 
endocytosis of the LDL receptor. 
Rare. Raised circulating LDL levels with 
phenotype similar to FH. 
Apolipoprotein A-I (Apo 
A-I) deficiency 
(OMIM# 107680) 
 
Autosomal 
dominant 
APOA1* APOA1 encodes Apo A-I, which is the major protein 
constituent of HDL. It mediates the interaction of HDL with 
cell surface receptors and other pathways. Mutations lead to 
very low circulating HDL levels. 
Rare. Heterozygotes have low circulating HDL 
levels and some variants are associated with 
premature CAD risk63, 64 whilst others are not.65 
Homozygotes with certain mutations may have 
xanthomata or corneal opacities and early CAD. 
Tangier disease 
(OMIM# 205400) 
Autosomal 
recessive 
ABCA1* ABCA1 encodes ATP-binding cassette A1. This acts as a 
cholesterol efflux pump, involved in cellular cholesterol 
homeostasis and HDL formation. Mutations lead to lipid 
accumulation within cells, including macrophages, which 
produces characteristic clinical and histological features. 
Rare. Affected homozygotes usually have 
pathognomonic enlarged orange tonsils. HDL 
levels very low, with increased CAD risk. Other 
features include: hepatosplenomegaly, 
lymphadenopathy, thrombocytopenia, anaemia, 
  
GI disturbance, neuropathy, corneal opacities. 
Heterozygotes have low HDL and increased CAD 
risk without the other clinical features.66 
Homocystinuria 
(OMIM# 236200) 
Autosomal 
recessive 
Cystathionine 
β-synthase 
Cystathionine β-synthase is an enzyme in the methionine 
metabolism pathway. It catalyses conversion of 
homocysteine and serine to cystathionine. Multiple loss of 
function mutations have been reported, producing high 
circulating homocysteine levels. The mechanisms leading to 
CAD are incompletely defined. 
Worldwide 1/300000, in Ireland 1/65000.67 
Affected homozygotes have ‘Marfanoid’ skeletal 
abnormalities, developmental delay/mental 
retardation, ectopia lentis, osteoporosis, and 
thromboembolism. Untreated, 50% risk of 
thromboembolic vascular events (including CAD) 
by age 30 years.68 
Autosomal dominant 
coronary artery disease 2 
(OMIM# 610947) 
Autosomal 
dominant 
LRP6 LRP6 encodes LDL receptor related protein 6, which is 
related to the LDLR gene and acts as a co-receptor in the 
Wnt signalling pathway. Missense mutation associated with 
reduced Wnt signalling, raised LDL, and premature CAD. 
Single Iranian pedigree. Elevated LDL, 
premature CAD and metabolic syndrome 
described in homozygotes and heterozygotes.69 
Autosomal dominant 
coronary artery disease 1 
(OMIM# 608320) 
Autosomal 
dominant 
Uncertain 
?MEF2A 
Genome-wide linkage analysis in a family with an 
autosomal dominant pattern of premature CAD identified 
chromosome 15q26 as a possible susceptibility locus.70 
Sequencing revealed a 21bp deletion in the MEF2A gene at 
this locus in affected individuals in that family, but analysis 
in other populations demonstrated that the 21bp MEF2A 
deletion did not co-segregate with CAD, suggesting it is not 
causative.71 Other MEF2A mutations do not appear to be a 
common cause of CAD in Caucasians. The gene and 
mechanism remain to be elucidated. 
Reported in isolated pedigrees. Premature CAD 
and MI. 
Sitosterolemia 
(OMIM# 210250) 
Autosomal 
recessive 
ABCG5 
ABCG8 
ABCG5/8 encode ATP-binding cassette G5/G8. These limit 
intestinal absorption, and promote biliary excretion, of non-
cholesterol sterols. Inactivating mutations lead to high 
levels of plasma sterols. 
Rare. Affected homozygotes have high plasma 
sterol levels, xanthomata, and premature CAD. 
OMIM# = NCBI Online Mendelian Inheritance in Man identifier. * genes for which variants have been shown to be contribute to lipid/cardiovascular phenotypes in the 
general population. FH = familial hypercholesterolemia. 
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The term familial hypercholesterolemia is usually used specifically for the syndrome 
associated with mutations in the LDLR gene, but similar phenotypes are associated 
with abnormalities of the APOB and PCSK9 genes.  Detailed investigation of patients 
with ‘FH’ phenotypes demonstrated that 79.1% were due to LDLR mutations, with 
5.5% due to APOB mutations, and 1.5% due to mutations in PCSK972.  Involvement 
of other genes may account for some of the remaining proportion.  The genes 
identified through studies of FH and other rarer Mendelian disorders may also have 
common variants that are associated with disease in the general population, and thus 
these rare conditions can identify candidate genes for further studies.  For example, 
commoner variants in both LDLR and PCSK9 have been shown in recent studies to 
contribute to population lipid levels and CAD susceptibility.  Furthermore, insights 
from investigations of FH were important in the development of statins, now used 
widely to reduce CAD risk at the population level. 
Apo A-I is the major protein constituent of HDL.  Mutations in the APOA1 gene 
cause Apo A-I deficiency, which is an autosomal dominant disorder.  Numerous 
mutations in the APOA1 gene have been reported, some of which lead to very low 
circulating HDL levels and increased risk of atherosclerosis63, 64, 73.  However, a 
variant of Apo A-I (named Apo A-I Milano) identified in an Italian pedigree was 
associated with reduced CAD risk in heterozygous carriers, despite reduced HDL 
levels and raised triglycerides65, 74, 75.  The Apo A-I Milano protein differs from native 
Apo A-I by the substitution of cysteine for arginine at position 173, which changes its 
properties and allows the formation of disulphide-linked homodimers and 
heterodimers with apoA-II76.  Recombinant Apo A-I Milano complexed with a 
naturally occurring phospholipid has been manufactured to mimic the properties of 
nascent HDL, and this has been shown to reduce the lipid and macrophage content of 
atherosclerotic plaques in animal models of atherosclerosis77-80.  Furthermore, a 
randomised double-blinded controlled trial in human subjects with acute coronary 
syndromes showed a significant reduction in coronary atheroma volume measured 
using intravascular ultrasound81.  These investigations suggest that recombinant Apo 
A-I Milano, or drugs mimicking the effect of the mutation on lipoprotein trafficking, 
could be useful for the stabilization, and possibly even regression, of atheromatous 
plaque in the wider population with CAD. 
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1.1.4.2 Candidate gene association studies 
CAD has been the subject of large numbers of ‘candidate gene’ association studies –
there are several hundred such published studies currently in the Genetic Association 
Database, an archive of association studies in human complex diseases14.  These 
studies investigate variation in genes that are already thought to be involved in the 
pathogenesis of the disease (based on experimental or theoretical grounds) by 
comparing allele or haplotype frequencies between cases and control groups.  A major 
limitation of this approach has been that relatively few gene-polymorphism 
associations have been consistently replicated82.  Many potential explanations for the 
inconsistent results between different studies have been proposed, which highlight the 
problems inherent in studying the genetics of a complex disease in which multiple 
genetic and non-genetic factors operate.  These include differences in genetic and 
environmental factors between populations studied, including genetic heterogeneity 
(whereby causative variants differ between the populations), differing patterns of 
linkage disequilibrium (whereby the causal variant is not captured by the same marker 
in a different population), or phenotypic heterogeneity (whereby the complex 
‘phenotype’ defined as CAD may differ between populations and be attributable to 
different risk factors)82.  Methodological factors pertaining to study design have also 
played a significant role, as many studies lack adequate statistical power to detect 
associations (false negative results); whereas in others, the presence of confounding 
factors between cases and control groups, or excessive subgroup analyses, increases 
the likelihood of false positive associations10.  However, perhaps the most important 
factors accounting for the apparently contradictory results of candidate gene studies 
are the criteria widely used to define and interpret ‘statistical significance’ and the 
presence of ‘publication bias’ favouring the reporting of positive associations83.  
Using a 5% threshold to define ‘significance’ a positive association would be 
expected for 1 in 20 tests due to chance alone.  Therefore in view of the multiple tests 
performed for different candidate genes in hundreds of different studies, a great 
number of false positive associations are expected.  However, the a priori chance of 
any particular gene of the 30,000 in the human genome being associated with a 
particular disease is likely to be small, even allowing for the fact that plausible 
candidates are selected for testing.  This needs to be considered in interpreting the 
results of such studies, and reinforces the importance of replicating results in 
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adequately powered studies.  The replication problems in the field were highlighted in 
a 2007 paper by Morgan et al which typed 85 variants in 70 genes previously claimed 
to be associated with the risk of acute coronary syndrome, finding just one borderline 
significant (P=0.03) association that was most likely due to chance84. 
Detailed discussion of the hundreds of association studies and candidate genes that 
have been investigated is not possible here.  Generally, however, the relative risks 
attributable to variants reported in association studies have been modest, in keeping 
with the CDCV hypothesis.  As individual studies were often too small to reliably 
confirm or refute associations, meta-analyses have been used to provide an 
assessment of composite effect, although the heterogeneity between studies must be 
considered when interpreting such data.  The results of several large-scale meta-
analyses are summarised in Table 1.2.  Considered as a whole, candidate gene 
association studies have identified multiple genes which may be connected with CAD, 
but replication and elucidation of causative mechanisms remain to be established in 
most cases. 
Increasing availability of high-throughput genotyping has allowed larger populations 
and larger numbers of polymorphisms to be screened, both within the same gene and 
in different genes.  This offers the potential for such studies to overcome many of the 
shortcomings that have limited them in the past, particularly with respect to 
inadequate sample size and statistical power.  However, an inherent limitation of the 
candidate gene approach is that it is restricted to the investigation of pathways within 
the sphere of prior, and incomplete, knowledge of the pathophysiology of CAD.  
Alternative approaches with the potential to identify novel associations and 
mechanisms are therefore extremely attractive, and one such approach that has been 
employed for CAD is the genome-wide linkage study. 
1.1.4.3 Family based linkage studies 
Linkage analysis involves the use of genetic and phenotypic data collected from 
families.  Polymorphic markers (commonly microsatellites or SNPs) at known 
locations throughout the genome are genotyped and statistical evidence of co-
segregation of these markers with the CAD phenotype is examined in family  
  
Table 1.2. Candidate gene polymorphisms associated with CAD in large-scale meta-analyses (>5000 CAD cases). 
Gene 
 
Variant (rs number) and risk allele Number of studies 
included 
Number of CAD cases / 
controls 
Relative risk (95% CI) References 
TaqIB (rs708272) –A allele 38 19035 / 32368 0.95 (0.92-0.99) per allele 101
 
I405V (rs5882) –G allele 18 10313 / 32244 0.94 (0.89-1.00) per allele 101
 
Cholesteryl ester transfer 
protein (CETP) 
-629C>A (rs1800775) –A allele 17 11599 / 23185 0.95 (0.91-1.00) per allele 101
 
Apolipoprotein E (APOE) ε2 isoform carrier 17 21331 / 47467 0.80 (0.70-0.90) 102
 
 ε4 isoform carrier 17 21331 / 47467 1.06 (0.99-1.13) 102
 
 ε4 / ε4 homozygote 17 21331 / 47467 1.22 (1.08-1.38) 102
 
Angiotensin type 1 receptor 
(AGTR1) 
+1166A/C (rs5186) –C allele 27 10180 / 17129 1.13 (1.04-1.23) per allele 103
 
Factor V G1691A (rs6025) –A [Factor V Leiden] 60 15704 / 26686 1.17 (1.08-1.28) per allele 104
 
Prothrombin (factor II) G20210A  - A allele 40 11625 / 14462 1.31 (1.12-1.52) per allele 104
 
Plasminogen activator 
inhibitor (PAI-1) 
[-675]4G/5G – 4G allele 37 11763 / 13905 1.06 (1.02-1.10) per allele 104
 
Paraoxonase (PON1) Q192R (rs662)  -R allele 43 10106 / 11786 1.12 (1.07-1.16) per allele 105
 
Endothelial nitric oxide 
synthase (eNOS) 
Glu298Asp –Asp/Asp homozygote 14 6036 / 6106 1.31 (1.13-1.51) 106
 
 Intron-4a –a/a homozygote 16 6212 / 6737 1.34 (1.03-1.75) 106
 
Apolipoprotein B (APOB) SpIns/Del  –DD homozygote 22 6007 / 5609 1.19 (1.05-1.35) 107
 
Methylene tetrahydrofolate 
reductase (MTHFR) 
677C>T (rs1801133) –TT homozygote 40 11162 / 12758 1.16 (1.05-1.28) 108
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pedigrees using bio-statistical algorithms82.  Evidence of cosegregation (suggested by 
a logarithm of the odds, or LOD score, greater than 3)40 suggests that the marker is 
near to a disease susceptibility locus.  Fine mapping of the region can then be 
performed by genotyping more markers in the region of interest and repeating the 
analysis, or gene maps can be consulted to suggest nearby candidates for association 
testing. 
Genome-wide linkage studies have the advantage that analyses are undertaken 
without the need for any a priori assumptions, and can therefore be regarded as 
hypothesis generating and capable of identifying entirely novel genetic associations 
(in contrast to the candidate gene approach).  However, the positional resolution and 
power to detect a given effect is lower than for association studies40, and extended 
pedigrees of sufficient size can be difficult to obtain. 
Several linkage studies have been performed in large collections of families with 
CAD85-94.  Linkage associations have been reported for chromosomes 1, 2, 3, 13, 14, 
16, 17 and X, but there was limited replication of any particular region and very few 
novel susceptibility genes have actually been identified using this method.  In the 
most well known study a genome-wide linkage scan of 713 individuals from 296 
families identified a susceptibility locus for MI at chromosome 13q12-13, where the 
ALOX5AP gene encoding 5-lipoxygenase activating protein (FLAP) was identified91.  
Association between SNPs in this gene and MI were demonstrated in a case-control 
study, and involvement of the locus was then replicated in an independent cohort.  
The genetic findings have not, however, been consistently replicated in other studies, 
some of which are substantially larger than the hypothesis-generating study84, 95-99.  
Summary of the evidence to date suggests that the effect of the haplotypes studied, if 
it exists, is of a much smaller size than originally estimated.  Based on the initial 
genetic findings, a clinical trial was conducted to examine the effect of FLAP 
inhibition on levels of biomarkers associated with MI risk in 191 patients who had 
already suffered an MI and carried at-risk variants in FLAP100.  The FLAP inhibitor 
led to suppression of plasma levels of leukotriene B4, myeloperoxidase, and C-
reactive protein without any adverse events, suggesting that larger-scale trials 
powered to detect differences in CAD endpoints would be of interest. 
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1.1.4.4 Genome-wide association studies 
Large scale GWA studies have some advantages over linkage studies and candidate 
gene studies for the investigation of common variants conferring susceptibility to 
complex diseases such as CAD.  Like genome-wide linkage studies they investigate 
association in a hypothesis-generating manner, without the need for a priori 
assumptions, and can therefore identify novel associations.  However, they have 
greater statistical power to detect common variants than linkage studies40 and do not 
require extended pedigree collections, which can be difficult to ascertain.  GWA 
studies still require careful attention to study design to ensure that past failings are not 
repeated – rigorous phenotyping, appropriate matching of cases and controls, accurate 
genotyping, adequate sample size, appropriate analysis techniques and significance 
thresholds, and robust replication of findings are all of paramount importance109. 
The large datasets that are generated from GWA studies have also proved challenging 
with respect to bioinformatic and statistical analysis.  The large number of association 
tests performed provides the potential for false positive results, and very stringent 
thresholds have therefore been adopted to define genome-wide significance (typically 
5x10-8)40, 109.  Analysis also requires strategies to confirm data quality, deal with 
missing and imputed data, and consider multi-marker effects109.  Another limitation 
with sample sizes reported in the first generation of such studies is that the power to 
detect associations is low for alleles with lower minor allele frequency (MAF) or 
weaker effects.  Once an association between common variants and phenotype has 
been found, establishing the mechanism of the association may not be 
straightforward.  A recent theoretical paper suggested that some association signals 
from GWA studies may be attributable to effects of multiple uncommon causal 
variants distributed over a relatively wide region, in which case the causal variants 
and pathways responsible for the association may be difficult to identify110. 
The first novel association with CAD using a ‘genome-wide type approach’ was 
published in 2002 by a Japanese group111, although the fact that only gene-based 
SNPs were typed and the relatively small number of included SNPs mean that this 
study is generally not considered to offer truly ‘genome-wide’ coverage.  Almost 
93,000 gene-based SNPs were typed in 1,133 cases with MI and 1,006 controls, 
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which identified a susceptibility locus on chromosome 6p21.  LD mapping and 
analysis of haplotype structure showed significant association with a five-SNP 
haplotype in the lymphotoxin-α (LTA) gene, which encodes a member of the TNF 
ligand family.  This finding was subsequently replicated in two additional cohorts112, 
113
.  The risk genotype was associated with increased expression of cell-adhesion 
molecules in coronary artery smooth muscle cells, which may facilitate neutrophil 
recruitment in a pro-inflammatory mechanism leading to plaque rupture3.  LTA 
knockout mouse studies supported a role of the gene in atherogenesis114.  However, 
the promising early results have not been successfully replicated in most other large 
studies.  Clarke et al tested the SNPs defining the risk haplotype at LTA in 6,928 cases 
of MI and 2712 controls from the ISIS genetic study115.  In this large study and a 
meta-analysis of other published data, they found no evidence of association between 
any LTA SNP and MI risk.  Those results ruled out the effect size obtained in the 
original study with a high degree of confidence and suggested at most a marginal 
association with disease risk.  LTA was not identified with genome-wide significance 
in the association studies described below, which were sufficiently large to detect 
effects of the magnitude suggested by the initial LTA studies. 
It was not until 2007, with the widespread availability of microarray based 
genotyping, that the first wave of a flood of GWA studies looking at CAD and a range 
of other complex diseases were published.  The main findings of those studies of 
relevance to phenotypes related to CAD are outlined below. 
1.1.5 GWA studies of CAD-related phenotypes 
1.1.5.1 CAD 
Four GWA studies of CAD reported in 2007 demonstrated conclusive evidence for 
association between common SNPs in the same ~100kb region on chromosome 9p21 
and CAD risk18-21.  The results of these studies are summarised in Table 1.3.   
 
  
Table 1.3. CAD susceptibility loci replicated in multiple GWA studies. 
Allele Frequency 
 
Study Phenotype Total 
patients / 
controls 
SNPs on 
array 
Locus / SNP / risk allele 
Controls Cases 
Relative risk (95% CI) 
heterozygote / homozygote 
P value 
WTCCC18 and 
Samani21 
CAD / MI 2,863 / 4,648 500,000 9p21 / rs1333049 / C 0.47 0.55 1.36 (1.27-1.46) per copy of risk allele 2.9x10-19 
    6q25.1 / rs6922269 / A 0.25 0.29 1.23 (1.15-1.33) per copy of risk allele 2.9x10-8 
    2q36.1 / rs2943634 / C 0.34 0.30 1.21 (1.13-1.30) per copy of risk allele 1.6x10-7 
Helgadottir19 MI / CAD 4,587 / 12,767 305,000 9p21 / rs2383207 / G 0.492 0.548 1.25 (1.18-1.31) per copy of risk allele 2.0x10-16 
    9p21 / rs10757278 / G 0.453 0.517 1.28 (1.22-1.35) per copy of risk allele 1.2x10-20 
McPherson20 CAD 4,306 / 20,119 100,000 9p21 / rs10757274 / G 0.487* 0.525* 1.18 (1.02-1.37) / 1.29 (1.09-1.52)* 4x10-3* 
    9p21 / rs2383206 / G 0.505* 0.541* 1.26 (1.09-1.46) / 1.26 (1.07-1.48)* 7x10-4* 
*Data shown from ARIC cohort only. 
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The Wellcome Trust Case-Control Consortium (WTCCC) study examined around 
400,000 SNPs in 1,988 British Caucasians with a validated history of MI or coronary 
revascularisation before the age of 66 years, and 3,004 controls18.  Associations were 
seen for SNPs across >100kb in the 9p21 region, with the strongest association 
demonstrated for rs1333049 (P=1.8x10-14).  For this SNP the heterozygote odds ratio 
was 1.47 (95% CI 1.27-1.70) and the homozygote odds ratio was 1.90 (95% CI 1.61-
2.24).  ‘Moderate’ associations, defined as SNPs with a P-value greater than 5x10-7 
but less than 1x10-5, were reported for six other loci.  Replication of the chromosome 
9 locus was achieved in a subsequent paper by Samani et al which added data from a 
cohort comprising 875 German Caucasians with MI before the age of 60 years and at 
least one family member with premature CAD, and 1,644 controls, which had been 
genotyped using the same chip21.  As shown in Table 1.3, two loci on chromosome 6 
and chromosome 2 were also replicated in the German cohort.  The combined analysis 
identified four additional loci potentially associated with CAD, one of which 
(chromosome 1p13.3) has subsequently been shown to be strongly associated with 
plasma LDL-cholesterol116.  An analysis of 55 candidate genes previously reported to 
show association with CAD only confirmed association for two SNPs tagging a 
variant in the lipoprotein lipase gene in these cohorts. 
Helgadottir et al performed a similar study in 1,607 Icelandic patients with MI (before 
age 70 years in males and 75 years in females) and 6,728 controls, typed for around 
300,000 genomewide SNPs using the Illumina Hap300 chip19.  The strongest 
association was found for three correlated SNPs in the same chromosome 9p21 region 
that was identified in the WTCCC study, each with P values of approximately 1x10-6. 
The association was replicated in four additional case-control cohorts.  Combining 
data from all groups, allele G of the SNP rs10757278 showed the strongest 
association with MI, with an odds ratio of 1.28 (95% CI 1.22-1.35, P=1.2x10-20) per 
allele. 
McPherson et al typed 100,000 SNPs in 322 cases of premature CAD and 312 
controls, and replicated positive associations in a further 1,658 cases and 9,380 
controls20.  Two SNPs located within 20kb of each other in the same region of 
chromosome 9p21 were significantly associated with CAD.  These two SNPs were 
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validated in three additional independent cohorts (with varying inclusion parameters 
for defining CAD). 
The 9p21 region had not been previously implicated in CAD susceptibility studies and 
its identification by genome-wide association highlights the ability of such studies to 
discover novel risk loci.  Furthermore, these studies showed a remarkably consistent 
association with CAD for the chromosome 9p21 risk region in multiple independent 
populations using varying inclusion criteria, in marked contrast to the replication 
problems that had been observed in previous studies of CAD genetics.  Further studies 
investigating this region are discussed in detail below (section 1.2). 
The only other loci replicated in separate studies were the chromosome 6q25.1 and 
chromosome and 2q36.3 loci reported by Samani et al.  Associated SNPs on 
chromosome 6q25.1 are located in introns within the gene for 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like protein 
(MTHFD1L).  This encodes the mitochondrial isozyme of C1-tetrahydrofolate 
synthase which is involved in the synthesis of purines and regeneration of methionine 
from homocysteine.  It has therefore been suggested that MTHFD1L activity may 
influence plasma homocysteine levels, which are a risk factor for CAD, although 
preliminary analysis of the lead SNP at this locus and homocysteine levels in 1,070 
individuals did not show such an association21.  The chromosome 2q36.3 locus 
contains one pseudogene and the mechanism of any association at this locus remains 
unclear. 
Subsequent GWA studies have identified multiple additional loci for CAD 
susceptibility including the MRAS gene on chromosome 3q22.322, the SLC22A3-
LPAL2-LPA gene cluster on chromosome 6q2623, and the SH2B3 gene on 
chromosome 12q2424.  However, individual GWA studies have been adequately 
powered to detect only high frequency alleles or large effects and it is likely that 
further loci will be identified through larger studies or combined meta-analyses109, 117.   
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1.1.5.2 Plasma lipids 
Recent GWA studies investigating plasma lipoprotein concentrations as quantitative 
traits have produced convincing associations at a number of loci, many of which have 
been replicated in separate analyses118-121.  These have confirmed multiple loci 
previously implicated in lipid metabolism and identified a number of novel genetic 
associations with HDL cholesterol, LDL cholesterol and triglyceride levels.   
Newly identified associations with LDL cholesterol include variants close to the 
CELSR2-PSRC1-SORT1 locus, which was identified in three independent studies118, 
120, 121
.  No mechanistic connection is obvious for the two genes closest to the 
association signal (CELSR2 and PSRC1), but variants may influence the nearby 
SORT1 gene which is involved in lipoprotein lipase metabolism.  An allele on 
chromosome 19p13.11 showed association with both increased LDL and triglycerides 
in multiple studies118, 121.  This variant is close to CILP2 and PBX4 and in strong LD 
with a neuronal proteoglycan NCAN, but with no obvious mechanism for its 
association with plasma lipids. 
Novel associations with HDL cholesterol include a locus on chromosome 12q24.11 
near to the neighbouring MVK and MMAB genes, which encode enzymes involved in 
cholesterol biosynthesis and degradation pathways respectively121.  A novel 
association for both HDL and triglycerides was found for a locus on chromosome 
1q42.13 within the first intron of GALNT2, a widely expressed glycosylotransferase 
with no known role in lipid metabolism118, 121.   
Replicated novel associations with triglycerides were found for variants near to 
MLX1PL and ANGPTL3, both of which are known to be regulators of lipid 
metabolism.  The probable mechanism of a further association with variants near to 
the TRIB1 gene on chromosome 8q24.13 remains obscure118, 119, 121. 
The first round of GWA studies have also provided confirmation of variants at loci 
previously implicated in lipid metabolism, including apolipoproteins (APOE, APOB 
and APOA5), cholesterol and cholesterol ester transporters (ABCA1 and CETP), 
lipoprotein receptors (LDLR), and lipases (LPL, LIPC and LIPG)121. 
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Willer et al examined the association of alleles linked to lipid metabolism with CAD 
in a combined cohort of the WTCCC sample and an expanded panel of British 
individuals121.  All of the alleles associated with LDL metabolism were more common 
in CAD cases than controls, with modest odds ratios of 1.04 to 1.29 per allele; the 
association was significant for eight of the 11 SNPs.  The CAD risk variant rs1333049 
was not associated with lipid levels in the same cohort however.  These findings 
suggest that the newly identified loci are potential targets for novel therapies affecting 
lipoprotein levels and CAD risk. 
1.1.5.3 Type II diabetes mellitus 
The first round of GWA studies provided similarly exciting insights into the genetic 
associations of type II diabetes, which is a major risk factor for cardiovascular 
disease.  In the case of type II diabetes, recent studies have confirmed loci in genes for 
which there was robust prior evidence of involvement (such as PPARG, KCNJ11 and 
TCF7L2); substantiated evidence of a link for other previously implicated genes (such 
as IGF2BP2, HHEX-IDE and SLC30A8); and identified novel loci and potential 
candidate genes previously unsuspected of involvement18, 122-127.  The latter group 
includes a locus on chromosome 6p22 in intron 5 of the CDKAL1 gene, the 
association with which has been robustly replicated in multiple studies (odds ratio for 
heterozygotes 1.12 to 1.20)18, 123-126.  The function of this gene is unknown, but it 
shares protein domain homology with kinases involved in beta-cell metabolism.  
Variants in the FTO gene which is associated with adiposity were also associated with 
type II diabetes18, 124. 
Interestingly, the recent GWA studies have also identified SNPs on chromosome 9p21 
associated with an odds ratio of 1.20 for diabetes risk in some populations124-126, 
although this was not reported in other groups127, 128.  Diabetes is a major risk factor 
for CAD, associated with features such as vascular endothelial dysfunction and 
hyperlipidemia that are also important in atherogenesis, raising the prospect of a 
shared pathophysiological mechanism for the two diseases.  However, the most 
strongly associated SNP for type II diabetes in the region (rs10811661) lies beyond 
the LD block that is strongly associated with CAD risk.  A large study simultaneously 
comparing the diabetes variant rs10811661 and CAD SNPs with CAD and diabetes 
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phenotypes showed that they were independent of each other, suggesting that the 
underlying pathophysiological mechanism may not be the same for the two 
diseases129.  This was confirmed by Helgadottir et al who in multiple large cohorts 
examined the association between the CAD risk variant rs10757278 and diabetes risk 
variant rs10811661 and a number of vascular phenotypes including abdominal aortic 
aneurysm, intracranial aneurysm, peripheral arterial disease, large artery 
atherosclerotic or cardiogenic stroke, CAD, and type II diabetes130.  The diabetes 
variant did not show association with any of the arterial disease phenotypes.   
A second SNP, rs564398 which is not in LD with rs10811661, was associated with 
diabetes in a meta-analysis of 14,586 cases.  This lies within the CAD associated 
region described in the WTCCC study, and shows moderate correlation 
(0.28<r2<0.42) with SNPs in the core CAD haplotype129.  rs564398 showed 
association with CAD in the study by Broadbent et al. (P=4x10-8), but once a marker 
of the CAD risk haplotype was included in the statistical model, this became non-
significant (P=0.08)129.  There is therefore no evidence for an effect of rs564398 on 
CAD risk independent of its association with the risk haplotype at the present time.  
However, insufficient numbers of people with and without CAD that are concordant 
and discordant for diabetes have been studied so far to enable a possible effect of 
rs564398 on both diabetes and CAD to be entirely ruled out. 
1.1.5.4 Hypertension 
In contrast to the phenotypes described above, the first wave of GWA studies 
investigating BP phenotypes failed to identify associations at the level of genome-
wide significance, despite documented heritability of this trait and similar sample 
sizes to studies which have detected loci for other diseases18, 126, 131-134.  Potential 
explanations cited for the lack of association were that hypertension may have fewer 
common risk alleles of sufficient effect size, variants may be poorly tagged by the 
typed SNPs, or the potential for misclassification of hypertensive individuals within 
the control group18.   
A GWA study published in January 2009 by Wang et al analysed 79,447 SNPs in the 
American Old Order Amish, a closed population descended from a small number of 
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common founders who emigrated from Switzerland in the early 1700s who have a 
relatively homogeneous lifestyle134.  Their initial genome-wide screen of 542 subjects 
from the Amish Family Diabetes Study135, in which families were ascertained through 
a proband with type 2 diabetes, identified a cluster of SNPs in the STK39 (serine 
threonine kinase 39) locus on chromosome 2q24.3 that were associated with BP 
(P=8.9x10-6 to 9.1x10-5) 134.  Although the P-value did not reach the conventionally 
accepted threshold for genome-wide significance136, the inclusion of additional data 
from an Amish and four non-Amish Caucasian cohorts led to a significant result 
(P=1.6x10-7) in the combined dataset of 7,125 individuals.  The replication cohorts 
included a further population of 2,842 individuals from a case-control study of 
diabetes and three smaller groups not selected for diabetes. 
The STK39 gene encodes the SPAK (Ste20-related proline-alanine-rich kinase) 
protein which interacts with ion cotransporters involved in salt transport and osmotic 
cell volume regulation, including the thiazide-sensitive and loop diuretic-sensitive 
cotransporters involved in renal salt excretion137, 138.  The STK39 gene contains 18 
exons spanning approximately 300kb on chromosome 2q24.3; SNPs associated with 
BP by GWA studies were located within introns 1-8, with no coding or splice variants 
identified by sequencing134.  Using transfection experiments with luciferase reporter 
constructs Wang et al demonstrated that alleles of one SNP (rs35929607), located in a 
conserved region of intron 2 altered expression of the reporter constructs in vitro.  
This SNP was in LD with the SNPs identified by GWA studies, suggesting a possible 
functional mechanism for the observed association. 
Despite these results, other large GWA studies and meta-analyses involving up to 
71,225 Caucasian individuals have failed to identify association between STK39 SNPs 
and BP that satisfies genome-wide significance thresholds18, 139, 140.  However, such 
data do not exclude an effect of this locus on BP, since the statistical threshold for 
replicating an association differs from the threshold for genome-wide ‘discovery’.  
Differences in the actual SNPs genotyped, patterns of LD, and phenotypic variation 
between populations might contribute to the lack of genome-wide significance in 
these studies, compared to the GWAS by Wang et al.  One recent GWA study looked 
specifically for evidence of correlation between STK39 SNPs and BP in 1,017 African 
American subjects and provided some supportive evidence for an association141.  
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SNPs in the STK39 region did not reach genome-wide significance, but the number of 
significantly associated SNPs at a nominal P threshold of P<0.05 was somewhat 
higher than expected by chance alone (9/136 for systolic BP and 33/136 for diastolic 
BP, compared to 7/136 expected by chance).  The association of STK39 SNPs with 
BP remains to be confirmed at present and further studies are required to investigate 
this. 
Despite the disappointing results of the early hypertension GWAs, subsequent GWA 
studies and very large meta-analyses (the Global BPgen and CHARGE consortia) 
have subsequently identify multiple loci convincingly associated with BP 
phenotypes139-142.  In common with the findings for other phenotypes discussed 
above, these studies confirmed previously implicated genes such as CYP17A1, a gene 
associated with a rare Mendelian form of hypertension, as well as identifying novel 
loci, such as ULK3 and ULK4 for which the mechanisms of the association with BP 
are completely unknown.  The small effect on BP of the individual common variants 
identified, which were in the order of 1mmHg systolic and 0.5mmHg diastolic per 
copy of the risk allele, underscores the need for large collaborative studies and may 
account for the lack of association seen in the initial smaller GWA studies. 
1.2 The chromosome 9p21 susceptibility locus 
1.2.1 Replication and further characterisation 
The association of the chromosome 9p21 locus with CAD has been replicated in 
multiple additional Caucasian case-control series and meta-analyses129, 143-146.  
Association has also been reported for populations of other ethnicities including 
Japanese147, 148, Korean148, US Hispanic149, Asian Indians150, and Chinese151-153 
populations.  Fine mapping and detailed characterisation of the locus was performed 
in a large case-control study of 4,251 CAD cases and 4,443 controls from four 
European populations by Broadbent et al129.  From an analysis of 62 SNPs in the 
region they identified a region of strong LD containing 14 SNPs that form four 
common haplotypes (cumulative frequency 89%), with the association of the linked 
SNPs at this locus a consequence of a perfect ‘yin-yang’ haplotype spanning 53kb.   
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The CAD association has shown little evidence of gene-environment interactions, 
with consistent findings in subgroups analysed by age, gender, smoking status, 
hypertension, or diabetes129.  Similarly, there has been little difference in the strength 
of association between populations ascertained for MI versus those with CAD but no 
previous MI, although the trend towards a stronger association with the non-MI 
phenotype suggests that the primary effect of the 9p21 locus is not on plaque 
rupture19, 21, 129.  This is in keeping with the findings from a number of studies 
suggesting that the risk allele is associated with the extent or progression of 
atherosclerosis154, 155. 
The mechanisms through which the 9p21 locus influences CAD susceptibility are not 
known.  Approaches to identifying pathways involved in causation include first, 
consideration of the relationship with other cardiovascular intermediate phenotypes 
which may provide mechanistic clues; and second, consideration of effects on 
expression of nearby candidate genes. 
1.2.2 Relationship to other phenotypes 
1.2.2.1 Intermediate phenotypes for CAD 
McPherson et al examined the relationship between risk alleles and traditional 
atherosclerosis risk factors in 2,872 cases with CAD and 18,107 controls.  They found 
no association of the risk alleles with age, gender, body mass index, BP, smoking, 
physical activity, fatty diet, or plasma levels of glucose, triglycerides, LDL 
cholesterol, HDL cholesterol, CRP, intercellular adhesion molecule-1, and vascular 
cell adhesion molecule-120.  This finding was subsequently extended by further 
studies that, in addition to replication of the negative association with the previously 
listed parameters, also found no association between the chromosome 9p21 risk locus 
and cardiovascular risk phenotypes including plasma levels of lipoprotein(a), 
albumin, fibrinogen, uric acid, and homocysteine129, 156.  The lack of association with 
traditional risk factors and intermediate phenotypes for atherosclerosis suggests that 
this locus may act via a novel mechanism.  This is discussed in greater detail in 
Chapter 6. 
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1.2.2.2 Other vascular phenotypes 
The relationship between risk SNPs for CAD and diabetes has already been discussed 
in detail.  Helgadottir et al also examined the association between the CAD risk 
variant rs10757278 and a number of vascular phenotypes including abdominal aortic 
aneurysm, intracranial aneurysm, peripheral arterial disease, and large artery 
atherosclerotic or cardiogenic stroke130.  The CAD risk variant was significantly 
associated with abdominal aortic aneurysm (OR 1.31, P=1.2x10-12) and intracranial 
berry aneurysm (OR 1.29, P=2.5x10-6), but after excluding potentially confounding 
cases of known CAD, it was not significantly associated with peripheral arterial 
disease, ischaemic stroke, or diabetes.  Other early studies also reported no 
association of 9p21 CAD variants with stroke risk157, 158, but subsequent studies have 
now shown convincing association of these SNPs with ischaemic stroke116, 159-162, and 
other markers of systemic atherosclerosis163.   
1.2.2.3 Non-vascular phenotypes 
Interestingly, SNPs close to the CAD risk region on chromosome 9p21 have also been 
identified in recent GWA studies as being associated with glioma164, 165, 
naevi/melanoma166, 167, and basal cell carcinoma168.  As discussed below, the region 
contains the recognised tumour suppressor genes CDKN2A and CDKN2B, providing a 
plausible mechanistic association for the involvement of these variants and genes in 
cancer aetiology.  In view of the known involvement of CDKN2A and CDKN2B in 
rare familial cancers, common variants in these genes had been previously 
investigated in ‘candidate genes’ studies and were reported to be associated with a 
range of different cancer phenotypes.  These studies, which are summarised in Table 
1.4, shared many of the limitations common to other candidate gene studies as 
previously discussed.  The sample sizes were often small, most of the positive 
findings were unreplicated, and significance thresholds were often unadjusted for 
multiple testing with over-interpretation of borderline results.  The issue of reporting 
bias favouring positive associations also needs to be considered in interpreting the 
results of these studies.  The location of SNPs that have been associated with disease 
phenotypes in the 9p21 region are illustrated in Figure 1.4. 
  
Table 1.4. Candidate gene polymorphisms previously associated with disease in the CDKN2A/ARF/CDKN2B region. 
Study Disease Polymorphism Population Evidence of association 
Kumar et al 
2001169 
Malignant melanoma rs3088440 2 SNPs in the 5’UTR of CDKN2A typed in 
229 patients with melanoma and 235 
controls. 
T allele of rs3088440 associated with melanoma (OR=1.7, 
95%CI 1.1-2.7, P=0.01). 
Straume et al 
2002170 
Survival in malignant 
melanoma 
rs3088440 2 SNPs in the 5’UTR of CDKN2A typed in 
185 malignant melanoma cases. 
No association with methylation status, p16 expression, or 
other clinicopathological variables. rs11515-C 
associated with improved survival (P=0.03). Not 
adjusted for multiple testing. 
Sakano et al 
2002171 
Clinical course of bladder 
cancer 
rs11515 
rs3088440 
2 SNPs in the 5’UTR of CDKN2A typed in 
309 patients with bladder cancer and 235 
controls. 
No association with bladder cancer. rs11515 associated 
with tumour progression in 219 patients with superficial 
bladder cancer (P=0.04) and tumour-specific survival 
(P=0.02).  Not adjusted for multiple testing. 
Debniak et al 
2005172 
Malignant melanoma rs3731249 3 CDKN2A SNPs typed in 471 cases and 1210 
controls. 
Risk (G) allele of rs3731249 associated with disease OR 
2.5 (P=0.0003). 
Debniak et al 
2005173 and 
2007174 
Breast cancer rs3731249 Single SNP typed in 4,209 cases and 3,000 
controls. 
Risk (G) allele present in 8/66 cases under 30 years of age, 
OR 3.8 (P=0.0002) and 168/3318 cases under 50 years, 
OR 1.5 (P=0.002). 
Chen et al 
2007175 
Age of onset of 
pancreatic cancer 
rs11515 
rs3088440 
2 SNPs in CDKN2A and 1 in Aurora-A typed 
in 148 patients with pancreatic cancer. 
Aurora-A and rs3088440-T had a synergistic effect on age-
associated risk for early diagnosis, with median age at 
diagnosis 12.6 years earlier (OR=3.9, 95%CI 1.9-7.8, 
P=0.0002). 
Gayther et al 
2007176 
Invasive epithelial 
ovarian cancer 
rs3731257 88 SNPs in cell cycle genes typed in 1,500 
cases and 2,500 controls, then 5 most 
significant SNPs typed in additional 2,000 
cases and 3,200 controls. 
Combined analysis showed rare allele for rs3731257 
associated with disease, OR for homozygotes 0.79 
(95%CI 0.65-0.95), P=0.008. Non-significant (P=0.37) 
after adjustment for multiple testing. 
Healy et al 
2007177 
Acute lymphoblastic 
leukaemia 
rs3731249 
rs2069416 
10 SNPs in 4 cell cycle genes typed in 240 
patients with ALL and 277 controls. 
Risk alleles at rs3731249 (P=0.008) and rs2069416 
(P=0.02) associated with ALL. 
 
 
    
  
Kang et al 
2008178 
 
p14ARF promoter 
methylation in 
colorectal cancer 
rs3218012 
rs2518723 
21 SNPs close to p14ARF CpG island typed in 
188 cases of colorectal cancer and 300 
controls. 
Risk haplotype associated with p14ARF promoter 
methylation (OR=8.3, 95%CI 2.4-28.4, P=0.0007). Not 
adjusted for multiple testing. 
Melzer et al 
2007179 
Reduced physical 
functioning in elderly 
rs2811712 
rs3218005 
25 CDKN2A/B SNPs typed in 3 elderly (aged 
65-80 years) cohorts (total n=3372). 
In screening cohort G alleles of rs2811712 and rs3218005 
associated with better physical function. rs2811712 
analysed in replication cohorts. Prevalence of severely 
limited physical function 15% in common homozygotes, 
7% in rare homozygotes (OR=1.48, 95%CI 1.17-1.88, 
P=0.001) 
Driver et al 
2008180 
Breast cancer rs3731239 
rs3218005 
240 SNPs in cell cycle genes typed in 2270 
cases and 2,280 controls. SNPs with P<0.1 
then typed in further 2,200 cases and 2,280 
controls. 
rs37371239 OR (CC/TT) = 0.90 (95%CI 0.79-1.03, 
P=0.013). rs3218005 OR (GG/AA) = 1.55 (95%CI 1.02-
2.37, P=0.013). P-values unadjusted for multiple testing. 
Yan et al 
2008181 
Histologic subtypes of 
epithelial ovarian 
cancer 
rs11515 
rs3088440 
2 SNPs analysed in 205 patients with ovarian 
cancer and 268 controls. 
No association with cancer. Subgroup analysis rs3088440 
associated with histologic subtype of tumour (P=0.02 
unadjusted for multiple testing). 
Zuchner et al 
2008182 
Late onset Alzheimer 
disease 
rs11515 
rs3731246 
80 9p21 SNPs typed in 674 families with late 
onset Alzheimer disease. 
rs11515 and rs3731246 significant for family-based 
association after adjustment for multiple testing. 
 
  
Figure 1.4. SNPs associated with disease in the chromosome 9p21.3 region.  
Genes are illustrated in blue at the top, with arrows representing the direction of transcription. SNPs typed in this study and SNPs associated with various diseases are 
represented by black bars. Diseases in bold are those with association data from genomewide association studies. The hatched box represents the core risk haplotype for CAD 
defined by Broadbent et al 129. Promoter regions for each gene are shown as pale blue boxes. DM = diabetes mellitus type II; BCC = basal cell carcinoma. 
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1.2.3 Candidate susceptibility genes in the 9p21 region 
1.2.3.1 CDKN2A and CDKN2B 
As shown in Figure 1.5, the chromosome 9p21 variants associated with CAD are 
located in a block of high LD that contains the cyclin-dependent kinase inhibitor 
genes CDKN2A and CDKN2B. These genes are well recognised as tumour-suppressor 
genes and are involved in regulation of cell cycle, ageing, senescence and 
apoptosis183, 184.   
Figure 1.5. LD in the chromosome 9p21 region between CAD risk variants, 
nearby genes, and microsatellite rs10583774.  
The figure shows LD in the HapMap CEU population, adapted from the HapMap website47.  Black 
numbers represent the chromosome 9 location (M=megabases). Shading indicates LD ranging from 
D’=1 in red to D’=0 in white. 
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The CDKN2A gene generates alternative transcript variants that have different first 
exons spliced to a common second and third exon; CDKN2A (p16, INK4a), and 
CDKN2A-ARF (p19, ARF)183, 185.  Although the proteins are encoded in alternative 
reading frames and do not show amino acid homology, both inhibit cell cycle 
progression.  The CDKN2A protein inactivates the cyclin-dependent kinases CDK4/6 
and thereby inhibits cellular proliferation by inducing G1 cell-cycle arrest.  The 
CDKN2A-ARF protein binds to and inactivates the MDM2 protein, resulting in p53 
stabilisation and inhibition of proliferation.  The CDKN2B protein is structurally 
similar to CDKN2A and acts through a similar mechanism. Although the three main 
transcripts have separate promoters and may respond independently in certain 
contexts186-188, recent evidence including discovery of a common cis-acting regulatory 
domain and co-ordinated repression by Polycomb-group complexes suggests that the 
entire locus is co-ordinately regulated184, 189.   
Deletions involving CDKN2A and CDKN2B have been implicated in multiple 
cancers185.  Experimental evidence suggests that these genes also play an important 
role in ageing, cellular senescence and apoptosis185.  Increased age is the dominant 
risk factor for atherosclerosis, and is associated with structural and functional changes 
in the vascular wall, and these genes have been shown to be widely expressed, 
including in atherosclerotic tissue190, 191.  Abnormal proliferation of leukocytes and 
vascular smooth muscle cells are a hallmark of atherosclerosis192, but other evidence 
also suggests that senescence and apoptosis are important in the atherosclerotic 
process193, 194.  Furthermore, CDKN2B expression may be induced by transforming 
growth factor beta, which has been implicated in the pathogenesis of 
atherosclerosis190, 191.  Taken as a whole, such data provide a plausible mechanism for 
the involvement of CDKN2A and CDKN2B in atherosclerosis and CAD, although 
whether expression would be up or down-regulated is uncertain. 
Helgadottir et al sequenced 93 early-onset MI patients across exons, exon-intron 
boundaries and regulatory regions of CDKN2A and CDKN2B19, and McPherson et al 
sequenced the coding regions of these genes in 96 affected individuals20.  These 
studies revealed no variants likely to account for the observed association with CAD 
risk. 
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1.2.3.2 ANRIL 
The CAD core risk region overlaps with exons 13-19 of ANRIL129, a newly annotated 
gene that was first reported in April 2007 by investigators examining a deletion in a 
large melanoma-neural system tumour syndrome family195.  In this original report, 
Pasmant et al used the dbEST database to identify several human expressed sequence 
tags (ESTs) of an unidentified transcript in the region of the 403kb chromosome 9p21 
deletion that they were investigating.  Using real-time PCR of cDNA from normal 
human testis with primers placed in the identified ESTs followed by sequence 
analysis of the PCR products, Pasmant et al identified two alternatively-spliced 
transcripts.  The first was 3,834 bp long and alignment to reference genomic DNA 
sequences showed that it contained 19 exons, with exon/intron junctions 
corresponding to the consensus sequences of donor/acceptor splice sites and a 
polyadenylation site in the last exon.  A second shorter transcript 2,659 bp in length 
composed of the same first 12 exons and an alternative 3’ exon 13 including an 
additional polyadenylation site was also characterised.  These transcripts overlapped 
and were transcribed in the opposite direction to CDKN2B (which is located entirely 
within the first intron of ANRIL, as was illustrated in Figure 1.5 on page 36).  These 
novel transcripts did not possess an open reading frame and appeared to be 
untranslated, and the gene was designated ANRIL for ‘antisense noncoding RNA in 
the INK4 locus’.  This has recently been given the official gene name ‘CDKN2B 
antisense RNA’ (CDKN2BAS)196, but as the name ANRIL is used widely in the 
literature and in common usage, that term will be used throughout this thesis.  At the 
time this project was undertaken, only these two transcripts had been reported.  
However, very recent work published in November 2009 has suggested that the 
situation may be more complex with the existence of multiple alternatively-spliced 
transcripts reported in cell lines derived from different tissues197.  Recent studies 
pertaining to alternative transcripts are discussed in detail in Chapter 4 (section 4.6.8, 
page 182), and a summary of all transcripts reported to date is also presented in 
Chapter 4 (Figure 4.14 on page 159). 
ANRIL produces a large non-coding RNA whose function is unknown.  Other large 
non-coding RNAs such as Xist and HOTAIR have been reported to be involved in 
regulation of gene expression through transcriptional and translational control 
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mechanisms198, 199.  Similar to Xist, ANRIL contains a high number of repetitive 
elements and encompasses binding sites for transcription factors responsible for 
transcriptional repression, suggesting that it may act through similar mechanisms200.  
Transcriptional repression by HOTAIR is mediated by recruitment of Polycomb 
complexes, which have also been shown to influence expression of CDKN2A and 
CDKN2B201.  It is therefore possible that ANRIL influences disease susceptibility 
through similar mechanisms, and it has been shown to be expressed in tissues relevant 
to CAD including heart, coronary smooth muscle, vascular endothelial cells, human 
monocyte-derived macrophages, carotid endarterectomy specimens, and abdominal 
aortic aneurysm samples129, 195.   
In view of its location, the CAD risk allele may act by altering ANRIL expression or 
function.  SNPs in the core risk region for CAD are not located within exons of 
ANRIL, but map to intronic and downstream sequences, which may be involved in the 
regulation of ANRIL expression.  Several expressed sequence tags map within the risk 
locus, but do not contain open reading frames extending more than a few amino acids.  
McPherson et al sequenced the CAD risk region in two homozygotes for the risk 
allele and one homozygote for the reference allele, identifying 35 sequence variants 
that were specific to the risk allele, one of which (a CAT repeat CNV) mapped to a 
splice transcript of ANRIL20.  CDKN2B antisense transcription, mapping to the first 
intron of ANRIL, has been shown to be associated with downregulation of CDKN2B 
expression in leukaemia cells and mouse embryonic stem cells, mediated in cis and 
trans through heterochromatin formation202.  This suggests that ANRIL expression 
may be involved in the regulation of CDKN2B expression.  A number of studies 
published after this project began that have examined the association of CAD risk 
SNPs with ANRIL expression are discussed in Chapter 4 (section 4.6.7, page 179). 
1.2.3.3 MTAP 
This gene encodes methylthioadenosine phosphorylase (MTAP), an enzyme that plays 
a role in polyamine metabolism, which appears to be constitutively expressed in 
human cells.  Polyamines are essential for cell growth and normal function, and 
MTAP has been shown to have a role in inhibiting cell growth under certain 
conditions in vitro203.  It was speculated that variants may influence plasma levels of 
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homocysteine which have been associated with CAD risk, although a recent study 
reported no variation in homocysteine levels in relation to genotype of the CAD risk 
SNP rs10757274144.  The mechanism through which MTAP might influence CAD 
susceptibility is unclear at present.  
1.2.4 Clinical implications 
1.2.4.1 Risk prediction 
The finding of new loci associated with CAD has attracted great excitement in the 
medical and scientific communities, but the way in which these findings could 
translate into tangible health benefits needs to be considered.  The use of SNP 
markers for genetic testing to improve risk stratification of individuals and the 
promise of ‘personalised medicine’ has been an often cited prospect.  However, 
statistical significance is not the same as clinical relevance, and the magnitude of the 
risk conferred by SNPs at the chromosome 9p21 locus is modest for individuals, with 
relative risks of ranging from 1.18-1.36 for heterozygotes, and 1.26-1.72 for 
homozygotes.  Because the frequency of the risk alleles is high, the population 
attributable risk associated with the chromosome 9p21 locus has been estimated to be 
between 10 and 22%, which is significant from a public health perspective, but it 
should be remembered that the case-control cohorts which have been used in studies 
to date have been specifically collected to be ‘genetically loaded’, predominantly 
including early onset cases and families in whom there is an affected relative-pair.  
The generalisability of results regarding the relative magnitude of a genetic 
contribution to risk in such selected cohorts to the entire population at risk of CAD is 
therefore questionable.   
From a practical point of view, the contribution of genotype at associated SNPs to the 
capacity to predict CAD in a representative population assessed for the ‘classical’ 
CAD risk factors is perhaps the most important question.  Several studies have 
investigated this.  Talmud et al typed the chromosome 9p21 CAD risk SNP 
rs10757274 in 2,742 men aged 50-64 years old who were free of CAD at baseline, 
who experienced 270 CAD events over a 15-year follow-up period144.  The area under 
the receiver operating characteristic (ROC) curve for the ‘classical’ risk factors was 
0.62 and did not increase significantly when rs10757274 genotype was included.  369 
Chapter 1: Introduction 
41 
men (13.5%) were reclassified into more accurate risk categories (based on four 
categories of 10-year CAD risk), which the authors argued might have clinical utility.  
However, the analysis is biased by the fact that the study did not include family 
history of CAD in the ‘classical’ risk model they used.  Brautbar et al reported similar 
findings in an analysis in 9,998 Caucasians, 1349 of whom developed incident CAD 
over 14.6 years of follow-up204.  Addition of rs10757274 genotype produced a 
statistically significant, but not clinically meaningful, change in the area under the 
ROC curve from 0.782 to 0.786, and reclassified 12% of individuals in the 
intermediate-low and intermediate-high risk categories.  Paynter et al performed a 
similar analysis in 22,129 white females aged over 45 (median age 52) years, who 
experienced 715 cardiovascular events over 10 years of follow-up205.  Addition of 
genotype at rs10757274 to a model based on traditional risk factors, CRP and family 
history of CAD did not improve risk prediction measured using the c-index.  The 
addition of genotype at rs10757274 also failed to improve the Net Reclassification 
Improvement score.   
Simulations performed by Talmud et al suggested that if 10 additional SNP genotypes 
of similar effect to rs10757274 could be identified, the area under the ROC curve 
could be increased to 0.76, a gain in predictive capacity which the authors judged to 
be potentially useful144.  However, it was noted that the proportion of individuals 
segregating multiple independently associated SNPs in any population would be low, 
limiting the likely clinical utility of such SNPs as predictors even if discovered.  
Moreover, the chromosome 9p21 locus is the strongest common genetic risk factor for 
CAD that has been discovered so far, and it seems unlikely that additional common 
loci will be discovered that confer a similar level of risk.  A subsequent analysis 
published in February 2010 by Paynter et al studied the predictive value of a genetic 
risk score based on genotypes at 101 SNPs reported to be associated with 
cardiovascular disease phenotypes with P<10-7 (and r2 <0.5 between included 
markers)206.  In the same cohort as their previous study the genetic risk score did not 
improve risk prediction or reclassification compared to classical risk factors.  After 
correction for other risk factors, the genetic risk score was not associated with 
cardiovascular disease risk, whereas self-reported family history remained 
significantly associated.  No studies have shown that testing 9p21 genotypes leads to 
improvements in measurable health outcomes, and although some private companies 
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are already offering testing of chromosome 9p21 SNPs for prediction of 
cardiovascular risk207, the current data do not support the use of such an approach in 
routine clinical practice. 
1.2.4.2 Novel insights into pathophysiology 
More important than the role of such markers for risk prediction is the potential of 
these genetic variants to provide novel insights into pathways involved in the 
pathophysiology of disease.  This can enhance our fundamental understanding of the 
biology and ultimately identify biomarkers for risk stratification and novel targets for 
treatment.  Genetic studies that identified the relationship between FLAP and CAD 
have already led to human trials evaluating the effect of inhibitors of this pathway on 
clinical parameters100.  The biological importance of such insights are not necessarily 
related to the strength of the genotype-phenotype association since the strength of 
association of a gene with a trait does not predict the potential effect of a drug 
designed to agonise/antagonise the product of that gene.  For example, common 
variants in the HMGCR gene involved in endogenous cholesterol synthesis have only 
a modest influence on plasma lipid levels118, yet statins which act by inhibiting the 
HMGCR enzyme have very significant effects on LDL reduction and hard clinical 
endpoints such as reduction of death and cardiovascular morbidity208.  Similarly, 
common variants of the KCNJ11 gene, which encodes the sulfonylurea receptor, have 
an odds ratio of 1.14 for diabetes in GWA studies125, but this gene has been the target 
of successful diabetes therapies that are in widespread clinical use209, 210.  Genes and 
pathways involved in mediating disease associations may be identified by studying 
the influence of risk variants on gene expression, as discussed below. 
1.3 Assessing effects of risk loci on gene expression 
1.3.1 Variation and regulation of gene expression 
Phenotypic variation is a consequence of genetic and non-genetic (environmental) 
factors.  DNA sequence variation may act by modifying either the nature of a gene 
product (its ‘quality’) or its expression levels (its ‘quantity’).  Before the results of 
recent GWA studies were available, most DNA variants that had been convincingly 
associated with human disease were in coding regions and their effects were mediated 
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through alterations in protein structure.  This was predominantly a reflection of the 
fact that such variants were easier to identify than those that influence gene 
expression; variants affecting amino acid sequence often have large phenotypic 
effects, and since their location is predictable, the coding regions for many genes have 
been systematically examined211.  Although these exonic polymorphisms are 
important causes of Mendelian disease, they are unlikely to account for most of the 
heritability of complex diseases such as CAD.  This has been confirmed by the results 
of multiple GWA studies reported since 2007, in which the SNPs associated with 
disease are frequently located in non-coding regions25, 212, with sequencing and 
mapping studies failing to reveal exonic variants in nearby genes that could account 
for the effects19, 20, 212. 
Mutations in non-coding regions causing disease have been well described for a 
number of disorders, including some complex diseases213-217, but the regulatory 
elements and their potential associations with disease remain poorly characterised for 
most genes218.  A number of factors complicate the genetic study of gene 
expression211, 219: multiple regulatory elements may influence expression of a gene; 
the location of regulatory elements may be difficult to predict (they may be within or 
near to the gene, but may be hundreds of kilobases away or on different 
chromosomes); the magnitude of phenotypic effect caused by individual variants in 
these elements may be small; effects may vary between tissues; the influence of 
regulatory elements on expression may vary depending on other factors (such as 
environmental or physiological conditions); and expression profiles can be altered by 
sample handling or immortalisation of cells in the formation of cell lines.  Of 
particular relevance to expression studies involving the chromosome 9p21 locus, 
expression of CDKN2A and CDKN2B in murine embryos has been shown to be 
altered by the process of culturing cells, with further changes as these cultured cells 
approached senescence220. 
1.3.2 Cis versus trans effects on expression 
Studies of gene expression profiles using RNA microarrays have confirmed the 
presence of significant inter-individual variation in gene expression levels in human 
populations, and demonstrated that heritable genetic factors are important 
determinants of expression levels221-224.  Genetic influences on expression levels may 
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act in cis or trans218, 225.  Cis-acting elements act on genes that are on the same 
chromosome and affect transcript synthesis or stability in an allele-specific manner.  
These include regulatory elements such as promoters and enhancers which are usually 
found close to the genes they regulate, although they may be hundreds of kilobases 
away226.  Trans-acting factors, such as transcription factors, are not usually located 
close to the genes whose expression they regulate (often being located on a different 
chromosome), and they affect the transcripts of both alleles of a gene.  These trans-
acting factors are themselves often regulated by other genetic or environmental 
influences. 
It has been estimated that cis-acting variation accounts for 25-35% of genetically 
determined variation in gene expression between individuals225.  However, estimates 
derived from genome-wide studies of total expression which classify cis and trans-
acting effects based on the proximity of the variant to the gene (typically defining cis 
effects as those within 100kb of a gene227) are likely to be inaccurate since distance 
cannot reliably distinguish effects that act in cis or trans.  Furthermore, physiological 
feedback mechanisms which tightly regulate total expression levels of a gene can 
prevent the detection of cis-acting effects in analyses measuring only total expression 
levels and underestimate the contribution of effects acting in cis225.  Evidence of 
common cis-acting effects have been detected in around 20-40% of human genes in 
large studies228, 229, although these are likely to be underestimates due to the relative 
insensitivity of the microarray platforms used in these studies to detect small effects.   
Identification of trans-acting variants influencing gene expression is relatively 
difficult since trans-acting elements may be located on any chromosome and genome-
wide approaches to discovery are therefore required.  Since the risk variants for CAD 
identified in recent GWA studies are not found in mature transcripts they do not 
encode diffusible trans-acting factors and are therefore likely to influence expression 
in cis.  The different genetic variants that may influence expression in cis, and the 
strategies used to detect and map such effects, are discussed below. 
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1.3.3 Genetic variation influencing expression in cis 
1.3.3.1 SNPs 
SNPs associated with cis-acting effects on gene expression have been widely 
reported230.  Most of these are located in upstream promoter regions and exert their 
effects through alteration of transcription225, although the involvement of variants in 
distant enhancers and other regulatory elements that also influence transcription has 
been increasingly appreciated212, 231, 232.  Variants have also been shown to have cis-
acting effects through other mechanisms including alteration of mRNA stability233, 
mRNA processing efficiency234, mRNA splicing215, or via epigenetic changes such as 
DNA methylation235.  The non-coding SNPs associated with CAD in the chromosome 
9p21 region may influence disease susceptibility directly through such mechanisms, 
or the association may be indirect, due to LD with other variants which have 
functional effects.  Studies investigating SNP associations with expression of genes in 
the chromosome 9p21 region are discussed in detail in Chapter 4. 
1.3.3.2 Microsatellites and variable number tandem repeats 
In addition to SNPs, other polymorphisms involving DNA segments of various sizes 
may have cis-acting influences on expression.  Microsatellites and minisatellites are 
repetitive sequences of 1-6 bp and 6-100 bp elements respectively that are present 
throughout the human genome.  These elements can influence expression in cis by 
interfering with transcription236, altering DNA methylation237, changing chromatin 
structure238, or changing the affinity for transcription factor binding239, 240.  Increasing 
microsatellite size has been associated with both increased and decreased gene 
expression in different settings238, 241.  Changes in expression associated with 
microsatellites can lead to human diseases such as the fragile X syndrome242 and 
Friedreich ataxia236.  Like CNVs, microsatellite alleles may also be tagged by SNPs, 
such that functional microsatellite effects could account for SNP associations with 
disease. 
Microsatellites influencing transcription may be located in various positions relative 
to the genes involved, but have been most frequently reported in promoter regions.  
Proximity to the 5’ end of transcripts and a high density of CpG islands have been 
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shown to be predictive of regions with promoter functions243.  The arrangement of 
genes in the chromosome 9p21 region is interesting as CDKN2A-ARF and ANRIL are 
transcribed in opposite directions, with just 300 base pairs separating the transcription 
start sites of ARF and ANRIL.  This region overlaps a CpG island, contains a number 
of conserved elements, and has been shown to have promoter activity for the ARF 
transcript of CDKN2A.  However, bidirectional promoters have been described at 
other loci with similar gene arrangements and it therefore seems possible that this 
region also has promoter activity with respect to ANRIL244.  A microsatellite is located 
close to this region, within the first intron of CDKN2A-ARF and 5’ to ANRIL, as 
shown in Figure 1.6.  This microsatellite does not have a specific ID, but is annotated 
in the SNP database as an insertion/deletion polymorphism, rs10583774.  That 
identifier will be used throughout this thesis.  Its proximity to the promoter region and 
evidence of cross-species sequence conservation suggest that it is subject to selection 
pressure and may have functionally important influences on expression of these 
genes.  As shown in Figure 1.7, in silico analysis using PROMO v3.0.2 software245-247 
showed multiple transcription factor binding sites in the region surrounding the 
microsatellite, which provides further evidence for involvement of this region in the 
regulation of gene expression.  Transcription factor activity may be variably disrupted 
by the number of ‘TG’ repeats, which is known to be polymorphic at this site42.  As 
previously shown in Figure 1.5 (page 36), it is in an LD block with CAD risk variants 
and variation at this microsatellite influencing expression could therefore contribute to 
CAD susceptibility at this locus. 
 
  
Figure 1.6. Location and sequence conservation of microsatellite rs10583774.  
Panel A shows the location of rs10583774 relative to CDKN2A-ARF, ANRIL and CpG islands. Panel B is a magnified view showing cross-species sequence homology for the 
repeat sequence within rs10583774. Figure reproduced from the UCSC Genome Bioinformatics Database44. 
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Figure 1.7. Human transcription factor binding sites around microsatellite rs10583774.   
Microsatellite repeats and surrounding sequence shown along the top.  Coloured bars represent human transcription factor binding sites. The microsatellite is located in a 
region with a high density of transcription factor binding sites. Figure produced using PROMO v3.0.2 software245. 
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1.3.3.3 Insertion/deletion variants and CNVs 
Large-scale pathological duplications and deletions have been known to occur in the 
human genome for many years from cytogenetic observations, but the widespread 
occurrence of CNVs within the human genome has been only recently appreciated248.  
Although the term CNV may be used to refer specifically to deletions or duplications 
involving stretches of DNA larger than 1kb249, smaller insertion/deletion (InDel) 
variants could also influence expression in cis, and in this thesis the term CNV is used 
to refer to copy number changes of any size.  The reported mechanisms through 
which CNVs may influence expression include altering gene dosage, disrupting 
coding sequences, or interrupting regulatory elements230.  Such structural variants 
have been associated with a range of human diseases, including complex phenotypes 
such as schizophrenia250 and autism251.  Common CNVs and SNPs may be in LD in 
the human genome252, such that SNP associations seen in GWA studies could be the 
result of the SNPs ‘tagging’ functional CNVs.  The possibility of CNVs in the 
chromosome 9p21 region is discussed in detail in Chapter 5. 
1.3.4 Assessment of cis-acting effects on expression 
1.3.4.1 In vitro approaches 
Cis-acting regulatory factors have traditionally been investigated using in vitro 
approaches225.  Transfection assays are often used to monitor the transcriptional 
activity of a synthetic reporter construct and assess whether a candidate regulatory 
polymorphism influences gene expression.  However, there are several limitations of 
these techniques.  First, appropriate selection of the regulatory elements to be 
incorporated into the construct is required, yet these are often poorly defined.  
Empirical targeting of upstream flanking sequences is frequently performed, but such 
sequences may not capture the complete regulatory elements that are biologically-
active, and do not consider the effects of covariation at other loci.  Second, in vitro 
transfection studies do not always model the situation in vivo accurately.  The 
prevailing environmental conditions and trans-acting influences in vitro are likely to 
be very different to those in vivo, which may alter the overall effect of polymorphisms 
in regulatory regions.  The problems with extrapolation of in vitro data was 
highlighted by Cirulli et al, who demonstrated that in vitro assays failed to predict in 
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vivo effects of regulatory polymorphisms in four genes well documented through 
reporter assays to have promoter polymorphisms influencing expression253. 
1.3.4.2 In vivo approaches: total expression versus allelic expression 
imbalance 
The most commonly used approach for investigating cis-acting influences on 
expression in vivo has been to compare total expression levels (without differentiating 
the contributions from each of the two alleles) between individuals with different 
genotypes at the putative cis-acting locus.  This approach treats total expression levels 
as a quantitative trait that is modified by the putative cis-acting locus (expression 
quantitative trait locus; eQTL).  The proximity of the eQTL to its target gene is seen 
as evidence for its cis-acting effect.  However, this approach is not specific for cis-
acting effects since total expression levels reflect the net effect of both cis and trans-
acting influences.  The sensitivity to detect cis-acting effects is therefore reduced in 
the presence of significant variation in trans-acting influences.   
An alternative approach that is specific for mapping cis-acting influences is to 
compare the relative expression of each allele within an individual.  An unequal 
amount of transcript arising from each allele in an individual who is heterozygous for 
a transcribed polymorphism, termed allelic expression imbalance (AEI), indicates the 
presence of cis-acting influences on expression218.  Correlation between genotype and 
quantitative allelic expression ratios can be tested to identify SNPs associated with 
cis-acting effects (allelic expression QTL, aeQTL)254.  While traditional analysis 
using total expression levels assesses the influence of polymorphisms by comparing 
expression between samples, AEI analysis compares the expression levels of alleles 
within individual samples.  This makes it much more robust to trans-acting influences 
that affect both alleles, such as experimental variability and inter-individual variation 
in other genetic/environmental factors, thereby maximising the sensitivity for 
detecting cis-acting effects.  In contrast to the in vitro methods discussed above, 
alleles are studied in their native environment with respect to the haplotype, 
chromatin, and tissue context. 
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Whereas eQTL analysis uses information from all members of the population, a 
limitation of aeQTL analysis is that AEI can only be measured in individuals who are 
heterozygous for a transcribed polymorphism.  A suitable polymorphism must 
therefore be present at a reasonable minor allele frequency in the population to permit 
sufficient numbers of informative individuals to be feasibly studied.  Sensitive 
techniques for accurately determining the relative expression of two alleles are also 
required.  AEI assessment may be possible using intronic SNPs in heteronuclear 
RNA, but this is more challenging and in general has only been shown to be 
successful for highly expressed genes228, 255.  AEI can result from epigenetic factors 
such as DNA methylation. 
For assessment of AEI to be a useful tool for the investigation of cis-acting genetic 
regulation in complex disease it must be both common and substantially influenced by 
genetic polymorphisms.  A number of surveys using different methodologies have 
confirmed that AEI is heritable and can be detected for 20-50% of human genes225, 228, 
256-259
.  To date, allelic expression analysis has provided evidence for sites of cis-
acting regulation for a number of genes involved in a range of human diseases260-265. 
AEI analysis has been used to confirm cis-acting loci previously identified as 
eQTLs266, and eQTLs have been used to validate loci showing AEI228, but the relative 
power of the two approaches to identify cis-acting loci has never been systematically 
compared.  Identifying the most efficient methodology for mapping cis-acting 
elements is important since this minimises the sample size that is required to detect 
variants with significant effects.  This is particularly relevant since tissue-specific 
influences on expression may require the analysis of tissues where large sample 
collections may be difficult to establish219.  Additionally, expression may be affected 
by several polymorphisms simultaneously and increased power may allow the 
contributions of individual sites to be investigated. 
1.3.4.3 Simulations comparing the power of eQTL and aeQTL mapping 
Simulations to explore the power of eQTL and aeQTL analysis to detect the effects of 
polymorphisms affecting expression in cis were conducted in collaboration with my 
co-supervisor Dr Mauro Santibanez-Koref (Institute of Human Genetics, Newcastle 
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upon Tyne).  Simulations were based on one transcribed and one cis-acting 
polymorphism, which were in linkage equilibrium unless otherwise specified.  The 
default MAF was set at 0.1 for the transcribed marker and 0.2 for the cis-acting 
polymorphism.  For each parameter configuration 10,000 replicates were analysed.  
Representative results of these simulations are displayed in Figure 1.8.   
Panel A shows the relationship between power and effect size for a single cis-acting 
polymorphism in the absence of other influences on transcription.  The power of the 
eQTL approach is higher than that of aeQTL analysis, since it uses information from 
all members of the population.  The power of aeQTL analysis increases with 
increasing LD between the transcribed and cis-acting polymorphisms, and also as the 
heterozygosity of the transcribed polymorphism increases.  The latter reflects the fact 
that allelic expression can only be measured in individuals who are heterozygous for a 
transcribed polymorphism and suggests that the power may be increased by 
combining information from several transcribed polymorphisms.  Such a strategy is 
illustrated in Panel B, which shows the effect of combining data from multiple 
transcribed polymorphisms, each with MAF of 0.1.  Increasing the number of 
transcribed polymorphisms increases the number of individuals in which allelic 
expression can be measured (assuming little LD between the transcribed SNPs) and 
therefore increases the power of the aeQTL analysis. 
The above simulations only considered a single cis-acting effect influencing gene 
expression, but a more realistic scenario would be to also take into account the effects 
of trans-acting variation.  As previously discussed, trans effects such as response to 
environmental stimuli, tissue specific factors, and experimental variables act on both 
alleles and can differ between individuals.  Comparing alleles within a sample should 
minimise the effect of trans-acting variation, thereby maximising the power to detect 
cis-acting effects.  A second set of simulations was therefore performed assuming that 
expression of both alleles was additionally affected by a trans acting factor, and that 
cis and trans effects act in an additive manner.  In these simulations, total expression 
for one individual was defined as the sum of the contributions from both 
chromosomes (i.e. 21 ee + ) and the ratio 21 /1 ee  was only available for individuals 
heterozygous for the transcribed allele.  As the trans-acting variance between 
individuals increases, the power to detect cis-acting effects decreases substantially  
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Figure 1.8. Comparison of the power of eQTL and aeQTL mapping to detect a 
cis acting polymorphism using simulated data.  
Panel A investigates the effect of MAF at the transcribed locus and LD between the transcribed and 
cis-acting locus. Panel B shows the effect of using more than one transcribed marker, each with a 
minor allele frequency of 0.1. Panel C considers an effect acting in trans and explores the effect of 
increasing its variance across individuals. Effect size is the the log of the change in expression that 
allele 2 at the cis-acting locus produces compared to allele 1 (as defined on p87). 
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faster for eQTL than for aeQTL analysis.  This suggests that allelic expression will 
have greater power for mapping cis-acting effects in genes which are substantially 
influenced by trans-acting factors.   
In the chromosome 9p21 region, many of the risk alleles associated with disease have 
MAF greater than 0.419-21 and there is substantial LD between risk variants and 
transcribed SNPs, suggesting that aeQTL mapping may be a powerful method for 
mapping cis-acting effects in this region even if there is relatively little trans-acting 
variation between individuals.  A number of trans-acting factors have been previously 
shown to influence expression at the CDKN2A/CDKN2B locus183, suggesting that 
aeQTL mapping may be more powerful then eQTL mapping, but the ability of both 
approaches needs to be compared experimentally since the extent of cis and trans-
acting variation, as well as the manner in which such effects interact, is poorly 
characterised. 
1.3.4.4 AEI assessment using the Sequenom platform 
AEI has been assessed using a range of different technologies, based on the use of 
fluorescent dideoxy terminators256, restriction-fragment length polymorphisms260, 
microarray analysis228, 258, 259, real time PCR267, polymerase colonies268, sequencing269-
271
, and real competitive PCR with MALDI-TOF mass spectrometry on the Sequenom 
platform272, 273.  Assessment using the Sequenom methodology is very sensitive for 
detection of AEI, allows accurate analysis from even small amounts of template, and 
offers the potential for assay multiplexing.  Coefficients of variation of <10% from 
three independent reverse transcription reactions, and <3% for four PCR replicates 
from the same reverse transcription product have been reported272.   
The methodology for the Sequenom technique described by Ding and Cantor is 
summarised in Figure 1.9272.  Essentially, total RNA from individuals heterozygous 
for a transcribed SNP is reverse transcribed to cDNA using random hexamers.  PCR 
is performed using the cDNA template to amplify the region containing the SNP of 
interest.  Because the two alleles are amplified in the same reaction and differ in 
sequence by only one base, the experimental conditions and reaction kinetics are the  
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Figure 1.9. Assessment of AEI using Sequenom (iPLEX). 
Figure adapted from Ding and Cantor272. 
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same for each allele.  Ideally, PCR primers should be designed to be cDNA specific 
(across exon boundaries) to prevent genomic DNA being amplified in the reaction.   
The amplified PCR product is treated with shrimp alkaline phosphatase to remove 
excess dNTPs.  A base extension reaction is performed using a single primer that 
binds adjacent to the SNP site and reaction mix containing mass-modified dNTPs.  
The resulting oligonucleotide products for each SNP differ by one base and have 
different masses.  The products are cleaned up with resin to optimise mass 
spectrometric analysis and then dispensed onto a SpectroCHIP prespotted with a 
matrix of 3-hydropicolinic acid.  The SpectroCHIP is analysed on the Sequenom 
platform by matrix assisted laser desorption/ionisation time of flight (MALDI-TOF) 
mass spectrometry.  Under high vacuum the matrix is irradiated with an ultraviolet 
laser that vaporises and ionises the DNA/matrix.  The ions are separated by their mass 
to charge ratio, and the peak area of each allele product is proportional to the relative 
amount of the allele that was present in the starting RNA.  The AEI ratio is calculated 
by dividing the peak area of allele 1 by the peak area of allele 2. 
The same process is repeated using gDNA to act as a control for biases in the 
detection method which could create an artefactual imbalance in allelic expression.  
Primers to amplify a portion of genomic DNA similar in size and sequence to the 
cDNA amplicon are used, with all other steps being identical.  The corrected allelic 
expression ratio is the ratio in cDNA divided by the ratio in gDNA. 
Detailed methodological issues relating to AEI assessment and normalisation are 
considered in Chapter 3. 
1.3.4.5 Mapping genetic effects on expression 
Mapping eQTLs using total expression may be performed by linear regression, in 
which expression levels are compared between groups of individuals who have zero, 
one, or two copies of the putative cis-acting allele.  Mapping aeQTLs is more 
complex and requires genotypes to be phased.  The principles underlying this process 
are outlined below. 
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Once the presence of AEI has been demonstrated at a transcribed polymorphism, 
providing evidence of cis-acting regulation of expression, the goal is to identify the 
causative polymorphisms responsible for (or at least predictive of) expression 
differences.  In this context, AEI is characterised not only by its presence or absence, 
but also by which of the alleles is over-expressed and by the extent of the differential 
expression, quantified using the allelic expression ratio (AER).  The principle behind 
the analysis is to compare the observed AER values with those that would be 
predicted under different assumptions.  The simplest case is when an association 
between the transcribed marker itself and AER is analysed, and predictions from two 
models are compared.  The first model assumes that allelic expression levels are 
independent of which allele is present at the transcribed locus, (i.e. there is no 
association between AER and genotype), in which case individual AER values would 
not deviate systematically from a 1:1 ratio.  The alternative model is that one of the 
alleles is preferentially overexpressed, in which case a systematic deviation from a 1:1 
ratio would be expected.  Any test that compares the mean AER to a 1:1 ratio would 
be suitable to assess association (such as a t-test). 
A more complicated situation is when trying to assess the cis-acting effect of a 
polymorphism that is not in the transcript.  In this situation two polymorphisms need 
to be considered; the transcribed one and the potential cis-acting one.  By 
experimental design all individuals are heterozygous at the transcribed SNP.  An 
association between genotype at the cis-acting site and expression can be detected if 
there are differences between AER in individuals with different genotypes at the cis-
acting locus.  As above, the first model assumes that AER is independent of which 
allele is present at the cis-acting locus, hence individual AER values would not 
deviate from a specific ratio (1:1 if the transcribed marker has no effect).  The second 
model assumes that genotype at the candidate cis-acting locus influences expression.  
This concept is illustrated in 
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Figure 1.10.  The alleles at the transcribed marker are designated ‘M’ and ‘m’, and the 
alleles at the putative cis-acting marker as ‘C’ and ‘c’.  In this example the transcribed 
polymorphism has no effect and the ‘C’ allele at the cis-acting locus causes 
overexpression of the transcript from the same chromosome.  Alleles ‘MC’ and ‘mC’ 
will be expressed at the same level as each other, and overexpressed compared to 
‘Mc’ and ‘mc’ (which are both expressed at the same lower level).  Since only relative 
transcript levels at the transcribed polymorphism are compared, AEI will only be 
detected in individuals who are heterozygous at the cis-acting site (since genotypes 
‘CC’ and ‘cc’ will have the same cis-acting effect on each allele of the transcribed 
polymorphism and therefore the ratio is 1:1 for both of these homozygotes).  If the 
cis-acting polymorphism influences expression, the AER in individuals who are 
heterozygous for the cis-acting polymorphism deviates from that seen in homozygotes 
at the cis-acting site, as shown in
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Figure 1.10.  Since the ‘C’ allele causes overexpression, the ‘MC/mc’ phased 
genotype would cause relative overexpression of the ‘M’ allele, while the genotype 
‘Mc/mC’ would cause the ‘m’ allele to be overexpressed.  Therefore to determine the 
effect of the putative cis-acting polymorphism requires the phase between the cis-
acting and transcribed polymorphisms to be estimated (i.e. the probability that 
individuals who are heterozygous at both sites have the genotypes ‘MC/mc’ or 
‘Mc/mC’).  Estimating phase and effect can either be done simultaneously or as 
separate steps.  The analysis is performed as a likelihood ratio test comparing the 
likelihood of the observations occurring assuming no effect from cis-acting 
polymorphism with the probability of the observations occurring assuming an effect 
of the putative cis-acting polymorphism.  It assumes that the variance of the 
observations is independent of the genotype, that the ratios follow a log-normal 
distribution, and that the mean AER effects observed are representative of the true 
effects.  The latter assumption means that the sample size has to be large enough to 
accurately assess the effect of a given genotype, which restricts the number of 
genotypes that can be reliably analysed for a given sample size. 
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Figure 1.10. Effect of cis-acting SNPs on AER at the transcribed marker. 
All individuals are heterozygous for the transcribed marker (i.e.‘M/m’). The four phase-known 
genotypes and the corresponding three phase-unknown genotypes are represented on the horizontal 
axis. The vertical diamonds represent the distribution of log AERs for each genotype, with the 
horizontal bar representing the mean. Cis-acting differences will be seen only in those individuals 
heterozygous at the cis-acting locus, hence the mean log AER is zero (corresponding to an AER of 1:1) 
in both ‘CC’ and ‘cc’ homozygous groups. The cis-acting effect is seen as a deviation from the 1:1 
ratio in ‘Cc’ heterozygotes, but the direction and magnitude (µ1)of this effect can only be estimated 
once the genotypes are phased (when it can be seen that the ‘C’ allele at the cis-acting SNP causes 
overexpression) . Figure adapted from Teare et al254. 
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1.4 Summary and overall project aims 
Recent GWA studies have identified a novel, well-replicated association between 
SNPs at the chromosome 9p21 locus and CAD.  The mechanism of the association of 
SNPs at this locus with CAD is unknown, but elucidating the pathways involved may 
provide valuable insights into the pathogenesis of CAD and provide novel risk 
biomarkers and therapeutic targets. 
An association of these SNPs with other diseases and intermediate phenotypes known 
to be important in cardiovascular disease may help to identify pathways involved in 
causation, and define the influence of these SNPs on other important cardiovascular 
diseases besides CAD. 
The chromosome 9p21 SNPs associated with CAD are not in protein-coding 
sequence, but may act through cis-acting influences on the expression of nearby 
genes.  Candidate genes in the region include ANRIL which produces a large non-
coding RNA of unknown function, the cell-cycle regulators CDKN2A and CDKN2B, 
and MTAP, which encodes an enzyme involved in polyamine metabolism.  Allelic and 
total expression can be used to investigate the influence of polymorphisms 
influencing expression in cis.  An association between CAD risk SNPs and expression 
of particular genes would suggest that the SNPs lie in regulatory elements that 
influence gene expression, and that the genes implicated in this way may play a role 
in the causation of CAD.  
This study aimed to investigate the association of chromosome 9p21 polymorphisms 
with intermediate phenotypes including traditional CAD risk factors and plasma 
levels of inflammatory mediators, as well as with other cardiovascular phenotypes 
including CIMT, LV structure/function, and congenital heart disease.  The study also 
aimed to investigate whether 9p21 SNPs are associated with allelic and total 
expression of nearby candidate genes, and determine whether other polymorphisms in 
the region such as microsatellites and CNVs might also play a role. 
A recent GWA study has reported an association between SNPs on chromosome 2q24 
and BP, but the findings need to be investigated in additional independent cohorts.  In 
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vitro functional studies suggested that the effect may be mediated by influences on 
expression of the nearby STK39 gene, which encodes a protein that interacts with ion 
cotransporters involved in salt transport.  Association of SNPs with allelic expression 
of STK39 could be used to confirm the effects on expression of this gene in vivo. 
This study aimed to investigate the association between reported risk SNPs for 
hypertension at the 2q24 locus and BP in a large British Caucasian cohort, and to use 
allelic expression analysis to determine whether these SNPs influence STK39 
expression in vivo. 
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2 Materials and methods 
This chapter outlines the general materials and molecular biology methods used in the 
following chapters.  Assay details specific to particular studies are highlighted in the 
materials and methods sections of the relevant chapters. 
2.1 Materials 
2.1.1 Participants and samples 
2.1.1.1 Northeast (NE) British Caucasian cohort 
Anonymised DNA and RNA samples were available for 187 healthy adults.  Five 
samples were excluded from analysis on the basis of inconsistencies between the 
genotyping results obtained in the DNA and cDNA samples, and five samples 
subsequently found to be duplicates were also excluded.  Of the 177 included 
samples, 152 were collected through a sub-study of the People of the British Isles 
study in 2007274, and 25 were control samples collected for a study investigating the 
genetics of colon cancer (the CAPP study)275.  50% were male and the median age 
was 63 years (range 25-101, lower quartile 51, upper quartile 69). 
The People of the British Isles study recruited healthy adults from different regions to 
investigate genetic variation within the UK.  To be eligible, at least three of their 
grandparents had to be born within a 30-40 mile radius of one another, and ideally be 
from a rural population.  Of the samples used in this study, 7 were from Cumbria, 1 
from Lancashire, and the remainder from northeast England (Northumberland, 
Tyneside or County Durham).   
The CAPP study controls were collected in 2006 as controls for a genetic study 
investigating colon cancer275 and comprised four healthy adult staff members at the 
Institute of Human Genetics, and 21 phenotypically unaffected adults who had 
undergone screening for cystic fibrosis or haemochromatosis carrier status. 
Informed consent was obtained from all participants and the studies were approved by 
the Newcastle and North Tyneside Local Research Ethics Committee. 
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2.1.1.2 South African (SA) cohort 
DNA and RNA samples were collected from 310 healthy adult volunteers at a blood 
donor clinic at the University of the Western Cape, Cape Town, South Africa.  
Samples were anonymised, but limited demographic data including age, gender, and 
self-reported ethnicity were collected.  Informed consent was obtained from all 
participants and the study was approved by the University of Cape Town Faculty of 
Health Sciences Research Ethics Committee. 
The self-reported ethnicity of the SA cohort was: 200 Cape mixed-ancestry; 67 
African black; 19 Indian; 10 white; 4 other/unknown. 42% were male, with median 
age 20 years (range 17-60, lower quartile 19, upper quartile 23).  
2.1.1.3 MLH1 validation samples 
For the purpose of training and optimisation of AEI techniques, initial validation work 
was carried out to assess AEI in stored RNA samples using MLH1, as pilot studies 
investigating AEI in this gene had been previously performed.  This validation work 
was performed using five heterozygous samples in which AEI had been previously 
assessed: two healthy volunteers without imbalance and three patients known to have 
imbalance of MLH1 expression who were recruited for the CAPP study.  Informed 
consent was obtained from all participants and the studies were approved by the 
Newcastle and North Tyneside Local Research Ethics Committee. 
2.1.1.4 HTO cohort 
DNA was available for this cohort comprising of 1425 members of 248 British 
Caucasian families ascertained through hypertensive probands and phenotyped for a 
quantitative genetic study of cardiovascular risk factors from 1993-200111, 156, 276.   
Sample ascertainment 
A detailed description of this series and the ascertainment strategy has been published 
previously276.  Families were selected through a proband with essential hypertension 
whose systolic and diastolic BP were in the top 5% of the population distribution 
(defined as daytime ambulatory BP >140/90mmHg; three clinic BP measurements 
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>160/95mmHg; or treatment with at least two antihypertensive medications).  
Secondary hypertension was excluded using the screening protocol applied in the 
hypertension clinic.  Families were required to consist of at least three siblings 
(including the proband) clinically assessable for BP if DNA from a parent of the 
sibship was available, or at least four siblings if no parental DNA was available. 
Qualifying sibships could be in the generation of the proband, or the offspring.  There 
was no requirement for additional members of the family to be hypertensive, but 
where additional members of the sibship were found to have hypertension (using the 
same criteria), families were extended and the spouses and offspring of hypertensive 
members also collected.  The majority (64%) of the individuals in the family 
collection therefore have BP within the conventionally accepted “normal range”, and 
the family collection includes some extended families, though most are nuclear 
families.  The median family size was 5 people, 60% of families comprising between 
4 and 6 genotyped and phenotyped members.  71% of families were 2-generation and 
29% were 3-generation.  84% of families had an assessable sibship in the generation 
of the proband, while 16% of families consisted of a proband and their nuclear family 
(spouse and children over 18 years) only.  Informed consent was obtained from all 
participants and the study was approved by the Central Oxford Research Ethics 
Committee and Newcastle and North Tyneside Local Research Ethics Committee.  
BP measurement 
The BP measurement protocol has been previously described276.  BP was measured 
using ambulatory monitoring for a period of 24 hours in all subjects willing to 
undergo monitoring, using the A&D TM2421 monitor.  Three readings were taken 
with the patient in a relaxed seated position at the start of the monitoring period.  
Simultaneous auscultation was carried out by a trained observer, to confirm 
satisfactory (within 5mmHg) agreement between the monitor and auscultatory values; 
if this criterion was not met, the cuff was repositioned until satisfactory agreement 
was obtained.  The three readings which had satisfactory agreement between the 
monitor and the observer in the final cuff position are referred to as “clinic readings”.  
The monitor was programmed to record blood pressure every half-hour during the 
daytime and every hour during the night, and a recording was considered of 
satisfactory technical quality if at least 20 daytime ambulatory data points were 
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available for analysis.  Patients also recorded the time they went to bed and rose in the 
morning to enable individualised calculation of the “daytime” and “night-time” 
periods. Mean values for systolic and diastolic blood pressures for the clinic, daytime 
and night-time periods were analysed for association with genotypes.  
Echocardiography and CIMT measurement 
Echocardiography and CIMT measurement was performed in a subset of individuals 
between 1999 and 2001, as previously described11.  Carotid artery ultrasonography 
was performed in 953 individuals by two sonographers, with all measurements made 
by a single observer.  The right and left common carotid arteries were scanned using a 
7.5 MHz linear array transducer (HP Sonos 5500) and measurements were made from 
the far wall of the distal 10mm of the common carotid artery.  Images were recorded 
for later offline analysis using computerised edge-detection software with manual 
editing.  Mean and maximal CIMT measurements were performed at end-diastole on 
each side, and the average reading from these was calculated.   
Trans-thoracic echocardiography was performed in 904 individuals according to a 
standard protocol in which 2D imaging, M-mode imaging and Doppler studies were 
performed.  Left ventricular (LV) wall and cavity measurements were performed by a 
single observer from the standard M-mode images.  LV mass (in grams) was 
estimated from M-mode images as recommended by the American Society of 
Echocardiography guidelines277, using the formula described by Devereux et al278.  
Measurements of LV mass were corrected for body surface area as described by Levy 
et al in the Framingham heart study cohort279.  Fractional shortening was calculated as 
100(LVIDs+LVIDd)/LVIDd, and LV ejection fraction was estimated according to the 
formula described by Teichholz et al280.  The E/A ratio was calculated using standard 
methodology from pulse-wave Doppler estimates of mitral valve inflow velocity281. 
Additional phenotyping 
A full clinical history was taken, which included the subject’s medical history and 
lifestyle factors including consumption of alcohol and tobacco, and habitual physical 
exercise.  Anthropometric data including height, weight and waist and hip 
circumferences were measured.  Blood samples were also analysed for other 
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phenotypes relevant to cardiovascular disease, using commercially-available assays.  
These included: plasma levels of total cholesterol, interleukin-6 (IL-6), tumour 
necrosis factor α (TNF-α), C-reactive protein (CRP)282, and leptin283. 
2.1.1.5 Congenital heart disease cohort 
The congenital heart disease cohort comprised 888 probands with congenital heart 
disease collected from two studies, the CHANGE study (Congenital Hearts: A 
National Gene/Environment study) and the FCH study (Freeman Congenital Heart 
Disease study)284.   
The multi-centre CHANGE study included Caucasian patients with tetralogy of Fallot 
(TOF), or the related conditions pulmonary stenosis/VSD and double outlet right 
ventricle284.  Blood or saliva samples were obtained from patients at centres in 
Newcastle, Leeds, Bristol and Liverpool.  Patients with recognised causes for TOF 
were excluded (including known chromosome 22q11 deletion syndrome, other 
malformation syndromes, known chromosomal abnormalities, developmental delay 
and learning difficulties, and known maternal exposure to significant teratogens 
during pregnancy). 444 TOF samples were available for analysis. 
The FCH study included Caucasian patients with other forms of congenital heart 
disease recruited at the Freeman Hospital in Newcastle.  Blood or saliva samples and 
phenotypic information were obtained from all patients.  444 non-TOF congenital 
heart disease samples were available for analysis. 
Informed consent was obtained from all patients or their parents/guardians and the 
studies were approved by the regional ethics committees. 
2.1.1.6 Cumbria control cohort 
The Cumbria control cohort comprised 1,089 Caucasian women of childbearing age 
from the North Cumbria Community Genetics Project (NCCGP)285 for whom usable 
DNA was available.  Between 1996 and 2003 cord blood samples were collected from 
infants born consecutively at West Cumberland Hospital, and from 1999 to 2003 
maternal blood samples were also collected286.  DNA extracted from these maternal 
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samples was used for the analysis.  Informed consent was obtained from all 
individuals and the studies were approved by the regional ethics committee. 
2.1.2 Labware 
All experiments were performed using standard sterile nuclease-free plasticware from 
recognised laboratory suppliers.  Barrier pipette tips were used for all pre-PCR 
preparation steps, which were performed in designated laminar-flow hoods. 
2.2 Methods 
2.2.1 DNA extraction and quantification 
2.2.1.1 DNA sample collection and extraction 
For the SA cohort, peripheral blood samples for DNA analysis were collected in 5mL 
EDTA tubes using standard venesection from veins in the antecubital fossa.  Samples 
were stored at -80oC until extraction and were extracted within two months.  DNA 
was extracted from the SA cohort using a standard phenol/chloroform method287 by 
technicians at the Department of Molecular Biology and Human Genetics, University 
of Stellenbosch, Cape Town.  
For the NE British Caucasian cohort, peripheral blood samples for DNA analysis had 
been previously collected using the PAXgene Blood RNA Kit (PreAnalytiX, 
Belgium).  DNA was obtained from 1µL of the eluate from the RNA extraction 
performed without the DNase step, and amplified using whole genome amplification 
(as described in section 2.2.1.4). 
For the HTO, Cumbria, and MLH1 samples, DNA from peripheral blood had been 
previously collected and extracted using standard phenol/chloroform methods287.  For 
the Congenital heart disease samples, DNA from either peripheral blood or saliva had 
been previously collected and extracted using standard methods: phenol/chloroform 
method287 for blood samples or the Oragene Self-Collection Kit protocol (DNA 
Genotek, Canada) for saliva samples. 
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Stock DNA solutions were diluted to working aliquots of 20ng/µL in 1xTE buffer 
(Fluka Analytical, Sigma-Aldrich, UK) and stored at -20oC. 
2.2.1.2 Quantification by Nanodrop 
DNA concentration was quantified by absorbance at 260/280nm using a NanoDrop 
ND-3000 Spectrophotometer (NanoDrop Technologies, USA) in 1µL of solution.  
Samples were mixed by vortexing or pipetting prior to measurement and two or three 
measurement replicates were performed per sample. 
2.2.1.3 Quantification by PicoGreen 
DNA quantification was also performed using the Quant-iT PicoGreen dsDNA kit 
(Invitrogen, USA) using the Thermo Fluoroskan Ascent FL (ThermoFisher Scientific, 
UK) following the manufacturer’s standard protocol. 
2.2.1.4 Whole genome DNA amplification 
For the northeast Caucasian samples, 4µL of 1/10 dilution of the extracted RNA/DNA 
solution was amplified using GenomePlex Complete Whole Genome Amplification 
Kit (Sigma-Aldrich, UK) following the manufacturer’s standard protocol. 
2.2.1.5 Ampure DNA purification 
Following WGA, DNA purification was performed using AMPure magnetic beads 
(Agencourt, Beckman Coulter, UK) following the manufacturer’s standard protocol 
and eluting the DNA in 40µL of TE buffer.  Amplified DNA concentration was 
quantified using optical densitometry, and working aliquots were diluted to a 
concentration of 20ng/µL in 1xTE buffer.  All amplified DNA was stored at -20oC. 
2.2.1.6 Electrophoresis and visualisation of DNA 
Samples and no-template controls from PCR reactions were analysed using agarose 
gel electrophoresis prior to Sequenom analysis or other downstream applications to 
confirm that the PCR reaction had been successful and exclude product in the no-
template controls. 
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2.5% agarose gels were made using 2.5g of SeaKem LE Agarose powder (Cambrex, 
USA) in 100mL of 1xTAE, containing 1µL of 1000xGel Red per mL of gel.  1.5µL of 
Orange G loading dye (Sigma-Aldrich, UK) was added to 3µL of PCR product and 
samples were loaded alongside 5µL of GeneRuler 100bp DNA ladder (Fermentas, 
Germany) for size determination of the products. Electrophoresis was carried out 
between electrodes 30cm apart for 30-40 minutes at ~160V in 1xTAE buffer.  Gels 
were visualised using a GeneGenius bioimaging system (Syngene, Synoptics Ltd, 
UK) and photographed using GeneSnap image acquisition software (Syngene, 
Synoptics Ltd, UK). 
2.2.2 RNA extraction and quantification 
2.2.2.1 General RNA procedures 
RNA work was performed in designated areas using dedicated equipment where 
possible.  External surfaces of equipment and working surfaces were prepared using 
RNase Away (Sigma-Aldrich, UK) prior to use, according to standard protocols.  
Designated RNA-only pipettes and sterile RNase-free labware were used for all RNA 
work.  Sterile nuclease-free water (Sigma-Aldrich, UK) was used for all applications. 
2.2.2.2 RNA sample collection 
Peripheral blood samples for RNA analysis were collected in a 2.5mL PAXgene 
Blood RNA tube using standard venesection from veins in the antecubital fossa.  
Samples were incubated at room temperature for 2-6 hours then stored at 4oC for up 
to 72 hours before being frozen, initially at -20oC for 24 hours and then at -80oC for 
long-term storage until extraction.  RNA extraction was performed within 3 months of 
sample collection. 
2.2.2.3 RNA extraction 
PAXgene Blood RNA extraction and purification was performed according to the 
manufacturer’s standard protocol, with omission of the DNase steps, such that the 
eluted solution contained both RNA and DNA.  This permitted DNA from the sample 
to be used for genotyping.  Nucleic acids were eluted in 80µL of elution buffer BR5 
and stored in nuclease-free capped tubes at -80oC. 
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2.2.2.4 DNase treatment 
RNA samples were DNase treated using RQ1 RNase-Free DNase (Promega, USA) 
prior to reverse transcription following the manufacturer’s standard protocol. 
2.2.2.5 Whole transcriptome amplification 
Whole transcriptome amplification was performed using Quantitect Whole 
Transcriptome Kit (Qiagen, Germany) following the manufacturer’s standard 
protocol. 
2.2.2.6 RNA LabChips 
RNA and cDNA fragment size and quality were tested for selected samples using the 
RNA 6000 Pico LabChip kit (Agilent, USA) for the Agilent 2100 bioanalyzer, 
following the manufacturer’s standard protocol. 
2.2.3 Reverse transcription 
For AEI measurements, approximately 2 µg of total RNA was reverse transcribed 
using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, USA) or 
Superscript VILO cDNA Synthesis Kit (Invitrogen, USA) following the 
manufacturer’s standard protocol, and eluted in 20µL.  
For teal-time PCR measurements, 500ng of total RNA was reverse transcribed using 
High capacity RNA-to-cDNA Master Mix (Applied Biosystems, USA) following the 
manufacturer’s standard protocol, and eluted in 20µL. cDNA was stored at -80oC. 
2.2.4 Sequenom assays for genotyping and AEI analysis 
2.2.4.1 Assay design 
Genotyping was carried out using Sequenom iPLEX Gold technology using 
multiplexed assays.  Initial AEI analysis was performed in uniplex using Sequenom 
hME technology based on the method reported by Ding and Cantor273. This 
methodology was subsequently adapted to utilise iPLEX Gold technology and allow 
multiplexing, as described below. 
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Multiplex assays for Sequenom genotyping were designed using Sequenom’s 
RealSNP288 and MassARRAY Assay Design v3.0 software (Sequenom, USA).  This 
designs primers, checks for compatibility between primers in a multiplex, and 
performs a BLAST search.  PCR primers which performed suboptimally were 
redesigned into subsequent assay designs, with manual selection of alternative PCR or 
extension primer sequences. 
Primers for AEI analysis were designed manually and using Primer3 v.0.4.0 
software289, 290 and genomic specificity was confirmed using BLASTN against the 
human reference sequence in the NCBI database196.   
A full list of the assay primers can be found in Appendix 1.  A 10 base non-
complementary tag was added to PCR primers for Sequenom analysis to increase their 
mass so that they would not fall within the window of the extension products during 
MALDI-TOF analysis. 
2.2.4.2 Primers 
PCR and extension primers were supplied lyophilised (Metabion, Germany) and were 
resuspended in nuclease-free water (to a concentration of 100µM for PCR primers 
and 300µM for extension primers), aliquoted, and stored at -20oC. 
2.2.4.3 PCR 
PCR setup was performed in a designated pre-PCR area in a laminar flow hood using 
barrier pipette tips and designated pre-PCR pipettes.  DNA was added in a separate 
laminar flow hood with DNA pipettes.  PCR reactions were performed using 10µL or 
15µL reaction volumes in 96-well plates (ThermoFisher Scientific, UK) sealed with 
adhesive lids or capped thin-walled PCR tubes (ThermoFisher Scientific, UK) using a 
thermal cycler (BioRad DNA engine Tetrad 2, BioRad, USA).  HotStar Taq 
polymerase (Qiagen, Germany), 10xPCR buffer (Qiagen), 25mM magnesium chloride 
(Qiagen, Germany), and 25mM dNTP mix (New England BioLabs, USA) were used 
for all reactions.  Optimisation of annealing temperatures and PCR conditions was 
performed for AEI assays using 50-70oC temperature gradients.  No-template controls 
and duplicate samples were included for quality control.  Agarose gel electrophoresis 
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of PCR products was performed for all plates to confirm successful PCR in sample 
wells and exclude PCR product in the no-template controls before proceeding to 
further analysis.  
PCR conditions for multiplex iPLEX genotyping 
PCR was performed using 20ng of DNA template in a 10µL reaction volume. A 
primer mix was prepared containing 5µL of each 100µM PCR primer solution in a 
total volume of 1000µL (final concentration of each primer 500nM).  The 10µL 
reaction mix for each sample contained 4.7µL nuclease-free water, 1.25µL 10xPCR 
buffer, 0.65µL 25mM magnesium chloride solution, 0.20µL 25mM dNTP mix, 2µL 
primer mix, 0.20µL HotStar Taq (5U/µL), and 1µL DNA in 1xTE buffer.  PCR 
conditions were 95oC for 15min, then 35 cycles of (95oC for 20sec, 56oC for 30sec, 
72oC for 1min), then 72oC for 1min, then 4oC hold. 
PCR conditions for multiplex iPLEX AEI assays 
PCR was performed for samples heterozygous at the transcribed SNP using 25ng of 
cDNA template in a 10µL reaction for rs3217992/rs1063192, and a 15µL reaction for 
rs3088440/rs10965215 and rs11515/rs564398 (to allow PCR products to be divided 
into two separate plexes for Sequenom analysis).  A primer mix was prepared 
containing 5µL of each 100µM PCR primer solution in a total volume of 1000µL 
(final concentration of each primer 500nM).  The reaction mix for each sample 
contained 4.7µL nuclease-free water, 1.25µL 10xPCR buffer, 0.65µL 25mM 
magnesium chloride solution, 0.20µL 25mM dNTP mix, 2µL primer mix, 0.20µL 
HotStar Taq (5U/µL), and 1µL cDNA in elution buffer.  PCR conditions for 
rs3217992/rs1063192 were 95oC for 15min, then 45 cycles of (95oC for 20sec, 56oC 
for 30sec, 72oC for 1min), then 72oC for 1min, then 4oC hold.  Conditions were the 
same for the other assays except for a temperature of 58.6oC in the annealing step. 
Estimation of allelic ratios in genomic DNA samples heterozygous for the transcribed 
SNP was performed using the identical protocol with 25ng of gDNA template in place 
of the cDNA template. 
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PCR conditions for uniplex iPLEX AEI assays 
PCR was performed for samples heterozygous at the transcribed SNP using 25ng of 
cDNA template in a 10µL reaction volume. The reaction mix for each sample 
contained 7.08µL nuclease-free water, 1µL 10xPCR buffer, 0.4µL 25mM magnesium 
chloride, 0.32µL 25mM dNTP mix, 0.08µL 25µM forward primer, 0.08µL 25µM 
reverse primer, 0.04µL HotStar Taq (5U/µL), and 1µL cDNA in elution buffer.  PCR 
conditions for rs3217992 and rs1063192 were 95oC for 15min, then 45 cycles of 
(95oC for 20sec, 56oC for 30sec, 72oC for 1min), then 72oC for 1min, then 4oC hold.  
Conditions were the same for the other assays except for a temperature of 58.6oC in 
the annealing step. 
Estimation of allelic ratios in genomic DNA samples heterozygous for the transcribed 
SNP was performed using the identical protocol with 25ng of gDNA template in place 
of the cDNA template. 
PCR conditions for uniplex hME AEI assays 
PCR was performed for samples heterozygous at the transcribed SNP using 25ng of 
cDNA template in a 10µL reaction volume. The reaction mix for each sample 
contained 3.9µL nuclease-free water, 1µL 10xPCR buffer, 0.8µL 25mM magnesium 
chloride solution, 0.4µL 20mM dNTP mix, 0.1µL 5µM forward primer, 0.1µL 5µM 
reverse primer, 0.1µL HotStar Taq (5U/µL), and 3µL cDNA in elution buffer.  PCR 
conditions were 95oC for 15min, then 45 cycles of (94oC for 20sec, 51oC for 30sec, 
72oC for 1min), then 72oC for 3min, then 4oC hold. 
Estimation of allelic ratios in genomic DNA samples heterozygous for the transcribed 
SNP was performed using the identical protocol with 25ng of gDNA template in place 
of the cDNA template. 
2.2.4.4 SAP treatment 
5µL of PCR product for each sample was transferred to a 384-well plate.  A SAP 
reaction mix was prepared containing 1.53µL water, 017µL 10xSAP buffer 
(Sequenom), and 0.3µL SAP enzyme (1U/µL) for each sample.  2µL of SAP reaction 
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mix were added to each well using a Multimek 96 automated pipettor (Beckman 
Coulter, USA).  The plate was sealed with an adhesive lid and centrifuged briefly at 
700rpm, and then incubated in a thermocycler (BioRad DNA engine Tetrad 2, 
BioRad, USA).  SAP reaction conditions were 37oC for 40min, followed by 85oC for 
5min, followed by 4oC hold. 
2.2.4.5 Primer extension reaction 
Extension reactions for iPLEX assays 
For iPLEX extension reactions containing three or fewer extension primers, a reaction 
mix was prepared containing 0.20µL 10x iPLEX buffer, 0.20µL iPLEX termination 
mix, 0.0375µL of each 300µM extension primer solution, 0.041µL iPLEX enzyme, 
and water to make the volume up to 2µL per sample.   
Because larger mass products are detected less efficiently in the MALDI-TOF 
detection system, a higher concentration of the larger mass extension primers was 
needed for highly multiplexed reactions (more then four extension primers).  In this 
case, extension primers were divided into four approximately equal groups based on 
their mass, and the volume of 300µM extension primer solution added for each of the 
four groups is shown in Table 2.1. 
Table 2.1. iPLEX extension reaction mix for multiplexed reactions 
Reagent Volume (µL) per sample 
10x iPLEX buffer 0.20 
iPLEX termination mix 0.20 
Primer group 1 (300µM) 0.01875 
Primer group 2 (300µM) 0.0249 
Primer group 3 (300µM) 0.0312 
Primer group 4 (300µM) 0.0375 
iPLEX enzyme 0.041 
Water To make volume up to 2µL per sample 
 
2µL of the reaction mix was transferred to each well of the 384-well plate containing 
the product of the SAP reaction using a Multimek 96 automated 96-channel pipettor 
(Beckman Coulter, USA).  The plate was sealed with an adhesive lid, briefly 
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centrifuged at 700rpm, and then incubated in a thermocycler (BioRad DNA engine 
Tetrad 2, BioRad, USA).   
For iPLEX genotyping assays extension reaction conditions were 94oC for 30sec, then 
40 cycles of (94oC for 5sec, followed by 5 cycles of (52oC for 5sec, then by 80oC for 
5sec)), then 72oC for 3min, then 4oC hold. 
For iPLEX AEI assays extension reaction conditions were 94oC for 30sec, then 30 
cycles of (94oC for 5sec, followed by 5 cycles of (52oC for 5sec, then by 80oC for 
5sec)), then 72oC for 3min, then 4oC hold. 
Extension reactions for hME assays 
A reaction mix was prepared containing 1.728µL water, 0.20µL ACG termination 
mix, 0.0545µL of 100µM extension primer, and 0.018µL ThermoSequenase enzyme 
(32U/µL).  2µl of the reaction mix was transferred to each well of the 384-well plate 
containing the product of the SAP reaction using a Multimek 96 automated 96-
channel pipettor (Beckman Coulter, USA).  The plate was sealed with an adhesive lid, 
briefly centrifuged at 700rpm, and then incubated in a thermocycler (BioRad DNA 
engine Tetrad 2, BioRad, USA).  Reaction conditions were 94oC for 2min, followed 
by 55 cycles of (94oC for 5sec, then 52oC for 5sec, then by 72oC for 5sec), followed 
by 4oC hold. 
2.2.4.6 Clean Resin step 
Reaction products were desalted with Clean Resin (Sequenom) prior to MALDI-TOF 
analysis.  For iPLEX reactions, 6mg of Clean Resin were added to each well of the 
384-well reaction plate containing the product of the extension reaction, using a 
dimple plate.  For hME reactions, 3mg of Clean Resin were added to each well of the 
384-well reaction plate containing the product of the extension reaction, using a 
dimple plate.  Samples were diluted with16µl of water using a Multimek 96 
automated 96-channel pipettor (Beckman Coulter, USA). 
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2.2.4.7 Quantitative MALDI-TOF analysis 
A Sequenom MassARRAY nanodispenser (Samsung, USA) was used to dispense 
15nL of reaction product onto a 384-element SpectroCHIP (Sequenom, USA) and 
MassARRAY Typer version 3.4 software (Sequenom, USA) was used to perform 
MALDI-TOF analysis, using the appropriate settings for genotyping or AEI assays as 
specified in the manufacturer’s protocol.   
2.2.4.8 Determining genotypes 
Spectra and automated genotype calls were manually reviewed and automated calls 
that appeared erroneous or ambiguous were excluded or manually reassigned.  This 
process was performed at the time of plate analysis and was not influenced by results 
of subsequent data analysis.  Individual samples with low genotype call rates (<80%) 
and SNP assays with poor quality spectra or cluster plots were excluded.   
2.2.4.9 Estimation of allelic expression ratios 
Spectra were manually reviewed and poor quality spectra were excluded.  Allelic 
expression ratios were estimated as the ratios of the area under the peak representing 
allele 1 to that representing allele 2.  Measurements were performed in four replicates 
for each sample.  Results from amplification of genomic DNA were used as an 
equimolar reference to normalise the cDNA values. 
2.2.5 TaqMan Genotyping 
TaqMan genotyping was performed using predesigned TaqMan SNP Genotyping 
Assays (Applied Biosystems, USA), using the Applied Biosystems 7900HT Fast 
System.  PCR was performed using 20ng of DNA template in a 5µL reaction volume 
in 384-well optical reaction plates.  The reaction mix for each sample contained 2.5µL 
Universal PCR Master Mix No AmpEraseUNG (Applied Biosystems, USA), 0.125µL 
40xAssay Mix (Applied Biosystems, USA), 1.375µL nuclease-free water, 1µL DNA 
solution in 1x TE.  PCR conditions were 95oC for 10min, then 40 cycles of (92oC for 
15sec, followed by 60oC for 1min).  No-template controls and duplicate samples were 
included for quality control.  Data were analysed using the allelic discrimination 
algorithms in SDS Software v2.3 (Applied Biosystems, USA) according to the 
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manufacturer’s protocol.  Automatic genotype calls were manually reviewed and 
edited if necessary. 
2.2.6 Quantitative real-time PCR 
Quantitative real-time PCR reactions were performed using TaqMan gene expression 
probes and reagents (Applied Biosystems, USA), using the 7900HT Real-Time PCR 
System (Applied Biosystems, USA).  PCR was performed using 25ng of cDNA 
template in a 15µL reaction volume in 384-well optical reaction plates.  Reactions 
were multiplexed to include a FAM-labelled target gene assay and VIC-labelled 
control gene assay in the same reaction.  The reaction mix for each sample contained 
5.5µL nuclease-free water, 7.5µL 2xTaqMan Gene Expression Master Mix (Applied 
Biosystems, USA), 0.75µL 20x target gene primer/probe mix (Applied Biosystems, 
USA), 0.75µL 20x control gene primer/probe mix (Applied Biosystems, USA), and 
0.50µL cDNA.  PCR conditions were 50oC for 2min, then 95oC for 10min, then 40 
cycles of (95oC for 15sec, followed by 60oC for 1min).  Target genes and all control 
genes used for normalisation of the sample were analysed on the same plate, and no-
template controls were included on each plate.  All reactions were performed using 
four replicates.  Specific assay details are given in Chapter 4. 
Relative total expression was analysed using the comparative cycle threshold (Ct) 
method using SDS 2.3 and RQ Manager 1.2 software (Applied Biosystems, USA). Ct 
values for each target gene were normalised to the mean Ct value of the reference 
genes, which is more reliable than normalisation to a single endogenous control 
gene291.  Normalised Ct values (= mean target gene Ct value – mean reference genes 
Ct value) were used for all analyses. 
2.2.7 Microsatellite analysis 
Microsatellites in genomic DNA were amplified by PCR with FAM-labelled primers, 
and the size of the products was quantified using capillary electrophoresis.  PCR was 
performed using 25ng of cDNA template in a 10µL reaction volume in 96-well 
reaction plates.  Custom PCR primers were used, with the forward primer FAM-
labelled (Metabion, Germany).  Primer sequences are shown in Appendix 1.  The 
reaction mix for each sample contained 7.08µL nuclease-free water, 1µL 10xPCR 
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buffer, 0.4µL 25mM magnesium chloride, 0.32µL 25mM dNTP mix, 0.08µL 25µM 
forward primer solution, 0.08µL 25µM reverse primer solution, 0.04µL HotStar Taq 
(5U/µL), and 1µL DNA in 1xTE.  PCR conditions were 95oC for 15min, then 35 
cycles of (95oC for 20sec, 61oC for 30sec, 72oC for 1min), then 72oC for 3min, then 
4oC hold.  Duplicate and no-template controls were included.  A master mix was then 
prepared containing 8.5µL of Hi-Di formamide (Applied Biosystems, USA) and 
0.3µL of Genescan-500 ROX size standard (Applied Biosystems, USA) per sample.  
8.8µL of the master mix was added to each well of a new 96-well semi-skirted, 
straight-edge PCR plate (StarLab, Germany), and 1µL of the PCR product was 
transferred to each well of this plate.  The plate was covered in foil to prevent photo-
degradation, before analysis by capillary electrophoresis on a 3130xl Genetic 
Analyzer (Applied Biosystems, USA).  Data were analysed using GeneMarker v1.8 
software (SoftGenetics, USA).   
Microsatellite genotypes were manually assigned by a single observer (MSC), with 
selected spectra and genotype calls reviewed independently by another observer 
(MSK).  Examples of selected spectra patterns and their interpretation are shown in 
Figure 2.1.  The spectra estimate the product size of the PCR amplicon, which 
consisted of 55 bases before, and 79 bases after, the microsatellite TG repeats.  The 
number of TG repeats in the microsatellite was therefore calculated as: N = (amplicon 
size – 134)/2 for each allele. 
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Figure 2.1. Examples of microsatellite analysis spectra.  
Spectra show the amplicon size along the X-axis and peak height on the Y-axis. The boxed numbers on 
the X-axis represent the peak positions detected using the GeneMarker autodetection algorithm. The 
location of true peaks are highlighted with red arrows for each spectrum and the interpretation of each 
spectrum is shown in the top left of each panel. It can be seen that interpretation is complicated by the 
presence of ‘slippage’ peaks, which are seen as peaks of lower magnitude to the left of each true peak. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178/192 
heterozygote
174/176 
heterozygote
174/174 
homozygote
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2.2.8 MLPA 
Analysis for copy number variation was performed using custom SALSA MLPA 
(Multiplex Ligation-dependent Probe Amplification) analysis (MRC Holland).  The 
SALSA MLPA P200-A1 reference probemix (MRC Holland, The Netherlands) was 
used to provide reference probes and control fragments.  Custom MLPA probes were 
designed manually and using the H-MAPD Human MLPA Probe Design software293, 
294
, using the default settings for probe design.  From the H-MAPD output, probes 
were manually reviewed and sorted for additional design criteria not included in that 
software: left primer oligo (LPO) hybridising sequence including a maximum of two 
G/C nucleotides in the five nucleotides at the 3’ end adjacent to the ligation site, and 
for LPO and right primer oligo (RPO) hybridisation sequences including a maximum 
of three G/C nucleotides directly adjacent to the primer recognition sequence).  Probe 
lengths of 92-140 nucleotides at four nucleotide intervals were designed, with the first 
nucleotide of the LPO hybridisation sequence T for the shortest probes, G for probes 
of intermediate length, and C for the longest probes.  Selected primers were checked 
for specificity using NCBI BLASTN, and checked against the human reference 
sequence to exclude the presence of SNPs in the hybridisation sequence using the 
Ensembl Genome Browser43.  Sequences of the MLPA probes are shown in Appendix 
1.  All custom MLPA probes were ordered from Integrated DNA Technologies 
(Belgium), with probes longer than 60 nucleotides ordered as Ultramers. 
MLPA was performed using the MLPA DNA detection/quantification protocol (MRC 
Holland, www.mlpa.com), using 100ng of DNA template in 5µL of 1xTE.  The 
volume of the PCR reaction step was reduced to 25µL.  The exact protocol used is 
shown in Appendix 1.  Duplicate samples and no-template controls were included.  
Amplification products were analysed using capillary electrophoresis using a 3130xl 
Genetic Analyzer (Applied Biosystems).  Data were analysed using GeneMarker v1.8 
software (SoftGenetics), using custom panel templates for the probesets used.  The 
SALSA MLPA P200-A1 reference probeset was used for internal normalisation of 
each reaction.  This contains reference probes in regions not expected to demonstrate 
CNV, and also contains control fragments including the Q-fragments that indicates if 
insufficient amounts of DNA have been used, and the D-fragment that indicates if the 
sample was not completely denatured.  The P200 probes are summarised in Table 2.2.  
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An example of the spectrum obtained from MLPA analysis using the chromosome 
9p21 custom assay is shown in Figure 2.2.  
 MLPA data for each sample were quality checked with respect to the Q-fragments, 
D-fragments, and dispersion of the control probes, and samples with poor quality 
results were excluded from analysis or repeated. 
Table 2.2. Probes in the SALSA MLPA P200-A1 reference probemix. 
Length (bases) SALSA MLPA probe Chromosomal 
position 
64-70-76-82 Q-fragments: DNA quantity; only visible with 
<100ng sample DNA 
NA 
172 Reference probe C01 7q31 
178 Reference probe C02 14q22 
184 D-fragment: low signal indicates incomplete 
denaturation. 
14q32 
190 Reference probe C03 20p13 
196 Reference probe C04 13q12 
202 Reference probe C05 20p12 
208 Chromosome X probe CX Xq26 
214 Reference probe C06 10p13 
220 Reference probe C07 12q24 
226 Reference probe C08 4q25 
232 Reference probe C09 18q11 
238 Chromosome Y probe CY Yq11 
244 Reference probe C10 5p15 
250 Reference probe C11 17p11 
 
 
  
Figure 2.2. Example of MLPA spectra for the custom chromosome 9p21 probeset obtained using GeneMarker software.  
Spectrum shows the custom probes (M01-M13) and the P200 control probes (C01-C11, CX, CY, and CD, as shown in Table 2.2).  The X-axis represents amplicon size (in 
nucleotides) and the Y-axis represents peak height.  The 82nt Q-fragments are small, indicating an adequate amount of DNA template, and the D-fragment peak (CD) is 
large, indicating adequate sample denaturation. 
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2.2.9 Statistical analyses 
2.2.9.1 General analyses 
Normality testing and data transformation 
Quantitative data were tested for normality using the Anderson-Darling test using 
Minitab v15.  Normally distributed data are presented as mean and standard deviation, 
with data that deviate from a normal distribution presented as median, range, and 
lower/upper quartiles.  Quantitative traits that deviated from a normal distribution 
were transformed (most often using a log transformation) to approximately normalise 
the distribution prior to correcting for covariates or performing association analysis.   
Adjustment for covariates and correlation analyses 
Effects of covariates for quantitative phenotypes were adjusted for using linear 
models in Minitab v15 or R software.  Covariate-adjusted data were used for all 
association analyses unless otherwise stated.  All correlations were performed using 
Pearson’s correlation test in SigmaPlot v11.0 unless otherwise stated.  Spearman’s 
rank correlation test was used when outliers or deviation from normality were likely 
to influence the analysis. 
Testing genotyping for Mendelian inheritance, D-statistics, and correspondence 
to Hardy-Weinberg proportions  
Family-based genotyping data was checked for Mendelian inheritance errors and 
correspondence to HWE proportions using PEDSTATS295.  Data from families with 
Mendelian errors were reviewed and re-genotyped if necessary, and where Mendelian 
errors persisted, families were excluded from analyses.  HWE checks were performed 
in the total population and in the unrelated founder members only to account for 
deviations that may be due to family structure.  Pedigree and data files were prepared 
as described on the PEDSTATS website.  Genotyping data from unrelated individuals 
was checked for correspondence to HWE proportions using standard formulae in 
Excel or Haploview296-298. 
The extent of deviation from HWE proportions was estimated for each SNP by 
calculation of the deviation statistic (D-statistic) in Excel according to the 
Chapter 2: Materials & Methods 
86 
formula ( )ppHD −−= 12 , where H is the observed heterozygosity and p the minor 
allele frequency.  Using this formula, negative D-values correspond to an excess of 
homozygosity, and positive values to an excess of heterozygosity.  
Significance thresholds for hypothesis testing and correction for multiple-testing 
Statistical significance was defined using an uncorrected significance threshold of 
0.05 unless otherwise stated.  Correction for multiple testing was performed using a 
Bonferroni correction299, in which the corrected significance threshold (α’) for n tests 
is calculated as, α’ = α/n.  
Linkage disequilibrium, tag SNPs, and LD plots 
LD plots and calculation of LD between SNPs were performed using Haploview 
v4.0297.  The Tagger function in Haploview was used to select a minimal set of SNPs 
that define a haplotype, parameters for which are specified in the relevant sections.  
LD for pairs of SNPs are presented as r2 and D’ values, following standard 
convention297, 299. 
2.2.9.2 Genotype-phenotype association testing 
Association testing using MERLIN 
Family-based association analysis for quantitative traits was performed using 
MERLIN v1.1.2 software300, which uses sparse inheritance trees for pedigree analysis.  
This performs rapid haplotyping, genotype error detection and affected pair linkage 
analyses and can handle more markers than other pedigree analysis packages. The 
association test implemented in MERLIN includes an integrated genotype inference 
feature, which can improve power when some genotypes are missing.  Pedigree, data 
and map files were prepared as described on the MERLIN website301. 
Association testing using UNPHASED 
Case-control association analysis for discrete traits was performed using UNPHASED 
v3.10302, 303.  This software implements maximum-likelihood inference on genotype 
effects while allowing for missing data such as missing genotypes.  Association 
testing for binary traits is performed using logistic regression, which can be done 
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using allele or genotype models.  Pedigree, data and map files were prepared as for 
MERLIN. 
Estimation of maximum SNP contribution to overall phenotypic variance 
For association analyses of quantitative traits, an approximate estimate of the 
maximum plausible genetic effect (G) of a given SNP on a particular trait based on 
the upper 95% confidence interval was calculated using the formula: G = (A + 
(2*SEA))2 * ((SDgenotype)2/(SDadj trait)2), where A=absolute regression coefficient, 
SE=standard error, SD=standard deviation. 
2.2.9.3 AEI analysis 
AERs were analysed using an extension of the approach published previously254.  
This has now been published304, but the principles are summarised below.  After 
normalisation to an equimolar control, AERs were log-transformed.  Outliers from 
each individual sample’s technical replicates were excluded using Grubb’s test.  In 
order to assess the effect of a potentially cis-acting polymorphism on allelic 
expression ascertained at a transcribed polymorphism, two things need to be 
estimated:  first, the phase between the alleles at both polymorphic sites; and second, 
the effect of the potential cis-acting marker on expression.  The simplest method is to 
first estimate the phase and then, given that phase, assess the effect of the 
polymorphism.  This approach was used in the chromosome 9p21 analysis, where 
genotypes for each population were phased using the hap procedure from the R-
package gap (as deposited in the CRAN archive)305.  Once the phase has been 
estimated it is possible to assess how likely the observed allelic expression ratio is 
given the phase relationships between transcribed and expressed polymorphisms 
under different assumptions on the effect.  The effect size that best explains the 
observed ratios is then selected, based on a likelihood maximisation procedure.  To 
establish significance, the effect estimate is compared with the likelihood obtained 
assuming no effect of the putative cis-acting polymorphism.  These likelihoods can be 
compared using a likelihood ratio test, the result of which is summarised as the 
significance P-value.  These analyses were performed using R and MatLab software.  
An alternative approach to AEI analysis is to determine phase and effect 
simultaneously, as described by Teare et al254.  This approach was used in the STK39 
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analysis in Chapter 7 using the statistical package R, but was computationally too 
challenging given the number of SNPs genotyped (and corresponding number of 
possible haplotypes) at the 9p21 locus.  For all analyses the effect size is defined as 
the logarithm of the ratio of (expression from the chromosome carrying allele 2 at the 
cis-acting locus /  expression from the chromosome carrying allele 1 at the cis-acting 
locus), i.e. the log of the change of expression that allele 2 produces compared to 
allele 1.  By convention this was performed defining allele 2 as the rare allele. 
2.2.9.4 Quantitative real-time PCR analysis 
The association between total expression, as measured by real time PCR, and each of 
the SNPs was assessed using linear regression of the log transformed normalised 
expression values on the genotype assuming no dominance or interactions between 
the effects of different SNPs.  Analyses were performed in R and SigmaPlot v11.0.  
The effect size is defined as the slope of the linear regression anlaysis. 
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3 Preliminary methodological studies for allelic 
expression analysis  
3.1 Introduction 
With the recent identification of multiple non-transcribed SNPs associated with 
disease phenotypes in GWA studies, interest has increased in techniques for 
investigating cis-acting effects on expression.  Previous AEI analyses have only 
considered the effects measured at individual transcribed SNPs, but simulations 
suggest that combining information from multiple transcribed SNPs in the same gene 
may improve the power of this approach for mapping cis-acting effects.  The 
chromosome 9p21 region has been recently associated with a range of diseases by 
GWA studies21, 126, 130, 164, 167, 168, and nearby genes in this region including CDKN2A, 
CDKN2B, ANRIL, and MTAP each have multiple exonic SNPs that could be used to 
investigate such an approach42. 
Published studies have varied considerably in the strategies used to normalise AER 
values.  Normalisation to an equimolar control is required to correct for any assay bias 
that could potentially give artefactual results, for example, with the Sequenom 
platform higher mass products tend to be detected less efficiently than lower mass 
products during MALDI-TOF mass spectrometry, and with the hME technology for 
which the technique was originally described272, alleles with multi-base extension 
tend to have smaller peaks than alleles with single-base extension.  Appropriate 
normalisation is important since such systematic assay biases could create artefactual 
associations for variants in high LD with the transcribed variant used to assess AEI.  
The most common strategy for normalising AEI data has been to correct for the allelic 
ratio obtained in genomic DNA from heterozygous individuals, based on the 
assumption that the alleles are present in a 1:1 ratio in genomic DNA.  However, 
reported approaches have included normalisation to the mean genomic ratio of all 
heterozygous individuals306, 307, normalisation to the mean of a subset of 
individuals260, normalisation to a single reference sample308, 309, and normalisation of 
each individual’s cDNA to the genomic DNA from the same individual310.  An 
alternative method is to normalise using the AER obtained from an experimentally 
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prepared equimolar standard.  This is done by mixing DNA in a 1:1 ratio from two 
individuals who are homozygous for alternative alleles at the transcribed 
polymorphism and using this mix as the template for AER assessment.  The extent to 
which different normalisation strategies influence AEI analysis has not been studied.  
The most commonly used method has been to normalise to pooled genomic DNA 
ratios, which should reduce the variability of the normalisation factor, but could be 
problematic in the presence of CNVs or variants in the amplicon sequence that 
influence the cDNA AER of individual samples. 
At the outset of this study, application notes and published literature for AEI 
assessment using Sequenom were only available for hME analysis and not the newer 
iPLEX technology.  hME analysis involves a multi-base extension process for 
detection of the higher mass allele, which tends to reduce the area of the higher mass 
peak relative to that of the lower mass allele which involves only single base 
extension for detection.  This occurs because some copies of the higher mass allele 
only extend by a single base during the extension reaction, as evidenced by the 
presence of a ‘pausing peak’ in the spectrum (an example of which is shown in Figure 
3.3 on page 100).  This peak may interfere with measurement of the lower mass allele 
peak area, and results in reduced peak area of the higher mass allele and skewing of 
AER.  However, the newer iPLEX technology, which involves single base extension 
for each allele, would be expected to reduce such biases and may offer improved 
accuracy and reduce reliance on accurate normalisation.  A further advantage of the 
iPLEX technology is that reactions can be multiplexed more easily, which is 
advantageous where samples are limited.  However, the use of iPLEX and 
multiplexing for AEI analysis needs to be experimentally validated. 
Experimental factors such as RNA storage and degradation may influence analyses 
involving total gene expression, since total expression levels are normalised to 
expression levels of different reference genes, but it has been shown that different 
mRNAs may degrade at different rates311.  AEI analysis would be expected be more 
resistant to such influences since alleles which differ in sequence by only a single 
nucleotide are compared within the same sample, but the extent to which such factors 
influence AEI assessment needs to be confirmed experimentally.  Assumptions 
involved in the AEI analysis such as linearity, normality, and constant variances of 
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AEI measurements also require experimental validation.  Furthermore, whether 
RNA/cDNA amplification alters AEI measurements is not known. 
3.2 Aims 
3.2.1 AEI studies using MLH1 
Preliminary AEI studies were performed using SNP rs1799977 in the MLH1 gene, for 
which pilot studies of techniques for AEI assessment had been previously performed 
by other members of the group.  The specific aims of these experiments were: 
• To determine the reproducibility of the reverse transcription step. 
• To investigate whether AEI could be reliably ascertained using stored RNA 
samples from the NE Caucasian cohort. 
• To compare AEI assessed using hME and iPLEX methodologies. 
• To determine whether amplified cDNA could be used for AEI analysis. 
3.2.2 AEI studies in the chromosome 9p21 region 
Methodological studies were also carried out for AEI assessment of CDKN2A, 
CDKN2B, ANRIL, and MTAP expression at the chromosome 9p21 locus.  The specific 
aims of these experiments were: 
• To determine whether expression of these genes could be reliably detected in 
peripheral blood and whether they displayed sufficient inter-individual 
variability in AEI to allow mapping of cis-acting effects. 
• To determine the amount of cDNA needed for AEI analyses of these genes. 
• To assess whether AEI assays could be reliably multiplexed using the iPLEX 
methodology. 
• To demonstrate linearity, normality, and constant variance of AEI estimates. 
• To compare the influence of different normalisation methods on mapping of 
cis-acting effects using AEI. 
• To investigate novel methodology using multiple transcribed SNPs per gene. 
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3.3 Materials and methods 
3.3.1 Participants and samples 
Expression studies at the chromosome 9p21 locus included two populations of healthy 
adult volunteers: the 310 individuals of the SA cohort and the 177 individuals from 
the NE Caucasian cohort.  Preliminary feasibility and optimisation work involving 
MLH1expression were performed using samples from affected cases and unaffected 
controls of the CAPP study.  Details of these populations and the nucleic acid 
preparation were presented in Chapter 2. 
3.3.2 Selection of transcribed SNPs for allelic expression analysis 
Using the NCBI Entrez Gene database196, transcribed transversion SNPs with 
expected heterozygosity >0.2 in Caucasian populations were selected as suitable 
candidates for assessment of allelic expression.  Variants lacking population 
frequency data were excluded.  Insertion/deletion polymorphisms were also excluded 
since these would alter the size of the PCR product produced for each allele, which 
could bias the AEI estimate.  The NCBI196 and Ensembl43 databases were also used to 
establish the location of transcribed SNPs with respect to reported transcript variants 
of each gene. 
Transcribed polymorphisms in ANRIL, which was not annotated in the databases at 
the time of the design, were identified by comparing the reported mRNA sequence195 
with NCBI dbSNP using the BLAST tool.  The expected heterozygosity of ANRIL 
exonic SNPs identified in this way was then checked in dbSNP.   
Transcribed SNPs selected using these criteria were: rs3088440 and rs11515 in exon 3 
of CDKN2A; rs3217992 and rs1063192 in exon 2 of CDKN2B; rs10965215 and 
rs564398 in exon 2 of ANRIL.  The two CDKN2A SNPs are also present in ARF, 
allowing the assessment of cis-acting influences on both of these transcripts.  Another 
SNP rs10738605 in exon 6 of ANRIL also satisfied these criteria but was excluded 
from initial AEI experiments because of extensive skewing of the allelic ratio in 
genomic DNA. 
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3.3.3 Selection of mapping SNPs 
3.3.3.1 SNPs associated with disease 
SNPs previously reported to be associated with disease phenotypes were selected for 
mapping effects on expression124, 125, 160, 169-173, 175-182, 312-314.  GWA studies for CAD 
showed association for multiple SNPs which were in strong LD in the chromosome 
9p21 region.  To reduce redundancy of genotyping but ensure inclusion of the most 
important SNPs, the ‘lead’ SNPs showing the strongest association with disease, 
subsequent refinement SNPs, and SNPs reported as tagging the risk haplotype were 
selected from GWA studies.  All SNPs reported to have significant associations with 
disease phenotypes in candidate gene studies (as previously summarised in Table 1.4 
on page 33) were included. 
3.3.3.2 SNPs altering transcription factor binding sites within regulatory 
regions 
SNPs within previously reported regulatory elements such as the CDKN2A, ARF and 
CDKN2B promoters186-189 or a putative ANRIL promoter region (which was arbitrarily 
defined as 1kb up and downstream of the transcription start site for the purposes of 
this study) were also selected.  SNPs in these regions were included if they were 
reported more than once in NCBI dbSNP, had expected heterozygosity >5%, and the 
alternative SNP alleles were predicted to alter human transcription factor binding sites 
using PROMO v.3.0.2 software246, 247. 
3.3.3.3 Tag SNPs to capture common variation in the region 
Additional tag SNPs required to capture common variation in the core region of 
interest (Chr9:21958155-22115505) based on HapMap CEU data were also selected 
using HaploView 4.0 Tagger software using the following parameters: minimum 
minor allele frequency 0.01, pairwise tagging, r2 threshold >0.8.  Transcribed or 
functional SNPs already selected for genotyping were ‘force included’ as tag SNPs in 
Tagger to reduce redundancy of genotyping.  Tagger output SNPs were manually 
checked for potential problems with Sequenom genotyping (e.g. rs6475608 had 
multiple deletions/repeats which would be problematic for Sequenom SNP analysis).  
Tagging was then repeated with SNPs likely to be problematic ‘force excluded’ from 
Chapter 3: Preliminary AEI studies 
95 
selection, to obtain a final panel of typable SNPs which adequately tagged the region.  
The SNPs selected for genotyping and reasons for including them are shown in the 
genotyping results summary table in the next chapter (Table 4.2 on page 130). 
3.3.4 Genotyping 
Multiplex SNP genotyping was performed using Sequenom methodology as described 
in Chapter 2.  The 56 SNPs were genotyped in five separate reactions (W1-W5). 
3.3.5 AEI assays 
PCR primers for the selected transcribed SNPs were designed manually and using 
Primer3 (v.0.4.0) software289.  For AEI analysis PCR primers were designed to anneal 
across exon boundaries, thus being specific for cDNA and not binding to genomic 
DNA.  Primers for genomic DNA normalisation were designed to produce products as 
similar as possible in size and sequence to those produced by the cDNA specific 
primers, to minimise differences in reaction kinetics.  CDKN2A primers span exons 3-
4 and include both transcribed SNPs (rs3088440 and rs11515) in the same amplicon. 
ANRIL primers span exons 1-2 and include both transcribed SNPs (rs10965215 and 
rs564398) in the same amplicon.  For CDKN2B, the distance of transcribed SNPs 
from the exon boundary meant that amplicons would be more than 1kb in size, and 
separate primer pairs for transcribed SNPs rs1063192 and rs3217992 were therefore 
designed entirely within exon 2.  These CDKN2B primers were therefore not cDNA 
specific, and analysis was performed using cDNA from DNase treated RNA.  
Measurements were performed in four replicates using 50ng of cDNA template.  
3.3.6 Genomic DNA normalisation assays 
Genomic DNA normalisation reactions for CDKN2B used the same PCR primers as 
used for cDNA, but for CDKN2A and ANRIL (where primers were cDNA-specific) 
separate assays designed to be as close as possible in size and location to the cDNA 
primers were used.  Genomic normalisation samples were checked both in uniplex 
reactions and multiplex combinations when these were used for the AEI analysis.   
The appropriateness of genomic normalisation ratios and linearity of the AER 
response were checked by mixing PCR products in varying ratios from individuals 
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homozygous for the minor and major alleles at each SNP, and using these as template 
for the allelic expression assays.  To do this, PCR was performed from cDNA samples 
homozygous for each transcribed SNP allele, using standard uniplex AEI protocols 
but with only 40 cycles.  The concentration of the PCR product from each 
homozygous sample was quantified using PicoGreen, performed in three replicates.  
For each pair of alleles at each SNP, the product with the highest concentration was 
diluted with 1xTE to obtain the same concentration as the less concentrated product.  
Further cycles of PicoGreen measurement and dilution were repeated until the 
measured concentration of each sample was the same.  Volumes of product from each 
allele pair were then mixed in known ratios (8:1, 4:1, 1:1, 1:4, 1:8), and for each 
mixture serial dilutions were performed with 1xTE until the molarity with respect to 
the DNA amplicons roughly equated to the molarity of genomic DNA in a 20ng/µL 
solution.  The resulting allele mixes were then used as template for PCR and AEI 
analysis following the standard protocol. 
3.3.7 Statistical analyses 
Allelic expression analysis was performed using the pre-phasing methodology 
described in Chapter 2.  A novel approach of combining allelic ratios from the two 
transcribed markers in each gene was used to increase the number of informative 
heterozygotes.  This included AERs measured at both transcribed SNPs in the analysis 
of each gene.  For individuals who were heterozygous for both transcribed SNPs, 
information from both was included allowing for different variances at each 
transcribed marker.  The best fitting parameters were determined using likelihood 
maximisation algorithms. 
3.4 Results 
3.4.1 Preliminary feasibility and optimisation work using MLH1 
3.4.1.1 Reproducibility of reverse transcription and effect of sample storage 
To test the effect of reverse transcription (RT) reactions on AER, the results of three 
separate RT reactions performed simultaneously from the same RNA solution were 
compared for two normal individuals.  AER for each sample was assessed using four 
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replicates.  As shown in Figure 3.1, there was no substantial difference in AER 
estimates from separate RT reactions in the same individual. 
To examine whether allelic expression analyses might be influenced by degradation of 
stored RNA, paired samples were used to compare AER results between RT from 
stored RNA (samples stored at -80oC for 1-2 years) and RT performed at the time of 
sample extraction and subsequently stored as cDNA (at -20oC for 1-2 years).  These 
analyses were performed using samples from three patients known to have imbalance 
in MLH1 expression.  As shown in Figure 3.1, the magnitude of AEI was similar for 
analyses of each patient, confirming that the RT step and sample storage do not 
appear to substantially affect AEI analysis. 
Figure 3.1. Effect of reverse transcription reactions on AER.   
MLH1 AER is shown on the Y-axis. X-axis shows three simultaneous RTs (RT1-RT3) from two 
normal individuals (A and B) who were heterozygous at the transcribed SNP, and RTs from stored 
RNA and stored cDNA for three patients with known allelic imbalance (C, D, and E).  Mean AER for 
each individual is represented by a different symbol (with standard error bars shown). 
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Although AER measurements from stored RNA and stored cDNA were comparable, 
it was important to confirm that these AER estimates were accurate and not both the 
result of artefacts due to sample storage (which might occur, for example, if one allele 
was preferentially degraded to the same extent in both the stored RNA and stored 
cDNA samples).  AER estimates from stored RNA were therefore compared with 
AER values obtained from the same samples at the time of their original extraction, 
for five individuals with varying degrees of allelic imbalance.  As shown in Figure 
3.2, AER values obtained from stored RNA samples were similar to values obtained 
using ‘fresh’ RNA in experiments performed by a different operator using the same 
assay 1-2 years previously (r= 0.99, P=0.001). 
Figure 3.2. Comparison of AER from stored RNA with AER obtained at the time 
of RNA extraction for MLH1. 
Correlation of AERs obtained at the time of RNA extraction (X-axis) and from stored RNA (Y-axis).  
Regression line is shown as a solid line with dotted 95% CI. 
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It was not surprising that the linear RT step introduced little variability into AER 
estimates, and the data suggest that replicates at the RT stage are not required for 
AER assessment.  Allelic expression analysis compares DNA sequences within 
individuals that differ by just a single base, and therefore should be relatively robust 
to the effects of RNA/cDNA degradation which would be expected to affect each 
allele equally and not alter the ratio between alleles.  This is in contrast to total 
expression analyses where expression is compared between different genes within a 
sample (for normalisation) and between samples from different individuals, both of 
which may be subject to differential degradation.  These data were particularly 
important since analyses in the NE Caucasian cohort would involve the use of stored 
RNA and stored cDNA, whereas analyses in the SA cohort would be performed using 
newly collected RNA. 
3.4.1.2 Comparison of AEI using hME and iPLEX 
Five samples representing a mixture of balanced and imbalanced allelic expression 
were analysed using each methodology.  PCR was performed using standard protocols 
in a 15µL reaction volume.  For each reaction, 5µL of the PCR product was used for 
hME analysis, and 5µL for iPLEX analysis.  This eliminated variation due to the PCR 
step and allowed the detection techniques to be directly compared.  The process was 
repeated for both hME and iPLEX analysis using genomic DNA from the samples, to 
allow appropriate correction of each assay to be performed. 
Examples of spectra from the same genomic DNA PCR product analysed with hME 
and iPLEX are shown in Figure 3.3, which clearly shows the pausing peak and 
difference in ratio between the peak areas for hME.  The overall G/A ratio for 
genomic samples using hME was 1.56, compared to 0.85 for iPLEX on the same 
samples.  This illustrates the importance of appropriate assay correction, as when the 
allelic expression ratios were corrected for genomic bias the correlation between AER 
for the two techniques was very high (r=0.99, P<0.0005), as shown in Figure 3.4.  
Since iPLEX offers advantages in terms of accuracy and multiplexing, all subsequent 
analyses were conducted using iPLEX. 
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Figure 3.3. Comparison of spectra from the same genomic PCR product 
analysed with hME and iPLEX showing difference in peak ratios. 
 
 
 
UEP peak 
A
T**
A
C**
Mass adjusted primers C*/T**
A
TddA
A
G allele 
A allele 
Pausing peak 
G allele 
A allele 
iPLEX 
hME 
UEP peak 
Chapter 3: Preliminary AEI studies 
101 
Figure 3.4. Comparison of AER using iPLEX and hME.   
Each point represents an individual AER measurement, with standard errors shown.  The linear 
regression line is shown as a solid line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1.3 Effect of cDNA amplification on AER 
Amplification of RNA/cDNA was investigated as a method of potentially increasing 
the amount of cDNA available for analysis.  This would be advantageous both for the 
present samples extracted from blood, and for future work using different tissues 
(such as atheromatous plaque) where working from small amounts of extracted tissue 
would be important. 
Quantitect Whole Transcriptome Kit (Qiagen) provides an integrated system for 
reverse transcription of RNA using random and oligo-dT primers, ligation of cDNA, 
and whole transcriptome amplification in an isothermal reaction.  This is reported to 
produce uniform amplification across sequences with negligible sequence bias from 
as little as 10ng of starting RNA315.  The transcript profiles of five genes were 
reported to be similar using amplified and unamplified cDNA according to the 
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promotional information from Qiagen, but examination of their data did reveal 
differences in the absolute expression levels between amplified and unamplified 
expression profiles.  Because this is an amplification process, even a small percentage 
difference in amplification efficiency between the two alleles of a SNP could 
significantly skew the AEI ratio and the effect of whole transcriptome amplification 
on AEI was therefore tested experimentally. 
The effect of amplification on AER was tested using five samples which had a range 
of allelic imbalance in MLH1.  For each RNA sample, RT was performed twice using 
the standard RT protocol, once with Quantitect 2 hour amplification, and once with 
Quantitect 8 hour amplification.  Amplification RT was carried out using 20-40ng of 
starting RNA, quantified using optical densitometry.  This amount of starting RNA 
was chosen because Quantitect amplification was reported to be reliable for amounts 
of starting RNA between 10-300ng, and 10-50ng was the average yield of total RNA 
that had been previously achieved in our group from laser micro-dissection of 
atheromatous plaque macrophages, which were potentially being considered for future 
AEI investigations.  AEI was assessed using the standard four replicates from each 
RT reaction.  The mean proportional peak area of the G allele (i.e. area of G allele 
peak divided by the combined area of the G and A allele peaks) for each reaction is 
shown in Figure 3.5.  This showed that the amplification process substantially 
distorted the relative allelic peak areas, with one amplified allele tending to become 
greatly over-represented and the other under-represented in each amplification 
reaction.  In some cases this was so extreme that only a single allele was detectable in 
the AEI analysis (which is the reason that the proportional area of the G allele rather 
than the AEI ratio is represented in Figure 3.5, since ratios with a denominator of zero 
cannot be shown).  Interestingly, it was not always the same allele that was over-
represented following amplification. 
Based on these data, the AER is significantly altered by amplification using the 
Quantitect kit from 10-40ng of starting RNA.  Unamplified RNA/cDNA was 
therefore used for all subsequent experiments. 
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Figure 3.5. Effect of Quantitect cDNA amplification on relative peak area of 
MLH1 alleles.   
The proportional area of the G allele is shown on the Y-axis for five different samples (A-E) shown on 
the X-axis, for standard RT (black circles), 2h amplification RT (inverted grey triangle ∇), and 8h 
amplification RT (grey triangle ∆).  Points represent mean values and standard errors. 
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Preliminary investigation of AER in a small number of samples was performed to 
determine whether there was variation in AER between samples to allow expression 
mapping using AER.  Substantial variation was seen in allelic expression of all 
markers in CDKN2A, CDKN2B, and ANRIL, which was subsequently confirmed in 
larger data sets (data shown in Chapter 4, pages 133 and 134).  However, MTAP 
showed little inter-individual variation in AER at either transcribed marker, as shown 
in Figure 3.6, suggesting that it would not be likely to be informative for mapping the 
effects of common variation acting in cis in a study of this size.  In light of this, no 
further analysis of MTAP was performed. 
Figure 3.6. Lack of inter-individual variation in AER for MTAP.   
Y-axes show AER for MTAP transcribed SNPs rs15735 (A) and rs7023954 (B).  Individual cDNA 
samples are represented as circles, and genomic DNA samples as triangles.  Points represent mean 
AER and standard error bars.  AER in cDNA showed little variation between individuals and did not 
substantially differ from the allelic ratio in gDNA, suggesting little evidence of cis-acting effects on 
expression. 
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3.4.2.2 cDNA dilution series 
A dilution series was repeated for the genes of interest on chromosome 9, since 
differing expression levels of the genes in blood could affect the amount of cDNA 
that was needed for AEI experiments.  A dilution series was performed for each gene 
using 1µL of cDNA solution per reaction diluted with water from a starting 
concentration of 50ng/µL to determine whether lower amounts of cDNA could be 
used for AEI measurements.  Results of these dilutions on AER estimates are shown 
in Figure 3.7.  MTAP, which is most highly expressed in blood, had consistent AEI 
ratios with narrow confidence intervals down to 1/64 dilution.  However, CDKN2A 
and ANRIL which are expressed at lower levels in blood were not reliably reproduced 
below 1/4 dilutions.  For ANRIL, which had the lowest expression level in blood, PCR 
product was not reliably detected in all replicates below 1/16 dilution.  Based on the 
dilution series, 1µL of cDNA solution (equivalent to 50ng of RNA) was used for AER 
assessment of all samples.  For genomic DNA normalisation, 1µL of 50ng/µL gDNA 
solution was used. 
Figure 3.7. AER at varying cDNA dilutions.   
Estimate of AER (Y-axis) at different cDNA dilutions (X-axis) for three different assays (represented 
by different symbols as shown in the legend).  Points show the mean AER estimate, with standard error 
bars shown.  Absent points or error bars indicate the presence of failed replicates, which occurred in the 
more dilute samples. 
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3.4.2.3 Effect of assay multiplexing on AER 
The possibility of multiplexing AEI assays was investigated since this might allow the 
expression of multiple SNPs to be tested in the same sample, thereby reducing the 
amount of cDNA needed for analyses.  In this experiment, PCR was performed for 20 
samples using both the CDKN2A and ANRIL PCR primers in the same reaction.  Each 
reaction was carried out in four replicates.  However, during RealSNP assay design 
for genotyping purposes the expressed polymorphisms for CDKN2A and ANRIL had 
been designed into different assays (rs3088440 and rs10965215 in W1; rs11515 and 
rs564398 in W2) and assays for these SNPs were not compatible for combined 
analysis because some products were too similar in mass for separate MALDI-TOF 
peaks to be accurately distinguished.  For these SNPs, the PCR reaction volume was 
increased to 15µL and the product was divided between two separate extension 
reactions.  The correlation of multiplexed AER with uniplexed AER for ANRIL SNPs 
within individuals is shown in Figure 3.8.  These values were strongly correlated 
(r=0.81, P<0.0005) and these multiplex combinations were therefore used in 
subsequent AEI experiments. 
Figure 3.8. Comparison of AER for ANRIL SNPs assessed in uniplex and 
multiplex.   
Points represent mean AER for each individual with standard error bars and regression line. Pearson 
correlation coefficient is shown. 
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3.4.2.4 Linearity and normality of AER estimates 
The appropriateness of genomic normalisation ratios and linearity of the AER 
response were checked by mixing PCR products from individuals homozygous for the 
minor and major alleles of each transcribed SNP in varying ratios (8:1, 4:1, 1:1, 1:4, 
1:8) and using these as template for the allelic expression assays.  As shown in Figure 
3.9, these experiments confirmed that allelic expression showed a linear response, 
which is essential for the analysis procedure, and that normalisation ratios obtained 
using allelic expression assays on a 1:1 mixture of alleles for each SNP correspond to 
normalisation ratios obtained from genomic DNA (see also Table 3.1, page 113).  The 
slope of the line was similar for the transcribed SNPs in a particular gene, such that 
AER values could be combined with no adjustment, as described in the section below.  
Despite the linearity of these measurements, the slope of the lines was not exactly 1 in 
all cases.  This could represent a bias in the efficiency with which each allele was 
amplified, or a bias in the dilution process of this experiment.  An experimental 
dilution bias would not influence the results of aeQTL mapping experiments.  If there 
was an effect due to differences in amplification efficiency, this would not affect the 
significance estimates for aeQTL mapping, but could influence the estimated 
magnitude of the cis-acting effect.  The measured effect would tend to underestimate 
the true effect in each case, and so, if anything the effect sizes reported in this study 
are conservative estimates of the magnitude of the true cis-acting effects.  
To assess the distribution of AER measurements and check that the variance of AER 
assessment was similar in samples with different degrees of allelic imbalance, AER 
assessment was performed using 20 replicates in two samples with different degrees 
of AER at the ANRIL transcribed SNP rs10965215.  Log-transformed AER values did 
not deviate significantly from a normal distribution (P>0.05 for the Anderson-Darling 
test) and there was no significant difference in the variance of these samples using the 
equal variance test (P>0.05). 
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Figure 3.9. Linear relationship between measured and expected allelic expression 
ratios for alleles mixed in known ratios.   
Plots show the expected (X-axis) and measured (Y-axis) AER for alleles mixed in known ratios (8:1, 
4:1, 1:1, 1:4, 1:8) at transcribed SNPs, along with the linear regression line.  (A) CDKN2A rs3088440. 
(B) CDKN2A rs11515. (C) CDKN2B rs3217992. (D) CDKN2B rs1063192. (E) ANRIL rs10965215. (F) 
ANRIL rs564398.   
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3.4.3 Combining multiple transcribed markers for AEI analysis 
AEI was assessed for each gene using two transcribed SNPs located in the same exon.  
AERs measured at the two transcribed SNPs in each gene were highly correlated 
(CDKN2A r=0.68 P=1.7x10-3; CDKN2B r=0.80 P=1.7x10-12; ANRIL r=0.90 P=1.0x10-
26; all genes combined r=0.96 P=3x10-61), as shown in Figure 3.10.  This was expected 
since the two transcribed SNPs selected to assess AER in each gene are located in the 
same exon and the same transcripts.  Furthermore, aeQTL mapping results were 
highly correlated for the two transcribed SNPs in each gene, as shown in Figure 3.11, 
suggesting that each transcribed SNP identified similar cis-acting effects.  This was 
important since in the absence of complete LD between the SNPs, individual 
transcribed SNPs could differentially represent the effects of different haplotypes 
which may lead to differences in the cis-acting effects detected.  Such effects, if 
present, could potentially be lost in a combined analysis.  The outlying points on 
Figure 3.11 were mostly effect estimates that were not statistically significant and 
therefore represented point estimates which had higher degrees of uncertainty rather 
than evidence of true differences in cis-acting effects detected at the different 
transcribed markers.   
In view of the correlations between AER and mapping results at the two transcribed 
SNPs in each gene, the AERs from both transcribed markers were used for aeQTL 
analysis.  As expected based on the above data, the results of aeQTL mapping using 
two transcribed SNPs per gene were highly correlated with the results obtained using 
information from single transcribed SNPs, as shown in Figure 3.12.  This validates the 
methodology used for the transcribed SNP analysis. 
All subsequent analyses use this methodology unless otherwise stated.  The influence 
of this approach on the number of informative heterozygotes at which allelic 
expression could be assessed for each gene and the power to detect significant effects, 
is presented in the following chapter (Table 4.4, page 138).   
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Figure 3.10. Correlation between AER in individuals heterozygous for both 
transcribed markers in a gene.  
The X- and Y-axes show the allelic expression ratio (AER) at the two transcribed SNPs in each gene. 
Each point represents an individual who is heterozygous for both transcribed SNPs in that gene. Circles 
represent CDKN2A, squares CDKN2B, and triangles ANRIL. 
 
 
 
 
 
 
 
Figure 3.11. Comparison of aeQTL mapping results for the two transcribed 
SNPs in each gene for CDKN2A, CDKN2B and ANRIL.  
Points represent the cis-acting effect for each of the 56 mapping SNPs in each of the three genes 
estimated at transcribed SNP one (X-axis) and transcribed SNP two (Y-axis) for each gene.  SNP effect 
is the the log of the change in expression that allele 2 at the cis-acting locus produces compared to 
allele 1 (as defined on p87). 
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Figure 3.12. Comparison of aeQTL mapping results using single versus multiple 
transcribed SNPs per gene for CDKN2A, CDKN2B and ANRIL.  
Points represent the cis-acting effect for each of the 56 mapping SNPs in each of the three genes 
estimated using a single transcribed SNP per gene (X-axis) and two transcribed SNPs per gene (Y-axis) 
in the SA population.  SNP effect is the the log of the change in expression that allele 2 at the cis-acting 
locus produces compared to allele 1 (as defined on p87). 
 
 
 
 
 
 
 
 
3.4.4 Investigation of normalisation methods 
3.4.4.1 Normalisation factor quantification 
Initially, a subset of Caucasian samples was used to estimate the gDNA normalisation 
factor for each transcribed SNP.  As shown in Figure 3.13, the gDNA ratios for each 
assay were highly reproducible for each individual (as indicated by the small standard 
errors) and there was little inter-individual variability, particularly in comparison with 
the variability observed between individuals in cDNA ratios (see Chapter 4 pages 133 
and 134 for comparison with cDNA ratios).  However, for some assays the allelic 
ratios measured in gDNA ratios did deviate from a 1:1 ratio, confirming that allelic 
ratios in cDNA require correction for assay bias even using iPLEX single-base 
extension technology, which has less inherent assay bias than the previous hME 
technology.   
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Figure 3.13. Allelic ratios for genomic control DNA.   
Y-axes show AER in the Caucasian gDNA normalisation samples for the following transcribed SNPs: 
(A) CDKN2A rs11515; (B) CDKN2A rs3088440; (C) CDKN2B rs3217992; (D) CDKN2B rs1063192; 
(E) ANRIL rs564398; (F) ANRIL rs10965215, (G) MTAP rs15735, (H) MTAP rs7023954. Each point 
represents an individual, with standard error bars shown. 
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For CDKN2A and ANRIL AEI assays, the cDNA primers were designed to be exon-
spanning to make them cDNA-specific, meaning that different primers were required 
for the gDNA normalisation assays.  Although these were selected to produce similar 
sized PCR products, the amplicon sequences partially differed from those in the 
cDNA assays.  Since the normalisation process was primarily intended to correct for 
biases in the allele detection methodology (at the level of the extension reaction and 
MALDI-TOF), it was anticipated that sequences differences in the PCR amplicons 
would make little difference to the allelic ratios, especially since the AER compares 
ratios between two SNP alleles in the same sample (which differ by only 1bp and are 
likely to have similar PCR kinetics).  To investigate this, the allelic ratios obtained in 
gDNA were compared with those obtained using experimental equimolar mixes 
(performed as previously described for the linearity assessment experiments), which 
are an exact sequence match for the cDNA assay.  The normalisation ratios obtained 
using these two techniques were similar, as shown in Table 3.1.   
Table 3.1. Allelic ratios in genomic DNA. 
Gene SNP Allele 1 
/ allele 2 
Method of 
assessment 
Number of 
samples 
Mean 
allelic ratio 
(A1/A2) 
Standard 
error 
ANRIL rs10965215 G/A gDNA 1 10 0.99 0.013 
   gDNA 2 19 0.97 0.011 
   Allelic mix 1 1.02  
 rs564398 G/A gDNA 1 9 0.79 0.009 
   gDNA 2 11 0.81 0.004 
   Allelic mix 1 0.83  
CDKN2A rs3088440 G/A gDNA 1 14 0.81 0.008 
   Allelic mix 1 0.82  
 rs11515 C/G gDNA 1 14 1.58 0.015 
   Allelic mix 1 1.36  
CDKN2B rs1063192 C/T gDNA 1 12 0.96 0.008 
 rs3217992 G/A gDNA 1 12 0.97 0.018 
MTAP rs15735 C/A gDNA 1 12 0.97 0.020 
 rs7023954 A/G gDNA 1 12 0.99 0.003 
*primers perfect control for cDNA sequence. P1 = primer pair 1, P2 = primer pair 2 (producing 
genomic amplicons of differing sequence). 
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As presented in the following chapter, AEI analysis for ANRIL showed substantial 
effects for the transcribed SNPs, which can occur with normalisation artefacts.  An 
additional gDNA primer pair for ANRIL that produced a product of similar size but 
different sequence showed no significant difference in the allelic ratio in gDNA 
(P>0.05), as shown in Table 3.1, confirming the appropriateness of the gDNA 
normalisation strategy.  Biases attributable to sequence differences in the gDNA 
normalisation assay were likely to be less than the potential biases that could be 
introduced using an experimental 1:1 equimolar mix, and the gDNA normalisation 
factor was therefore used for normalisation in all subsequent analyses. 
For CDKN2B the same primers were used to measure the AER in cDNA and gDNA.  
This had the advantage that AERs in genomic DNA were perfect experimental 
controls for normalisation of the cDNA, but the disadvantage that gDNA remaining in 
the RNA solution or gDNA contamination could potentially influence the results.  To 
exclude effects from DNA remaining in the RNA solution after DNase treatment, 
control reactions were performed using the DNase treated RNA solution as template 
for the PCR reaction.  There was no amplification in controls, demonstrating that 
DNase treatment was adequate (as illustrated in Figure 3.14). 
Figure 3.14. Agarose gel electrophoresis showing no amplification of DNA from 
RNA solution after DNase treatment.  
Gel shows the products of 45-cycle multiplex CDKN2B AEI PCR, run alongside a DNA ladder with 
100bp markers. Amplification is seen in genomic DNA controls (gDNA) but not in the no-template 
controls (NTC) or DNase treated RNA samples without reverse transcription (DNase). This confirmed 
that DNase treatment adequately removed genomic DNA and that this would not bias the AEI assay. 
 
 
 
 
 
 
 
 
 
gD
N
A 
1
NT
C 
1
gD
N
A 
2
N
TC
 
2
NT
C 
3
NT
C 
4
DN
as
e 
1
DN
as
e 
2
DN
as
e 
3
gD
N
A 
3
NT
C 
5
gD
N
A 
4
NT
C 
6
NT
C 
7
NT
C 
8
DN
as
e 
4
DN
as
e 
5
DN
as
e 
6
gD
N
A 
1
NT
C 
1
gD
N
A 
2
N
TC
 
2
NT
C 
3
NT
C 
4
DN
as
e 
1
DN
as
e 
2
DN
as
e 
3
gD
N
A 
3
NT
C 
5
gD
N
A 
4
NT
C 
6
NT
C 
7
NT
C 
8
DN
as
e 
4
DN
as
e 
5
DN
as
e 
6
100bp 
500bp 
Chapter 3: Preliminary AEI studies 
115 
3.4.4.2 Comparison of allelic ratios in genomic DNA in the Caucasian and SA 
cohorts 
Genomic ratios were subsequently analysed in all individuals from the SA cohort to 
exclude any effects of genomic copy number variants or rare sequence variants 
influencing primer binding sites, and to allow a comparison of different normalisation 
strategies of normalising each individual’s cDNA ratio to the ratio obtained in their 
own genomic DNA, versus normalising all cDNA samples to a mean genomic ratio.  
As shown in Table 3.2, mean genomic allelic ratio in the SA cohort showed small 
magnitude but statistically significant differences from the original estimates in the 
Caucasian population for some assays.  However, these experiments were performed 
several months after the original experiments analysing the cDNA samples and 
estimating the normalisation ratios in the Caucasian cohort.  In the intervening period 
the Sequenom MALDI-TOF analyser had been physically moved to a different 
building and been serviced/repaired (including recalibration), and improvements had 
been made to the SpectroChips, advertised as improving peak resolution and in 
particular reducing salt adduct peaks, which could potentially influence assessment of 
AER.  Allelic ratios in gDNA were therefore repeated using the same samples 
originally used for estimation of genomic ratio in the Caucasian cohort.  As shown in 
Table 3.2, the repeated measurements differed from the original estimates, but were 
similar to the estimates obtained in the SA cohort.  It therefore seemed likely that the 
difference between the original Caucasian ratios and the SA ratios was due to assay 
shift due to the changes in the Sequenom hardware and SpectroChips.  When the SA 
genomic samples were normalised to the repeated Caucasian genomic results, AER 
did not differ between the populations, as shown in Table 3.2.  The mean gDNA ratio 
was therefore used for normalisation of all samples.  Although the absolute changes 
resulting from these differences in conditions were small, these experiments highlight 
the principle that samples that are to be compared should be analysed in exactly the 
same way, and that genomic normalisation should be performed at the same time as 
the samples.  However, recalibration of the assay using a panel of genomic controls 
can be used to correct for assay bias if unavoidable changes in conditions do occur. 
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Table 3.2. Comparison of genomic ratios obtained after Sequenom modifications. 
Gene SNP Allele 1 
/ allele 2 
Measurement Mean gDNA 
ratio 
P-value for 
comparison 
between original 
Caucasian AER 
and adjusted SA 
AER** 
ANRIL rs10965215 G/A Original Caucasian 0.97 
   SA 0.96 0.70 
   Repeat Caucasian 0.96 
 
 rs564398 G/A Original Caucasian 0.81 
   SA 0.87* 0.10 
   Repeat Caucasian 0.85 
 
CDKN2A rs3088440 G/A Original Caucasian 0.88 
   SA 0.95* 0.37 
   Repeat Caucasian 0.96 
 
 rs11515 C/G Original Caucasian 1.26 
   SA 1.29 0.42 
   Repeat Caucasian 1.27 
 
CDKN2B rs1063192 C/T Original Caucasian 0.96 
   SA 1.03* 0.03 
   Repeat Caucasian 1.07 
 
 rs3217992 G/A Original Caucasian 0.98 
   SA 0.98 0.79 
   Repeat Caucasian 0.98  
* P<0.05 for comparison between AER in original Caucasian measurement and SA measurement.      
** Adjusted SA AER measurement obtained by normalising the SA samples to the mean repeat 
Caucasian AER (dividing SA AERs by the repeat Caucasian mean AER).  Groups compared using 2-
sample t-test or Mann-Whitney test if not normally distributed. 
3.4.4.3 Influence of normalisation factor on mapping of cis-acting effects 
An analysis was performed to assess what effect variations in normalisation factor 
estimates of the size that had been observed had on mapping of cis-acting effects.  
Results of SNP mapping were compared for data normalised using the original 
Caucasian gDNA ratios, and data normalised using the uncorrected SA gDNA ratios 
(i.e. without correction for assay shift), as discussed above and presented in Table 3.2.  
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As shown in Figure 3.15, mapping results were highly correlated using the different 
normalisation factors (r=0.997, P=2x10-179).  As expected, estimates of SNP effects 
were most influenced for the transcribed SNPs themselves, but little difference was 
seen for other SNPs, despite the strength of LD in the region, suggesting that the 
methodology is robust to the effects of small variations in normalisation ratios.  The 
methodology of combining AERs from multiple transcribed SNPs per gene will tend 
to reduce errors associated with normalisation problems. 
Figure 3.15. Effect of different normalisation ratios on mapping of cis-acting 
effects for CDKN2A, CDKN2B and ANRIL. 
Points represent SNP effects for the 56 mapping SNPs in each of the three genes. SNP effect is the the 
log of the change in expression that allele 2 at the cis-acting locus produces compared to allele 1 (as 
defined on p87). 
 
 
 
 
 
 
 
3.4.4.4 Comparison of individual genomic versus pooled genomic 
normalisation 
The results of expression mapping using two different normalisation strategies were 
compared in the SA cohort: normalising to a mean population normalisation factor 
versus normalising each individual’s cDNA to their own gDNA ratio.  There was no 
significant difference in the results obtained using these two normalisation strategies, 
as shown in Figure 3.16.  The mean gDNA ratio was therefore used for normalisation 
of all samples. 
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Figure 3.16. Effect of individual normalisation of allelic expression ratios.  
Scatter plots show the estimates of effect size (A) and significance of association (B) for each of the 56 
SNPs in the three genes tested.  Each plot compares the values obtained using allelic expression ratios 
normalised to a combined normalisation factor (X-axis) versus individual normalisation of each cDNA 
ratio to the gDNA ratio from the same individual (Y-axis). Pearson correlation coefficient and the P-
value for each association are shown. SNP effect is the the log of the change in expression that allele 2 
at the cis-acting locus produces compared to allele 1 (as defined on p87). 
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3.5 Discussion 
Simulations suggest that combining data from multiple transcribed SNPs would be 
expected to increase the power of aeQTL analysis, but this study provides important 
data to support the feasibility of such an approach.  The study demonstrates that AER 
measured at multiple transcribed markers in the same transcript are closely correlated, 
and moreover, that the cis-acting effects estimated using single or multiple transcribed 
SNPs per gene are also similar.  This supports the validity of combining multiple 
markers.  This methodology may allow wider application of the aeQTL approach for 
genes which have several transcribed SNPs that are individually too rare to otherwise 
provide sufficient numbers of informative individuals.  All four of the genes we 
investigated had multiple transcribed variants, suggesting that this is not an 
uncommon situation such that this approach is likely to be of practical value.   
MTAP showed little evidence of AEI in the pilot investigations.  Although this does 
not exclude the presence of cis-acting effects that could be mapped in a study of this 
power, it means that any such effects are likely to be of small magnitude.  This gene is 
also the furthest from the CAD risk locus and had the least supportive evidence for a 
potential role in the pathogenesis of CAD and hence it was not investigated further in 
this study.   
The study demonstrates that AEI can be reliably assessed in RNA that has been stored 
for longer than a year.  Similar AEI results were obtained with hME and iPLEX 
methodologies and with multiplexed AEI reactions, offering the potential to increase 
the throughput and decrease the cost of AEI analysis on the Sequenom platform.  As 
previously discussed, a number of different approached have been used for 
normalisation of AEI measurements260, 306-309.  The consistency of AEI measurements 
in gDNA and finding that normalisation using a small number of samples did not 
substantially alter the results of aeQTL mapping compared to normalising each 
sample individually to its own gDNA ratio supports the approach of using gDNA as 
an equimolar reference for normalisation.  This suggests that the gDNA ratio may not 
need to be measured in every individual for these genes, although the situation would 
need to be investigated at other loci to exclude potential effects of CNVs and 
unannotated variants in primer-binding sequences that could alter AEI measurements.  
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A reasonable pragmatic approach might be to investigate the variance of gDNA AEI 
ratios in a subset of individuals which could then be used for normalisation if there 
was little variation in gDNA measurements, but with measurement of additional/all 
gDNA samples if there was significant inter-individual variability.  Confirmation of 
the gDNA ratio in individuals which are outliers for cDNA AEI expression should 
also be performed.  Small differences in the normalisation ratio did not substantially 
alter the results of AEI mapping, which is likely to be particularly the case when 
multiple transcribed markers are used.  The approach of measuring AEI in 
experimental equimolar mixes provides a method of confirming the normalisation 
ratio in cases of doubt.  The same machine, reagents, and analysis settings should be 
used for cDNA and normalisation experiments, preferably performed at a similar 
time, to reduce the risk of biases due to assay shift. 
The results of AEI analysis in the chromosome 9p21 region presented in the following 
chapter are based on combined transcribed markers, iPLEX methodology, and 
normalisation to pooled gDNA ratios. 
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4 Influence of chromosome 9p21 polymorphisms on 
gene expression in cis 
4.1 Abstract 
SNPs on chromosome 9p21 are associated with CAD, diabetes and multiple cancers.  
Most risk SNPs are not present in mature transcripts, suggesting that they influence 
expression and act in cis.  This study examined the association between 56 SNPs in 
this region and peripheral blood expression of the three nearest genes CDKN2A, 
CDKN2B and ANRIL using total and allelic expression in two populations of healthy 
volunteers: 177 British Caucasians and 310 mixed-ancestry South Africans.  Total 
expression of the three genes was significantly correlated, suggesting that they are co-
regulated.  SNP associations mapped by allelic and total expression were similar 
(r=0.97, P=4.8x10-99), but the power to detect effects was greater for allelic 
expression.  The proportion of expression variance attributable to cis-acting effects 
was 8% for CDKN2A, 5% for CDKN2B, and 20% for ANRIL.  SNP associations were 
highly correlated in the two populations (r=0.94, P=10-72).  Multiple SNPs were 
independently associated with expression of each gene after correction for multiple 
testing, suggesting that several sites may modulate disease susceptibility.  Individual 
SNPs correlated with changes in expression up to 1.4-fold for CDKN2A, 1.3-fold for 
CDKN2B, and 2-fold for ANRIL.  Risk SNPs for CAD, stroke, diabetes, and 
melanoma were all associated with reduced allelic expression of ANRIL, while 
association with the other two genes was only detectable for some risk SNPs.  SNPs 
had an inverse effect on ANRIL and CDKN2B expression, supporting a role of 
antisense transcription in CDKN2B regulation.  This study suggests that modulation of 
ANRIL expression mediates susceptibility to several important human diseases. 
4.2 Introduction 
Recent GWA studies and candidate gene studies have shown that chromosome 9p21 
variants are associated with a range of conditions (as previously summarised in Figure 
1.4 on page 35).  Although candidate gene approaches usually focused on transcribed 
variants, most of the SNPs associated with disease in GWA studies are located in non-
coding regions, suggesting that their effects are likely to be mediated by influences on 
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gene expression.  Since most do not appear in mature transcripts, and there are no 
known or predicted microRNAs mapping to this region44, 316-318, these variants are 
unlikely to produce diffusible trans-acting factors and are therefore likely to influence 
expression of nearby genes in cis.  Genes in the region include the cyclin-dependent 
kinase inhibitors CDKN2A and CDKN2B, the products of which are established 
tumour suppressors that influence physiological processes that may be relevant for 
CAD such as replicative senescence, apoptosis, and stem-cell self-renewal184.  The 
region also contains the non-coding RNA ANRIL.  The function of ANRIL is 
unknown, but other processed non-coding RNAs are involved in the regulation of 
gene expression through transcriptional and translational control mechanisms199.    
At the time this study was undertaken, no other studies investigating the relationship 
between risk variants and expression in the chromosome 9p21 region had been 
published.  Two ANRIL transcript variants had been described, a short isoform 
comprised of exons 1-13, and a longer isoform containing exons 1-12 spliced to exons 
14-20195.  The AEI assay used to investigate ANRIL expression in this study used 
primers located in the first and second exons, as described in the previous chapter.  
This was primarily selected because transcribed SNPs of suitable allele frequency 
were located in exon 2.  Previous work had also suggested that antisense transcription 
within the first intron of ANRIL downregulates CDKN2B expression in cis202, hence 
the assay spanning ANRIL exons 1-2 had the advantage that it would have a plausible 
mechanistic basis for effects mediated through its expression.  However, a number of 
very recent studies suggest that the situation may be more complicated with respect to 
ANRIL alternative splicing and transcript-specific expression, as presented in the 
discussion chapter155, 197, 200.  Throughout this chapter, unless otherwise stated 
‘ANRIL’ expression will be used to refer to expression measured using the exon 1-2 
assay.  Preliminary work using assays located in different ANRIL exons will be 
presented separately.  
As previously discussed, genetic effects on expression can be investigated using total 
expression levels (eQTL mapping) or allelic expression levels (aeQTL mapping).  
Simulations suggest that the power to detect cis-acting effects will be greater for the 
aeQTL approach in the presence of significant trans-acting influences.  Expression of 
CDKN2A/ARF and CDKN2B has been shown to be influenced by factors that are 
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likely to act in trans, including age, chemotherapeutic agents, levels of transcriptional 
regulators, and DNA damage by ultraviolet or ionizing radiation183, suggesting that 
analysis of allelic expression may be superior to total expression for mapping cis-
acting effects at this locus.  However, the power of the two approaches has never been 
compared experimentally.  Cis-acting regulatory elements for CDKN2A and CDKN2B 
have been identified in vitro using reporter assays186, 187, 189, 319, 320, but the in vivo 
relevance of these elements also needs to be confirmed.   
Caucasian populations have strong LD in the chromosome 9p21 region which limits 
the ability to separate the effects of individual SNPs on expression129.  Populations of 
African ancestry in general show less LD than Caucasian populations321, 322, and this 
has been exploited to improve the fine-mapping of functional polymorphisms 
associated with quantitative traits at other loci 266, 323.  Analysis of LD in the HapMap 
YRI population suggested that such an approach may be useful in the chromosome 
9p21 region. 
4.3 Aims 
The aims of this chapter were: 
• To map the variants associated with CDKN2A, CDKN2B and ANRIL 
expression in the chromosome 9p21 region and determine whether disease-
associated variants correlate with expression of these genes. 
• To investigate whether effects on gene expression could be mapped with 
greater resolution using a population of African ancestry. 
• To determine whether multiple loci are independently associated with 
expression at the chromosome 9p21 region. 
• To compare the power of total and allelic expression for mapping cis-acting 
effects. 
• To investigate whether cis-acting effects differ between transcripts for 
CDKN2A/ARF and ANRIL isoforms.  
• To investigate the influence of microsatellite rs10583774 on expression of 
CDKN2A, CDKN2B and ANRIL expression. 
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4.4 Materials and methods 
4.4.1 Participants, samples, genotyping, mapping SNPs, and AEI 
methods 
As described in the previous chapter.  AEI assays were performed using iPLEX 
methodology and were normalised to pooled gDNA controls.  Microsatellite 
genotyping was performed as described in Chapter 2. 
4.4.2 Relative quantification of total gene expression using real-
time PCR 
Real-time PCR reactions were performed using TaqMan methodology as described in 
Chapter 2. Commercially available FAM-labelled TaqMan assays (Applied 
Biosystems) were used for CDKN2A exons 2-3 (Hs00923894_m1) and ANRIL exons 
1-2 (Hs01390879_m1).  A custom FAM-labelled assay was used for exon 2 of 
CDKN2B.  Commercially available VIC-labelled TaqMan assays were used for three 
reference genes shown to be suitable for normalisation of expression in peripheral 
blood291, 292: B2M (4326319E), GAPDH (4326317E), and HPRT1 (4326321E).  
TaqMan assays are validated by the manufacturer to have close to 100% amplification 
efficiency and assays were selected to quantify the same transcripts as the allelic 
expression assays.  PCR was performed according to the manufacturer’s protocol 
using four replicates, 25ng cDNA template per reaction, and the following multiplex 
combinations: CDKN2A/B2M, CDKN2B/GAPDH, and ANRIL/HPRT1. 
For transcript-specific analyses, a commercially available FAM-labelled assay was 
used for exon 1β of ARF.  Custom FAM-labelled assays were also used, with 
primer/probesets located within CDKN2A exon 1α, ANRIL exon 13, and ANRIL exon 
20.  The VIC-labelled TaqMan assays for B2M and GAPDH (described above) were 
used for reference of these assays, using the following multiplex combinations: 
CDKN2Aspecific/B2M, ARF/GAPDH, ANRILexon13/B2M, and 
ANRILexon20/GAPDH.  Normalisation was performed using the reference genes 
performed on the same plate as the target genes.  The methodology was otherwise 
unchanged. 
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Relative total expression was analysed using the comparative cycle threshold (Ct) 
method.  Ct values for each target gene were normalised to the average Ct value of the 
reference genes291.  Standard errors and variances of measurements for allelic and 
total expression analyses in the SA population are shown in Table 4.1.  
Table 4.1. Comparison of variances between total expression and allelic 
expression measurements in the SA cohort. 
 
 Total expression  Allelic expression 
 Variance 
within 
samples 
Variance 
between 
samples 
Transcribed 
marker 
Variance 
within 
samples 
Variance 
between 
samples 
rs3088440 0.016 0.111 CDKN2A 0.057 0.434 
rs11515 0.028 0.064 
rs1063192 0.043 0.044 CDKN2B 0.038 0.478 
rs3217992 0.018 0.039 
rs10965215 0.073 0.106 ANRIL  0.590 0.697 
rs564398 0.063 0.076 
 
4.4.3 Statistical analyses 
4.4.3.1 aeQTL and eQTL mapping 
Allelic expression analysis was performed as described in Chapters 2 and 3304.  The 
association between total expression and each of the mapping SNPs was assessed 
using linear regression of the log transformed normalized expression values on the 
genotype.  Plots illustrating the associations between genotype and total expression 
for selected SNPs are shown in Figure 4.1.  The effect of including age, sex, and 
ethnicity as covariates, as well as excluding outlying individuals was investigated.  
Self reported ethnicity was included as a categorical variable (categorised as “Cape 
mixed-ancestry”, “black African”, “white”, “Indian”, and “other”).   
Since total expression data was only available for the SA cohort, unless otherwise 
stated analyses directly comparing allelic and total expression data only included 
allelic expression data from the SA cohort to make the results comparable. 
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Figure 4.1. Effect of genotype on total expression of ANRIL for selected SNPs.  
Y-axis shows the normalised total expression value for ANRIL. X-axis shows genotype for SNPs with 
cis-acting effects: (A) rs564398; (B) rs10965215; (C) rs7865618. Linear regression lines are shown as 
solid lines, with dotted lines indicating the 95% confidence intervals 
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4.4.3.2 Correction for multiple testing 
For both total and allelic expression, multiple testing was taken into account by 
calculating the family wise error rate using a Bonferroni correction for the 56 SNPs 
tested.  Associations with family wise error rate (FWER) below a threshold of 0.05 
(corresponding to a nominal P-value of 8.9x10-4, –log10P of 3.05, and –log10FWER of 
1.3) were considered significant. 
4.4.3.3 Estimation of cis and trans effects 
From the allelic and total expression data it is also possible to estimate the proportion 
of total expression variance that is due to cis-acting effects.  This assumes that cis and 
trans-acting factors act in an additive manner, do not interact, are independent, and 
that there is random mating, no segregation distortion (i.e. an equal probability of 
each allele being passed on to offspring), and the locus is not subject to imprinting.  
Under these assumptions, expression from each allele (designated as e1 and e2) can be 
decomposed into two components, one that is allele specific resulting from cis-acting 
factors and one that is shared between both alleles and reflects trans-acting 
influences.  Total expression is the sum of the contributions from both chromosomes 
(i.e.  21 ee + ).  The ratio 21 /1 ee  and cis and trans effects on expression are assumed to 
be the same for maternal and paternal alleles in the population.  Based on these 
assumptions, calculations to estimate the proportion of total expression variance that 
was due to cis-acting effects were derived by Dr Mauro Santibanez Koref as follows: 
The variance due to cis acting effects, ( )cV , can therefore be estimated as 
( ) ( )∑
=






+
−
−
=
n
i i
i
Ti
r
r
e
n
cV
1
2
2
1
1
12
1
ˆ
, where ir is the allelic expression ratio for individual i, 
and the proportion of the total variance due to cis acting effects can be estimated as 
( )
( )TeV
cV
ˆ
ˆ2
, where ( )TeVˆ  is the estimated total variance, i.e. 
( ) ( )∑
=
−
−
=
n
i
TTiT ee
n
eV
1
2
1
1
ˆ with ∑
=
=
n
i
TiT e
n
e
1
1
 and Tie represent the total expression 
level for individual i as determined by real time PCR.  
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4.5 Results 
4.5.1 Genotyping results 
Information on the selected SNPs and genotyping data are summarised in Table 4.2.  
A higher proportion of SNPs in the NE Caucasian cohort showed significant 
deviations from HWE at the P<0.05 threshold (12/53, 23%) and the P<0.01 threshold 
(2/53, 4%) than would be expected by chance alone.  Using the same assays in the SA 
cohort, only 1/56 SNPs (1.7%) deviated from HWE at the P<0.05 threshold.  This 
issue and its further investigation are dealt with in detail in Chapter 5. 
4.5.2 Variability of CDKN2A, CDKN2B and ANRIL expression 
4.5.2.1 Inter-individual variation in expression 
Total expression levels showed substantial inter-individual variation for each of the 
three genes, up to 13.9-fold for CDKN2A, 36.1-fold for CDKN2B, and 25.5-fold for 
ANRIL.  Plots of the normalised total expression Ct values are shown in Figure 4.2.  
Allelic expression ratios at individual transcribed markers also showed considerable 
inter-individual variation, up to 5.6-fold for CDKN2A, 2.4-fold for CDKN2B, and 6.8-
fold for ANRIL.  Plots of the allelic expression ratios at each transcribed SNP in the 
SA and Caucasian cohorts are shown in Figure 4.3 and Figure 4.4.  Systematic 
overexpression of one allele was observed at both transcribed SNPs in ANRIL (D’=1, 
r
2
=0.14 between these SNPs in the SA cohort), suggesting that cis-acting influences 
on expression were attributable to the transcribed SNPs themselves, or to elements in 
strong LD with them.  The transcribed markers in the other genes did not show 
consistent overexpression of one allele, but the increased variability of the expression 
ratios compared to the gDNA samples indicated the presence of cis-acting effects 
attributable to loci that were not in strong LD with the transcribed markers. 
Standard errors for ANRIL were higher than for the other two genes in both the allelic 
and total expression assays, which is likely to be due to the fact that peripheral blood 
expression of ANRIL was lower than for CDKN2A and CDKN2B. 
  
Table 4.2. Summary of included SNPs.  
Caucasian cohort SA cohort 
SNP ID Chr position Gene info Functional info Selection reason % Genotyped MAF Heterozygosity Alleles HW P-value % Genotyped MAF Heterozygosity Alleles HW P-value 
rs7023954 21806758 MTAP   MTAP gene 96.0 0.44 0.50 G:A 1.00 94.8 0.34 0.42 G:A 0.33 
rs15735 21852271 MTAP   MTAP gene 100.0 0.25 0.44 A:C 0.06 98.7 0.41 0.40 A:C 0.003 
rs1134871 21852897 MTAP   MTAP gene 98.9 0.23 0.40 T:A 0.20 100.0 0.43 0.43 A:T 0.04 
rs3731257 21956221   Ovarian ca Phenotypic association 97.7 0.32 0.39 G:A 0.23 99.4 0.21 0.35 G:A 0.41 
rs3088440 21958159 CDKN2A transcribed 
Melanoma, Pancreatic ca, 
Ovarian ca, Bladder ca 
CDKN2A Transcribed 
100.0 0.07 0.13 G:A 1.00 100.0 0.21 0.33 G:A 0.87 
rs11515 21958199 CDKN2A transcribed 
Alzheimer’s, Bladder ca, 
Pancreatic ca 
CDKN2A transcribed 
98.9 0.11 0.19 C:G 1.00 100.0 0.14 0.24 C:G 0.64 
rs3731249 21960916   Breast ca, melanoma, ALL Phenotypic association 98.3 0.02 0.04 C:T 1.00 99.7 0.01 0.02 C:T 1.00 
rs3731239 21964218   CAD, breast ca Phenotypic association 95.5 0.35 0.44 T:C 0.73 100.0 0.15 0.26 T:C 1.00 
rs3814960 21965017 CDKN2A promoter   Promoter F     98.7 0.38 0.44 C:T 0.23 
rs36228834 21965319 CDKN2A promoter   Promoter 98.3 0.02 0.04 T:A 1.00 99.7 0.01 0.02 T:A 1.00 
rs7036656 21980457     Tag 96.6 0.25 0.40 T:C 0.56 100.0 0.23 0.36 T:C 0.87 
rs2811711 21983964 ANRIL promoter   Promoter 98.3 0.16 0.28 T:C 1.00 99.4 0.09 0.16 T:C 0.67 
rs1801022 21984347 ANRIL promoter   Promoter 97.7 0.00 0.00 C:C 1.00 99.7 0.00 0.00 C:C 1.00 
rs2518723 21985882 CDKN2AARF promoter Colorectal ca Phenotypic association 92.1 0.43 0.41 C:T 0.05 99.4 0.45 0.50 C:T 0.97 
rs3218022  21987723 CDKN2AARF promoter   Promoter 97.7 0.00 0.01 T:C 1.00 99.7 0.03 0.06 T:C 1.00 
rs3218020  21987872 CDKN2AARF promoter   Promoter 100.0 0.42 0.42 G:A 0.08 99.7 0.25 0.40 G:A 0.29 
rs2811712 21988035 CDKN2AARF promoter Frailty, breast ca Phenotypic association 97.2 0.06 0.12 A:G 1.00 99.7 0.22 0.37 A:G 0.11 
rs3218018 21988139 CDKN2AARF promoter Diabetes Phenotypic association 98.3 0.04 0.09 T:G 1.00 99.7 0.08 0.15 T:G 1.00 
rs3218012 21988660 CDKN2AARF promoter Colorectal ca Phenotypic association 97.7 0.50 0.45 G:A 0.18 99.7 0.46 0.53 G:A 0.33 
rs3218009 21988757 CDKN2AARF promoter CAD Phenotypic association 96.0 0.13 0.22 G:C 1.00 100.0 0.03 0.06 G:C 0.08 
rs3218005 21990247   Breast ca Phenotypic association 96.6 0.04 0.08 T:C 1.00 99.4 0.21 0.36 T:C 0.18 
rs3217992  21993223 CDKN2B transcribed CAD CDKN2B transcribed 98.3 0.46 0.41 G:A 0.02 100.0 0.24 0.36 G:A 1.00 
rs1063192 21993367 CDKN2B transcribed Glioma CDKN2B transcribed 98.9 0.42 0.40 T:C 0.02 100.0 0.18 0.28 T:C 0.70 
rs3217986 21995330 CDKN2B transcribed   CDKN2B transcribed 96.6 0.08 0.14 A:C 0.55 100.0 0.08 0.14 A:C 0.64 
rs2069418 21999698 CDKN2B promoter   Promoter 97.7 0.44 0.43 C:G 0.15 98.7 0.18 0.30 C:G 1.00 
rs495490 22000412 RDINK4/ARF   Promoter 95.5 0.11 0.19 T:C 0.69 100.0 0.03 0.05 T:C 1.00 
rs7044859 22008781   CAD, stroke Phenotypic association 98.9 0.48 0.44 A:T 0.14 100.0 0.30 0.43 A:T 0.97 
rs496892 22014351   CAD, stroke Phenotypic association 100.0 0.40 0.42 G:A 0.14 100.0 0.30 0.45 G:A 0.35 
rs615552 22016077     Tag 95.5 0.41 0.39 A:G 0.02 99.7 0.17 0.29 A:G 1.00 
rs10965215 22019445 ANRIL transcribed   ANRIL transcribed 100.0 0.46 0.40 A:G 0.01 100.0 0.42 0.50 G:A 0.71 
  
rs564398 22019547 ANRIL transcribed Diabetes, CAD, stroke ANRIL transcribed 97.7 0.38 0.39 A:G 0.02 100.0 0.17 0.28 A:G 0.99 
rs7865618 22021005   CAD, stroke Phenotypic association 98.9 0.41 0.39 A:G 0.02 100.0 0.18 0.27 A:G 0.22 
rs17694493 22031998     Tag 96.6 0.09 0.18 C:G 0.50 100.0 0.10 0.18 C:G 1.00 
rs10738605 22039130 ANRIL transcribed   ANRIL transcribed 98.9 0.45 0.41 G:C 0.02 99.4 0.45 0.50 G:C 1.00 
rs11790231 22043591     Tag 96.6 0.12 0.21 G:A 0.96 100.0 0.06 0.11 G:A 0.64 
rs2184061 22051562     Tag 93.2 0.38 0.41 A:C 0.10 99.7 0.40 0.49 A:C 0.91 
rs1011970 22052134   Melanoma Tag 83.6 0.16 0.28 G:T 0.96 97.4 0.28 0.42 G:T 0.45 
rs10811650 22057593     Tag 95.5 0.47 0.37 C:G 0.001 100.0 0.29 0.41 C:G 1.00 
rs16905599 22059144     Tag F     91.9 0.19 0.29 G:A 0.51 
rs10116277 22071397   CAD, stroke Phenotypic association 100.0 0.49 0.36 T:G 0.0002 100.0 0.26 0.37 T:G 0.63 
rs10965227 22071796     Tag 96.0 0.22 0.35 A:G 1.00 100.0 0.09 0.15 A:G 0.20 
rs1547705 22072375     Tag 96.0 0.12 0.19 A:C 0.75 99.7 0.11 0.19 A:C 0.95 
rs10965228 22072380     Tag 96.6 0.12 0.21 A:G 0.96 100.0 0.03 0.06 A:G 1.00 
rs1333040 22073404   CAD, stroke Phenotypic association 100.0 0.36 0.37 T:C 0.02 99.4 0.41 0.48 T:C 0.94 
rs7857345 22077473     Tag 93.2 0.27 0.39 C:T 1.00 100.0 0.14 0.21 C:T 0.02 
rs10757274 22086055   CAD Phenotypic association 100.0 0.49 0.40 G:A 0.01 100.0 0.38 0.45 A:G 0.50 
rs10125231 22092128     Tag 94.9 0.02 0.03 G:A 1.00 100.0 0.01 0.02 G:A 1.00 
rs2383206 22105026   CAD, stroke Phenotypic association 100.0 0.47 0.40 G:A 0.01 100.0 0.48 0.51 G:A 0.81 
rs2383207 22105959   CAD, stroke Phenotypic association 90.4 0.42 0.44 G:A 0.33 100.0 0.23 0.32 G:A 0.15 
rs1333045 22109195   CAD Tag 96.6 0.48 0.42 C:T 0.05 99.7 0.49 0.51 T:C 0.97 
rs10757278 22114477   CAD, stroke Phenotypic association 99.4 0.50 0.42 A:A 0.05 100.0 0.36 0.41 A:G 0.05 
rs1333049 22115503   CAD Phenotypic association 100.0 0.50 0.43 C:G 0.08 100.0 0.38 0.45 G:C 0.41 
rs2891169 22121825   Diabetes Phenotypic association F     99.4 0.48 0.49 G:A 0.92 
rs2383208 22122076   Diabetes Phenotypic association 93.2 0.18 0.29 A:G 0.84 99.4 0.24 0.35 A:G 0.40 
rs10811661 22124094   Diabetes Phenotypic association 100.0 0.17 0.28 T:C 0.84 99.7 0.11 0.19 T:C 0.61 
rs10757283 22124172   Diabetes Phenotypic association 97.7 0.47 0.42 C:T 0.06 99.7 0.49 0.49 C:T 0.76 
F = SNP removed from analysis in this cohort as genotype available for <80% of individuals. CAD = coronary artery disease; MAF = minor allele frequency; HW = Hardy-
Weinberg. 
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Figure 4.2. Total expression values in the SA cohort.  
Y-axes show normalised total expression Ct values relative to reference genes for: (A) CDKN2A; (B) 
CDKN2B; (C) ANRIL. Each point represents an individual, with standard error bars shown. 
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Figure 4.3. Allelic expression ratios at transcribed SNPs in the SA cohort.  
Y-axes show AER for the following transcribed SNPs: (A) CDKN2A rs11515; (B) CDKN2A 
rs3088440; (C) CDKN2B rs3217992; (D) CDKN2B rs1063192; (E) ANRIL rs564398; (F) ANRIL 
rs10965215. Each point represents an individual, with standard error bars shown. Black circles 
represent cDNA measurements and blue circles genomic DNA measurements. 
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Figure 4.4. Allelic expression ratios at transcribed SNPs in the Caucasian cohort. 
Y-axes shows AER for the following transcribed SNPs: (A) CDKN2A rs11515; (B) CDKN2A 
rs3088440; (C) CDKN2B rs3217992; (D) CDKN2B rs1063192; (E) ANRIL rs564398; (F) ANRIL 
rs10965215. Each point represents an individual, with standard error bars shown. Black circles 
represent cDNA measurements and blue circles represent genomic DNA measurements. 
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4.5.2.2  Proportion of variance attributable to cis and trans effects 
The proportion of the variance in total expression that can be attributed to cis-acting 
effects for each transcribed SNP in the three genes was estimated, as shown in Table 
4.3. 
Table 4.3. Proportion of variance in total expression attributable to cis-acting 
effects estimated at each transcribed SNP. 
Gene Transcribed 
SNP 
Proportion of variance in total expression 
attributable to cis-acting effects 
CDKN2A rs3088440 8% 
 rs11515 4% 
CDKN2A rs3217992 5% 
 rs1063192 5% 
ANRIL rs10965215 20% 
 rs564398 19% 
  
These data demonstrate that most of the variance in expression of these genes 
observed between different individuals in the population is due to trans-acting effects.  
The proportion attributable to cis-acting effects was higher for ANRIL than for 
CDKN2A and CDKN2B. 
4.5.2.3 Correlation of CDKN2A, CDKN2B and ANRIL expression 
Total expression levels of CDKN2A, CDKN2B and ANRIL showed a modest but 
statistically significant correlation (r=0.24 to 0.30, all P<4x10-5), as shown in Figure 
4.5.  The finding of a very significant correlation between expression of these genes 
suggests that their expression is co-regulated by common trans-acting factors.  
However, the observation that the degree of correlation was only modest suggests that 
other influences on expression differ between the genes. 
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Figure 4.5. Correlations between total expression levels of CDKN2A, CDKN2B 
and ANRIL.  
Scatter plots show correlations between total expression levels for: (A) CDKN2A and CDKN2B; (B) 
CDKN2A and ANRIL; (C) CDKN2B and ANRIL. Expression values on the X- and Y-axes are shown as 
delta Ct values for the target gene relative to the three internal control genes. Circles represent 
individual samples and the crosses represent three outliers excluded from correlation analyses. Linear 
regression lines are shown as solid lines, with dotted lines indicating the 95% confidence intervals. 
Pearson correlation coefficient (r) and the P-value for each association are shown in the top left of each 
plot. 
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4.5.3  Allelic expression versus total expression for mapping cis-
acting effects 
As previously presented in Chapter 3, AERs measured at the two transcribed SNPs in 
each gene were highly correlated (r=0.96, P=3x10-61).  AEI analysis was therefore 
performed using AERs from both transcribed markers in each gene.  This approach 
increased the number of informative heterozygotes for each gene and the power to 
detect significant effects compared to the conventional single marker approach, as 
shown in Table 4.4.  
Unlike allelic expression ratios, total expression data may be influenced by covariates 
that influence expression in trans.  Total expression values were therefore corrected 
for covariates (age, sex, and ethnicity) and outlying individuals were excluded.  These 
corrections did not significantly alter the results of the eQTL analysis, as shown in 
Figure 4.6.  All subsequent analyses are presented using the covariate-corrected eQTL 
data.   
Cis-acting effects assessed by eQTL and aeQTL mapping were compared, as shown 
in Figure 4.7.  There was a strong correlation both for the effect size (r=0.87, 
P=4.7x10-51) and significance of association (r=0.97, P=4.8x10-99) at each mapping 
SNP between the two techniques, confirming that they are indeed measuring the same 
effects as expected.  However, the associations were more significant for allelic 
expression than for total expression analysis, indicating that allelic expression had 
greater power for detecting cis-acting effects.  As shown by the simulations presented 
in Chapter 1, the power of the AEI approach to detect cis-acting effects is expected to 
be greater than that of the total expression approach in the presence of substantial 
trans-acting influences on expression, since allelic expression analysis is more robust 
to the effects of trans-acting variance.  The finding of greater power with the aeQTL 
approach is therefore consistent with the estimates that cis-acting effects account for 
only between 4 and 20% of the overall inter-individual variance in expression of these 
genes. 
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Table 4.4. Increase in number of informative heterozygotes and associated SNPs 
using two transcribed SNPs per gene. 
 
Transcribed SNP Number (%) of 
informative 
heterozygotes 
in Caucasian 
cohort 
(n=177) 
Number (%) of 
informative 
heterozygotes 
in SA cohort 
(n=310) 
Number (%) of 
mapping SNPs 
significantly 
associated with 
AER at 
transcribed 
SNP(s) in 
Caucasian cohort* 
(n=53 SNPs) 
Number (%) of 
mapping SNPs 
significantly 
associated with 
AER at 
transcribed 
SNP(s) in SA 
cohort* 
(n=56 SNPs) 
CDKN2A rs3088440 23 (12%) 103 (33%) 5 (9%) 2 (4%) 
CDKN2A rs11515 33 (18%) 75 (24%) 0 (0%) 9 (16%) 
CDKN2A markers 
combined 
54 (29%) 159 (51%) 3 (6%) 11 (20%) 
     
CDKN2B rs3217992 71 (38%) 112 (36%) 0 (0%) 4 (7%) 
CDKN2B rs1063192 70 (37%) 87 (28%) 0 (0%) 2 (4%) 
CDKN2B markers 
combined 
90 (48%) 164 (53%) 5 (9%) 5 (9%) 
     
ANRIL rs10965215 70 (37%) 155 (50%) 25 (47%) 27 (48%) 
ANRIL rs564398 67 (36%) 85 (28%) 23 (43%) 22 (39%) 
ANRIL markers 
combined 
80 (43%) 187 (61%) 30 (57%) 31 (55%) 
 
* Multiple testing was taken into account by calculating the FWER using a Bonferroni correction for 
the 56 SNPs tested. Associations with FWER using a threshold of 0.05 (that corresponds to a nominal 
P value of 8.9x10-4 or –log10P of 3.05) were considered significant. SNPs with less than eight 
informative heterozygotes were excluded. 
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Figure 4.6. Effect of adjustment for covariates and outliers on total expression 
mapping.  
Scatter plots depict the estimates of effect size (A) and significance of association (B) for each of the 
56 SNPs obtained using unadjusted total expression values (X-axis) versus values adjusted for 
covariates (age, sex, ethnicity) and with outliers removed (Y-axis). Pearson correlation coefficient (r) 
and the P-value for each association are shown in the top left of each plot. SNP effect is the the log of 
the change in expression that allele 2 at the cis-acting locus produces compared to allele 1 (as defined 
on p87). 
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Figure 4.7. Significance of associations and effect size estimates using total and 
allelic expression.  
Scatter plots depict the P-values (A) and estimates of effect size (B) obtained for each SNP for all three 
genes by eQTL (X-axis) and aeQTL (Y-axis) mapping. Bar charts show the comparison of the 
significance of association for CDKN2A (C), CDKN2B (D), and ANRIL exons1-2 (E); and the effect 
size estimates for CDKN2A (F), CDKN2B (G), and ANRIL exons1-2 (H). The Y-axes on the bar charts 
show the 56 SNPs ordered by chromosome location (most telomeric at the top). Grey bars to the left 
represent total expression and black bars to the right represent allelic expression. SNP effect is the the 
log of the change in expression that allele 2 at the cis-acting locus produces compared to allele 1 (as 
defined on p87). 
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4.5.4 Comparison of cis-acting effects between populations 
As shown in Figure 4.8, LD was lower in the SA cohort than the Caucasian cohort in 
the region, as expected for a population of African ancestry.  The MAF in the SA 
population was higher for 33 of the 53 SNPs typed in both populations, which 
increases the proportion of informative heterozygotes for allelic expression analysis. 
Results of aeQTL mapping were compared between the SA and British Caucasian 
samples.  These were highly correlated between the two populations, both for the 
significance of the detected association (r=0.94, P=10-72) and the estimated magnitude 
of the effect on expression for each SNP (r=0.82, P=2x10-38), as shown in Figure 4.9.  
These data suggest that the cis-acting effects on expression for each mapping SNP 
were similar in the two populations despite the difference sin LD between them. 
 
 
  
Figure 4.8. LD in the SA and Caucasian cohorts.  
Figures show linkage disequilibrium between the 56 SNPs in each population: (A) D’ in Caucasian cohort; (B) D’ in SA cohort; (C) r2 in Caucasian cohort; (D) r2 in SA 
cohort. Colouring in (A) and (B) represents D’ values: D’=1, LOD<2 (blue); D’=1, LOD>2 (red); D’<1, LOD>2 (shades of pink); D’<1, LOD<2 (white). Shading in (C) and 
(D) represents r2 values: r2=1 (black); 0< r2<1 (shades of grey); r2=0 (white). 
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Figure 4.9. SNP effects in the SA and Caucasian cohorts.  
Scatter plots show the correlation between aeQTL results obtained in the SA (Y-axis) and Caucasian 
cohorts (X-axis) for: (A) significance of association with expression (-log P value) for all three genes; 
(B) effect size at each SNP for all three genes; (C) effect size at each SNP for CDKN2A only; (D) 
effect size at each SNP for CDKN2B only; (E) effect size at each SNP for ANRIL only. Linear 
regression line for the association is shown as a solid line with the 95% confidence intervals shown as 
dotted lines. SNP effect is the the log of the change in expression that allele 2 at the cis-acting locus 
produces compared to allele 1 (as defined on p87). 
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4.5.5 AEI analysis in the combined population 
In view of the similarity of the effects in the two cohorts, the data were combined in 
subsequent analyses, increasing the power to detect cis-acting effects of smaller 
magnitude and enabling adjustment for the effects of individual SNPs.  The 
significance of association and effect estimate for each SNP in the combined cohort 
are shown in Table 4.5.  Associations with a FWER threshold of 0.05 (corresponding 
to a nominal P-value of 8.9x10-4) were regarded as significant, and nominal P-values 
are reported in the text.  The maximum change in allelic expression associated with 
any SNP was 1.4-fold for CDKN2A, 1.33-fold for CDKN2B, and 1.97-fold for ANRIL.   
The significance of associations for individual SNPs are summarised graphically in 
Figure 4.10.  A greater number of SNPs in the chromosome 9p21 region were 
significantly associated with expression of ANRIL than with CDKN2A or CDKNB.  
Furthermore, the significance of the SNP associations was much greater for ANRIL 
than for CDKN2A or CDKN2B.  All risk variants for CAD were highly associated 
with reduced ANRIL expression, but associations with expression of the other two 
genes were not consistently seen.  Variants associated with diabetes, glioma and 
melanoma in GWA studies were also all significantly associated with ANRIL 
expression, but not consistently with expression of the other two genes.  The effects of 
SNPs associated with gene regulation in vitro and particular diseases are discussed in 
greater detail in the following sections. 
 
  
Table 4.5. Effect size and significance of association for all SNPs.  
Data shown are for aeQTL mapping in the combined population. Effects are reported as fold changes in expression for individuals who are homozygous for the minor allele 
relative to individuals who are homozygous for the major allele (calculated from allelic expression data using two transcribed SNPs per gene). Association for each SNP is 
presented as the –log10 P-value and the –log10 of the FWER using a Bonferroni correction for the 56 SNPs tested. Associations that were significant using a FWER threshold 
of 0.05 (corresponding to –log10P of 3.05, or –log10FWER of 1.3) were regarded as significant.  Significant associations for each gene are shaded grey. 
 
SNP Promoter Reported phenotypic 
associations 
Risk 
allele 
Minor 
allele  
CDKN2A 
effect  
(fold 
change) 
CDKN2A  
-log10P 
CDKN2A  
-
log10FWER 
CDKN2B 
effect  
(fold change) 
CDKN2B  
-log10P 
CDKN2B  
-log10FWER 
ANRIL 
effect (fold 
change) 
ANRIL  
–log10P 
ANRIL 
-log10FWER 
rs7023954     A 0.989 0.2 0 1.000 0 0 0.949 0.5 0 
rs15735     C 1.026 0.5 0 1.003 0.1 0 1.040 0.3 0 
rs1134871     A 0.997 0 0 1.038 2 0.3 1.057 0.5 0 
rs3731257  Ovarian ca G A 0.883 3.8 2.1 1.011 0.4 0 0.596 24.1 22.4 
rs3088440  Melanoma, pancreatic 
ca, ovarian ca, bladder 
ca 
A A 0.919 3.8 2.1 1.050 1.8 0.1 0.828 2.1 0.4 
rs11515  Alzheimer’s, bladder ca, 
pancreatic ca 
C G 1.084 4.7 3.0 0.880 8.7 7.0 0.968 0.2 0 
rs3731249  Breast ca, melanoma, 
ALL 
T T 1.404 7.5 5.8 0.752 4.1 2.4 0.899 0.1 0 
rs3731239  CAD, breast ca A C 0.947 1 0 0.997 0.1 0 1.652 25.2 23.5 
rs3814960 CDKN2A    T 0.898 3.7 2.0 0.988 0.4 0 1.039 0.3 0 
rs36228834 CDKN2A    A 1.404 7.5 5.8 0.752 4.1 2.4 0.899 0.1 0 
rs7036656     C 1.119 8.7 7.0 0.931 4.9 3.2 1.217 3.1 1.4 
rs2811711 ANRIL    C 1.197 4.2 2.5 0.965 1.1 0 1.099 0.7 0 
rs1801022 ANRIL    C NA NA NA NA NA NA NA NA NA 
rs2518723 CDKN2A/A
RF 
Colorectal ca promoter 
methylation 
C T 1.119 6.1 4.4 0.971 2 0.3 1.669 51.5 49.8 
rs3218022  CDKN2A/A
RF 
   C 1.045 0.2 0 0.985 0.1 0 0.995 0 0 
  
rs3218020  CDKN2A/A
RF 
   A 0.989 0.2 0 1.008 0.3 0 0.587 38.2 36.5 
rs2811712 CDKN2A/A
RF 
Frailty, breast ca A G 1.079 2.9 1.2 0.938 3.1 1.4 1.155 1.5 0 
rs3218018 CDKN2A/A
RF 
Diabetes G G 1.108 4 2.3 0.805 14.5 12.8 1.097 0.4 0 
rs3218012 CDKN2A/A
RF 
Colorectal ca promoter 
methylation 
A A 0.919 3.8 2.1 1.026 1.8 0.1 0.605 53.1 51.4 
rs3218009 CDKN2A/A
RF 
CAD G C 1.059 0.4 0 0.990 0.2 0 1.659 7.7 6.0 
rs3218005  Breast ca, frailty C C 1.087 3.2 1.5 0.940 2.7 1.0 1.163 1.5 0 
rs3217992   CAD A A 0.990 0.1 0 1.009 0.4 0 0.579 39.7 38.0 
rs1063192  Glioma C C 1.036 0.5 0 0.976 1.4 0 1.829 61.3 59.6 
rs3217986     C 0.914 2.2 0.5 1.049 1.1 0 0.605 8.3 6.6 
rs2069418 CDKN2B    G 1.031 0.5 0 0.976 1.4 0 1.852 72 70.3 
rs495490 RDINK4/ARF    C 1.131 1.1 0 0.955 1.2 0 1.970 12.8 11.1 
rs7044859  CAD, stroke A T 1.089 3.6 1.9 0.945 6.4 4.7 1.797 61.7 60.0 
rs496892  CAD, stroke G A 1.102 4.5 2.8 0.952 4.7 3.0 1.775 63.3 61.6 
rs615552     G 1.028 0.4 0 0.980 1 0 1.857 80 78.3 
rs10965215     A 0.936 2.1 0.4 1.014 0.7 0 0.599 76.6 74.9 
rs564398  Diabetes, CAD, stroke A G 1.034 0.5 0 0.978 1.2 0 1.865 81.3 79.6 
rs7865618  CAD, stroke A G 1.035 0.5 0 0.979 1.1 0 1.870 78.2 76.5 
rs17694493     G 1.103 3.5 1.8 0.862 10.2 8.5 1.234 1.9 0.2 
rs10738605     C 1.116 5.6 3.9 0.968 2.4 0.7 1.689 57.5 55.8 
rs11790231     A 1.006 0 0 0.980 0.4 0 0.618 7.1 5.4 
rs2184061     C 1.021 0.4 0 1.010 0.4 0 1.697 53.2 51.5 
rs1011970  Melanoma T T 0.995 0.1 0 0.953 2.5 0.8 0.802 3.8 2.1 
rs10811650     G 0.988 0.2 0 1.000 0 0 0.629 31.7 30.0 
  
rs16905599     A 0.907 3.6 1.9 1.028 0.7 0 0.684 8.1 6.4 
rs10116277  CAD, stroke T G 0.979 0.4 0 0.984 0.7 0 1.573 21.9 20.2 
rs10965227     G 0.966 0.5 0 0.949 2.2 0.5 1.008 0 0 
rs1547705     C 1.031 0.4 0 0.999 0 0 0.734 3.6 1.9 
rs10965228     G 1.104 0.8 0 0.958 1.2 0 1.504 6 4.3 
rs1333040  CAD, stroke T C 0.963 1 0 1.012 0.4 0 1.406 12.1 10.4 
rs7857345     T 0.935 1.3 0 1.016 0.5 0 1.779 25 23.3 
rs10757274  CAD G G 1.039 1 0 0.975 1.2 0 0.685 14.5 12.8 
rs10125231     A 1.101 0.3 0 0.961 0.3 0 1.280 0.7 0 
rs2383206  CAD, stroke G A 0.968 0.9 0 1.007 0.2 0 1.456 15 13.3 
rs2383207  CAD, stroke G A 0.946 1.5 0 0.982 0.7 0 1.468 14 12.3 
rs1333045  CAD C C 1.037 1 0 0.981 0.8 0 0.700 12.8 11.1 
rs10757278  CAD, stroke G G 1.039 0.9 0 0.986 0.5 0 0.700 11.7 10.0 
rs1333049  CAD C C 1.023 0.5 0 0.996 0.1 0 0.704 12.1 10.4 
rs2891169  Diabetes G A 1.042 1 0 0.977 0.8 0 1.059 0.5 0 
rs2383208  Diabetes G G 1.081 1.9 0.2 0.989 0.3 0 1.239 3.4 1.7 
rs10811661  Diabetes T C 1.182 4 2.3 0.957 1.8 0.1 1.339 4.6 2.9 
rs10757283  Diabetes T T 1.010 0.2 0 1.002 0.1 0 1.024 0.2 0 
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Figure 4.10. Significance of association with expression for SNPs in the combined 
population.  
The Y-axis represents the –log P value for individual SNPs (shown in chromosomal order along the X-
axis) for: CDKN2A (A); CDKN2B (B); ANRIL (C). The horizontal black line on each graph represents 
the significance threshold after adjustment for multiple testing (FWER=0.05 corresponding to -
log10P=3.05). The relative location of genes and promoter elements is represented at the top (CDKN2A 
and CDKN2A/ARF promoters yellow; ANRIL promoter blue; CDKN2B promoter orange; 
CDKN2A/ARF regulatory domain red). Letters along the bottom represent associations from GWA 
studies (C=CAD, D=diabetes, M=melanoma, G=glioma) and the black bar at the bottom represents the 
core risk haplotype for CAD defined by Broadbent et al 129. 
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4.5.6 Adjusting for the effects of individual SNPs 
As shown in Figure 4.10, multiple SNPs were associated with cis-acting influences on 
expression of CDKN2A, CDKN2B and ANRIL.  This could be the result of multiple 
independent loci influencing expression of each gene, but could also be a reflection of 
strong LD in the region since associations might be observed for ‘non-functional’ 
SNPs (that do not directly influence expression) which are in LD with other 
‘functional’ polymorphisms.  Adjusting for the effect of individual SNPs was used to 
assess whether multiple SNPs were independently correlated with expression of the 
three genes, as shown in Figure 4.11.  For each gene stepwise adjustments were made 
for the effect of the SNP which showed the most significant association with 
expression, until independent effects could no longer be detected.  Associations 
remained significant after adjusting for the top SNP for CDKN2A and CDKN2B, and 
the top two SNPs for ANRIL. 
These results indicate that even after adjusting for the effects of the most significant 
marker, some of the remaining SNPs still showed significant association with ANRIL 
expression.  This could be explained by the presence of more than one functional 
polymorphism affecting expression, but could also reflect the presence of a functional 
polymorphism that is in LD with both markers.  However, examination of the allelic 
expression patterns provides additional support for the presence of multiple sites 
affecting expression.  For example, Figure 4.12 shows the allelic expression ratios 
observed at the transcribed SNP rs564398 in ANRIL, grouped according to the 
genotype at rs10965215.  These two SNPs are in strong LD (D’=0.98), hence the 
absence of individuals homozygous for the A allele at rs10965215 that are 
heterozygous at rs564398.  The G allele of the transcribed SNP (rs564398) was 
overexpressed (G/A AER values greater than 1), however overexpression was 
stronger (P=10-15 using the Mann-Whitney test) for individuals that were also 
heterozygous at the second polymorphism (rs10965215).  This pattern is not 
consistent with allelic expression being determined by a single biallelic polymorphism 
acting in cis and suggests that there is more than one functional polymorphism or that 
this polymorphism is multiallelic.  
 
 150 
 
Figure 4.11. Effect of sequential adjustment for most highly associated SNPs.  
The Y-axis represents the –log P value for individual SNPs (shown in chromosomal order along the X-axis). (A) Unadjusted. (B) Adjusted for the most highly associated 
SNP for each gene (CDKN2A rs7036656, CDKN2B rs3218018, ANRIL rs564398). (C) Adjusted for the two most highly associated SNPs for each gene (CDKN2A rs7036656 
and rs36228834, CDKN2B rs3218018 and rs3814960, ANRIL rs564398 and rs10965215). Values in the top right corner are the number of significantly associated SNPs after 
each round of adjustment, following correction for multiple testing. The remaining SNP showing association with ANRIL expression was rs495490.  The horizontal black line 
on each graph represents the significance threshold after adjustment for multiple testing (FWER=0.05 corresponding to -log10P=3.05). 
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Figure 4.12. Effect of genotype at rs10965215 on allelic expression ratio of 
transcribed ANRIL SNP rs564398.  
 
Diamonds represent the allelic expression ratio for each individual, all of whom are heterozygous for 
the transcribed SNP rs564398. The first column shows individuals who are homozygous for 
rs10965215 (mean ratio 1.57), and the second column shows individuals who are heterozygous for 
rs10965215 (mean ratio 2.00). The third column shows the expression ratio obtained from genomic 
DNA in individuals who are heterozygous for the transcribed SNP rs564398, where the two alleles are 
present in a 1:1 ratio (mean ratio 1.00).  
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The direction of cis-acting effects on expression was compared between genes for 
SNPs showing significant associations with expression of each gene, as shown in 
Table 4.6.  SNP effects for CDKN2A and ANRIL were in the same direction for all 10 
SNPs, meaning that alleles associated with overexpression of CDKN2A were also 
associated with overexpression of ANRIL.  By contrast, for all 8 SNPs that were 
significantly associated with allelic expression of both CDKN2A and CDKN2B, the 
alleles associated with CDKN2A overexpression were associated with CDKN2B 
underexpression.  Similarly for all 3 SNPs significantly associated with allelic 
expression of both CDKN2B and ANRIL, alleles associated with overexpression of 
CDKN2B were associated with ANRIL underexpression.  The total expression analysis 
had insufficient power for similar analyses to be performed.  
 
Table 4.6. Correlation of SNP effects between genes by aeQTL mapping.  
The table shows the SNP effect between genes for SNPs that show significant association (using 
FWER threshold of 0.05) with expression of both genes. Gene pairs are shown along the top. SNP 
effects in the same direction means that a SNP is associated with overexpression or underexpression of 
both genes, whereas SNP effects in the opposite direction means that a SNP associated with 
underexpression of one gene is associated with overexpression of the other gene. 
 
 
 CDKN2A-ANRIL CDKN2B-ANRIL CDKN2A-CDKN2B 
SNP effects 
same direction 
10 0 0 
SNP effects 
opposite 
0 3 8 
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4.5.7 In vivo effects of putative regulatory elements identified in 
vitro 
Whether SNPs within regulatory regions previously identified by in vitro reporter 
assays were associated with cis-acting effects on expression in vivo was also 
investigated (full data contained in Table 4.5).  
CDKN2A expression was significantly correlated with SNPs in its promoter and the 
ARF  transcript promoter186, 187, 319, 320, and with SNPs close to the regulatory domain 
(RDINK4/ARF) that has been shown to regulate expression of CDKN2A, ARF and 
CDKN2B in vitro189.  
CDKN2B expression was also significantly correlated with SNPs in the CDKN2A and 
ARF promoter regions, suggesting that these elements influence expression of both 
genes.  CDKN2B expression was not significantly correlated with the single SNP 
typed in its promoter (rs2069418) prior to adjustment, but this became significant 
after adjustment for the most significant SNP in the ARF promoter (rs3218018).  
ANRIL expression was strongly associated with SNPs in the CDKN2B promoter 
(P=10-72), ARF promoter (P up to10-53) and RDINK4/ARF domain (P=10-12), as well as 
with SNPs adjacent to the CDKN2A promoter (rs3731239, P=10-25).  
These data confirm in vivo the function of the regulatory elements identified by in 
vitro transfection studies, and provide further evidence that shared cis-acting elements 
influence expression of CDKN2A, CDKN2B and ANRIL. 
4.5.8 Effects of disease associated SNPs on expression 
The study also examined the correlation of allelic expression of CDKN2A, CDKN2B 
and ANRIL with SNPs reported to confer disease susceptibility (full data contained in 
Table 4.5). 
4.5.8.1 CAD and stroke 
SNPs within the core risk haplotype region for CAD129 were associated with ANRIL 
expression (P up to 10-21), but none were associated with CDKN2A or CDKN2B 
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expression.  CAD risk alleles were all associated with reduced ANRIL expression, up 
to 1.9-fold, suggesting that expression of ANRIL, rather than CDKN2A or CDKN2B, 
might mediate atherosclerosis susceptibility.  However, other CAD risk variants 
located telomeric to the core risk haplotype region such as rs7044859 and rs496892 
showed substantially larger effects and stronger associations with ANRIL expression 
(P<10-60 for each SNP), and were also significantly associated with CDKN2A and 
CDKN2B expression (P<10-4 for each SNP).  The CAD risk alleles at these SNPs 
correlated with reduced expression of ANRIL and CDKN2A, but increased CDKN2B 
expression.  Associations for these SNPs remained significant after adjusting for the 
effect of the lead CAD SNPs within the core risk haplotype region (rs10757274, 
rs2383206, rs10757278 and rs1333049)129, but SNPs within the core risk haplotype 
were no longer significantly associated with ANRIL expression after adjusting for the 
effect of SNPs at the distal locus (rs10965215 and rs564398).  This suggests that the 
core CAD risk haplotype does not account for all of the observed association with 
ANRIL expression in peripheral blood. 
Based on evolutionary conservation and effects on ANRIL transcription, rs1333045 
within the core risk haplotype has been previously highlighted as a potential 
functional variant responsible for conferring susceptibility to CAD at the 9p21 
locus200.  In our analysis rs1333045 was associated with ANRIL expression (P=10-12), 
but not with CDKN2A or CDKN2B expression.  Its effects were similar to those of 
other SNPs in the core risk haplotype for CAD.  After adjusting for the effect of 
rs1333045, 32 SNPs remained significantly associated with ANRIL expression, 
suggesting that the effect attributed to such variants was not due to LD with 
rs1333045. 
4.5.8.2 Diabetes 
The lead chromosome 9p21 SNPs associated with diabetes in GWA studies are 
located in a separate LD block to the CAD risk variants125, 130, and the phenotypic 
effects of CAD and diabetes variants have been shown to be independent129.  Diabetes 
risk alleles in this region (rs10811661-T and rs2383208-A) were associated with 
under-expression of ANRIL, but were not associated with CDKN2A or CDKN2B 
expression in our Caucasian population.  However, these SNPs showed no association 
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with expression of ANRIL in the SA population, despite greater power to detect 
effects in this cohort. 
A separate locus for diabetes susceptibility in the chromosome 9p21 region in 
Caucasians is located within the region associated with CAD risk.  The rs564398-T 
risk allele at this locus is associated with diabetes124, CAD129 and stroke159.  This SNP 
had the strongest association with ANRIL expression of all the SNPs we tested (P=10-
81), but was not significantly associated with CDKN2A or CDKN2B expression.  The 
rs564398-T risk allele was associated with ANRIL underexpression, and the 
association remained significant after adjusting for the effect of rs10811661, the lead 
diabetes SNP.  However, the association with rs10811661 was no longer significant 
after adjustment for rs564398. 
4.5.8.3 Cancers and frailty 
GWA studies have recently identified chromosome 9p21 SNPs correlated with 
susceptibility for glioma164, 165 and malignant melanoma167.  The glioma risk allele 
rs1063192-C was highly correlated with increased ANRIL expression (P=10-61), while 
the melanoma risk variant rs1011970-T correlated with reduced expression of ANRIL.  
Neither was associated with CDKN2A or CDKN2B expression.  
Multiple candidate gene association studies have reported associations between SNPs 
in this region and susceptibility to a variety of diseases.  These have mostly involved 
cancer phenotypes because the cell-cycle regulators CDKN2A and CDKN2B are 
recognised to be involved in predisposition to certain cancers.  Such association 
studies have implicated 9p21 SNPs as being potentially involved in the development 
or therapeutic response to pancreatic175, 314, breast173, 174, 180, ovarian176, 181, and 
bladder171 carcinoma, as well as acute lymphoblastic leukaemia177, and melanoma169, 
170, 172
.  All of the SNPs associated with these phenotypes showed a significant 
correlation with allelic expression of one or more of the genes we examined, as 
summarised in Table 4.5.  A SNP (rs2811712) that was reported to be associated with 
severely limited physical function in older people179 was significantly associated with 
CDKN2B expression, but not with ANRIL expression. 
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4.5.9 Preliminary investigation of expression of exons involved in 
other transcripts 
4.5.9.1 Exon-specific AEI analysis 
This study explored whether AEI could be used to investigate transcript-specific 
expression and mapping of cis-acting effects for CDKN2A and ANRIL. 
Multiple transcript variants are now annotated for CDKN2A43, two of which are 
known to produce the functionally-important proteins CDKN2A and CDKN2A-ARF.  
These transcripts and the location of SNPs with heterozygosity greater than 0.2 that 
are suitable for AEI assessment are illustrated in Figure 4.13.  Several transcript-
specific assays were investigated; the primer locations are illustrated in Figure 4.13 
and the PCR product sizes are shown in Table 4.7.  A limitation of the AEI approach 
for investigation of expression of particular exons is that it requires a transcribed SNP 
of reasonable heterozygosity within the amplicon.  There were no such SNPs within 
ARF exon 1β, meaning that transcript-specific amplicons were designed to include a 
primer in exon 1β and a primer downstream of the transcribed SNPs in exon 3.  As 
shown in Table 4.7, PCR products could not be reliably detected for these long 
products as initially designed (CDKN2A-specific-1 and ARF-specific-1), despite using 
45 cycles and extensive attempts to optimise the PCR conditions (adjusting 
temperatures, magnesium concentrations, and adding Q solution).  The assays were 
therefore redesigned to give the shortest transcript-specific products possible (ARF-
specific-2, CDKN2A-specific-2 and CDKN2A-specific-3).  After optimisation, PCR 
product was detectable for some samples by agarose gel electrophoresis, but was still 
not reliably detectable from many samples for the longer amplicons (ARF-specific-2 
and CDKN2A-specific-2).  In contrast, the shorter products for the CDKN2A-specific-
3 and CDKN2A&ARF assays were reliably detected for most samples. 
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Figure 4.13. CDKN2A transcripts and transcribed SNPs.  
Panel A shows the 11 CDKN2A transcript variants annotated in Ensembl  01/03/1043, with the 
chromosome 9 reference sequence loction shown on the X-axis. Panel B shows the two protein-coding 
transcripts. SNPs suitable for AEI analysis are illustrated as black bars with the SNP ID in bold above. 
Black arrows indicate the location of PCR primer pairs for AEI assays. 
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Table 4.7. Transcript-specific AEI assays for CDKN2A and ANRIL. 
Primer pairs Expected product 
size 
Optimised 
annealing 
temperatur
e (oC) 
Comment 
CDKN2A-specific-1 861 - PCR product not reliably detected. 
CDKN2A-specific-2 479 58.4 PCR product not reliably detected. 
CDKN2A-specific-3 73 61.8 Satisfactory PCR on agarose gel. 
    
CDKN2A&ARF 150 58.4 Satisfactory PCR on agarose gel. 
    
ARF-specific-1 635 - PCR product not reliably detected. 
ARF-specific-2 407 66.8 PCR product not reliably detected. 
    
ANRILexons1-2 150 58.4 Satisfactory PCR on agarose gel. 
ANRILexons6-19 154, 161, 290, 354, 
490, 624, 2058 
- Expected PCR products not detected in 2 
tests. 
ANRILexons6-13 167, 303, 378, 571 55.5 167 bp and 303 bp products faintly 
detected in 2 tests. 
ANRILexons2-6 314 64.6 314 bp product detected in 2 tests. 
MTAP4-ANRIL2 290 - PCR product not detected in 2 tests. 
ANRILexons6-6 49 56.0 Satisfactory PCR on agarose gel. 
 
A recent report suggested that ANRIL has more splice variants than the two that were 
originally described by Pasmant et al195.  The ANRIL transcripts annotated in the 
NCBI and Ensembl databases (as of 01/03/10) are shown in Figure 4.1443, 196, with the 
two original isoforms highlighted in red (both of which contain exons 1-2, in which 
the primers for the AEI assay used in the studies reported above were located).  The 
transcripts reported to date broadly fall into two groups; a short form ending with 
exon 13, and a long form ending with exon 2043, 196.  However, this may be related to 
the methodology used to investigate alternative transcripts by Folkersen et al, which 
only used primers located in exon 13 and exon 20197.   
 
  
Figure 4.14. ANRIL transcripts.  
Panel A shows reported transcripts with transcribed SNPs indicated as black bars (rs10965215 and rs564398 in exon 2 and rs10738605 in exon 6). The transcripts described 
in the original report by Pasmant et al195 in human testis are shown in red. Panel B shows the locations of primers used in expression studies.  
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Some recent reports suggested that short and long transcripts may be differentially 
expressed155, 200, and the study therefore aimed to investigate the cis-acting effects in 
assays involving different ANRIL exons.  Transcribed SNPs with heterozygosity 
greater than 0.2 which may be suitable for AEI analysis were located in exon 2 and 
exon 6.  AEI assays were designed to investigate expression of the ‘long transcript’ 
(with primers in exon 6 and exon 19) and the ‘short transcript’ (with primers in exon 6 
and exon 13), as summarised in Table 4.7 and Figure 4.14.  Another assay was 
designed with primers in exon 2 and exon 6 aiming to assess the correlation between 
AER measured at rs10965215/rs564398 (in exon 2) and rs10738605 (in exon 6) in the 
same transcript.  An MTAP-ANRIL fusion transcript has also been reported166, and a 
further assay was designed to determine whether expression of this transcript could be 
detected in blood and mapped using AEI (using primers in MTAP exon 4 and ANRIL 
exon 2). 
No evidence was detected for the MTAP-ANRIL product on gel electrophoresis.  
Products of the expected size were also not detected for the ‘ANRILexons6-19’ assay.  
Some faint bands of other sizes were seen at low temperatures during temperature 
gradient optimisations, but these were not consistent between different tests and were 
likely to represent non-specific primer binding.  PCR products at some of the 
expected sizes were seen for the other assays, as summarised in Table 4.7.  These 
assays require replication in larger numbers of samples using the optimised reaction 
conditions shown in the Table 4.7.  If these assays perform reliably in larger numbers 
of samples then they may be utilised for aeQTL mapping of different transcripts.   
It was noted for both the CDKN2A and ANRIL assays discussed above that assays 
involving longer PCR products were not reliably detected in most samples, whereas 
the shorter amplicons showed less variability between samples.  One explanation 
considered for the failure of assays involving longer products was that RNA/cDNA 
integrity might be insufficient to allow the identification of complete longer 
transcripts, especially since the samples had been stored for a considerable time and 
been through several freeze-thaw cycles.  RNA quality and cDNA size were therefore 
checked for a selection of samples using the RNA 6000 Pico LabChip kit (Agilent) 
for the Agilent 2100 bioanalyzer.   
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As shown in Figure 4.15, this confirmed high RNA quality with a 28S:18S ratio 
greater than two.  However, cDNA fragments were predominantly between 25 and 
500 bases in length, which is likely to account for the failure of assays with products 
above that size.  On review of the study methods, it was noted that the High capacity 
RNA-to-cDNA Master Mix (Applied Biosystems) that was used for reverse 
transcription of the samples in the above analyses is optimised for cDNA targets less 
than 1000 bases in length.  Other RT systems were investigated to see whether longer 
cDNA could be obtained, including the SuperScript III First-Strand Synthesis System 
for RT-PCR (Invitrogen) which is advertised as permitting detection of RNA targets 
more than 12kb in size324.  As shown in Figure 4.15, cDNA fragment size was not 
substantially greater with the different systems, suggesting that analysis of the longer 
assays was not possible in these samples. 
The two assays using previously untested transcribed SNPs which had shown reliable 
performance on agarose gel electrophoresis were tested for AEI analysis: ‘CDKN2A-
specific-3’ (using transcribed SNP rs3814960) and ‘ANRILexons6-6’ (using 
transcribed SNP rs10738605).  The ‘ANRILexons6-6’ assay worked well in both 
gDNA and cDNA.  The ‘CDKN2A-specific-3’ assay worked well in gDNA and some 
cDNA samples, but had a higher measurement variability and proportion of failed 
replicates in cDNA samples than other AEI assays.  This may be accounted for by low 
expression levels of this transcript variant in peripheral blood, suggesting that higher 
starting amounts of cDNA should be used for analysis using this assay.   
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Figure 4.15. Assessment of RNA integrity and cDNA size. 
Images show the output of obtained with the Agilent 2100 bioanalyzer for RNA samples and cDNA 
samples reverse transcribed with different RT systems. Y-axis represents fluorescence. X-axis on the 
RNA figures represents time in seconds, and on the cDNA figures represents cDNA fragment size in 
nucleotides. The 18S and 28S ribosomal RNA peaks are labelled on the RNA samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RNA
cDNA ABI Mastermix
cDNA Superscript III 1st strand synthesis system
cDNA Superscript VILO
18S
28S
18S
28S
Chapter 4: 9p21 expression mapping 
163 
4.5.9.2 Exon-specific total expression analysis 
Exon-specific expression was also investigated using analysis of total expression 
levels in the SA cohort.  This was simpler since there was no requirement for 
amplicons to include a transcribed polymorphism and therefore large products were 
not necessary.  A suitable cDNA-specific predesigned assay was available for ARF 
(Applied Biosystems assay ID Hs00924091_m1), but not for CDKN2A or ANRIL.  
For CDKN2A, the assay previously reported by Liu et al was tested325,  but replicates 
did not perform consistently.  On investigation of the assay design, the difference 
between primers and probe annealing temperatures was greater than recommended for 
such assays and a new custom assay was therefore designed with primers and probes 
located within exon 1α.  For ANRIL, custom assays were designed within exon 13 for 
the ‘short’ transcript and within exon 20 for the ‘long’ transcript (as shown in Figure 
4.14, page 159).  These assays were multiplexed with B2M and GAPDH reference 
genes respectively. 
Transcript-specific total expression levels of CDKN2A and ARF were highly 
correlated with each other (r=0.63, P=7x10-61) and with expression assessed using the 
combined CDKN2A-ARF assay (using B2M and GAPDH as reference genes), as 
shown in Figure 4.16.  Furthermore, SNP effects for CDKN2A and ARF mapped by 
eQTL analysis were also correlated (r=0.47, P=0.0003), as shown in Figure 4.17.  
This suggests that the loci influencing expression in cis are similar for these 
transcripts.  Associations for few individual SNP effects achieved statistical 
significance, reflecting the relatively low power of this analysis compared to the 
combined AEI analysis. 
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Figure 4.16. Correlations between total expression levels of CDKN2A, ARF and 
CDKN2A/ARF.  
Axes show expression Ct values normalised to B2M/GAPDH. Each point represents an individual. The 
regression line is shown in solid black, with dotted 95% confidence intervals. Pearson correlation 
values are shown. 
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Figure 4.17. SNP effects estimated using eQTL analysis with assays specific for 
CDKN2A, ARF and CDKN2A/ARF.  
Axes show cis-acting effect for the 56 mapping SNPs, each of which is represented as a point. The 
regression line is shown in solid black, with dotted 95% confidence intervals. Pearson correlation 
values are shown, but results were similar using Spearman’s rank correlation. SNP effect is the the log 
of the change in expression that allele 2 at the cis-acting locus produces compared to allele 1 (as 
defined on p87). 
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Preliminary investigation of transcript-specific expression of ANRIL was also 
performed.  As shown in Figure 4.18, transcript-specific total expression of ANRIL 
exon 13 and exon 20 showed a weak but significant correlation.  Total expression at 
exon 13 was weakly correlated with total expression at exons 1-2 as used previously, 
but there was no significant correlation between expression at exon 20 and exons 1-2.  
Interestingly, SNP effects for exon 13 and exon 20 mapped by eQTL analysis were 
positively correlated, but both showed a significant negative correlation with SNP 
effects measured at exons 1-2, as shown in Figure 4.19.  These data suggest that 
expression of the exon 13 and exon 20 transcripts are co-regulated and influenced by 
the same cis-acting effects.  However, the cis-acting influences on expression of the 
exons 1-2 transcript act in the opposite directions, and the overall expression levels of 
this transcript relate poorly to expression of the other two transcripts studied.  
Expression levels at exon 13 and exon 20 were higher than at the exons 1-2 when 
identical reference genes were used for normalisation, which suggests that the exon 
13 and exon 20 assays do not reflect the levels of the two originally reported 
transcript variants (as shown in red in Figure 4.14), both of which contain exons 1-2 
meaning that expression measured at this ‘summed’ assay would be expected to be 
higher than that of the individual transcript variants.  The significance of cis-acting 
effects on expression was substantially less for the eQTL analysis using the exon 13 
and exon 20 assays, with associations achieving significance for only a single SNP.  
This could mean that the transcripts assessed using these assays have less influence of 
cis-acting effects, or it could result from poor precision of the measurements and 
‘background noise’ of the assay.  These results therefore require additional 
investigation with the same and independent assays and must be regarded as 
preliminary at present. 
 
Chapter 4: 9p21 expression mapping 
167 
Figure 4.18. Correlations between total expression levels of different ANRIL 
transcripts.   
Axes show expression Ct values normalised to B2M/GAPDH. The regression line is shown in solid 
black, with dotted 95% confidence intervals. Pearson correlation values are shown. 
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Figure 4.19. SNP effects estimated using eQTL analysis for different ANRIL 
transcripts.  
Axes show cis-acting effect for the 56 mapping SNPs. The regression line is shown in solid black, with 
dotted 95% confidence intervals. Pearson correlation values are shown, but results were similar using 
Spearman’s rank correlation. SNP effect is the the log of the change in expression that allele 2 at the 
cis-acting locus produces compared to allele 1 (as defined on p87). 
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4.5.10 Microsatellite rs10583774 effects on expression 
A comparison of microsatellite analyses using WGA DNA and native gDNA showed 
that spectra were more difficult to interpret in WGA DNA for some samples as the 
pattern of the ‘slippage’ peaks was not as predictable as it was in native genomic 
DNA, as illustrated in Figure 4.20.  In unamplified DNA, the true peak was highest, 
with smaller ‘slippage’ peaks at two-nucleotide intervals of progressively decreasing 
size.  In amplified DNA, there was less difference in size between the true peak and 
nearest ‘slippage’ peak which made spectra more difficult to interpret for individuals 
who were heterozygous for similarly sized alleles.  Analyses were therefore 
performed using unamplified genomic DNA for all individuals in both cohorts.  The 
distribution of the microsatellite alleles was similar in the SA and British Caucasian 
cohorts as shown in Figure 4.21. 
Figure 4.20. Example of microsatellite spectra from unamplified DNA and WGA 
DNA from the same sample.  
Amplicon size (X-axis) and product yield (Y-axis) are shown for the same sample with and without 
WGA. Numbers on the X-axis represent the peak size estimates obtained using GeneMarker 
autodetection software. In unamplified DNA the true peak (giving the greatest size product) had the 
greatest peak height. However, in WGA DNA the ‘slippage’ peak height exceeded the height of the 
true peak, which complicated the genotyping interpretation. In the example below, the native DNA 
suggests a 178/178 homozygote genotype but the pattern in the WGA sample could be consistent with 
a 176/178 heterozygote genotype. The explanation and interpretation of the spectra patterns is 
explained in Chapter 2. 
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Figure 4.21. Relative frequency of microsatellite rs10583774 alleles in the SA and 
Caucasian cohorts. 
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with the results of the previous combined total microsatellite allele length.  All of 
these analyses were performed with exclusion of a single outlying individual with a 
particularly low number of TG microsatellite repeats (as highlighted in Figure 4.22). 
Table 4.8. Correlation of total expression levels with number of microsatellite 
TG repeats. 
 CDKN2A CDKN2B ANRIL 
Correlation between TE and total number of TG repeats -0.12 
(P=0.04) 
-0.14 
(P=0.02) 
-0.08 
(P=0.14) 
Correlation between TE and number of TG repeats at the 
alternative allele in individuals with 1 copy of the common 
allele 
-0.08 
(P=0.38) 
-0.05 
(P=0.63) 
-0.19 
(P=0.05) 
Shaded cells represent statistically significant correlations. TE = total expression. 
 
Figure 4.22. Effect of number of microsatellite rs10583774 TG repeats at the 
alternative allele in individuals who have the common (20 TG repeats) allele on 
total expression of ANRIL exons1-2 in the SA cohort. 
Each point represents an individual. Regression line and correlation coefficients are shown after 
exclusion of a single outlier (shown as a cross). 
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Phasing the microsatellites was difficult because the large number of alleles created a 
large degree of uncertainty around the phase.  Therefore the cis-acting influence of 
microsatellite size was investigated in individuals who had at least one copy of the 
commonest allele using the approach described above with absolute log-transformed 
AER values at each transcribed SNP (adjusted for the effect of the transcribed SNP).  
This analysis was performed for each transcribed AEI marker separately, and could 
only be performed for individuals who had one copy of the common microsatellite 
allele and who were heterozygous at the transcribed SNP (to permit AEI 
measurement).  The number of informative samples was therefore low and no 
significant correlation was seen between number of microsatellite repeats and AER at 
any of the transcribed markers in CDKN2A, CDKN2B and ANRIL using this approach.   
The above analyses assume a linear relationship between microsatellite length and 
cis-acting effect on expression, but previous in vitro studies have suggested that the 
relationship between microsatellite length and expression is not linear in all cases241.  
Using a regression analysis for total expression with multiple alleles as categorical 
variables (which allows each allele to have an independent effect) showed a 
significant association between microsatellite genotype and expression of ANRIL 
exons1-2 (P=0.0047), but not CDKN2A or CDKN2B.  This suggests that the genotype 
at rs10583774 is associated with ANRIL exons1-2 expression, but that the relationship 
may not be linearly proportional to the number of TG repeats at this locus. 
4.6 Discussion 
This is the most detailed study to date of cis-acting influences on expression at the 
chromosome 9p21 locus.  It has shown that multiple sites in the 9p21 region 
independently influence CDKN2A, CDKN2B and ANRIL expression.  SNPs 
associated with diseases including CAD, diabetes, and cancers are all highly 
associated with expression of ANRIL exon 1-2, suggesting that modulation of ANRIL 
expression may mediate disease susceptibility.  The study also reports novel 
methodology for allelic expression analysis that allowed data from multiple 
transcribed polymorphisms to be combined and the effects of particular SNPs to be 
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adjusted for.  The study has demonstrated that this approach has greater power than 
total expression analysis for mapping cis-acting effects. 
4.6.1 Relationships between CDKN2A, CDKN2B and ANRIL 
expression 
Total expression levels of CDKN2A, CDKN2B and ANRIL exons 1-2, which reflect 
the combined influence of cis and trans-acting factors, were positively correlated.  
This corroborates other recent data197, 325, 326, and suggests that expression of these 
genes is co-regulated.  Trans-acting influences account for the majority of the 
observed variance in expression of these genes (80-96%), and the correlation in total 
expression levels is likely to reflect co-regulation of the genes through trans-acting 
factors.  In addition, the allelic expression analysis demonstrated that expression is 
also influenced by shared cis-acting elements in the region.  Despite the positive 
correlation in total expression levels, cis-acting effects associated with individual SNP 
alleles may act in opposite directions; the effect of individual SNPs on CDKN2B 
expression were opposite to effects on expression of CDKN2A and ANRIL exons 1-2 
(which were concordant) in this study.  Although cis-acting effects account for only a 
small proportion of the overall variance in expression of these genes, this does not 
diminish the potential biological significance of the cis-acting effects.  ANRIL 
overlaps and is transcribed in antisense with respect to CDKN2B195.  It is modestly 
conserved across species200 and its function is not known, but recent work has 
demonstrated that antisense transcription from CDKN2B downregulates CDKN2B 
expression in cis through heterochromatin formation202.  This is consistent with our 
observation of an inverse effect of SNPs on ANRIL exons 1-2 and CDKN2B 
expression.  By contrast, CDKN2A and ANRIL exons 1-2 showed positive correlations 
for both allelic and total expression in our study.  CDKN2A and ANRIL do not 
overlap, but are transcribed divergently from transcription start sites separated by just 
300 base pairs.  Although the ANRIL promoter is currently not characterised, it may 
share promoter elements with CDKN2A and the resulting co-regulation could account 
for the positive correlation in expression we observed for these genes, similar to that 
described at other sites244.  In this context, inhibition of CDKN2B expression by 
ANRIL would enable a level of crosstalk between CDKN2A and CDKN2B expression, 
which would be consistent with the inverse cis-acting effect of SNPs on CDKN2A and 
CDKN2B that was observed.  The observation that cis-acting genetic effects played a 
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greater role in expression of ANRIL compared to CDKN2A and CDKN2B (20% 
compared to less than 8% and 5% respectively) makes it a good candidate for genetic 
causation mediated through influences on expression. 
A recent mouse study demonstrated that deletion of a 70kb non-coding region 
orthologous to the human CAD core risk region resulted in severely reduced 
expression of Cdkn2a and Cdkn2b in heart tissue, indicating the presence of distant-
acting regulatory functions in the CAD risk interval327.  Allele-specific analyses 
demonstrated that these effects were mediated by cis-acting mechanisms.  Although 
sequence conservation of ANRIL is not seen in this orthologous region, this may be 
due to high rates of sequence evolution without loss of functional activity that has 
been proposed for long non-coding RNAs328.   
4.6.2 aeQTL mapping of cis-acting effects 
The study compared total expression and allelic expression for the investigation of 
cis-acting influences on expression.  For aeQTL mapping a novel adaptation of 
previously reported methodology254 was developed to combine multiple transcribed 
SNPs per gene, which increased the number of informative individuals and the power 
for detecting cis-acting effects.  This approach was demonstrated using two 
transcribed polymorphisms per gene, but the methodology offers the potential for the 
inclusion of multiple additional transcribed variants.  The results obtained by eQTL 
and aeQTL mapping were similar, consistent with previous work suggesting that the 
two approaches identify the same cis-acting loci266.  However, the present study 
demonstrated that aeQTL analysis had substantially greater power than the eQTL 
approach.  Adjusting for trans-acting covariates including age, sex and ethnicity in the 
eQTL analysis did not substantially alter the results.  An influence of age on CDNK2A 
has been reported329, but there was little variability in the age of the SA cohort (90% 
of whom were between the ages of 18 and 30 years).  The fact that allelic expression 
is a more efficient way to identify cis-acting influences on expression has implications 
for future studies investigating the effects of SNPs on expression at other loci, for 
example for the hundreds of non-coding SNPs correlated with different diseases by 
recent GWA studies25.  
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Allelic expression quantifies the relative contributions of each allele to the mRNA 
pool irrespective of the absolute mRNA levels, and therefore provides information 
about transcriptional effects and polymorphisms within the transcript influencing 
RNA degradation in cis.  By contrast, total expression analyses that quantify absolute 
mRNA levels are also sensitive to post-transcriptional regulatory effects, such as 
mRNA degradation by microRNAs.  In extreme cases tight post-transcriptional 
regulation could keep total mRNA levels constant irrespective of the contributions of 
each allele to the total mRNA pool.  The fact that the results of eQTL and aeQTL 
mapping were so similar in this study suggests that the effect of regulation at the post-
transcriptional level is limited, although regulation of CDKN2A expression by a 
microRNA has been described330.  In general, although allelic expression is a robust 
method for mapping sites influencing expression in cis, investigation of total 
expression and other intermediate phenotypes such as protein levels or protein activity 
will provide complementary information that contributes to fully understanding the 
phenotypic effects of cis-acting polymorphisms.  It would be desirable to determine 
whether the significant associations with mRNA expression observed for CDKN2A 
and CDKN2B are confirmed at the protein level. 
4.6.3 Trans-ethnic expression mapping 
Although it had been hoped that trans-ethnic fine-mapping could be used to refine the 
associations with expression, the results of aeQTL mapping were in fact very similar 
in the SA and Caucasian populations.  This replication in a separate cohort strongly 
supports the validity of the findings and enabled a combined analysis of the two 
cohorts to be performed.  This approach of pooling data from ethnically-divergent 
populations has been previously shown to increase the power to detect influences on 
expression that are shared across populations266, 331.  The principal difference 
identified between the two populations was for the SNPs associated with type II 
diabetes.  The lead diabetes SNP rs10811661 was correlated with ANRIL 
underexpression in the Caucasian cohort, but not in the SA population, despite greater 
power to detect effects in that cohort.  This may reflect differences in LD between the 
populations, but suggests that if rs10811661 is the causal variant influencing diabetes 
susceptibility the effects are unlikely to be mediated through influences on ANRIL 
expression.  Alternatively, if modulation of ANRIL expression is the mechanism 
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through which the association of rs10811661 with diabetes is mediated, as suggested 
by the association in Caucasian populations, rs10811661 itself is unlikely to be the 
‘functional’ variant causing the effect (but is likely to be in LD with the functional 
variant in the Caucasian but not the SA population).  Studies to determine whether 
this SNP is associated with diabetes in populations of African origin would be of 
interest. 
4.6.4 Consideration of ‘causal’ variants 
The power of the analyses to detect differences in expression enabled the effects of 
individual SNPs to be adjusted for.  Using this approach demonstrated that 
expression, and therefore probably disease predisposition, was independently 
influenced by multiple sites and that the observed effects cannot be explained by a 
single polymorphic site.  From this analysis the existence of rare variants with large 
effects cannot be excluded, but previous resequencing studies in this region did not 
find rare variants associated with disease phenotypes19, 20.  It is uncertain whether the 
individual SNPs for which associations were found are the actual ‘causal’ variants 
responsible for the effects on expression, or if the association simply reflects LD 
between these SNPs and the causative polymorphisms.  Although fine mapping 
studies often purport to identify causal variants, in the context of complex diseases 
identifying pathways involved in disease predisposition may be more important.  This 
is of particular interest for these genes where variation in expression is mostly due to 
trans effects which may be substantially influenced by non-genetic factors, raising the 
prospect that it may be amenable to therapeutic modulation.  The putative causal 
variants rs10757278 and rs1333045 previously associated with altered ANRIL 
expression200, 325 were significantly associated with reduced ANRIL exons 1-2 
expression in vivo in this analysis, but their effects were relatively modest compared 
to other SNPs in the region and adjustment for the effect of these SNPs accounted for 
only a small proportion of the effect observed at other SNPs.  The maximum changes 
in expression associated with individual SNPs were substantial, up to 2-fold for 
ANRIL exons 1-2, but effects of much smaller magnitude were also detected; the 
minimum significant effect was associated with just a 1.05-fold change in expression.  
Although the associations of SNPs with expression that were observed were 
statistically highly significant, it is uncertain what impact such effects on expression 
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have on disease risk.  However, even small differences in gene expression due to 
genetic factors that are present throughout an individual’s lifetime could contribute to 
differences in common late-onset phenotypes such as CAD and diabetes, and the 
effects may be even greater in tissues related to disease. 
Genotype at microsatellite rs10583774 appears to be associated with expression of 
CDKN2A, CDKN2B and ANRIL exons 1-2.  Such an association may be ‘indirect’, 
resulting from LD between the microsatellite and other variants which have true 
functional effects on expression.  Alternatively, it is possible that the number of 
microsatellite TG repeats has a direct functional influence on expression, as has been 
reported for other microsatellites in vitro238, 241.  The location of this microsatellite 
within a promoter region likely to influence both CDKN2A and ANRIL expression 
supports the notion that it could have direct functional effects, perhaps through 
affecting transcription factor binding similar to that described for other 
microsatellites236.  However, it is interesting that an increasing number of TG repeats 
was associated with reduced expression of all three genes, including CDKN2B which 
is transcribed in the opposite direction to ANRIL (i.e. the microsatellite is located at its 
3’-end and not in a promoter region for this gene).  These effects could potentially be 
mediated through changes in chromatin structure which up or downregulate 
expression of the whole locus, similar to the effects described for other 
microsatellites238.  A recent 2010 paper has shown that methylation of the CpG island 
in this region abolishes binding of the chromatin insulator protein CTCF and reduces 
expression of CDKN2A, CDKN2B and ANRIL326.  The association between 
microsatellite genotype and ANRIL expression was stronger using a categorical rather 
than a linear model.  Non-linear relationships between repeat elements and expression 
have been reported for other microsatellites, which may be due to steric effects such 
as the proximity and interaction of transcription factors within three-dimensional 
space of the helical DNA structure241.  If rs10583774 has direct influences on 
expression, genotyping this microsatellite may add to the predictive value of SNPs at 
this locus.  The functional role could be investigated using transfection experiments 
with reporter constructs.  It is possible that microsatellites may be the functional 
elements responsible for SNP associations detected at other loci in GWA studies, and 
these elements should not be overlooked. 
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4.6.5 Confirmation of regulatory elements in vivo 
This study examined in vivo expression in primary cells rather than in transformed 
cell lines.  Although cell lines have been extensively used to investigate cis-acting 
influences on expression227, 331, patterns of expression may be altered in immortalised 
cells, particularly for genes such as these that are associated with senescence and cell-
cycle regulation220.  Furthermore, widely used cell lines are pauciclonal or 
monoclonal255, 332 and since a significant proportion of human genes exhibit random 
patterns of monoallelic expression within single clones of cell lines333, cis-acting 
effects in these cells are unlikely to be representative of polyclonal cell populations in 
vivo.  Previous studies have delineated the promoters and other elements regulating 
CDKN2A/ARF and CDKN2B expression using reporter assays186, 187, 189, 319, 320.  Such 
studies are valuable to identify causative polymorphisms, but since they examine the 
effects on expression outside of the normal haplotype, chromatin and cellular context 
their findings require confirmation by in vivo studies225, 253.  This analysis confirmed 
that polymorphisms in upstream regulatory elements identified by in vitro assays were 
significantly associated with cis-acting effects on expression in vivo, but also 
demonstrated that other loci located up and downstream were associated with effects 
on expression of similar or even larger magnitude.  These data highlight the 
complexity and multiplicity of sites influencing expression in the region.  The assays 
used to investigate CDKN2A expression also included the ARF transcript variant.  
This gave the potential to detect sites influencing expression of both transcripts, and 
effects of SNPs in both the CDKN2A and ARF promoter regions were detected in the 
study, although differential effects of loci on individual transcripts cannot be 
distinguished using this approach.  
4.6.6 Tissue-specific considerations 
All of the SNPs in the region associated with disease in GWA studies were associated 
with influences on ANRIL exons 1-2 expression, suggesting that modulation of ANRIL 
expression may mediate susceptibility to these phenotypes.  SNPs in the CAD core 
risk haplotype region129 that are most strongly associated with CAD in GWA studies 
were associated with reduced expression of ANRIL exons 1-2, but other SNPs 
associated with CAD which lie outside of the core risk haplotype region showed 
independent and stronger associations with underexpression of ANRIL exons 1-2.  
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This may reflect differences in the relative importance of particular sites in the tissues 
responsible for the association with CAD.  Indeed, the patterns of association 
observed in peripheral blood in healthy individuals may differ from those in primary 
disease tissues.  Similarly, differences in the relative contribution of each SNP to 
modulation of expression in the tissues crucial for the pathogenesis of the different 
conditions could explain why particular diseases are associated with different subsets 
of SNPs that influence ANRIL expression.  Recent work also suggests that ANRIL has 
multiple transcripts, which may be differentially expressed between tissues197, 200.  
Confirmation of the findings of the present study in tissues relevant to each disease 
and for different ANRIL transcripts would therefore be desirable, although for CAD 
and other complex diseases the exact cell populations responsible for mediating 
disease susceptibility are not certain and may be inaccessible.  Although tissue 
specificity of cis-acting influences is well documented, variation in cis-acting effects 
is primarily explained by genetic variation, with allele-specific expression for most 
transcribed SNPs being the same in different tissues of the same individual which 
express the gene of interest269.  Analysis of expression in blood is therefore likely to 
give biologically relevant information despite the fact that this may not be the tissue 
in which influences on expression actually mediate disease susceptibility.  
4.6.7 Other studies of chromosome 9p21 expression 
Previous genome-wide expression analyses using microarrays and immortalised cell 
lines did not identify association of CDKN2A and CDKN2B expression with markers 
in this region, although they did not examine ANRIL expression227, 331.  However, 
several recent studies have specifically examined the relationship between CAD risk 
variants and total expression levels of transcripts in the chromosome 9p21 region.  
These studies are described below, and the locations of the primers used relative to 
the annotated ANRIL transcripts are illustrated in Figure 4.14 (page 159).   
The first study investigating the association between CAD risk variants and 9p21 gene 
expression was published by Liu et al in April 2009325.  This study measured total 
expression levels of CDKN2A, CDKN2A-ARF, CDKN2B, MTAP and ANRIL in 
peripheral blood T-cells from 170 healthy subjects using TaqMan assays, and 
analysed the association with three CAD risk SNPs (rs10757278, rs518394 and 
rs564398).  The risk allele of rs10757278 which is located within the CAD core risk 
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region defined by Broadbent et al129, was significantly associated with reduced 
expression of CDKN2A, CDKN2A-ARF, CDKN2B and ANRIL.  This supports the 
finding of the present study that CAD risk variants are associated with reduced ANRIL 
expression.  However, rs10757278 and other SNPs in the core CAD risk region were 
not associated with expression of CDKN2A or CDKN2B in the present study, which 
conflicts with the findings of Liu et al, but is supported by the findings of other larger 
studies as described below.  Liu et al found no association with expression for the 
other two CAD risk variants studied, despite them being in moderate LD with 
rs10757278 (D’=0.66 with rs10757278 for both).  This is surprising since rs564398 
was strongly associated with a 1.9-fold reduction in allelic expression of ANRIL in the 
present study, which was larger and more significant than the effect associated with 
rs10757278.  The assay used by Liu et al to measure ANRIL expression spanned 
exons 4-5 whereas the assay used in the present study spanned exons 1-2.  Recent data 
suggests that ANRIL may have multiple transcripts and it is possible that the different 
assays used in the studies capture different transcripts that are differentially regulated.  
This could potentially account for the lack of association between ANRIL expression 
and rs564398 genotype and that was observed by Liu et al. 
Liu et al also found no correlation of risk variants associated with diabetes 
(rs10811661), frailty (rs2811712), and melanoma (rs11515) with expression of any of 
the genes studied.  However, significant associations with allelic expression were 
found for these variants in the present study: rs10811661 with CDKN2A and ANRIL; 
rs2811712 with CDKN2B; rs11515 with CDKN2A and CDKN2B.  The effects and 
significance of associations for these variants were smaller than those detected 
between rs10757278 and ANRIL expression, and the fact that the present study was 
able to detect such effects that were not detected by Liu et al is likely to reflect the 
greater power of the present study due to the larger sample size and increased 
sensitivity of the aeQTL mapping approach.   
Jarinova et al investigated the functional effects of four conserved sequences within 
the CAD risk region using in vitro reporter gene expression in primary aortic smooth 
muscle cells200.  One of the conserved sequences demonstrated enhancer activity, and 
the CAD risk allele rs1333045-C in this sequence was associated with higher 
expression compared to the T allele.  The study then went on to examine the 
Chapter 4: 9p21 expression mapping 
181 
association of this putative functional SNP with total expression of CDKN2A, 
CDKN2B, MTAP, and ANRIL in peripheral blood from 120 healthy individuals200.  In 
keeping with the results of the present study Jarinova et al found no significant 
association between rs1333045 genotype and expression of CDKN2A and CDKN2B, 
but did find a significant association with ANRIL expression.  Primers located in 
different exons were used to investigate effects on expression of the ‘long’ and ‘short’ 
ANRIL transcripts described by Pasmant et al195.  Primer pairs were located in exons 1 
and 5 (transcript EU741058), within exon 13 (transcript DQ485454/EU741058), and 
in exons 15 and17 (transcript DQ455453).  The CAD risk allele was associated with 
increased expression of the ‘short’ transcripts (DQ485454/EU741058 and EU741058) 
but reduced expression of the ‘long’ transcript (DQ455453), suggesting that these 
ANRIL transcripts are differentially regulated.  The ANRIL assay spanning exons 1-2 
used in the present study is expected to capture both the ‘long’ and ‘short’ transcript 
variants, and the finding that CAD risk variants reduce expression measured at ANRIL 
exons 1-2 is consistent with the findings of Jarinova et al if the ‘long’ isoform is 
expressed at higher levels in peripheral blood than the ‘short’ isoform.  Exon-specific 
total expression assays performed in the present study did indeed demonstrate higher 
expression of the exon 20 assay (specific for the ‘long’ transcript), compared to the 
exon 13 assay (specific for the ‘short’ transcript), although expression measured with 
these assays was not significantly associated with rs1333045 genotype.  Jarinova et al 
also performed whole-genome expression analysis using microarrays in subsets of 
healthy subjects who were homozygous for the risk and non-risk allele.  These 
analyses suggested that pathways associated with cell proliferation and vascular 
endothelial growth factor signalling were upregulated in individuals who were 
homozygous for the risk allele, suggesting that the risk allele may act by modifying 
expression of cell cycle regulatory genes. 
A study by Folkersen et al also used investigated the association between a 
chromosome 9p21 CAD risk variant (rs2891168) and whole genome total expression 
data from microarrays197.  Association with microarray expression was analysed in 
five separate datasets comprising: 57 CEU lymphoblastoid cell lines; 87 CEU and 89 
YRI lymphoblastoid cell lines; 117 carotid endarterectomy specimens; 88 mammary 
artery medial samples; and 89 aorta medial samples.  No significant associations with 
expression in trans were found in these datasets, and there was also no evidence of a 
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cis-acting effect on expression of the neighbouring genes including CDKN2A, 
CDKN2B and ANRIL.  However, the power of the association analysis was limited 
due to the small numbers studied, low expression levels of ANRIL, and relative 
insensitivity of the microarray platform.  These factors are likely to account for the 
lack of association observed by Folkersen et al, which contrasts with the findings of 
the present study and the other published studies. 
A recent study by Holdt et al published in January 2010 investigated the association 
of CAD risk variants with total expression of chromosome 9p21 genes in peripheral 
blood mononuclear cells from 1,098 patients with varying degrees of CAD assessed 
by coronary angiography155.  In keeping with results of the present study CAD 
variants were not consistently associated with CDKN2A or CDKN2B expression, but 
were associated with ANRIL expression.  The study investigated expression of one 
‘long’ and two ‘short’ ANRIL transcripts using different primer pairs located in 
ANRIL exons 1 and 5 (transcript EU741058), exons 4 and 5 (transcript 
DQ455454/DQ455453), and exons 18 and 19 (transcript DQ455453).  The CAD risk 
haplotype was associated with increased expression of the ‘short’ transcript variant 
EU741058, but had no effect on expression of the other ‘short’ transcript variant 
DQ485454.  Expression of these transcripts was associated with the severity of 
atherosclerosis, providing the first direct evidence linking ANRIL and atherosclerosis 
susceptibility.  In contrast to the findings of Jarinova et al200, however, the CAD risk 
haplotype was associated with increased expression of the ‘long’ transcript 
DQ455453.  Similar findings were obtained in whole blood from 154 individuals free 
from CAD.  The assays used to try and study transcript-specific expression by 
Jarinova et al and Holdt et al were located in different exons, and recent data suggests 
that complexity of ANRIL transcripts beyond the three isoforms considered in these 
studies might account for the differences in the findings, as discussed below. 
4.6.8 Consideration of transcript-specific ANRIL expression 
The report by Folkersen et al, which was published in November 2009 after the 
expression studies discussed above were conducted, suggested that the situation with 
respect to ANRIL splice variants may be more complex than had previously been 
suspected197.  Investigation of splice variants was performed using real-time PCR 
amplification and sequencing in cDNA libraries from cell lines derived from three 
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different tissues: human umbilical vein endothelial cells (HUVEC), brain, and lung.  
This study amplified sequence between PCR primers located in exon 1 and exon 20 
for each cell type, and for the HUVEC cells additionally amplified sequence between 
PCR primers located in exon 1 and exon 13.  Using these assays, Folkersen et al were 
unable to identify ‘full length’ transcripts of 3,834 or 2,659 bp as previously described 
by Pasmant et al195.  However, a number of shorter transcripts were detected, which 
appeared to differ between the different cell lines studied (as summarised in Figure 
4.14 on page 159).  Based on these observations the authors proposed that ANRIL 
undergoes extensive alternative-splicing, and that there is tissue-specific expression of 
ANRIL transcripts.  In the report by Folkersen et al there is no data presented to show 
that the cDNA quality and methodology used was adequate for the detection of long 
transcripts.  This is important since failure to detect the ‘full length’ ANRIL transcripts 
could be the result of inadequate cDNA fragment length or other methodological 
issues (similar to the problems in detecting long transcripts encountered in the present 
study) and positive controls for other long transcripts would be useful.  Furthermore,  
other recent work has shown that culture of human cells is commonly associated with 
culture-induced copy number changes in genomic DNA and changes in gene 
expression, particularly for genes involved cell-cycle regulation334.  The implications 
of the findings from Folkersen et al’s study with respect to in vivo expression remains 
uncertain at present.  Deletions related to cell culture could account for the failure to 
detect certain blocks of exons that was observed.  It seems perhaps unlikely that this 
would occur in three separate cell lines within the same gene, but particular genes that 
are prone to culture-induced anomalies have been previously demonstrated334.  The 
methodology used by Folkersen et al to study transcript variants did not allow the full 
range of potential transcripts to be surveyed, and the possible range of transcript 
isoforms in different native tissues is unclear. 
Taken together, the results of the present study and other published studies clearly 
suggest that CAD variants are associated with expression of ANRIL transcripts but are 
not consistently associated with CDKN2A, CDKN2B or MTAP expression.  However, 
additional work is needed to fully characterise the alternative transcripts and loci that 
influence their expression in different tissues. 
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4.6.9 Mechanistic considerations 
The finding that disease associated SNPs are all associated with ANRIL exons 1-2 
expression suggests that ANRIL plays a role in influencing disease susceptibility.  
Although little is known about the targets of ANRIL, its effects may be mediated 
through antisense transcription regulation of CDKN2B in the tissues critical for the 
pathogenesis of the different diseases.  The observation that the effects of sequence 
variants acting in cis were stronger for ANRIL than for CDKN2B may reflect selection 
pressure against variants that have substantial direct effects on the expression of 
critical genes.  CDKN2A, ARF and CDKN2B are cell cycle regulators and are 
plausible candidates for involvement in the pathogenesis of the diseases for which 
SNP associations with ANRIL were found.  Mutations involving these genes are well 
documented in glioma335, 336 and melanoma195, 337, 338.  Overexpression of CDKN2A 
and CDKN2B in murine models is associated with pancreatic islet hypoplasia and 
diabetes339, 340, and there is also emerging evidence that vascular cell senescence 
involving these pathways is involved in the pathogenesis of atherosclerosis193, 194. 
4.6.10 Summary 
This study shows that multiple independent sites in the chromosome 9p21 region 
influence CDKN2A, CDKN2B and ANRIL expression.  SNPs associated with a 
number of different diseases in GWA studies are all associated with ANRIL 
expression, indicating that modulation of ANRIL expression mediates susceptibility to 
a variety of conditions. 
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5 Investigation for copy number variation in the 
chromosome 9p21 region 
5.1 Abstract 
Departure from HWE is frequently analysed in genetic studies as a screening check 
for genotyping errors, although this phenomenon may be due to many other factors.  
In the NE Caucasian cohort a higher proportion of SNPs in the chromosome 9p21 
region deviated from the proportions expected under HWE than expected by chance 
alone (12/53 at the P<0.05 threshold), with genotyping demonstrating an excess of 
homozygosity.  The aim of this chapter was to investigate the possible causes of the 
observed departure from HWE.  Review of the genotyping and repeat genotyping by 
both Sequenom and TaqMan methodologies in the same cohort showed no evidence 
of substantial genotyping errors.  Analysis of published datasets which had genotyped 
SNPs in this region revealed that departure from HWE with an excess of 
homozygosity was also more prevalent for SNPs in these cohorts than would be 
expected by chance alone; these data could be consistent with the existence of 
common deletions (leading to null alleles in the typed SNPs) in Caucasian 
populations.  Genotyping the 1425 members of 248 families of the HTO cohort for 17 
SNPs that had previously shown HWE departures showed no significant deviations 
from HWE in that population, but analysis of pedigrees with Mendelian errors 
revealed patterns which could be consistent with segregation of a null allele in nine 
families.  MLPA analysis with 12 custom probes in the region of interest showed no 
evidence of CNV in these nine individuals, or 118 unselected individuals from the NE 
Caucasian and HTO cohorts.  In summary, the observed departure from HWE was not 
attributable to genotyping errors and was not replicated in the HTO cohort; nor was 
there evidence of deletion polymorphisms in the region using MLPA. 
5.2 Introduction 
The Hardy-Weinberg law states that allele and genotype frequencies of a large, 
randomly-mating population remain constant between generations in the absence of 
migration, mutation, and selection341, 342.  According to this law, if two alleles, G and 
g, with frequencies p and q = 1 – p, are in equilibrium in a population, then the 
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proportion of people with genotypes GG, Gg and gg will be p2, 2pq and q2.  Although 
the assumptions underlying HWE are rarely met in human populations343, it has been 
proposed that testing for HWE can be used to detect errors or peculiarities in datasets 
analysed in genetic association studies344.  As presented in Chapter 4, a higher 
proportion of SNPs genotyped in the NE Caucasian cohort showed deviation from 
HWE than would be expected by chance alone: 12/53 SNPs (23%) at the P<0.05 
threshold, and 2/53 SNPs (4%) at the P<0.01 threshold.  A higher proportion of SNPs 
in this region also deviated from HWE in some other published series (presented in 
section 5.5.1.2 on page 201).  This chapter investigates possible causes and 
implications of the observed departure from HWE in the study population. 
The most common reason for testing for departure from HWE in datasets used for 
genetic studies is to screen for genotyping errors.  However views differ on the 
usefulness of analysing HWE in this context, as recognised in a recent consensus 
guideline for good practice in the reporting of genetic association studies345.  Whilst 
some authors propose that it should be used as a ‘quality control’ for genotyping and 
form an essential part of any genotyping study344, 346, others have argued that it should 
not be used as a tool to identify genotyping errors, and that its use is unnecessary and 
even unhelpful as it may alter the type-I error rate of the association test347.  Departure 
from HWE may detect gross systematic genotyping errors, but the power to detect 
genotyping errors of smaller magnitude has been shown to be low109, 347.  Consensus 
is also lacking on the appropriate P-value threshold for HWE-related quality control.  
Rather than recommending routine HWE testing, the current guidelines simply 
recommend transparent reporting of whether such testing was done and the thresholds 
used348.  The first part of this chapter presents the studies that were performed to 
investigate genotyping error as a cause of the departure from HWE that was observed 
in the study population. 
Factors that violate any of the assumptions of HWE may lead to deviation from the 
expected genotype proportions.  These include non-random mating, such as 
inbreeding which tends to increase homozygosity; and population stratification, in 
which the population is comprised of a mix of sub-populations with different allele 
frequencies and possibly other confounding factors349.  The significance of these with 
respect to the study population is considered in the discussion.   
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Departure from HWE may also be due to copy number polymorphisms299; these are of 
particular interest since CNVs may modulate gene expression and be involved in 
complex disease causation249, 350, 351.  Genome-wide surveys have reported common 
deletion polymorphisms352, 353 and segmental duplications354, 355 in the human 
genome.  With many genotyping techniques, including the Sequenom assay used in 
this study, SNPs that are hemizygous for a deletion are miscalled as homozygous for 
the allele that is present, as illustrated in Figure 5.1.  Deletion polymorphisms may 
therefore cause departure from HWE with an apparent over-representation of 
homozygotes.  The disequilibrium coefficient (D-statistic) can be used to determine 
whether departures from HWE are due to an excess of homozygosity343, 356.  CNVs 
have been shown to be associated with complex disease351, and recent studies have 
shown that many common deletions are in LD with SNPs, such that they are 
effectively assayed by proxy in SNP-based association studies252, 355.  Hence if 
common deletions in the chromosome 9p21 region were functionally important and 
influenced disease predisposition, they could potentially account for at least some of 
the association of SNPs in this region with disease phenotypes.  Although previous 
studies sequencing this region did not identify deletions associated with disease, 
neither did they exclude them as causes of potentially important effects.  McPherson 
et al sequenced the complete 58kb risk interval in only two homozygotes for the risk 
haplotype20, and whilst Helgadottir et al studied 93 affected individuals19, they only 
sequenced exons, exon-intron junctions, and regulatory regions of CDKN2A and 
CBKN2B and hence did not exclude CNVs in the ANRIL region where the greatest 
departure from HWE was observed.  SNPs and other known variants discovered to 
date account for only a small proportion of the genetic risk for MI, and CNVs which 
remain largely unexplored territory may account for some of the unexplained 
heritability in MI and other complex diseases357. 
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Figure 5.1. Illustration of homozygous genotyping miscalling in samples with a 
hemizygous deletion.  
Heterozygous individuals produce two different extension products and two peaks on MALDI-TOF 
analysis. By contrast, individuals who are homozygous or have a hemizygous deletion (null allele) both 
produce a single extension product and one peak on MALDI-TOF analysis, resulting in miscalling of 
samples with a hemizygous deletion as homozygous. 
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Deletions of the chromosome 9p21 region have been reported in rare pedigrees with 
familial cancers195, but whether there are also common CNVs in this region has not 
been established.  The Database of Genomic Variants358 showed that deletions in this 
region were detected in a number of small genome-wide CNV surveys, as shown in 
Figure 5.2.  Perry et al used CNV arrays in cell lines from 30 HapMap samples from 
four populations and identified a 200kb deletion in one individual359.  De Smith et al 
used CNV arrays in peripheral blood from 50 French controls, normalised to a cell 
line reference, and identified a 1kb deletion in one individual360.  Bentley et al 
performed Illumina sequencing in a cell line from a single Yoruban individual and 
identified two small deletions in the region; one of 299bp and one of 147bp361.  These 
findings suggest that CNV in this region may exist in apparently healthy individuals, 
although data derived from cell lines requires corroboration since immortalised cell 
lines have been shown to exhibit copy number changes that are not present in the 
primary cells362.  The detection of CNVs in studies involving small numbers of 
individuals suggests that they may not be rare, although it must be noted that other 
genome-wide surveys have not identified CNV in this region352, 355.  One GWA study 
has specifically investigated the association of CNVs with MI, using 1,320 CNV 
probes in 2,967 cases with early-onset MI and 3,075 controls363.  Although this study 
was able to identify significant associations for SNPs in nine regions (including 
chromosome 9p21), no significant associations were found for any of the CNVs 
tested.  However, there was no CNV probe in the region investigated in the present 
study, with the nearest probes located >1Mb distant each side (chromosome 9: 
20,791,650 and 23,353,115); the results therefore do not provide evidence against the 
possibility of an important CNV associated with CAD in the region showing 
departure from HWE. 
 
  
Figure 5.2. CNVs annotated in the Database of Genomic Variants in the chromosome 9p21 region genotyped in the study.   
Chromosome 9: 21,806,758 - 22,124,172. Diagram downloaded from Database of Genomic Variants 18/02/2010358. 
 
 
 
 
 
 
 
 
 
 
 
22048081 
Key to CNVs shown: 
Variation_33079 (Perry et al 2008). CNV array targeting known CNV regions at 1kb resolution in cell lines from 30 control individuals from 4 HapMap populations359. 
Variation_11339 (de Smith et al 2007). Genomewide CNV array survey of 50 French control individuals using peripheral blood referenced to single cell line sample360. 
Variation_47695 & variation_47696 (Bentley et al 2008). Whole-genome Illumina sequencing in a cell line of a single Yoruban individual361. 
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Multiplex Ligation-dependent Probe Amplification (MLPA) is a sensitive method for the 
detection of CNV364, 365.  In this technique, which is summarised in Figure 5.3, multiple 
probesets are designed to hybridise to regions of interest in genomic DNA.  Probesets 
consist of two halves, each of which contains a target-specific hybridising sequence and 
universal primer sequence (with or without a variably sized non-complementary stuffer 
sequence).  Probesets are designed so that the hydridising sequences of each half bind 
adjacently on the target DNA and can be joined in a ligation reaction.  Each probeset is 
designed to produce a product of unique size, and only probesets adjacently bound to their 
target sequence are ligated.  This process results in production of a series of continuous 
probes of different sizes all of which are flanked by universal primer binding sites that can 
then be amplified by PCR, without amplification of unbound probe halves.  The amount 
of ligated probe and resulting PCR product is proportional to the copy number of the 
original target sequence.  The different sized amplification products are separated using 
capillary electrophoresis and checked for data quality before proceeding to analysis.  The 
first step of the analysis is intra-sample normalisation, in which the peak area generated 
by each probe is expressed proportional to a panel of reference probes.  The second step is 
inter-sample normalisation, in which each sample is compared to reference samples of 
normal copy number, or to the population average (if looking for de novo CNVs where 
reference samples are unavailable).  The relative peak heights/areas after normalisation 
indicate copy number changes, and deletions/duplications can be defined using the MLPA 
ratio (peak area relative to the area in the reference sample). 
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Figure 5.3. Summary of the steps involved in MLPA.   
Figure adapted from MRC-Holland website366. 
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5.3 Aims 
The broad aim of this chapter was to investigate possible causes of the departure from 
HWE that was observed for SNPs in the chromosome 9p21 region in Caucasian 
populations. 
Specific aims were: 
1. To exclude genotyping error as a source of departure from HWE in the NE 
Caucasian cohort. 
2. To investigate the direction and significance of HWE departures for these SNPs in 
other Caucasian cohorts including: 
a. Previously published datasets 
b. The HTO cohort 
3. To look for evidence of inheritance patterns consistent with null allele segregation 
at these SNPs in families with Mendelian errors of inheritance in the HTO cohort. 
4. To investigate for evidence of deletions and CNV in the chromosome 9p21 region 
in the NE Caucasian and HTO cohorts using custom MLPA analysis of unselected 
individuals and individuals with Mendelian inheritance errors consistent with null 
allele segregation. 
5.4 Materials and methods 
5.4.1 Participants and samples 
Genotyping checks and MLPA analysis for CNV were undertaken in the NE Caucasian 
cohort, in which genotyping results were initially shown to deviate from the proportions 
expected under HWE.  However, the amount of sample remaining for many of these 
individuals was very limited, with only WGA DNA available for most of the samples.  
Additional genotyping and MLPA analyses were therefore performed in the HTO 
Caucasian cohort.  
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For validation of the ability of the custom MLPA design to detect CNV, positive control 
DNA samples were used from a small number of individuals in which the number of 
copies of target genes had been previously quantified.  These comprised: 
• Five samples from the CHANGE study of families with congenital heart disease 
that had been characterised for the presence of 22q11 deletion syndrome 
(DiGeorge syndrome). Three samples had known deletion involving the CLDN5 
gene, and two samples had two copies of this gene (samples and data provided by 
Dr A Topf, Institute of Human Genetics, Newcastle upon Tyne). 
• Six samples that had been characterised for copy number at the DUSP22 gene.  
These samples comprised one individual with one copy, one individual with two 
copies, three individuals with three copies, and one individual with four copies 
(samples and data provided by Ms R Soemedi and Professor S Pearce, Institute of 
Human Genetics, Newcastle upon Tyne). 
• Five samples provided by the Northern Regional Genetics Service that had been 
characterised for CNV of the PMP22 gene that is associated with Hereditary 
Motor and Sensory Neuropathy (Charcot-Marie-Tooth disease). These samples 
comprised one individual with one copy, one individual with two copies, and three 
individuals with three copies (samples and data provided by Dr O O’Brian, 
Northern Regional Genetics Service, Newcastle upon Tyne). 
For each of these sets of control samples, an individual with two copies of the target gene 
who could be used as a normalisation reference was identified, but the other samples were 
analysed with blinding to the number of copies expected.  The actual number of copies 
present was revealed after analysis of the samples with custom MLPA. 
5.4.2 Genotyping 
Genotyping was performed by Sequenom and TaqMan methodologies using the standard 
protocols outlined in Chapter 2. 
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5.4.3 HWE and D-statistic analysis 
The extent of deviation from HWE proportions was estimated for each SNP by 
calculation of the deviation statistic (D-statistic) in Excel according to the 
formula ( )ppHD −−= 12 , where H is the observed heterozygosity and p the minor allele 
frequency.  Using this formula, negative D-values correspond to an excess of 
homozygosity, and positive values to an excess of heterozygosity.  The significance of the 
deviation from HWE proportions (which tests the likelihood of D=0 versus D≠0) was 
estimated by standard formulae using Excel or Haploview for datasets of unrelated 
individuals296-298.  For datasets containing related individuals, such as the HTO cohort, 
PEDSTATS295 was used to estimate the significance of the deviation in the total dataset 
and in the unrelated founder members only, to account for deviations caused by the 
family-structure.   
The HWE D-statistics and P-values were calculated for chromosome 9p21 SNPs 
genotyped in the study populations outlined above, and also in other large populations for 
which genotyping data in this region were available from a review of the literature and 
online databases.  Details of the other cohorts for which data were available are shown in 
Table 5.1.  Genotype data were obtained from the NCBI dbSNP website42 for the 
‘HapMap CEU’ and ‘AFD/other’ cohorts, and from the individual sources for the other 
cohorts, as referenced in Table 5.1. 
Table 5.1. Other cohorts with chromosome 9p21 SNP genotyping data reported. 
Cohort N Ethnicity Details 
PROCARDIS 
controls129 
4443 Caucasian European ancestry controls self-
reportedly free of CAD at age 65. 
1958 Birth 
Cohort367 
1500 Caucasian 
(>96%) 
Cross-sectional study of all individuals 
born during one week in March 1958. 
UK Blood Service 
cohort368 
1500 Caucasian Healthy UK blood donors. 
HapMap CEU 
cohort47 
60 Caucasian Utah residents with Northern and 
Western European ancestry from the 
CEPH collection. 
AFD/other 
Caucasian cohorts42 
24 / 
variable 
Caucasian Individuals of European American 
descent. 
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5.4.4 MLPA 
Analysis for CNV using MLPA was performed according to the methodology described 
in Chapter 2.  Population normalisation was used, except for the control experiments 
investigating copy number in the small number of patients with known 
deletions/duplications, which used internal control probe normalisation relative to an 
individual known to have two copies of the target gene.  Data were analysed with 
GeneMarker v1.8 software using MLPA ratio analysis, with deletions defined as ratios 
<0.75 and duplications as ratios >1.3 unless otherwise stated.  
A core region (chromosome 9: 21,990,300-22,117,096) where the highest proportion of 
SNPs showed departure from HWE was selected for MLPA analysis (based on the SNP 
‘heatmap’ presented in Figure 5.4 on page 202).  Using custom MLPA with the P200 
reference probeset, a maximum of 13 custom probes can be designed into each assay.  
Ten probes were spaced evenly throughout the core region of interest to provide a ‘screen’ 
for CNV, with a view to performing more detailed mapping of any significant CNVs that 
were discovered using additional MLPA assays with more closely spaced probes.  An 
additional probe was placed in a different region that showed HWE deviations for a group 
of SNPs in the HapMap CEU samples only (chromosome 9: 21,854,535-21,921,896).  
One probe was placed in an adjacent region where SNPs did not deviate from HWE in 
any cohort (chromosome 9: 21,807,158).  The approximate location of the chromosome 
9p21 MLPA probes is highlighted in blue on Figure 5.4 (page 202). 
To demonstrate the ability to detect CNV using the custom MLPA analysis, control 
probes were also designed in two different regions known to show common CNV in 
Caucasian populations (DEFA3 on chromosome 8p23369, 370, and OR4K2 on chromosome 
14q11.2371), and for three genes for which control samples with previously characterised 
CNVs were available (CLDN5 on chromosome 22q11, PMP22 on chromosome 17p12, 
and DUSP22 on chromosome 6p25).  The two MLPA assays used are summarised in 
Table 5.2, and MLPA probe sequences can be found in Appendix 1. 
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Table 5.2. Location of probes used in the MLPA assays. 
MLPA assay 1*  MLPA assay 2 § 
Probe Location Length 
(nt) 
 Probe Location Length 
(nt) 
9p21_01 9p21 control region 
21807158 
92  9p21_01 9p21 control region 
21807158 
92 
8p23_DEFA3 DEFA3 CNV 
6863598 
96  8p23_DEFA3 DEFA3 CNV 
6863598 
96 
9p21_02 9p21 H region 
21892247 
100  9p21_02 9p21 H region 
21892247 
100 
9p21_03 9p21 core region 
22027375 
104  14q11_OR4K2 OR4K2 CNV 
1344825 
104 
9p21_04 9p21 core region 
22038430 
108  9p21_04 9p21 core region 
22038430 
108 
9p21_05 9p21 core region 
22048364 
112  22q11_ CLDN5 CLDN5 CNV 
2667283 
 
112 
9p21_06 9p21 core region 
22054243 
116  9p21_06 9p21 core region 
22054243 
116 
9p21_07 9p21 core region 
22064638 
120  9p21_07 9p21 core region 
22064638 
120 
9p21_08 9p21 core region 
22074944 
124  17p12_ PMP22 PMP22 CNV 
14743013 
124 
9p21_09 9p21 core region 
22087232 
128  9p21_09 9p21 core region 
22087232 
128 
9p21_10 9p21 core region 
22094524 
132  6p25_ DUSP22 DUSP22 CNV  
260236 
132 
9p21_11 9p21 core region 
22104164 
136  9p21_11 9p21 core region 
22104164 
136 
9p21_12 9p21 core region 
22114749 
140  9p21_12 9p21 core region 
22114749 
140 
* MLPA assay 1 used for 9p21 CNV assessment.§ MLPA assay 2 used to check ability to detect CNVs in 
controls. nt = nucleotides, H region = region deviated in HapMap samples only (as shown on Figure 5.4). 
Probe locations are given as a general description along with the specific chromosome location of the first 
nucleotide of the left-hand probe hybridising sequence. 
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5.5 Results 
5.5.1 Deviation from Hardy-Weinberg proportions and genotyping 
checks 
5.5.1.1 Genotyping checks 
As presented in Chapter 4, a higher proportion of SNPs in the NE Caucasian cohort 
showed significant deviations from HWE than would be expected by chance alone: 12/53 
SNPs (23%) at the P<0.05 threshold, and 2/53 SNPs (4%) at the P<0.01 threshold.  
However, using the same assays in the SA cohort, only 1/56 SNPs (1.7%) deviated from 
HWE at the P<0.05 threshold.  Since correspondence of genotypes to the proportions 
expected under HWE is commonly used as a screen for genotyping errors, a number of 
steps were taken to investigate this possibility. 
Review and repeat analysis of Sequenom genotyping calls 
The correspondence of genotypes in the SA cohort to the proportions expected under 
HWE, which was performed using the same assays and reaction conditions, suggested 
that the deviations observed in the NE Caucasian cohort were not due to systematic bias 
in the assays.  The results of genotyping in the Caucasian cohort were therefore carefully 
reanalysed.  Sequenom spectra, cluster plots, and genotype call rates were manually 
reviewed by the operator (MSC) and appeared generally satisfactory, with changes made 
to few individual sample genotypes.  Data processing steps were then repeated to exclude 
errors during data handling.  These steps did not alter the results of the analysis, with the 
same SNPs still deviating from the proportions expected under HWE.  The raw Sequenom 
data and analysis were then independently reviewed by experienced Sequenom 
technicians (Dr D Hall and Mr J Eden, Institute of Human Genetics, Newcastle upon 
Tyne) and judged to be satisfactory. 
To check the consistency of genotyping calls and exclude errors due to sample switching, 
a subgroup of samples was re-genotyped using the same Sequenom assays.  14 SNPs 
selected to include those that most significantly deviated from HW proportions were re-
genotyped (rs3088440, rs10965215, rs10738605, rs3217992, rs1063192, rs10116277, 
rs10757274, rs10757278, rs1333040, rs1333049, rs2383206, rs496892, rs7044859, 
rs7865618).  Repeat genotyping was performed using WGA DNA from a panel of 64 
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samples, which during preliminary analysis as a subgroup had shown significant deviation 
from HWE for some of the SNPs.  A total of 896 genotyping comparisons were made (14 
SNPs in 64 samples) and were analysed blinded to the results of the original genotyping.  
A difference in genotype call was found for only one sample at one SNP, which did not 
significantly alter HWE proportions.  This demonstrated that the Sequenom genotyping 
assays were reproducible, and the same in native DNA (used for original genotyping) and 
WGA DNA (used for the repeat analysis).  These analyses suggested that genotyping 
errors in the Sequenom assays were unlikely to account for the observed deviations from 
HWE.  
Comparison with TaqMan genotyping results 
In the association studies presented in Chapter 6, four of the chromosome 9 SNPs had 
been previously genotyped in the HTO population using the TaqMan platform: 
rs7044859, rs496892, rs7865618, rs1333049.  Although these SNPs did not deviate 
significantly from the proportions expected under HWE in either the NE Caucasian 
samples (Sequenom) or the HTO cohort (TaqMan), genotypes from both methods were 
available for 90 unrelated individuals of the HTO population, which had been used to 
optimise the Sequenom assay.  Comparison of 360 genotypes for these individuals (4 
SNPs in 90 samples) showed no inconsistencies in genotype calls, suggesting that 
Sequenom genotyping was accurate for those SNPs. 
To check the accuracy of genotyping for SNPs which deviated from HWE proportions in 
the NE Caucasian samples, the SNP showing the most significant deviation (rs10116277) 
was retyped in the same population using a pre-designed TaqMan assay 
(C__29991625_20).  Genotype calls at this SNP were obtained for 187 samples using 
Sequenom and 169 samples using TaqMan, as summarised in Table 5.3.  Only three 
samples showed genotyping inconsistencies between the two techniques, with no 
systematic bias in the genotype calls (SeqGG/TaqGT, SeqGT/TaqTT, SeqGT/TaqGG).  
The 18 genotypes with missing TaqMan genotypes did not differ from the proportions 
observed in the rest of the population using Sequenom genotyping (GG 7, GT 6, TT 5).  
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Table 5.3. Comparison of Sequenom and TaqMan genotyping calls for rs10116277. 
Genotypes TaqMan Sequenom 
GG 52 59 
GT 61 68 
TT 56 60 
Absent 18 0 
HWE P-value 0.0003 0.0002 
 
Taken together, the above data suggest that genotyping deviations from HWE proportions 
for SNPs in the NE Caucasian cohort were not due to genotyping errors. 
5.5.1.2 D-statistic analysis and comparison with other cohorts 
As discussed above, deletions in the region could cause departure from HWE, in which 
case SNPs showing deviations would be expected to have an excess of homozygotes (for 
the reasons previously presented in Figure 5.1 on page 189).  Analysis of the D-statistics 
for SNPs showing HWE deviations in this study demonstrated that most of the SNPs 
showing deviations from proportions expected under HWE had an excess of 
homozygosity consistent with the presence of common deletions in the region.   
The genotyping data from other large cohorts where multiple SNPs in this chromosome 
9p21 region had been genotyped were analysed to determine whether a higher than 
expected proportion of SNPs in these studies also deviated from the proportions expected 
under HWE assumptions.  HWE P-values and D-statistics were calculated for SNPs in 
these studies to determine whether the pattern suggested an excess of homozygosity 
consistent with the presence of a null allele.   
As shown in Figure 5.4, other cohorts also showed deviations from HWE proportions in 
the region of interest, which were mostly attributable to an excess of homozygosity.  A 
core region (chromosome 9: 21,990,300-22,117,096) highlighted in Figure 5.4 was 
identified where SNPs showed deviations in multiple Caucasian cohorts at a higher rate 
than was observed in surrounding regions.  This suggested that the rate of deviation in this 
region was different to the ‘background’ deviation rate (for example as observed for SNPs 
in regions shown at the top and bottom of Figure 5.4).   
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Figure 5.4. Heatmap of SNP departures from HWE in Caucasian cohorts.  
Different cohorts are shown in columns. Each row represents a SNP and colours show the extent and 
direction of HWE deviation, as shown in the legend. A core region showing greatest HWE departure which 
was used for MLPA analysis is magnified. The approximate location of MLPA probes is illustrated by 
highlighting the closest SNP to each probe in blue (all MLPA probes were designed not to overlie SNPs). 
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It must be noted that due to LD between SNPs these tests were not independent and 
therefore a deviation from HWE caused by a particular haplotype/mutation may be 
expected to affect SNPs in LD in a similar fashion, such that the high proportion showing 
deviation from HWE might be considered a less dramatic finding than if this was seen at 
multiple unrelated sites.  However, this would not account for the observation that the 
same region showed deviations in multiple independent cohorts.  Of particular interest, 
the core region showing deviation from HWE contained the SNPs associated with CAD in 
GWA studies, and completely overlapped the ANRIL gene, expression of which is 
associated with variants correlated with disease (see Chapter 4).  This raised the 
interesting possibility that common deletions involving ANRIL, leading to HWE 
deviations in the region of that gene, might be causally associated with disease, and that 
SNP associations observed in GWA studies may be due to SNPs ‘tagging’ the CNV.  
Further investigation to look for evidence of common null alleles in this region in 
Caucasian cohorts was therefore performed. 
 
Table 5.4. Summary of SNPs in the core region of deviation that differed from 
expected HWE proportions in each cohort. 
Cohort Number (%) of SNPs in 
the core region of 
deviation with P<0.05 for 
correspondence to HWE 
Number (%) of deviating 
SNPs showing excess 
homozygosity 
PROCARDIS controls129 6/31 (19%) 6/6 (100%) 
1958 Birth Cohort367 11/42 (26%) 9/11 (82%) 
UK Blood Service 
cohort368 
0/22 (0%) NA 
NE Caucasian cohort 14/31 (45%) 14/14 (100%) 
HapMap CEU cohort42 6/92 (7%) 1/6 (17%) 
Other Caucasian cohorts42 27/48 (56%) 26/27 (96%) 
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5.5.2 Investigation of deviations from HWE and evidence for null 
alleles in a family cohort 
5.5.2.1 HWE analysis 
Since other reported Caucasian datasets had also shown evidence of deviations from 
proportions expected under HWE for SNPs in the chromosome 9p21 region, it was 
decided to investigate this further in the HTO cohort.  This had two main advantages: 
• It allowed investigation of whether the observed deviation in HWE proportions 
was replicated in a larger Caucasian cohort. 
• Because the HTO cohort was composed of related family members, it allowed 
investigation for a possible ‘null allele’ (resulting from heterozygous allele 
deletion) by studying allele segregation in families with Mendelian errors in 
inheritance.  This approach could detect deletions that were too rare to account for 
deviation from HWE proportions and identify samples that could be tested for 
presence of a null allele using MLPA. 
17 SNPs that showed deviations from the proportions expected under HWE in either the 
NE Caucasian cohort or one of the other cohorts analysed were selected for genotyping in 
the HTO cohort and redesigned into a single Sequenom assay.  As shown in Table 5.5, 
only a single SNP (rs564398) deviated significantly from the proportions expected under 
HWE in this cohort including all individuals, and no SNPs showed a significant deviation 
when only the founders were considered (to account for deviations that could be attributed 
to the family structure of the population).  This did not support the hypothesis that a 
common null allele in Caucasian populations might explain the deviations observed for 
these SNPs in the other cohorts.
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Table 5.5. SNP genotyping results in the HTO cohort. 
NE Caucasian cohort  HTO cohort SNP Chr 9p21 
position 
Alleles 
% 
Genotyped 
MAF HW P-
value* 
 % 
Genotyped 
MAF HW P- 
Value all 
HW P- 
Value 
founders 
rs1063192 21993367 T:C 98.9 0.42 0.02  99.5 0.47 0.32 0.18 
rs615552 22016077 A:G 95.5 0.41 0.02  99.0 0.47 0.13 0.22 
rs10965215 22019445 A:G 100.0 0.46 0.01  99.5 0.45 0.38 0.32 
rs564398 22019547 A:G 97.7 0.38 0.02  91.9 0.44 0.00003 0.61 
rs11790231 22043591 G:A 96.6 0.12 0.96  99.4 0.10 0.37 0.53 
rs2184061 22051562 A:C 93.2 0.38 0.10  93.4 0.43 0.08 0.80 
rs10811650 22057593 C:G 95.5 0.47 0.001  99.0 0.40 0.95 0.31 
rs10116277 22071397 T:G 100.0 0.49 0.0002  99.0 0.44 0.91 0.46 
rs1333040 22073404 T:C 100.0 0.36 0.02  99.4 0.43 0.96 0.71 
rs7857345 22077473 C:T 93.2 0.27 1.00  99.8 0.30 0.48 0.47 
rs10757274 22086055 G:A 100.0 0.49 0.01  96.9 0.45 0.82 0.90 
rs10125231 22092128 G:A 94.9 0.02 1.00  93.6 0.03 0.05 1.0 
rs2383206 22105026 G:A 100.0 0.47 0.01  98.5 0.46 0.91 0.39 
rs2383207 22105959 G:A 90.4 0.42 0.33  99.6 0.46 0.74 0.38 
rs1333045 22109195 C:T 96.6 0.48 0.05  98.7 0.48 0.74 0.62 
rs10757278 22114477 A:A 99.4 0.50 0.05  97.8 0.44 0.74 1.0 
rs1333049 22115503 C:G 100.0 0.50 0.08  99.7 0.44 0.87 1.0 
MAF = minor allele frequency; HW = Hardy-Weinberg.  * Included SNPs which have HW P-values >0.05 
in the NE Caucasian cohort showed significant deviations in other populations analysed. 
 
5.5.2.2 Investigation for Mendelian errors consistent with segregation of a null 
allele 
PEDSTATS software295 was used to identify 78 Mendelian inheritance errors in 20 
families.  Genotyping spectra and cluster plots were manually reviewed for parent-
offspring trios with Mendelian errors, and samples with low quality spectra and borderline 
calls likely to represent genotyping miscalls were excluded.  The remaining samples were 
then re-genotyped, leaving 38 Mendelian errors in 16 individuals from 13 families.  
Pedigrees of these individuals were examined to determine whether the observed patterns 
were consistent with a null allele, as summarised in Table 5.6. 
Chapter 5: 9p21 CNV studies 
206 
Table 5.6. Mendelian errors consistent with presence of a null allele. 
Sample ID 
(Family_individual) 
Number of Mendelian errors in 
SNPs consistent with null allele 
Number of Mendelian errors in 
SNPs not consistent with null 
allele 
36_9 6 0 
104_8 1 0 
115_4 1 0 
150_6 1 0 
155_5 1 0 
155_7 1 0 
190_3 9 0 
118_5 1 1 
202_3 3 1 
107_4 0 1 
118_4 0 1 
118_5 0 2 
118_6 0 1 
124_5 0 2 
170_13 0 2 
238_3 0 1 
 
For seven individuals the pattern of genotyping in the pedigree was consistent with the 
presence of a null allele, i.e. one of the parents and the offspring were homozygous for 
different alleles.  Two further individuals had Mendelian errors consistent with a null 
allele at some SNPs, but other SNPs where the pattern was not consistent with a null 
allele.  In the remaining seven individuals the pattern was inconsistent with a null allele at 
all SNPs; this could result from sample switching/contamination, genotyping miscalling, 
or mistaken paternity.  Pedigrees illustrating examples of the different patterns observed 
are shown in 
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Figure 5.5. 
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Figure 5.5. Examples of pedigrees with Mendelian errors consistent or inconsistent 
with a null allele.  
Family pedigrees with genotypes and sample identifiers shown below. (A) Mendelian error in individual 
115_4 (red) consistent with presence of a possible null allele. (B) Possible null allele in 115_2 and 115_4 
(orange) that could explain the genotyping results. (C) Mendelian error in individual 238_3 (red) that could 
not be attributed to the presence of a null allele. 
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5.5.3 MLPA results 
5.5.3.1 Effect of DNA amplification on MLPA analysis 
The NE Caucasian cohort showed the most significant deviations from HWE and it was 
therefore intended to investigate the possibility of CNV in that population using MLPA.  
However, DNA for most individuals in that population was only available in limited 
amounts from the RNA extraction.  MLPA ideally requires 50-200ng of high quality 
DNA since impurities and poor quality DNA can potentially influence MLPA results.  
Exploratory experiments were performed to determine whether the RNA/DNA solution 
from the RNA extraction could be used for analysis.  MLPA was performed for four 
samples, using 1µL and 3µL of the RNA/DNA solution as template for each.  These 
samples showed unreliable results, with ‘scattering’ of the control probes and complete 
failure of one sample, as shown in Figure 5.6.  Separate DNA samples were available for 
a small number of samples in this cohort, which were analysed using MLPA.  As shown 
in Figure 5.7, the 12 samples which had acceptable MLPA data showed no evidence of 
CNV in the chromosome 9p21 region. 
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Figure 5.6. Suboptimal MLPA results from DNA in the RNA extraction eluate for 
the NE Caucasian samples.  
The 13 points on the left-hand side of each plot represent the custom probes for chromosome 9p21 (except 
for point 2 which is a control in DEFA3), and the 14 points on the right-hand side represent the P200 control 
probes (with control probe 7 on the X chromosome and control probe 12 on the Y chromosome). Points 
outside of the parallel lines indicate CNVs. Plots show MLPA results in the same four individuals using 
1µL and 3µL of RNA/DNA solution, and illustrate poor quality data that could not be used for reliable CNV 
assessment. For comparison, see Figure 5.7 which shows satisfactory quality plots, with no deviation of the 
control probes. 
 
 
 
 
 
 
 
 
 
 
 
Sample failed
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Figure 5.7. MLPA results showing no evidence of CNV in the chromosome 9p21 
region in DNA samples from the NE Caucasian cohort.  
The 13 points on the left-hand side of each plot represent the custom probes for chromosome 9p21 (except 
for point 2 which is a control in DEFA3), and the 14 points on the right-hand side represent the P200 control 
probes (with control probe 7 on the X chromosome and control probe 12 on the Y chromosome). Points 
outside of the parallel lines indicate CNVs. None of these samples showed chromosome 9p21 CNV. 
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Since amplified DNA was available for all of the NE Caucasian samples, an experiment 
was performed to investigate whether MLPA detection of CNV could be performed using 
amplified DNA.  As shown in Figure 5.8, MLPA results derived from paired samples of 
native DNA and WGA DNA from the same individuals performed on the same plate 
using the same reaction mastermix were substantially different in the 10 samples, 
indicating that WGA DNA could not be used for reliable assessment of CNV.  WGA 
samples showed apparent copy number variations for multiple probes, including the 
control probes, which were not present in the native DNA, suggesting that the 
amplification process amplified some regions of DNA more efficiently than others. 
5.5.3.2 Custom MLPA in the chromosome 9p21 region in additional Caucasian 
samples 
In addition to the NE Caucasian samples, MLPA analysis was also performed in 106 
unrelated individuals from the HTO cohort to investigate the possibility of low frequency 
CNV which did not result in deviation from the proportions expected under the 
assumptions of HWE.  Using the standard MLPA ratio thresholds of <0.75 or >1.3, only 
one sample showed a deviation from two copies (zero copies of probe 9p21_01), and this 
sample was of borderline quality with some deviation in the control probes, suggesting 
that it was most likely to be due to artefact.  With the deletion threshold of 0.75, a number 
of samples showed borderline evidence for deletion at the DEFA3 probe.  Increasing the 
lower threshold to 0.8 resulted in samples that looked suggestive for DEFA3 deletion 
becoming significant and led to only one additional chromosome 9p21 probe deviation 
(one copy of probe 9p21_04). The results of the analysis using the deletion threshold of 
0.8 are shown in Table 5.7.  Overall, there was no strong evidence for CNV for any of the 
probes in 118 Caucasian samples tested. This suggested that CNV was not common in 
this region in Caucasian cohorts, and was unlikely to account for the deviation from HWE 
proportions that was observed in the genotyping of the NE Caucasian cohort. 
 
 
  
Figure 5.8. MLPA results in native DNA versus WGA DNA from the same individuals.  
The 13 points on the left-hand side of each plot represent the custom probes for chromosome 9p21 (except for point 2 which is a control in DEFA3), and the 14 points on the 
right-hand side represent the P200 control probes (with control probe 7 on the X chromosome and control probe 12 on the Y chromosome). Points outside of the parallel lines 
indicate CNVs. Results in gDNA and WGA DNA are shown for the same samples. WGA led to unreliable CNV assessments. 
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Table 5.7. MLPA results at the chromosome 9p21 locus and two loci known to 
show CNV. 
Number of copies MLPA probe 
0 1 2 3 4 
9p21_01 1** 0 118 0 0 
9p21_02 0 0 118 0 0 
9p21_03 0 0 75* 0 0 
9p21_04 0 1§ 118 0 0 
9p21_05 0 0 75* 0 0 
9p21_06 0 0 118 0 0 
9p21_07 0 0 118 0 0 
9p21_08 0 0 75* 0 0 
9p21_19 0 0 118 0 0 
9p21_10 0 0 75* 0 0 
9p21_11 0 0 118 0 0 
9p21_12 0 0 118 0 0 
8p23_DEFA3 1 33 78 5 1 
14q11_OR4K2 0 1 23 17 2 
Data shown using the MLPA ratio threshold of 0.8 to define deletion. * Fewer samples for probes 
replaced with alternative probes in assay-2 used to test for known CNV controls in different regions in 
a subset of 43 samples. ** Deviation in sample of borderline quality, with some deviation in control 
probes, likely spurious. § Two copies using the MLPA threshold of 0.75. 
 
However, since this was a custom assay investigating for the presence of potential 
CNVs that had not been previously characterised, there were no samples with 
confirmed deletions that could be used as positive controls to test the sensitivity of the 
custom MLPA analysis for the detection of true CNVs.  To demonstrate that assays 
designed and analysed using this methodology were capable of detecting CNVs, 
custom probes were designed for two genes previously reported to display common 
CNV in human populations (DEFA3 on chromosome 8p23369, 370, and OR4K2 on 
chromosome 14q11.2371), and for three genes for which control samples with 
previously characterised CNVs were available (CLDN5 on chromosome 22q11.21, 
PMP22 on chromosome 17p12, and DUSP22 on chromosome 6p25.3).   
As shown in Table 5.7, CNVs were detected in the population using the custom 
DEFA3 and OR4K2 probes.  The observed OR4K2 duplication prevalence was 19/43 
(44%), which was similar to the prevalence of 37% reported previously371.  Similarly, 
Chapter 5: 9p21 CNV studies 
215 
the observed CNV rates for DEFA3 were broadly comparable to published data369, 370, 
as shown in Figure 5.9.  The custom assays also accurately quantified the known 
CNVs from patient samples at the other loci studied, as shown in Table 5.8.  The two 
instances where copy number estimation did not exactly correlate with the known 
number of copies occurred in reactions with considerable scatter of the control probes, 
indicating suboptimal quality of the assay.   
Figure 5.9. Comparison of CNV detected in DEFA3 gene with published data370. 
The graph shows the proportion individuals in the population (Y-axis) with different numbers of copies 
of the gene (X-axis) observed in the current study (black) and a previously published series (grey). 
Results were similar in the two populations 
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Table 5.8. Copy number variation detected by custom MLPA compared to actual 
number of copies present for three different loci. 
 
CNV region Number of copies in 
sample 
Number of copies detected 
with MLPA 
1 1 
1 1 
1 1 
2 2 
22q11 
2 2 
 
  
1 2 
2 2* 
3 3 
3 3 
3 3 
DUSP22 
4 4 
 
  
1 1 
2 2* 
3 2 
3 3 
HMSN 
3 3 
* Sample used as reference to normalise MLPA assay. Shaded rows highlight samples where the 
custom MLPA probe did not identify the expected number of copies in the sample (however in both of 
these cases the control probes were fairly scattered, indicating that the individual reaction or sample 
may have been suboptimal). 
 
These data indicate that the custom MLPA was able to accurately detect and quantify 
CNVs.  As shown in Table 5.9, in 118 samples screened the probability of not 
observing a null allele of a frequency that could account for the magnitude of HWE 
departure observed in the NE Caucasian cohort was small for all SNPs in the MLPA 
region.  The study was therefore adequately powered, suggesting that common CNVs 
in this region do not account for the observed departure from HWE and are unlikely 
to account for the associations of common SNPs with phenotypes observed in GWA 
studies.   
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Table 5.9. Probability of missing a null allele that could account for the observed 
magnitude of HWE departure in 118 Caucasian samples for SNPs in the MLPA 
region. 
 
SNP HWE P-value 
in NE 
Caucasian 
cohort 
Frequency of null allele 
that could account for 
this magnitude of HWE 
departure 
Probability of not 
observing a null allele 
of this frequency in 118 
individuals 
rs3217992 0.02 0.10 2.2x10-11 
rs1063192 0.02 0.10 1.8x10-11 
rs615552 0.01 0.11 3.0x10-12 
rs10965215 0.01 0.11 4.5x10-13 
rs564398 0.02 0.10 1.5x10-11 
rs7865618 0.01 0.10 1.0x10-11 
rs10738605 0.02 0.10 2.0x10-11 
rs10811650 0.00 0.14 1.1x10-16 
rs10116277 0.00 0.16 1.1x10-18 
rs1333040 0.01 0.10 6.6x10-12 
rs10757274 0.01 0.12 1.8x10-13 
rs2383206 0.01 0.11 1.7x10-12 
rs1333045 0.04 0.09 7.4x10-10 
rs10757278 0.03 0.09 5.0x10-10 
 
5.5.3.3 MLPA analysis in individuals with possible null alleles 
MLPA analysis was performed for all nine samples (and the relevant parent) whose 
patterns of Mendelian errors were consistent with null allele segregation in some or 
all of the SNPs (as presented in section 5.5.2.2 and Table 5.6).  As shown in Figure 
5.10, MLPA in the chromosome 9p21 region did not show evidence for deletions or 
other CNVs in any of these individuals.   
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Figure 5.10. MLPA results in the nine individuals with Mendelian inheritance 
errors consistent with null allele segregation within the pedigree.  
The 13 points on the left-hand side of each plot represent the custom probes for chromosome 9p21 
(except for point 2 which is a control in DEFA3), and the 14 points on the right-hand side represent the 
P200 control probes (with control probe 7 on the X chromosome and control probe 12 on the Y 
chromosome). Points outside of the parallel lines indicate CNVs. None of the individuals demonstrated 
chromosome 9p21 CNVs. 
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5.6 Discussion 
SNP genotyping in the NE Caucasian cohort showed departures from HWE with an 
excess of homozygosity at a higher rate than expected by chance alone.  Analysis of 
HWE in this study was performed as a check for genotyping errors, which is 
consistent with widespread practice in other genotyping studies129, 344, although some 
have suggested that HWE testing should not be performed since real-life populations 
are never exactly in HWE343 and it is not a sensitive method for detecting genotyping 
errors347.  Extensive genotyping checks, including repeat analysis by different 
methodologies, excluded genotyping error as the cause of the observed departure from 
HWE seen in this population.  These investigations confirmed that the genotyping 
performed in this study was highly accurate. 
Although the excess of homozygosity observed for SNPs showing departure from 
HWE could be consistent with the presence of common deletions in the region, CNV 
was not detected using custom MLPA in 118 Caucasian samples analysed.  However, 
it must be noted that MLPA was not performed for most samples from the NE 
Caucasian cohort which showed the highest frequency of departure from HWE 
because insufficient native DNA was available for these individuals, and it was 
demonstrated that assessment of copy number could not be reliably performed in 
WGA DNA.  No CNV was detected in the small number of samples that were 
analysed from this population.  Although consistent departures from HWE with an 
excess of homozygosity in this region have also been observed in other large 
datasets129, raising the possibility that common deletions may exist in Caucasian 
populations, we did not find evidence to support this in the HTO cohort.  Using the 
family-based approach to look for Mendelian errors consistent with null allele 
segregation should provide greater power to detect deletions present at a frequency 
below that which would cause departure from HWE, but no deletions were seen even 
in this subset of individuals.  Although this approach provides a method to identify 
individuals with potential null alleles, it cannot identify null alleles that do not result 
in Mendelian errors of inheritance, such as in offspring where one parent has a null 
allele but the other parent is homozygous for the undeleted allele (for example: 
offspring ‘G-’ from parents and ‘GG’ and ‘G-’ would not appear as a Mendelian 
error), although the screen of 118 Caucasian individuals suggests that such CNVs are 
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not common in the population.  The errors of Mendelian inheritance observed in this 
study which are not attributable to CNV may be the result of non-paternity, sample 
confusion/contamination, or genotyping error.  Repeat genotyping should have 
minimised the possibility of genotyping error in the present study.   
Because MLPA was being used for the investigation of unknown CNVs, positive 
controls and reference samples were not available, raising the possibility that the 
custom MLPA design was insensitive for the detection of CNVs.  Although the 
chromosome 9p21 custom probes could not be directly validated, custom probes 
designed and analysed using identical methodology for five separate control regions 
were accurate in detecting CNVs.  In the analysis of amplified DNA which contained 
copy number artefacts, the custom chromosome 9p21 probes detected significant 
CNVs that were similar to the patterns seen in the control probes, suggesting that they 
were able to detect CNVs when present.  Taken together, these data along with the 
low variability observed in the 9p21 probes in native DNA, make it unlikely that the 
MLPA results represent false negative findings.  Previous genomewide surveys of 
CNV have reported four deletions in this region in three separate individuals, one of 
which was 200kb in size and the other three of which were all less than 1kb.  The 
chromosome 9p21 probes used in the present study were spaced at approximately 
10kb intervals throughout the region of interest, and it is therefore possible that CNVs 
smaller than 10kb would not have been detected.  However, deletions sufficient to 
account for the departure from HWE observed across a region of this size would have 
been detected with the spacing of our MLPA probes.  The sample size of the 
Caucasian cohort screened was sufficient to confidently exclude deletions of a 
frequency that could account for the magnitude of the HWE departure observed in the 
NE Caucasian cohort.  However, the analysis does not exclude the presence of rare 
variants with significant effects on expression or disease phenotypes, such as those 
that have been previously reported in pedigrees with familial cancers195.  The 
possibility that rare CNVs in this region confer susceptibility to CAD or other disease 
phenotypes in some individuals therefore cannot be excluded. 
This study demonstrated that CNV assessment consistently differed in native DNA 
and WGA from the same individuals, with WGA DNA showing significant deviations 
for multiple MLPA probes in each sample that are not present in native DNA.  Copy 
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number artefacts associated with DNA amplification have been previously reported 
for Phi29 polymerase multiple-strand displacement techniques372-374, which at least in 
part relate to the GC content of the region372.  The Genomeplex kit uses degenerate 
oligonucleotide primer PCR-based amplification, and has been used to detect both 
whole chromosome copy number changes 375 and copy number changes involving 
regions as small as 8.3Mb376, although the latter study did note increased variability 
associated with amplified compared to unamplified DNA.  A subsequent study by the 
same group, published after the experiments reported in this chapter were performed, 
showed that analyses using tiling oligo arrays in Genomeplex amplified DNA could 
not reliably detect CNVs of less than 3Mb due to the variability introduced by 
amplification377.  In the present study, the artefacts associated with Genomeplex 
amplification were non-random, with systematic deviations occurring for particular 
MLPA probes in different samples.  It may be possible to correct for such systematic 
biases by normalising to other amplified samples, which has been proposed for 
analysis of amplified data from multiple-strand displacement techniques373. 
The assumptions of HWE are never exactly met in real populations, and violations of 
any of these assumptions may cause deviation from the proportions expected, 
particularly population stratification and selection bias349.  The cohort was composed 
principally of individuals from the People of the British Isles study, the ascertainment 
strategy of which involved recruitment of individuals with three generations of family 
born within a 40-mile radius of one another in rural populations in NE England (from 
Northumberland, Tyneside, County Durham, and Cumbria).  Effectively, this selected 
individuals whose family had lived for generations the same village/town, 
geographically distinct from that of the other members of the cohort.  This violated 
the HWE assumption of random-mating and may have produced stratification of the 
combined population which might account for the higher incidence of HWE departure 
observed in this population compared to the HTO cohort, although this would not 
account for the HWE departure seen in other published cohorts at the same locus.  
However, LD between SNPs in this region means that tests of correspondence to 
HWE proportions are not independent for each SNP, and deviation at one SNP is 
likely to be associated with deviation at other SNPs in strong LD with it.  This inflates 
the proportion of analysed SNPs showing deviations, and could account for the 
clustering of HWE departures seen within the various cohorts. 
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In summary, the deviations from HWE that were observed were not due to genotyping 
error, and MLPA analysis showed no evidence of common CNVs in Caucasian 
cohorts.  It is likely that the deviations observed in the NE Caucasian cohort and other 
published series can in varying degrees be accounted for by the ascertainment 
strategy, random chance, and LD between markers. 
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6 Association of 9p21 polymorphisms with 
cardiovascular phenotypes 
6.1 Abstract 
The mechanisms through which novel CAD risk variants identified by GWA studies 
influence disease is unknown; their relationship to other cardiovascular phenotypes 
may give mechanistic clues.  Carotid artery intima-media thickness (CIMT) is a 
subclinical marker of atherosclerosis associated with stroke that can be used to 
investigate the association of these SNPs with extra-coronary arterial manifestations.  
Chromosome 9p21 CAD risk variants are also associated with non-atherosclerotic 
intracranial aneurysms, which are themselves associated with congenital 
cardiovascular abnormalities, suggesting that risk variants may have more generalised 
influences on vascular and cardiac structure.  This study investigated the association 
of CAD risk variants with intermediate phenotypes, CIMT, and echocardiographic 
measures of cardiac structure and function in 1425 members of 248 British Caucasian 
families ascertained through a hypertensive proband.  The association of risk variants 
with congenital heart disease was also investigated in a case-control study of 888 
affected individuals and two control cohorts of 1144 and 1500 unaffected individuals.  
CAD risk SNPs were genotyped using TaqMan and Sequenom. MERLIN software 
was used for family-based association testing and case-control association analysis 
was performed by logistic regression using UNPHASED software.  No significant 
association was found between genotype at any SNP and BP, obesity, cholesterol, 
CRP, interleukin-6, TNF-α, or leptin.  Nor were SNPs significantly associated with 
CIMT, echocardiographic parameters, or congenital heart disease (at 0.05 significance 
level corrected for multiple testing).  In summary, novel CAD variants do not appear 
to mediate the risk of atherothrombosis through the known risk factors studied and are 
not associated with CIMT, LV structure/function or congenital heart disease.  Further 
investigations will be required to determine the mechanisms by which these SNPs are 
associated with CAD. 
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6.2 Introduction 
A number of common SNPs have been associated with CAD in recent GWA 
studies,19-21 but, in contrast to associations derived from candidate gene analyses, the 
mechanisms underlying the associations with CAD are unknown.  A relationship of 
these variants to intermediate cardiovascular phenotypes may give important 
mechanistic clues to pathways involved in causation. 
Previous studies had demonstrated that CAD risk variants at the chromosome 9p21 
locus were not associated with traditional risk factors including BP, BMI, cholesterol 
and glucose20; nor with biochemical parameters including lipoprotein(a), fibrinogen, 
albumin, bilirubin and homocysteine129.  However, the association with intermediate 
phenotypes from other pathways known to be important in the pathogenesis of CAD 
had not been investigated.  Neither had the association of phenotypes with CAD risk 
variants at two other replicated loci from GWA studies (on chromosome 6 and 
chromosome 2) been investigated. 
Atherosclerosis involves an ongoing inflammatory response, and there is increasing 
evidence for the role of inflammation in mediating all stages of atherosclerosis from 
plaque initiation and progression to the thrombotic complications378-380.  The 
inflammatory cytokine interleukin-6 (IL-6) is a regulator of the acute phase response 
which stimulates the production of all of the acute phase proteins including CRP and 
tumour necrosis factor-α (TNF-α)380.  It has diverse actions that may be involved in 
atherogenesis including regulation of fibrinogen levels, increasing platelet 
aggregation, influences on endothelial function, and mediating leukocyte 
recruitment380.  Cardiovascular risk factors such as smoking increase plasma IL-6 
levels381, 382, which in turn have been associated with atherosclerosis development and 
adverse clinical outcomes from atherosclerotic disease383-386.  Furthermore, genetic 
variants which increase plasma IL-6 levels have been shown to be associated with 
atherosclerosis prevalence387 and adverse clinical outcome after acute coronary 
syndromes388, suggesting that IL-6 may be involved in causation rather than simply 
being a marker of disease.  Plasma levels of the inflammatory marker C-reactive 
protein (CRP) and TNF-α are also associated with atherosclerosis389-391, although 
whether they were causally implicated was unknown at the time of this study.  The 
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hormone leptin that is involved in the regulation of body weight has also been shown 
to be involved in platelet aggregation, vascular calcification, and development of 
atherosclerosis in murine models392-394.   
Carotid artery intima-media thickness (CIMT) is a subclinical marker of 
atherosclerosis that is associated with cardiovascular disease risk factors and an 
independent predictor of atherosclerosis and clinical outcomes including stroke395, 396.  
CIMT progression may be reduced or reversed with interventions that reduce the risk 
of future cardiovascular events, supporting the concept that CIMT measurement can 
be used as an early marker for atherosclerosis395, and it has been validated as a 
surrogate for cardiovascular disease endpoints in statin trials397.  Although it does not 
directly measure carotid atherosclerosis, a close correlation between CIMT and 
carotid plaques has been demonstrated398.  Investigating the relationship of CAD risk 
variants with CIMT may help to establish whether such variants are associated with 
atherosclerotic manifestations outside of the coronary arteries, and whether CIMT 
might permit the early effects of genetic variants to be investigated in other cohorts, 
even before the onset of clinical disease.   
CAD risk variants on chromosome 9p21 have also been associated with non-
atherosclerotic intracranial aneurysms130, 399, suggesting that they may have broader 
influences on cardiovascular structure and integrity that are independent of the 
association with atherosclerosis.  Abnormalities of cardiac structure and function such 
as LV dysfunction, hypertrophy, and dilatation are important predictors of adverse 
prognosis in population-based cohorts400-403, and can be easily assessed non-
invasively by transthoracic echocardiography.  These phenotypes are heritable404, 405, 
suggesting that they have a genetic basis, but the genes responsible for most of the 
heritability remain unknown.   
Interestingly, intracranial aneurysms have also been associated with congenital 
cardiovascular disease.  The association between aortic coarctation, bicuspid aortic 
valve, and intracranial berry aneurysm has been well reported and reviewed406-408.  
Although it has been suggested that hypertension resulting from coarctation could 
account for the association with intracranial aneurysms409, pathological arterial wall 
changes have been demonstrated in normotensive adults long after coarctation repair 
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and also distal to the coarctation, suggesting that it may be associated with a more 
generalised arteriopathy410, 411.  Moreover, subarachnoid haemorrhage may occur 
many years after coarctation repair and in normotensive individuals408, 412.  Case 
reports and retrospective series have also shown that intracranial aneurysms, as well 
as intracranial dissections and AV malformations, may be associated with a range of 
different congenital heart defects including transposition of the great vessels, 
persistent truncus arteriosus, tricuspid atresia, pulmonary artery stenosis, and 
pulmonary valve stenosis413-415.  Furthermore, the combination of intracranial 
aneurysms and cardiac defects is a component of a number of congenital syndromes, 
suggesting that these phenotypes may have a common aetiology416-418.  Neural crest 
cells are involved embryologically in the development of the heart, aortic arch, and 
muscular arteries of the head and neck, and ablation of the neural crest has been 
shown experimentally to produce a range of cardiac defects419.  It has been proposed 
that abnormal development of cells arising from the neural crest may be the common 
pathogenic factor responsible for the association between congenital cardiac defects 
and intracranial aneurysms413.  SNPs influencing expression of genes controlling 
cellular proliferation and senescence (such as CDKN2A, CDKN2B and ANRIL) could 
be involved in the development of cardiac defects during embryogenesis.  In view of 
the unexpected association between chromosome 9p21 risk variants and intracranial 
aneurysm130, investigating whether CAD risk SNPs are associated with congenital 
heart disease is also of interest. 
6.3 Aims 
The broad aim of this chapter was to investigate the association of novel CAD risk 
variants with a range of acquired and congenital cardiovascular phenotypes.  
The chapter is divided into two separate parts as outlined below. 
1.   Investigation of CAD risk variants with acquired quantitative cardiovascular 
phenotypes in the HTO cohort that has been previously shown to have adequate 
power to detect small genetic influences on quantitative traits, including CIMT11, 420.   
The specific aims were: 
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• To investigate the association of CAD variants on chromosomes 9p21, 6q25 
and 2q36 with intermediate phenotypes not previously examined including 
plasma IL-6, CRP, TNF-α, and leptin, as well as waist-hip ratio. 
• To investigate the association of novel CAD variants on chromosomes 6q25 
and 2q36 with traditional risk factors, and confirm the negative associations 
previously observed with these phenotypes for chromosome 9p21 variants. 
• To investigate the association of CAD variants on chromosomes 9p21, 6q25 
and 2q36 with CIMT and echocardiographic measures of cardiac structure and 
function including LV dimensions, LV systolic function and LV diastolic 
function. 
2.   Investigation of chromosome 9p21 variants with congenital cardiovascular 
phenotypes in a case-control study. 
The specific aims were: 
• To determine whether risk variants for CAD/intracranial aneurysm and SNPs 
most strongly associated with expression of CDKN2A/2B/ANRIL are 
associated with congenital heart disease. 
6.4 Association with CIMT, cardiac function, and intermediate 
phenotypes for CAD  
6.4.1 Materials and methods 
6.4.1.1 Participants and samples 
Association between SNPs in the chromosome 9p21 region and acquired 
cardiovascular phenotypes was investigated in the Caucasian HTO population.  This 
cohort comprised 1425 members of 248 British Caucasian families who were 
ascertained through hypertensive probands and who had been characterised for 
phenotypes relevant to cardiovascular disease, as described in Chapter 2. 
Chapter 6: 9p21 association studies 
229 
Individuals with an established aetiology for LV impairment or dilatation were 
excluded from the analysis of echocardiographic parameters, since these would 
reduce the ability to detect effects attributable to the SNPs under investigation.  This 
resulted in exclusion of 37 individuals with previous MI (based on history, ECG and 
echo findings) and 38 with valvular heart disease.  All individuals with available 
measurements were included in the analysis of the other phenotypes. 
6.4.1.2 Genotyping 
SNPs were selected from each of the three regions that had shown replicated 
association with CAD in more than one GWA study at the time the experiments were 
carried out (chromosome 9p21.3, chromosome 6q25.1 and chromosome 2q36.3)21.  
Four SNPs selected to tag the two chromosome 9p21 haplotype blocks associated 
with CAD in Caucasian populations described by Samani et al21 were genotyped.  
These comprised rs7044859, rs496892 (formerly known as rs1292136) and rs7865618 
in the first LD block, and rs1333049 in the second LD block18, 21.  The lead SNPs 
showing the strongest association with CAD at each of the other two replicated CAD 
loci were also genotyped: rs6922269 on chromosome 6q25.1 and rs2943634 on 
chromosome 2q36.321. 
TaqMan genotyping was performed as described in Chapter 2, using made-to-order 
SNP genotyping assays (Applied Biosystems) with the following assay IDs: 
C_2618037_10 (rs7044859), C_2618027_10 (rs496892), C_2618016_10 
(rs7865618), C_1754666_10 (rs1333049), C_29894051_10 (rs6922269), 
C_15949769_10 (rs2943634).  Genotyping calls were manually reviewed and edited 
if required. 
6.4.1.3 Statistical analysis 
Mendelian inheritance and correspondence of genotype frequencies to HWE 
proportions was checked in both the total population and the unrelated founders using 
PEDSTATS 295.  Phenotypes were examined for normality and log-transformed if 
required (log transformed phenotypes highlighted in results Table 6.2, page 231).  
Phenotypes were adjusted for significant covariates using linear regression, 
considering age, sex, cardiovascular medications, smoking status 
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(current/former/never), alcohol consumption (units per week) and exercise habit 
(frequency per week).  For each phenotype, stepwise regression was used initially to 
identify significant covariates to be included in the linear regression model for that 
phenotype.  The residual values from the linear regression were then used for 
association testing.   
Association between genotypes and adjusted phenotypes was assessed using 
MERLIN v1.1.2 software300.  This evaluates the evidence for association under an 
additive genetic model, which was selected based on the data from previous 
publications showing that SNP effects were additive21.  The upper bound of the 
genetic effect that is plausibly associated with each SNP for each phenotype was 
estimated using linear regression models.  Robust "sandwich" variance estimations, to 
compensate for family clustering, were fitted to model additive genetic effects using 
Stata v9.2. 
6.4.2 Results 
1425 participants were included: mean age 50 (lower quartile 35, upper quartile 60) 
years, 678 (47.6%) male. General characteristics of the study participants are shown 
in Table 6.1.  
Table 6.1. General characteristics of the included HTO study population. 
Characteristic N Median 
(LQ, UQ) 
Previous ischaemic heart disease 61 (4.3%) - 
Previous stroke 33 (2.3%) - 
Previous peripheral vascular disease 13 (0.9%) - 
Diabetes 35 (2.5%) - 
Current or former smoker 507 (35.6%) - 
Hypertension 512 (35.9%) - 
Daytime systolic blood pressure (mmHg) 958 131 (121.1, 144.1) 
Daytime diastolic blood pressure (mmHg) 958 78.6 (72.0, 88.0) 
Plasma total cholesterol (mmol/l) 1289 5.6 (4.8, 6.4) 
BMI (kg/m2) 1402 25.4 (23.1, 28.2) 
WHR 1357 0.85 (0.78, 0.91) 
N=1425 HTO participants; BMI = body mass index; WHR = waist-hip ratio; LQ = lower quartile; UQ 
= upper quartile. 
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854 participants had measurable CIMT, as shown in Table 6.2. Median maximal 
CIMT values of 0.858mm in men and 0.803mm in women were within the normal 
population range (0.36-1.07mm). 
Genotyping results are shown in Table 6.3.  Genotyping data were complete for more 
than 93% of individuals at all loci and allele frequencies were similar to those 
reported in the HapMap CEU population42.  Only one SNP, rs6922269, showed a 
significant deviation from the proportions expected under HWE at the P=0.05 
threshold, but this SNP showed no departure in the unrelated founders and was 
therefore regarded as acceptable.  LD between the typed SNPs on chromosome 9p21 
is shown in Figure 6.1. 
Table 6.2. Cardiovascular phenotypes in the study population and estimated 
maximum genetic effect on total phenotypic variance for the typed SNPs. 
Variable N Median (LQ, UQ) Maximum genetic effect for 
typed SNPs † 
BMI (kg/m2)* 1402 25.4 (23.1, 28.2) 0.4-1.7% 
WHR 1357 0.85 (0.78, 0.91) 0.6-1.4% 
Daytime systolic blood pressure 
(mmHg)* 
958 131 (121.1, 144.1) 0.5-0.7% 
Mean CIMT (mm)* 854 0.76 (0.65, 0.91) 0.7-1.5% 
Max CIMT (mm)* 856 0.83 (0.71, 1.00) 0.7-1.4% 
Plasma total cholesterol 
(mmol/l)* 
1289 5.6 (4.8, 6.4) 0.5-1.4% 
Plasma IL-6 (pg/mL)* 1186 0.78 (0.48, 1.38) 0.4-0.7% 
Plasma TNF-α (pg/mL)* 1186 0.74 (0.35, 1.66) 0.6-1.3% 
Plasma CRP (mg/L)* 1314 1.40 (0.55, 3.2) 0.4-1.7% 
Plasma Leptin (ng/µL)* 1319 8.6 (4.6, 15.3) 0.5-1.0% 
LVIDd (mm) 829§ 49 (46, 53) 0.8-2.0% 
LVIDs (mm) 829§ 29 (26, 33) 0.6-2.4% 
Fractional shortening (%) 823§ 39 (35, 45) 0.6-2.0% 
Ejection fraction (%) 823§ 69 (64, 76) 0.6-2.2% 
E/A ratio 563§ 1.0 (0.8, 1.3) 0.8-2.0% 
LV mass/BSA (g/m2) 590§ 115 (94, 139) 0.8-3.2% 
 
* Variables log-transformed before analysis to approximately normalise the distributions. † Numbers 
represent the range of maximum plausible genetic contribution to total phenotypic variance of each 
trait for typed SNPs. § After exclusion of 75 patients with established MI or valvular heart disease. LQ 
= lower quartile; UQ = upper quartile. 
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Table 6.3. Genotyping results. 
 
SNP 
 
Chromosome 
location 
Number 
(%) 
genotyped 
MAF Alleles HW P-
value all 
rs7044859 9p21 
 
1336 
(93.7%) 
0.44 A:T 0.39 
rs496892 9p21 
 
1329 
(93.2%) 
0.49 C:T 0.85 
rs7865618 9p21 
 
1328 
(93.1%) 
0.45 A:G 0.50 
rs1333049 9p21 
 
1380 
(94.8%) 
0.45 C:G 0.31 
rs6922269 6q25 1331 
(93.3%) 
0.33 A:G 0.01 
rs2943634 2q36 1343 
(94.0%) 
0.35 A:C 0.71 
 
Figure 6.1. LD between typed SNPs on chromosome 9p21. 
LD plot for chromosome 9p21 SNPs showing in each diamond the D’ (on top) and r2 values (on 
bottom) for typed SNP combinations in our population. The relative position of ANRIL is shown for 
reference along the top in blue. Figure adapted from Haploview297. 
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There was no evidence of a significant association between genotypes and plasma 
cholesterol, CRP, IL-6, TNF-α, or leptin concentrations; nor clinical measurements of 
blood pressure, or waist-hip ratio, using an uncorrected significance threshold of 
P=0.05.  Covariate adjusted log-transformed body mass index (BMI) was associated 
with rs1333049 genotype with a nominal P-value of 0.03, but association of this 
magnitude was not unexpected in view of the number of tests performed and was 
likely to be related to chance.  Waist-hip ratio, which is another measure of obesity, 
was not associated with genotype at rs1333049.  The association between BMI and 
rs1333049 was no longer significant after Bonferroni correction for the three 
independent chromosomal loci tested, producing a corrected significance threshold of 
P=0.017. 
There was no significant association between genotype and CIMT at the loci studied.  
The upper bound of the contribution to the total population variance in maximal 
CIMT was between 0.7% and 1.4% for the typed SNPs, and of a similar order for the 
other traits tested (Table 6.2, right-hand column).  A stepwise backward-elimination 
multivariate regression procedure failed to find any multilocus models showing 
association (removal P-value > 0.2) to the CIMT phenotype.  This is a powerful 
approach for examining tightly linked SNPs in association models that avoids the 
computational complexity and degrees of freedom that accompany a formal haplotype 
analysis421.  It is therefore unlikely that chromosome 9p21 haplotypes are associated 
with CIMT, recognising that the power to detect subtle associations is very low for 
minor haplotypes with frequencies < 5%. 
Echocardiographic measures of LV size, mass, and function also showed no 
convincing evidence of association with genotype at the tested SNPs.  The T allele of 
rs7044859 on chromosome 9p21 showed nominal association with LVIDs (P=0.018), 
fractional shortening (P=0.034), and ejection fraction (P=0.024).  However, it is 
important to note that these three measures are not independent since calculation of 
each depends on the LVIDs, and it is therefore not surprising that they show similar 
effects.  The alternative (A) allele at this SNP is associated with CAD in GWA 
studies21.  None of the associations remained significant after Bonferroni correction 
for the three chromosomal loci tested.   
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6.5 Association with congenital heart disease 
6.5.1 Materials and methods 
6.5.1.1 Participants and samples 
Association between SNPs in the chromosome 9p21 region and congenital 
cardiovascular phenotypes was investigated in 888 affected probands from the 
CHANGE and FCH cohorts, compared to 1089 unaffected individuals from the 
Cumbria control cohort and 1500 unaffected individuals from the 1958 birth cohort367.  
These populations were described in Chapter 2. 
6.5.1.2 Genotyping 
Genotyping was performed using Sequenom methodology. Two SNPs that are 
associated with CAD were selected; the lead SNP rs1333049 from GWA studies21, 368,  
and an additional SNP rs1547705 required to fully characterise the core risk haplotype 
for CAD defined by Broadbent et al129.  Based on the hypothesis that an association 
between the chromosome 9p21 region and congenital heart disease might be mediated 
through effects on expression of CDKN2A, CDKN2B, and ANRIL, SNPs highly 
associated with expression of each of these genes in the NE Caucasian cohort (see 
Chapter 4) were also selected for genotyping.  So that the 1958 birth cohort could be 
used as controls, only SNPs that had been genotyped in that population were selected 
for inclusion; this included the SNPs most strongly associated with CDKN2B 
(rs3218018) and ANRIL (rs564398) expression, but the SNP most strongly associated 
with CDKN2A expression (rs7036656) was not genotyped in the 1958 birth cohort.  
An alternative SNP, rs2811708, which was in strong LD with rs7036656 in the 
HapMap CEU samples (D’=1, r2=0.92) was therefore selected instead. 
6.5.1.3 Statistical analysis 
Mendelian inheritance and correspondence of genotype frequencies to HWE 
proportions was checked using standard formulae in Excel298.  Association between 
genotypes and binary phenotypes was assessed by logistic regression using 
UNPHASED v3.1.3302, 303 and STATA v10 software.   
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6.5.2 Results 
888 individuals with congenital heart disease were included, 50.9% of whom were 
male.  The principal diagnoses of the affected individuals are summarised in Table 
6.4.  Classification of congenital heart disease for the investigation of genetic 
causation is complicated by the great phenotypic heterogeneity and fact that widely-
used clinical classifications, such as cyanotic versus non-cyanotic, do not necessarily 
imply common developmental anomalies.  Furthermore, affected individuals often 
have multiple separate abnormalities.  The classification used here was suggested by 
Professor Robert Anderson, an expert in cardiac anatomy and congenital cardiac 
anomalies, and groups together pathologies involving common developmental 
processes (personal communication Professor R Anderson, University College 
London).  Individuals were classified according to the major abnormality present, and 
those with multiple major abnormalities not separately categorised were termed 
“complex”. 
Genotyping results are shown in Table 6.5.  Genotyping data were complete for more 
than 93% of individuals at all loci and allele frequencies in the Cumbria control 
cohort were similar to those in the 1958 birth cohort.  No SNPs showed significant 
deviation from the proportions expected under HWE.   
As shown in Table 6.6, none of the SNPs tested showed a significant association with 
congenital heart disease using either an allele or a general genotype model in the 
Cumbria control group or the 1958 birth cohort.  Nor was there any association for the 
tested SNPs when the TOF and non-TOF individuals were analysed separately.   
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Table 6.4. Cardiac phenotypes in the congenital heart disease cohort. 
 
Predominant phenotype Number (%) 
TOF 450 (50.7%) 
Common AV junction (including AVSD) 25 (2.8%) 
VSD 29 (3.3%) 
Left sided lesions (aortic/mitral valve abnormalities, chamber 
hypoplasia, coarctation) 
86 (9.7%) 
TGA and DORV with subpulmonary defect 59 (6.6%) 
Abnormal  looping (double inlet LV, tricuspid atresia, 
congenitally corrected TGA) 
7 (0.8%) 
TOF-like (pulmonary atresia plus VSD, DORV with subaortic 
VSD) 
21 (2.4%) 
Common trunk 8 (0.9%) 
ASD, PFO 88 (9.9%) 
Ebstein’s anomaly 9 (1.0%) 
PDA 18 (2.0%) 
Complex 73 (8.2%) 
Other 15 (1.7%) 
AV=atrioventricular; VSD=ventricular septal defect; TGA=transposition of the great arteries; 
DORV=double outlet right ventricle; ASD=atrial septal defect; PFO=patent foramen ovale; 
PDA=patent ductus arteriosus. 
 
  
Table 6.5. Genotyping results in the congenital heart disease and control cohorts. 
All congenital heart disease TOF congenital heart disease Non-TOF congenital heart 
disease 
Cumbria control cohort 1958 
BC 
SNP 
% 
genotyped 
MAF HWE P-
value 
% 
genotyped 
MAF HWE P-
value 
% 
genotyped 
MAF HWE P-
value 
% 
genotyped 
MAF HWE P-
value 
MAF 
rs2811708 94.8 0.26 0.75 98.2 0.25 0.17 98.6 0.27 0.28 93.7 0.26 0.25 0.27 
rs3218018 97.0 0.09 0.56 99.6 0.09 0.30 99.3 0.09 0.89 99.7 0.10 0.97 0.09 
rs564398 95.1 0.43 0.73 99.3 0.44 0.95 99.1 0.43 0.76 96.6 0.43 0.48 0.44 
rs1547705 96.9 0.12 0.74 99.6 0.12 0.02 99.3 0.13 0.07 99.7 0.12 0.86 0.12 
rs1333049 96.7 0.48 0.93 98.7 0.47 0.90 99.3 0.47 0.09 99.6 0.49 0.41 0.48 
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Table 6.6. Significance of the association with congenital heart disease for tested 
SNPs. 
SNP All congenital v 1958 BC P-value 
(allele / genotype model) 
All congenital v Cumbria controls P-value 
(allele / genotype model) 
rs2811708 0.23 / 0.11 0.78 / 0.12 
rs3218018 0.33 / 0.71 0.45 / 0.60 
rs564398 0.67 / 0.72 0.64 / 0.72 
rs1547705 0.56 / 0.40 0.28 / 0.56 
rs1333049 0.42 / 0.06 0.25 / 0.19 
 
6.6 Discussion 
Chromosome 9p21 SNPs have been associated with CAD and MI, but the 
mechanisms through which these SNPs influence disease are unknown.  This study 
examined the association of risk SNPs with intermediate phenotypes that may give 
clues to mechanistic pathways involved in causation, and found no association with 
any of the clinical and biochemical phenotypes examined, including several 
inflammatory markers.  This suggests that the CAD susceptibility mediated by this 
locus is not primarily mediated through the pathways and risk factors studied here, 
and may involve novel mechanisms.  
The lack of association observed in this study extends the findings of two previous 
studies which found no association between chromosome 9 risk variants that are in 
strong LD (r2>0.8) with the typed SNPs and traditional CAD risk factors including 
BP, BMI, and plasma cholesterol and glucose20; nor with biochemical parameters 
including plasma lipoprotein(a), fibrinogen, albumin, bilirubin and homocysteine129.  
The present study replicated and confirmed the lack of association with BP, BMI, and 
cholesterol, but was the first to demonstrate the lack of association with these 
inflammatory markers; this is important as inflammation is known to play a key role 
in the pathogenesis of atherosclerosis378-380. 
This study also investigated the association between chromosome 9p21 risk SNPs and 
CIMT.  This was of interest since these variants had not been previously associated 
with extra-coronary manifestations of atherosclerosis except for aortic aneurysm, and 
association with CIMT could permit the early effects of genetic variants to be 
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investigated in other cohorts prior to the onset of clinical disease.  No association was 
found with CIMT.  The lack of association was confirmed in a similar larger study 
published at around the same time, involving CIMT measurements in 2,277 young 
Finns (aged 24 to 39 years) and a further 1,295 individuals aged 46 to 76 years422, 
which also found no evidence of association with endothelial dysfunction as measured 
by brachial artery flow-mediated dilatation.  These data suggested that chromosome 
9p21 variants influence CAD though mechanisms that do not involve changes in 
carotid artery wall thickness.  Interestingly, at the time the present study was reported, 
only one study examining the association between chromosome 9p21 polymorphisms 
and stroke had been published, which found no significant association between the 
CAD risk SNP rs10757278 (for which rs1333049 is a perfect proxy) and ischaemic 
stroke, once potentially-confounding cases of known CAD were excluded from the 
analysis130.  These data and the lack of association with CIMT raised the possibility 
that chromosome 9p21 variants might confer risk for CAD and MI without 
influencing stroke risk.  Several small studies have reported negative associations 
with stroke risk157, 158, but other studies have demonstrated convincing association of 
these SNPs with ischaemic stroke116, 159-162, as well as with other atherosclerotic 
phenotypes such as abdominal aortic aneurysm130 and stiffness of the abdominal 
aorta163.  An analysis of CIMT in 769 Austrian Caucasians found no association with 
CIMT, but did show a significant association with carotid atherosclerosis assessed 
ultrasonographically154.  A subsequent large population-based study of CIMT in more 
than 14,000 individuals from the Atherosclerosis Risk in Communities (ARIC) study 
confirmed the lack of association of chromosome 9p21 variants with CIMT, and 
showed a borderline association with the presence of carotid atheromatous plaques in 
whites (P=0.047 after adjustment for covariates)157.  The study that demonstrated an 
association with aortic stiffness found no association between risk variants and aortic 
IMT163.   
There are a number of potential explanations that need to be considered to explain the 
lack of association with IMT for variants that have now been shown to be associated 
with extra-coronary atherosclerosis and ischaemic stroke.  The present study and the 
others examining IMT were performed in relatively homogeneous Caucasian 
populations similar to those in which the associations with CAD were demonstrated, 
making it unlikely that the results are due to bias caused by selection of a different 
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population.  In the present study, the maximum plausible genetic effect for the typed 
SNPs on CIMT and the other phenotypes studied, calculated based on the observed 
mean effect and 95% confidence interval, was low in all cases.  Therefore, although 
this study cannot exclude any effect of the typed SNPs on these phenotypes, it 
demonstrates that such effects could only be of small magnitude and are unlikely to be 
clinically significant.  The consistent lack of association with CIMT  in multiple 
studies and the very large cohorts used in the studies by Samani et al422 and the ARIC 
study157 makes it unlikely that the results represent false acceptance of the null 
hypothesis in the presence of a real effect; the study by Samani et al had greater than 
99% power at an alpha of 0.01 to detect a 0.2mm difference in CIMT (expected to be 
associated with a 30-40% increase in stroke risk395) between homozygotes for the risk 
and non-risk alleles.  The power of the ARIC study which was substantially larger 
would be expected to be even greater157.  In the present study, selection through 
hypertensive probands could potentially introduce bias if there were an interaction 
between hypertension and the variants studied, but only 36% of the participants were 
hypertensive and the variants did not associate with hypertension. On the other hand, 
using a population enriched for individuals with hypertension, a trait strongly related 
to cardiovascular risk, resulted in selection of individuals with an increased range of 
CIMT values and mean CIMT 33% higher than the general population, which should 
increase the power for the detection of variants with small effects.  
CIMT has been commonly used as a surrogate marker for atherosclerosis397, 423.  It is 
an independent predictor of atherosclerosis and clinical outcomes395, 396, but it is 
important to recognise that despite the close association between CIMT and carotid 
plaques398, increased CIMT is not synonymous with carotid atheroma395.  The 
presence of carotid plaque, which is more specific for atherosclerosis, showed a 
significant association with 9p21 variants at the nominal significance threshold in 
both studies in which this was investigated, in contrast to the negative findings for 
CIMT in the same studies154, 157.  The extent to which the pathophysiological 
mechanisms underlying CAD and stroke overlap with CIMT is uncertain424; the lack 
of association of 9p21 risk variants with CIMT highlights that they are at least 
partially distinct.  Other factors that alter CIMT measurements, such as hypertension, 
may do so through pathophysiological mechanisms that differ from those involved in 
atherosclerosis425.   
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It appears that the chromosome 9p21 risk variants influence the risk of CAD and 
stroke through mechanisms that are not manifested by early changes in arterial wall 
thickness.  This suggests that CIMT measures should not be used as a surrogate for 
disease endpoints in studies of the genetic risk associated with markers at 
chromosome 9p21. 
There was no significant association between chromosome 9p21 CAD variants and 
echocardiographic assessments of cardiac structure and function in individuals 
without evidence of MI or valve disease.  At the time the study was performed, no 
similar data from other cohorts had been reported, but two subsequent studies are 
consistent with the findings of the present study.  Farzaneh-Fah et al reported no 
association of chromosome 9p21 SNPs with echo parameters in 593 Caucasians with 
stable CAD426, but the limited sample size and use of a population with CAD in that 
study meant that a significant association between risk variants and cardiac structure 
and function in the general population could not be excluded427.  Vasan et al 
performed a GWA study of 2.5 million SNPs with echocardiographic traits in five 
community-based cohorts totalling 12,612 Caucasians, with subsequent replication in 
two additional cohorts totalling 4,094 Caucasian individuals428.  In stage one, 16 loci 
were associated with five traits, of which five were replicated in stage two.  No SNPs 
in the chromosome 9p21 showed significant associations at either stage using the 
genomewide significance threshold of 5x10-7, or a less stringent threshold of 10-5.  
These data are consistent with the lack of association with chromosome 9p21 variants 
observed in the present study, although failure to achieve genomewide significance 
levels does not exclude an effect of these SNPs on such phenotypes. 
 The association between chromosome 9p21 CAD variants and incident heart failure 
was assessed in 14,000 individuals of the ARIC study over median follow-up of 17 
years157.  Prevalent cases of CAD were excluded at baseline, and heart failure 
episodes were ascertained through annual telephone contact and surveillance of 
hospital and death records.  CAD risk alleles were associated with a 30% increase in 
the risk of heart failure after adjusting for covariates (HR=1.30, 95%CI 1.07-1.58, 
P=0.008), which remained significant when CAD events were censored at their 
occurrence (HR=1.28, 95%CI 1.00-1.62, P=0.046).  The association of CAD variants 
with heart failure is not surprising, since heart failure is often a consequence of CAD, 
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but the significant association after exclusion of both prevalent CAD at baseline and 
censoring for incident cases of CAD has led to speculation that 9p21 variants might 
contribute to heart failure independently of clinical CAD events157.  However, 
unrecognised or subclinical CAD might still account for the association even after 
censoring for recognised CAD. 
A number of issues should be considered with respect to the present study.  Firstly, 
associations with echo measurements were available for a maximum of 829 
individuals, and only 563 for the E/A ratio assessment of diastolic dysfunction.  This 
raises the possibility that the lack of association observed could be due to a lack of 
statistical power.  However, as discussed above for the other phenotypes examined, 
the maximum plausible genetic effect for the typed SNPs on the echocardiographic 
parameters was low in all cases.  Furthermore, Farzaneh-Far et al estimated that they 
had >80% power to detect a 3% difference in LV ejection fraction in their smaller 
sample of 593 individuals, although they used a more accurate methodology to 
quantify LV function in that study.  Therefore, although the current study cannot 
exclude that some of the typed SNPs have effects on cardiac structure and function, 
any such effects are likely to be small and unlikely to be clinically meaningful.  A 
limitation of the present study is that LV function assessment was derived from single 
dimension M-mode measurements.  This methodology has been widely used and has 
been shown to be reproducible with low inter-observer and intra-observer 
variability429, and provides useful information for clinical studies277.  However, the 
geometric assumptions required to estimate three-dimensional volume from two-
dimensional measurements may produce inaccuracies, especially in the presence of 
regional wall motion abnormalities, and its use as a sole measure of LV function is no 
longer recommended in clinical practice277.  Similarly, E/A ratio was used as a sole 
measure of diastolic dysfunction and more recent parameters such as tissue Doppler 
measurements were not available.  The limitations of these estimates may have 
reduced the power to detect significant associations with cardiac function in the 
present study. 
To date, this is the only study to investigate the association of novel CAD risk 
variants on chromosome 2q36 and 6q25 with traditional risk factors, intermediate 
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CAD phenotypes, and cardiac structure and function. No association with these loci 
was found for any of the phenotypes examined. 
This study investigated SNP associations with a number of intermediate phenotypes 
to identify causative pathways through which genotypes at these SNPs influence risk.  
No associations were found, suggesting that the effects are mediated through 
unknown pathways.  Further investigations will be required to determine the 
mechanisms by which these SNPs are associated with CAD.  
This is the first study to investigate the association between chromosome 9p21 SNPs 
and congenital heart disease.  No association was found for CAD risk variants or for 
SNPs that are associated with expression of CDKN2A/2B/ANRIL.  This suggests that 
the typed SNPs are not involved in conferring susceptibility to congenital heart 
disease, although small effects that could not be detected in this sample size cannot be 
excluded.  A number of other factors that could account for the observed lack of 
association should be considered.  The study included a heterogeneous population of 
probands with diverse congenital heart defects of varying severity.  Population 
stratification caused by differential SNP effects in particular phenotypes could 
therefore potentially obscure the association with particular subgroups in the 
combined cohort.  Separate analysis of TOF and non-TOF groups did not show any 
trend towards association for either, but there were insufficient numbers with other 
phenotypes to permit meaningful separate analyses.  However, since intracranial 
aneurysms and experimental neural crest ablation have been associated with a wide 
range of cardiovascular phenotypes419, there were few data to justify restricting the 
cohort to include only particular phenotypes.  Indeed, congenital heart disease is a 
complex phenotype and identical genetic abnormalities may be associated with a 
range of cardiac manifestations, such as are seen in the chromosome 22q11 deletion 
syndrome430.  Investigation in a larger cohort powered to allow analysis of individual 
phenotypes could address this issue, but given the rarity of individual phenotypes this 
would require a multicentre collaborative study.   
Selection bias might also reduce the ability to detect an association.  All cohorts were 
Caucasian, but whilst the Cumbrian controls were women of childbearing age, the 
cases were mostly ascertained during infancy and were of both genders.  An 
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interaction with gender could potentially obscure an association with congenital heart 
disease using these two cohorts, but the same allele frequencies and lack of 
association was seen using the mixed-gender 1958 birth cohort controls, making this 
unlikely.   
In addition to the SNPs associated with CAD/intracranial aneurysms, this study also 
genotyped three SNPs which were strongly associated with CDKN2A, CDKN2B and 
ANRIL expression in peripheral blood, to investigate the hypothesis that congenital 
heart disease might be mediated by variants that influence expression of these genes.  
Although these SNPs were not associated with congenital heart defects, a role of these 
genes in the pathogenesis of congenital heart disease cannot be excluded since the 
tissue-specific influences on expression are likely to be substantially different during 
cardiac development.  It therefore remains possible that rare variants or other common 
variants could mediate disease through effects on expression of these genes during 
embryogenesis. 
Although the aetiology of intracranial aneurysms is widely accepted to be 
independent of atherosclerosis, intracranial aneurysms and CAD do share some 
common risk factors in adult populations431, and some authors have suggested that 
berry aneurysms are acquired degenerative lesions409, such that the association with 
CAD risk variants and intracranial aneurysm could reflect the same 
pathophysiological process.  However, the demographics of the population in which 
the association with intracranial aneurysms were observed differ substantially from 
that in the CAD population, with a mean age <50 years and 66% female130, making it 
unlikely that they represent the same phenomenon. 
In summary, novel CAD variants do not appear to mediate the risk of 
atherothrombosis through known risk factors and are not associated with CIMT, LV 
structure/function or congenital heart disease.  Further investigations will be required 
to determine the mechanisms by which these SNPs are associated with CAD.  
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7 Association of STK39 polymorphisms with blood 
pressure and STK39 expression 
7.1 Abstract 
Although BP has significant heritability, the genes responsible remain largely 
unknown.  No associations were found in the first wave of GWA studies, but SNPs at 
the STK39 locus on chromosome 2q24 were recently associated with hypertension by 
genome-wide association in an Amish population; in vitro data from transient 
transfection experiments using reporter constructs suggested that altered STK39 
expression might mediate the effect.  However, other large studies have not 
implicated STK39 in hypertension.  To determine whether reported SNPs influenced 
STK39 expression in vivo, or were associated with BP in a large British cohort, 1425 
members of 248 Caucasian families ascertained through a hypertensive proband were 
genotyped for reported risk variants in STK39 (rs6749447, rs3754777, rs35929607) 
using Sequenom technology.  MERLIN software was used for family-based 
association testing.  Cis-acting influences on expression were assessed in vivo using 
allelic expression ratios in cDNA from peripheral blood cells in 35 South African 
individuals heterozygous for a transcribed SNP in STK39 (rs1061471) and quantified 
by mass spectrometry (Sequenom).  No significant association was seen between the 
SNPs tested and systolic or diastolic BP in clinic or ambulatory measurements (all 
P>0.05).  The tested SNPs were all associated with allelic expression differences in 
peripheral blood cells (P<0.05), with the most significant association for the intronic 
SNP rs6749447 (P=9.9x10-4).  In individuals who were heterozygous for this SNP, on 
average the G allele showed 13% overexpression compared to the T allele.  In 
summary, STK39 expression is modified by polymorphisms acting in cis and the 
typed SNPs are associated with allelic expression of this gene, but there is no 
evidence for an association with BP in a British Caucasian cohort. 
7.2 Introduction 
Hypertension is a major risk factor for vascular and renal disease and thereby 
contributes to substantial worldwide morbidity and mortality432.  Although BP has 
been shown to have significant heritability (30-60%)433, the genes conferring 
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susceptibility to hypertension remain largely unknown.  As presented in Chapter 1, a 
relatively small study by Wang et al suggested that SNPs in the STK39 gene on 
chromosome 2q24 may be associated with BP, and that the effects might be mediated 
by influences on STK39 expression that were demonstrated in vitro134. 
This study aimed to test whether the STK39 SNPs identified in the report by Wang et 
al134 were associated with BP in a large family-based Caucasian cohort ascertained 
through probands with essential hypertension156, 276.  This cohort has a higher average 
BP (134 v 128mmHg systolic) and lower proportion of diabetics (2.5 v 22.2%) 
compared to the Amish population used for the initial genome-wide study by Wang et 
al, but has 24-hour ambulatory BP recordings which provide a more reproducible and 
precise measure of true BP, with better prediction of cardiovascular events, compared 
to clinic BP measures434, 435.  Selecting the same SNPs typed by Wang et al and using 
a cohort enriched for hypertension with ambulatory BP data should increase the 
power to detect effects associated with these variants in the study population.  
Transfection studies in cell lines may fail to adequately model in vivo effects on 
expression in complex human tissues253, but AEI provides a powerful method for 
evaluating cis-acting influences in expression in vivo. 
7.3 Aims 
This chapter is divided into two parts, with the specific aims described below. 
1.  Investigation of the association of STK39 SNPs with BP.   
The specific aim was to determine whether STK39 SNPs reported to be associated 
with BP in the Amish population are associated with BP in a British Caucasian 
cohort. 
2.  Investigation of the association of STK39 SNPs with STK39 expression in vivo.   
The specific aim was to determine whether STK39 SNPs shown to have cis-acting 
effects on STK39 expression in vitro influence expression of this gene in vivo assessed 
using AEI in the SA cohort. 
Chapter 7: 2q24 STK39 studies 
248 
7.4 Materials and methods 
7.4.1 Association of SNPs with blood pressure 
7.4.1.1 Participants and samples 
Association of STK39 SNPs and BP was investigated using the Caucasian HTO 
cohort, which comprised 1425 members of 248 British Caucasian families who were 
ascertained through hypertensive probands, as described in detail in Chapter 2.  All 
1372 family members in whom DNA was available were genotyped in the present 
study.  The results of 24-hour ambulatory BP monitoring were available for 1134 
participants who had agreed to undergo monitoring.  Mean values for systolic and 
diastolic blood pressures for the clinic, daytime and night-time periods were analysed 
for association with genotypes.  
7.4.1.2 Genotyping  
Four SNPs reported to be associated with hypertension by Wang et al134 were selected 
for genotyping; three at the STK39 locus on chromosome 2q24.3 (rs6749447, 
rs3754777 and rs35929607) and one on chromosome 9p21.3 (rs4977950) which gave 
the most significant signal for genome-wide association in the same study134.  SNP 
genotyping was performed using Sequenom methodology, as described in Chapter 2.   
7.4.1.3 Statistical analysis 
Mendelian inheritance and correspondence of genotype frequencies to HWE 
proportions was tested using PEDSTATS295.  The analysis was performed using log 
transformed BP values to approximately normalise the distribution276.  Adjustments 
were then made for significant covariates determined by linear regression, considering 
age, sex, cardiovascular medications, smoking status (current/former/never), alcohol 
consumption (units per week) and exercise habit (frequency per week).  For those 
participants taking antihypertensive medication, the effects of the main drug classes 
(diuretics and β-blockers) were estimated from the data by regression, and the 
appropriate adjustment made to the on-treatment BP values, as previously 
described276.  Association between genotypes and adjusted phenotypes was assessed 
using MERLIN v1.1.2300, 436.  In order to estimate the upper bound of the genetic 
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effect that is plausibly associated with each phenotype/SNP combination, linear 
regression models were fitted to model additive genetic effects using Minitab v15.  . 
7.4.2 Association of SNPs with STK39 allelic expression 
7.4.2.1 Identification of transcribed markers for allelic expression analysis 
Allelic expression measures the relative amount of transcript arising from each allele 
in individuals heterozygous for a transcribed polymorphism.  NCBI dbSNP was used 
to identify SNPs in transcribed regions of STK39 with minor allele frequencies greater 
than 5%42.  Nine transcribed variants were identified (rs1061471, rs3769429, 
rs7425806, rs3769428, rs56330212, rs56697518, rs56031549, rs1802105, 
rs56048258).  Only two of these had previously been validated (minor alleles 
observed in at least two chromosomes) according to dbSNP42: rs1061471 in exon 18 
(3’ untranslated region) and rs56031549 in exon 11 (missense A/G SNP).  Three of 
the reported variants (rs7425806, rs3769429 and rs3769428) were non-polymorphic 
in all HapMap populations.  SNP rs1061471 was non-polymorphic in the Caucasian 
HapMap CEU population, but had a minor allele frequency of 11% and informative 
heterozygote frequency of 24% in the African HapMap YRI population.  Population 
frequency data were unavailable for the other SNPs.  Therefore, in order to find 
transcribed markers suitable for assessing allelic expression, rs1061471 and the five 
SNPs for which HapMap population frequencies were not available (rs1802105, 
rs56031549, rs56048258, rs56330212, rs56697518) were genotyped in the SA cohort. 
7.4.2.2 Participants, samples and genotyping 
In view of the lack of transcribed polymorphisms in Caucasian populations, 
investigation of SNP effects on expression using AEI was performed in the 310 
healthy individuals of the SA cohort.  Genotyping was performed using Sequenom 
methodology as described in Chapter 2.   
35 individuals heterozygous for the transcribed variant rs1061471 suitable for allelic 
expression analysis were identified.  The other five SNPs tested had minor allele 
frequencies <1%, giving an insufficient number of heterozygotes to be used for AEI 
assessment (Table 7.1). 
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Table 7.1. Allele frequency of transcribed SNPs in 310 South African individuals. 
SNP Alleles* Number genotyped 
Number of 
heterozygotes MAF 
HapMap YRI 
MAF 
Hardy-Weinberg 
p value 
rs1061471 G / A 298 35 0.069 0.119 0.15 
rs1802105 A / C 298 0 0 NA - 
rs56031549 C / T 298 2 0.003 NA 0.95 
rs56048258 A / G 296 5 0.008 NA 0.88 
rs56330212 G / A 296 0 0 NA - 
rs56697518 C / T 298 2 0.003 NA 0.95 
* Major allele given first; MAF, minor allele frequency; YRI, HapMap YRI African cohort; NA, not 
available. 
7.4.2.3 Measurement of STK39 allelic expression ratios: 
Quantification of the allelic expression ratio using 50ng of cDNA was performed by 
Sequenom methodology, as described in Chapter 2.  Results from amplification of 
gDNA from 19 individuals (performed in 4 replicates) were used as the equimolar 
reference to normalise the cDNA values. 
7.4.2.4 Statistical analysis: 
Mendelian inheritance and correspondence of genotype frequencies to HWE 
proportions was checked using standard formulae in Excel298.  Analyses were 
performed using the logarithm of the normalised allelic expression ratios as published 
by Teare et al254 and presented in Chapter 2.  
7.5 Results 
7.5.1 Association with blood pressure 
1372 individuals with available DNA were included.  649 (47%) were male and the 
mean age was 49 (standard deviation 15.5) years.  490 (36%) were hypertensive, 298 
(22%) were current smokers, 35 (3%) had diabetes, 55 (4%) had structural heart 
disease, and 456 (33%) were taking antihypertensive or antianginal medication.  
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Median alcohol consumption was 3 (interquartile range 0-12) units per week. 43% 
reported no regular exercise per week, with 21%, 22% and 14% exercising once, 
twice, and three or more times per week respectively.  The BP parameters of 
participants, heritability (h2) of each phenotype and proportion of phenotypic 
variation accounted for by covariates (r2) are shown in Table 7.2.   
Table 7.2. BP characteristics of the Caucasian participants. 
Characteristic N Median (LQ, UQ) 
in mmHg 
Proportion of 
phenotypic variability 
(r2) explained by 
covariates for log-
transformed variable 
Heritability 
(h2) for 
adjusted 
variable 
Clinic Systolic BP 1138 134 (121.3, 152.3) 27.2 11.2 
Clinic Diastolic BP 1130 82 (73.7, 92) 19.7 12.2 
Day Systolic BP 1134 132.5 (122.1, 146) 20.4 13.6 
Day Diastolic BP 1133 79.7 (72.5, 90) 17.9 10.7 
Night Systolic BP 903 113 (103.8, 126) 11.4 24.3 
Night Diastolic BP 902 66 (60.2, 73.6) 13.6 34.6 
N=1372 Caucasian participants. BP = blood pressure; LQ = lower quartile; UQ = upper quartile. 
Genotyping was complete for more than 99% of individuals at all loci.  Allele 
frequencies for typed SNPs are shown in 
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Table 7.3; these were similar to the HapMap CEU population and did not deviate 
significantly from HWE proportions. 
There was no significant association between genotype and covariate-adjusted, log 
transformed BP parameters at the loci studied using an unadjusted P-value threshold 
of 0.05.  Estimates of effect size with 95% confidence intervals are shown in Table 
7.4; the upper bound of the contribution of typed SNPs to the total population 
variance was low for all of the phenotypes tested (ranges: rs3754777 0.4-1.1%; 
rs35929607 0.5-1.7%; rs6749447 0.4-1.4%; rs4977950 0.4-0.6%). 
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Table 7.3. Allele frequencies of the SNPs typed in study participants. 
SNP Chromosome location Alleles* 
Number 
genotyped 
HW P-
value Frequency of putative risk allele 
     
Caucasian 
cohort 
HapMap 
CEU 
SA 
cohort 
rs3754777 2q24 
(STK39 intron) 
G/A 1367 0.63 0.17 0.13 0.16 
rs35929607 2q24 
(STK39 intron) 
A/G 1361 0.79 0.19 0.18 0.34 
rs6749447 2q24 
(STK39 intron) 
T/G 1369 0.32 0.29 0.28 0.52 
rs4977950 9p21 
(not within 
gene) 
G/C 1365 0.46 0.15 0.18 Not 
typed 
* Major allele given first, putative risk allele for hypertension identified by Wang et al shown in bold. 
Table 7.4. Effect sizes of tested SNPs. 
BP phenotype* N rs3754777 rs35929607 rs6749447 rs4977950 
Clinic Systolic 1138 0.2 (-1.8, 2.3) 1 (-1, 2.9) 0.5 (-1.2, 2.2) 0 (-2.1, 2.1) 
Clinic Diastolic 1130 -0.3 (-1.6, 1.1) 0.4 (-0.9, 1.7) 0.1 (-1, 1.2) 0.3 (-1.1,1.7) 
Day Systolic 1134 -0.1 (-1.9, 1.7) -0.3 (-1.5, 2) 0.1 (-1.4, 1.6) 0.2 (-1.7, 2) 
Day Diastolic 1133 -0.1 (-1.4, 1.1) 0.2 (-1, 1.4) 0.1 (-0.9, 1.2) 0.4 (-0.9, 1.7) 
Night Systolic 903 0.4 (-1.4, 2.1) 0.9 (-0.8, 2.6) 0.7 (-0.7, 2.2) -0.2 (-2.1, 1.7) 
Night Diastolic 902 0.7 (-0.5, 1.9) 1.1 (0, 2.3) 0.8 (-0.2, 1.8) -0.1 (-1.3, 1.2) 
* All phenotypes log-transformed to approximately normalise distributions and adjusted for covariates 
before analysis;  Effect sizes are the mmHg difference attributable to 1 copy of the risk (minor) allele, 
with 95% confidence interval given in brackets. P-value >0.05 for all effects.  
7.5.2 Association with allelic expression 
Two of the 35 samples failed quality control criteria for allelic expression 
measurements at the transcribed SNP rs1061471 because of high standard error 
between replicates and were excluded from the analysis; all replicates for the 
remaining 33 samples were included.  The experimental variability was low and the 
average standard error of the log-transformed ratio for the four technical replicates 
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was the same in gDNA (0.0146) and cDNA (0.0149). The standard deviation of the 
sample means (represented in Figure 7.1) was 0.030 in genomic DNA and 0.039 in 
cDNA. 
 
Figure 7.1. Effect of genotype at rs6749447 on allelic expression ratio of the 
transcribed SNP rs1061471.  
Circles represent allelic expression ratio for each individual, with horizontal bars representing the mean 
values for each group (shown alongside). The first column shows genomic DNA where the alleles are 
present in a 1:1 ratio, giving a mean ratio of approximately 1. The second column shows individuals 
who are homozygous for either allele of rs6749447. In this group, the cis-acting influence on 
expression from each allele is the same, giving a mean allelic expression ratio of approximately 1 at the 
transcribed marker rs1061471 (P>0.05 for the comparison with genomic DNA). The third column 
shows individuals who are heterozygous for rs6749447. In this group each of the two transcribed 
alleles is expressed at a different level, causing increased imbalance in allelic expression (P<0.005 for 
the comparisons with genomic DNA and individuals homozygous for rs6749447) 
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The tested SNPs were all significantly associated with allelic expression differences 
in peripheral blood, as shown in Table 7.5.  The most significant association with 
expression was for rs6749447 (P=9.9x10-4).  This SNP is located in intron 1 of STK39 
and in the SA sample had minor allele frequency 0.48 and D’ 0.54 with the 
transcribed SNP rs1061471 located in the 3’ untranslated region of the gene.  Of the 
33 included individuals who were heterozygous for the transcribed SNP rs1061471, 
14 were heterozygous for rs6749447.  If a SNP affects expression in cis then 
individuals heterozygous for that SNP should show a greater allelic imbalance at the 
transcribed SNP than homozygous individuals.  Figure 7.1 shows the allelic 
expression ratios grouped by whether individuals are heterozygous or homozygous for 
rs6749447, compared to the ratio seen in genomic DNA (where alleles are present in a 
1:1 ratio).  There was no difference in allelic expression ratios between genomic DNA 
and individuals homozygous at rs6749447 (P=0.07 using the Mann-Whitney U test).  
However, individuals heterozygous for rs6749447 have on average a higher allelic 
expression ratio than the homozygous individuals (P=0.005 using the Mann-Whitney 
U test), which is consistent with a cis-acting effect and also suggests that the 
overexpressing allele is preferentially in phase with the G allele at the transcribed 
locus.  In individuals who were heterozygous for rs6749447 on average the G allele of 
rs6749447 showed 13% overexpression compared to the T allele.  Once the effect of 
this SNP was adjusted for, the association for the other SNPs no longer remained 
significant (as shown in Table 7.5).  Differences in allele frequencies and patterns of 
linkage disequilibrium between the Caucasian and South African populations are 
summarised in 
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Table 7.3 and Figure 7.2. 
Table 7.5. Association of tested SNPs with allelic expression differences. 
SNP P-value P-value adjusted for 
rs6749447 
rs35929607 0.02 0.39 
rs3754777 0.006 0.71 
rs6749447 0.001 - 
Figure 7.2. LD between typed SNPs at the chromosome 2q24 STK39 locus in 
Caucasian and SA participants. 
Shading represents r2 values (r2=0 white, with higher r2 values darker shades of grey). Numbers show 
D’ values (and r2 values in brackets) between SNPs. NP, non-polymorphic in Caucasian population. 
Figure adapted from Haploview. 
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7.6 Discussion 
The STK39 SNPs reported to be associated with BP and hypertension by Wang et 
al134 did not show a significant association with BP in the British Caucasian families.  
Other published GWA studies and two large recent meta-analyses did not identify 
associations achieving genome-wide significance levels for STK39 polymorphisms 
and BP, despite powerful analyses of combined cohorts involving 34,433 and 71,225 
Caucasian individuals which successfully identified multiple other susceptibility 
loci139, 140.  Although failure to achieve genome-wide significance levels does not 
exclude an effect of this locus on BP, any effect of sequence variation at STK39 on 
BP is too small to be detected in these data and is perhaps something particular to the 
Amish population.  No association with BP was found for the chromosome 9p21.3 
SNP rs4977950 which was the top signal in the GWA studies by Wang et al (P = 
9.1x10-8), and the only SNP to achieve significance at the genome-wide threshold in 
their study.   
Inadequate power is an unlikely explanation for the lack of association in this study as 
the maximum plausible genetic effect for the typed SNPs on BP phenotypes, which 
was calculated based on the observed mean effect and 95% confidence intervals, was 
low in all cases and the data exclude an effect as large as the 3mmHg increase in 
systolic BP per copy of the risk allele reported by Wang et al in the Amish 
population.  Families in the present study were selected through a hypertensive 
proband and had a higher proportion of hypertensive individuals and wider 
distribution of BP values; this should increase the power to detect an association with 
BP phenotypes compared to the cohorts in the study by Wang et al, which were not 
selected for BP.  The use of 24-hour ambulatory BP recordings in the present study 
provides a more reproducible assessment of ‘usual’ BP and reduces misclassification 
due to ‘white-coat’ or masked hypertension that may occur with isolated clinic 
measurements434, 435; this should also reduce the noise and increase the power of the 
study.  The heritability of night-time BP measures was significantly higher than clinic 
BP measures, which should increase the power for detecting genetic effects.  Studies 
first reporting a novel association often show a more extreme odds ratio than 
subsequent replication studies437; if the effect size estimated by Wang et al is an 
upwardly biased estimate this might explain the negative association in the present 
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study and the other reported GWA studies.  The effect due to STK39 alleles observed 
by Wang et al was strongest in the Amish population and substantially weaker in the 
other Caucasian cohorts tested in their study.  Data from the present study suggest that 
the effect of the typed STK39 SNPs on BP is at most modest in a UK Caucasian 
population.  If the reported association was caused by LD between the typed SNPs 
and another functional variant, then weaker LD in other populations, compared to the 
Amish population, could account for the results; this is particularly pertinent since 
closed founder populations are expected to exhibit extensive LD.  Heterogeneity 
between the populations, including differences in population history, recruitment 
strategy, and phenotypes (such as the proportion of diabetics and hypertensives) might 
also contribute to the differences in genetic associations we have observed.  The 
analysis was performed using an additive model because this was the model used to 
report the most significant overall association by Wang et al. 
The study has demonstrated that SNPs in the STK39 gene correlate with in vivo allelic 
expression of this gene in peripheral blood cells.  This corroborates and extends the 
findings from reporter gene constructs in the study by Wang et al.  Using a luciferase 
assay in HeLa and HEK293 cell lines they examined the effect on transcription of two 
SNPs (rs12692877 and rs35929607) that are in conserved elements and which were in 
complete LD with two of the SNPs associated with BP in their GWAS in the Amish 
population (rs6749447 and rs3754777 respectively).  They demonstrated that the G 
allele of rs35929607, which was the allele reported to be associated with increased 
BP, was in isolation associated with a greater than two-fold increase in transcriptional 
activity compared to the A allele of this SNP, or either allele of rs12692877.  Such in 
vitro studies have limitations since results depend on the constructs that are used and 
expression is considered outside of the normal chromatin and cellular context, which 
may not reflect true expression in complex tissues in vivo225, 253.  Allelic expression 
analysis allows in vivo assessment of RNA transcripts in their native environment and 
regulatory context, and by controlling for trans-acting influences has high sensitivity 
to detect cis-acting effects.  This study found a stronger association between genotype 
and allelic expression for rs6749447 than for rs35929607, with the G allele of 
rs6749447 associated with a 13% increase in expression relative to the T allele.  
However, if the effect of rs6749447 is not accounted for, then the allelic expression 
analysis found that the G allele of rs35929607 was significantly associated with 
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increased expression.  This is consistent with the in vitro data from Wang et al, 
although the magnitude of the relative increase in our study was lower at 7%.  The 
difference in the magnitude of effect we observed compared to the in vitro 
transfection studies is not surprising in view of the fact that in vivo expression is 
likely to result from the interaction of multiple elements that modulate expression, 
rather than just a single SNP.  
AEI can only be assessed in individuals who are heterozygous for a transcribed 
polymorphism in the gene of interest – there were no suitable transcribed SNPs in 
STK39 in Caucasian populations and in the SA cohort the number of suitable 
heterozygotes was relatively small because of a low minor allele frequency (7%) at 
the transcribed SNP rs1061471.  However, measurement of allelic expression ratios 
within samples is very sensitive for detection of cis-acting influences since trans-
acting and experimental factors are identical for each allele; this allows significant 
cis-acting effects to be detected in relatively few samples, as demonstrated in this 
study.  Sensitivity of the technique for the detection of significant effects in equivalent 
sample sizes has been previously demonstrated260, 266.  Populations of African-descent 
show on average smaller regions of high LD compared to Caucasian populations321, 
438
, and therefore using a South African cohort increases the sensitivity to separate the 
effects of different SNPs on expression.  In the case of STK39, using a population of 
different ethnicity allowed allelic expression to be measured in the absence of 
transcribed polymorphisms in the Caucasian population.  Correlation between STK39 
SNPs and expression of this gene does not necessarily mean that these SNPs will 
influence BP and the finding of an association with STK39 expression in this study is 
therefore not at odds with the lack of association with BP that was observed.   
A limitation of the present study is that expression was only tested in white blood 
cells, rather than in a tissue of potentially greater relevance to BP regulation.  
However, many cis-acting influences on gene expression are expected to be the same 
in different cell types439, although tissue-specific differences have been described440.  
In the case of STK39 this approach is supported by the fact that rs35929607 genotype 
correlated with expression in immortalised cell lines derived from cervical tumour 
cells (HeLa) and embryonic kidney cells (HEK293) in the study by Wang et al, as 
well as with expression in blood in the present study.  However, the effects may vary 
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in other tissues.  This study analysed the SNPs influencing expression in a SA cohort 
of mixed ethnicity, but the SNPs associated with expression may vary in different 
populations due to differing allele frequencies and LD patterns.  Although the 
associations of SNPs with STK39 expression were highly statistically significant, the 
biological significance of these findings is less certain, since it is not known what 
impact such an effect on expression has on disease risk.   
Future studies will be necessary to investigate the association of other SNPs at the 
STK39 locus with BP, or to determine whether rare mutations at this locus contribute 
significantly to population blood pressure variation, as has been shown for other 
genes implicated in hypertension causation441.  
7.7 Conclusions  
STK39 expression is modified by polymorphisms acting in cis, but there is no 
evidence that these SNPs affecting STK39 transcription are associated with BP in a 
British Caucasian cohort. 
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8 General discussion and future directions 
CAD and other cardiovascular phenotypes such as hypertension have a significant 
genetic component, yet the pathways through which genetic factors mediate disease 
susceptibility remain largely unknown.  Studying intermediate phenotypes, including 
gene expression, may lead to the identification of the genes and pathways involved in 
the pathogenesis of disease.  As well as being of intrinsic scientific interest, this may 
allow the development of novel biomarkers to aid diagnosis or improve risk 
stratification, but more importantly, offers the potential for developing novel 
therapeutic interventions which influence these mechanisms to modify disease risk.  
An advantage of the recent GWA approach is that associations are identified in a 
‘hypothesis-free’ manner, which offers the potential to provide truly novel insights 
into biology, as illustrated by discovery of the chromosome 9p21 region which was 
not previously implicated in the pathogenesis of CAD.   
This study examined the association of 9p21 risk variants with a range of intermediate 
phenotypes to identify pathways implicated in causation.  There was no association 
with traditional cardiovascular risk factors or plasma levels of inflammatory 
mediators known to be involved in atherogenesis, suggesting that the association at 
this locus might be mediated through previously unsuspected mechanisms.  There was 
no association with CIMT, suggesting that this cannot be used as an intermediate 
phenotype in studies investigating modulation of risk associated with this locus.  
Furthermore, although the association of risk variants with intracranial aneurysms 
raised the possibility of more widespread cardiovascular effects not linked to 
atherosclerosis, there was no association with congenital heart disease or 
echocardiographic measures of cardiac structure and function in adults.   
The study also examined the association of risk variants with expression of genes in 
the 9p21 region that were not previously implicated in the pathogenesis of CAD. The 
study yielded a number of novel findings.  There was a strong relationship between 
risk variants and expression of ANRIL transcripts measured using an assay spanning 
exons 1-2, with CAD variants associated with an up to two-fold reduction in ANRIL 
expression.  Multiple loci were independently associated with expression, suggesting 
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that several sites rather than a single ‘causal’ variant may modulate disease 
susceptibility.  Risk variants for diabetes, glioma and melanoma were also associated 
with ANRIL expression.  These results suggest that modulation of ANRIL expression 
in the CDKN2B antisense region mediates susceptibility to several important human 
diseases.  ANRIL is therefore clearly identified as a target for further investigation to 
determine its function, how it is affected in disease, and whether it can be modified to 
influence disease susceptibility.     
The effects of various disease states on ANRIL expression require further 
investigation, but a very recent 2010 report provided further evidence to support a link 
between ANRIL and CAD, showing that ANRIL expression levels in blood and 
atherosclerotic plaque are associated with the severity of atherosclerosis155.  The 
finding that CAD risk variants are associated with ANRIL expression in young healthy 
individuals in the present study suggests that levels of ANRIL expression are likely to 
be a cause, rather than a consequence, of atherosclerosis; the median age of the 
healthy volunteers in the SA cohort was 20 years making the presence of significant 
atherosclerosis extremely unlikely in that cohort.  Furthermore, the observation that 
ANRIL expression shows considerable variation even in healthy volunteers suggests 
that therapeutic manipulations aimed at influencing levels of ANRIL expression may, 
at least in principle, be tolerated.  A recent 2010 report by Visel et al showed that 
mice with homozygous knockout of a 70kb region orthologous to the CAD core risk 
region were viable and fertile without obvious morphological or behavioural 
phenotypes, but did demonstrate severely reduced expression of CDKN2A and 
CDKN2B, and increased proliferation of vascular smooth muscle cells as occurs in 
atherosclerosis327.  However, these mice also had a reduced life expectancy due to an 
excess of cancers.  A limitation of such models with respect to atherosclerosis is that 
most mice strains do not develop CAD, and the effect of knocking out this region on 
atherosclerotic phenotypes is not known.  Further studies may investigate this in 
murine models of atherosclerosis.  However, a further problem with respect to studies 
in mice models is that although the CAD risk region overlaps the 3’ end of ANRIL in 
humans, the ANRIL sequence is not conserved beyond primates44, 200, and therefore 
the relationship of the orthologous knockout region to any functionally similar 
molecule in mice is unknown.  Whether components of the ANRIL pathway can be 
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manipulated to influence disease risk without unacceptable sequelae from the 
perturbation of normal function is as yet unknown. 
The study also demonstrated and validated a novel approach for AEI analysis, 
combining data from multiple transcribed markers per gene.  This improved the 
power to map cis-acting effects compared to standard single-marker analysis, and 
gave considerably higher power than conventional mapping techniques based on 
analysis of total expression levels.  These findings have important implications for 
future studies investigating cis-acting effects, for example for the numerous non-
coding variants associated with diseases in GWA studies at other loci.  Utilising a 
more powerful approach means that significant effects can be detected in a smaller 
sample size, which may be particularly important for investigating tissue-specific 
effects where large sample collections may be difficult to establish.  The combined 
analysis of allelic and total expression levels gave interesting insights into the 
potential mechanisms regulating expression at the important 9p21 locus.  Total 
expression levels of CDKN2A, CDKN2B and ANRIL exons1-2 were correlated, as 
observed in other studies, likely representing co-regulation by shared trans-acting 
elements, perhaps from a common bidirectional promoter between CDKN2A and 
ANRIL.  However, SNPs had opposite cis-acting effects on expression of ANRIL 
exons 1-2 and CDKN2B, suggesting that antisense transcription may be involved in 
CDKN2B regulation202.  A proposed model to unify these observations is shown in 
Figure 8.1.  
The study also used AEI techniques to confirm in vivo the association of chromosome 
2q24 polymorphisms with STK39 expression that had been previously identified in 
vitro134.  However, association analysis showed no association of these variants with 
BP in a large cohort of British Caucasian families, and excluded an effect of the 
magnitude previously reported in an Amish population134.  This highlights the 
importance of replication of genetic associations in independent populations.  
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Figure 8.1. Proposed model of factors influencing transcription of genes in the 
chromosome 9p21 region.  
Trans-acting factors such as transcription factors (dark green arrow) influence expression of all genes 
in a co-ordinated manner (bright green arrows) from shared promoter/enhancer elements. ANRIL 
transcription has an inverse effect on CDKN2B expression mediated through antisense transcription. 
The magnitude of trans effects is greater than cis effects (represented by increased arrow thickness) 
such that total expression levels of CDKN2B and ANRIL are positively correlated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another interesting approach employed in the current studies for both the 
chromosome 9p21 and chromosome 2q24 regions was the use of populations of 
African ancestry for association analyses.  Characterisation of genomic sequence and 
genetic variation such as SNPs has primarily been performed using Caucasian 
populations, and most association studies performed to date have studied populations 
of European ancestry25.  However, populations of African ancestry exhibit greater 
genetic diversity which has a number of potential advantages.  First, the average size 
of haplotype blocks is smaller in African populations than in Caucasian populations53.  
Strong LD limits the ability of association analysis to separate the effects of 
individual variants within haplotype blocks, and African populations can therefore be 
used to improve the resolution with which functional elements can be fine-mapped323.  
Although in the present study LD in the core CAD risk region remained strong and 
did not allow much separation of the effects of individual variants contained within it, 
interesting differences were detected for other more distant variants.  The most 
notable example of this was the diabetes variant rs10811661125, which was associated 
with ANRIL expression in the Caucasian but not the SA cohort.  The lack of 
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association with ANRIL expression in the SA cohort implies that this SNP is either not 
the functional variant that acts through effects on ANRIL expression, or alternatively, 
if this SNP is the causative variant, that the association with diabetes is not primarily 
mediated through effects on ANRIL expression.  It will be interesting to determine 
whether this variant is associated with diabetes in African cohorts.  A second 
advantage of African populations is that in addition to greater haplotype diversity, 
they also display greater nucleotide diversity321, 438.  Recent sequencing of two 
complete Khoisan and Bantu genomes from southern Africa revealed that each 
contained more than a million single base pair changes that were not found in each 
other or in any of the previously published genomes442.  Furthermore, analysis of 
partial genome sequences from three other Khoisan individuals showed that in terms 
of nucleotide substitutions, these individuals were on average more different from 
each other than a European and an Asian442.  These data suggest that even greater 
genetic diversity remains to be discovered in African populations.  Such diversity was 
exploited in the STK39 allelic expression analysis presented here, where using the SA 
population permitted allelic expression to be measured in the absence of transcribed 
polymorphisms in the Caucasian population.  Similarly, the greater number of 
variants in populations of African ancestry may allow the novel approach of 
combining AEI data from multiple transcribed SNPs to be used in such populations 
when multiple transcribed variants are not present in a gene in Caucasians. 
Several areas are identified for future study.  First, the range of ANRIL transcripts and 
their relationship to chromosome 9p21 variants in different tissues requires further 
investigation.  A systematic survey of the ANRIL transcripts present in different 
primary tissues could be performed using sequencing techniques, such as rapid 
amplification of cDNA ends (RACE)287.  The relationship of genetic risk variants to 
different ANRIL transcripts could then be more fully characterised.  The effects of 
ANRIL also remain to be fully elucidated.  Cell models could be used to evaluate the 
effect of ANRIL knockdown using inhibitory RNAs.  These could be designed to 
selectively target specific ANRIL exons, which may allow the effects of different 
transcripts to be characterised.  Effects of ANRIL on expression of other unknown 
targets could be investigated in such models using whole-genome microarray 
expression data.  Studies in animal models are complicated in view of the fact that the 
ANRIL sequence is poorly conserved in other species and at present it is not known 
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whether orthologous regions, such as that knocked out in mice by Visel et al327, 
contain large noncoding RNAs that are functionally similar in spite of the sequence 
differences.  The relationship between microsatellite rs10583774 genotype and ANRIL 
expression could be investigated using in vitro transfection studies with reporter 
constructs.  Based on the hypothesis that disease susceptibility is mediated by changes 
in ANRIL expression, it would also be interesting to determine whether haplotypes 
most strongly associated with ANRIL expression offer increased power for prediction 
of disease in association studies.   
The relationship between risk variants and expression also needs to be confirmed for 
the tissues in which the effects are believed to be mediated for the different diseases.  
A tissue bank of 110 atheromatous carotid endarterectomy specimens has been 
previously collected by our group between 2004 and 2007.  Samples were snap-frozen 
in liquid nitrogen at the time of the operation and subsequently stored at -80oC.  I 
have performed preliminary optimisation work to establish techniques for extracting 
RNA from these samples with the aim of performing expression mapping in this 
tissue which is of potentially greater biological relevance for investigating the effect 
of chromosome 9p21 risk variants on gene expression related to CAD.  Optimised 
protocols defining the methodology for extracting adequate RNA from these samples 
are under development.  However, the cell types in which chromosome 9p21 variants 
influence CAD susceptibility through effects on expression are uncertain, and the 
relevant tissue may not be accessible in the numbers/quantity required to perform 
expression analyses.  In addition to the carotid endarterectomy specimens described 
above, other sources of arterial tissue that could be utilised include sections of 
macroscopically-normal radial or internal mammary arteries harvested during 
coronary artery bypass graft surgery, or samples of diseased aorta from aortic 
aneurysm repair surgery.  Such samples include heterogeneous cell types, and 
although laser capture microdissection can be used to isolate specific cell populations 
(such as vascular smooth muscle cells or macrophages) the amount of RNA obtained 
using this technique is small, and may be insufficient for expression analysis without 
amplification443.  Induced pluripotent stem cells could be obtained from individuals 
with selected genotypes at loci thought to influence expression444.  These could then 
be differentiated into various tissue types, such as cardiomyocytes, and the effects of 
expression studied in cell populations with different genotypes at putative risk loci.  
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Using an AEI approach for such studies would reduce the influence of experimental 
and trans-acting factors.  However, such in vitro expression models may not 
accurately represent the true in vivo effects253. 
Identifying the mechanisms through which genetic variants identified in GWA studies 
mediate disease is an important goal.  This work has identified associations between 
SNPs associated with a number of different diseases and expression of genes at the 
chromosome 9p21 locus, and has demonstrated a new approach to AEI analysis that 
may improve the power for mapping variants associated with disease at other loci. 
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10 Appendix 1: Assay details 
10.1 Assay primers 
Table 10.1. Sequenom AEI and genotyping assays. 
SNP Assay PCR primer 1 PCR primer 2 
Amplicon 
size 
Extension primer sequence 
9p21 genotyping assays for expression mapping    
rs3088440 W1 ACGTTGGATGAGATCATCAGTCACCGAAGG ACGTTGGATGTCTACGTTAAAAGGCAGGAC 140 CGAAGGTCCTACAGGGC 
rs15735 W1 ACGTTGGATGAGTAGAGATTACCCTCCACC ACGTTGGATGATGACTAGTAAACATGTGGG 136 GAGAAGAGAATGGTGGG 
rs1333049 W1 ACGTTGGATGTTGCTTACCTCTGCGAGTGG ACGTTGGATGGTGTATGACACTTCTTAGGC 140 CTGCGAGTGGCTGCTTTT 
rs10965215 W1 ACGTTGGATGAGGAGCTGAGGAATCATCAC ACGTTGGATGGAGACTTGTCTGACAAATCC 138 TTGGAATCCTTTGAAATGT 
rs1333040 W1 ACGTTGGATGCATTCAAGAGAGACAGGAGG ACGTTGGATGCATTGAGATTTGGGAGCCAC 138 gGGGTCAGAGGTAAGAATG 
rs10757278 W1 ACGTTGGATGACTCTGTCTTGATTCTGCAT ACGTTGGATGTGGAAAGTGACAAAGAGGAC 139 cccTGATTCTGCATCGCTGC 
rs10757274 W1 ACGTTGGATGCATGGTGATGGGAGGTACTG ACGTTGGATGGAATTCCCTACCCCTATCTC 139 gAAATCTAAGCTGAGTGTTG 
rs1063192 W1 ACGTTGGATGCATGTTACTTCATTTCTGG ACGTTGGATGACTGTGGGATCCACAATAAC 121 GGAATCTTTCCTAATGACAAC 
rs496892 W1 ACGTTGGATGCCTGTTCCCCACAAAAATGC ACGTTGGATGACTTTGTTGGAGGACCAAGG 140 ccctGCAGGCACCCCTGAATCC 
rs7865618 W1 ACGTTGGATGTTTCACCAGGTGTAGTTAGG ACGTTGGATGAATGCCCCACAAATACATTG 140 TGTTTGTTTAGCTTCTTAAACC 
rs3217992 W1 ACGTTGGATGGCTGATGAAACAGCTAAACC ACGTTGGATGTGGGTATCAATTACCACCTG 131 TGGCATTGATAAGTTACTATTT 
rs10738605 W1 ACGTTGGATGCTAGGGTTCAAGCATCACTG ACGTTGGATGCTCTGATGGTTTCTTTGGAG 140 ttccAGCATCACTGTTAGGTGTG 
rs7023954 W1 ACGTTGGATGTTTCATTGCATGCAGCCATC ACGTTGGATGTCCTTTAGTAGTAACATCC 134 GGAAGATAAAAAATGTTGATTGC 
rs10116277 W1 ACGTTGGATGTGGTAATACCTAGCCTAAAC ACGTTGGATGCTCTAGAATCGATTCTTGGG 140 ctcCAAGAGTTCACTCATAAATCT 
rs2383206 W1 ACGTTGGATGCATGGCCCGATGATTTTCAG ACGTTGGATGGGTTCAGGATTCAGGCCATC 135 cTTTCCTTAGAAATGTTATTGTAGT 
rs7044859 W1 ACGTTGGATGTCCTCCTATTTCAATCTAC ACGTTGGATGGGGCTCAATATTTTGAGTGG 138 aagAATGTGAACATGAAATCTTGAA 
rs2383207 W2 ACGTTGGATGGAACTCAAAGATACTTAGCC ACGTTGGATGTTGGGCAGCTCTTTTCATAC 150 CCTGTTCGGATCCCTTC 
rs11515 W2 ACGTTGGATGCAGACATCCCCGATTGAAAG ACGTTGGATGATGAAAACTACGAAAGCGGG 150 AGGCTCTGAGAAACCTC 
rs564398 W2 ACGTTGGATGTGATGATTCCTCAGCTCCTC ACGTTGGATGGATGGTTTCCCAAACAGCAC 149 GCCCCCATGACTTTCTTTG 
rs1134871 W2 ACGTTGGATGGGGAGGGATACTGGGATAAT ACGTTGGATGGAACTGGATCTTTCTAAATC 147 TCACATTTTTCTACAGTGAAT 
rs11790231 W3 ACGTTGGATGCTCTCTCTTCCCTTTTCCTC ACGTTGGATGGGGAAGAAAGAAAGTGGTAG 98 CCCTTTTCCTCCAACTC 
rs17694493 W3 ACGTTGGATGTTTGGATGGTGAGAGCAGTC ACGTTGGATGGAGTCTGTCAACTCATGTAA 99 AGAGCAGTCACACTGTT 
rs615552 W3 ACGTTGGATGAGACTCTACCCAGTGATGAG ACGTTGGATGCAAAAATGTGGCCACACTGC 96 AGTGATGAGGAACGGGA 
rs16905599 W3 ACGTTGGATGGGCCCAGGAATGAAATTATC ACGTTGGATGGTGTGAAAATAATGCGTGGG 82 TATCGCTCTGTATGACCTA 
rs3217986 W3 ACGTTGGATGCGTGATCCAGGGATTTTAGC ACGTTGGATGAACTCCACCAGATAGCAGAG 92 CATCTGTCGTCGCTTGCACA 
rs10965227 W3 ACGTTGGATGGGTGCCATGTTCTTCCTTTC ACGTTGGATGTCAGTTTCCCCATCTGGCAC 99 CATGTTCTTCCTTTCTACATT 
rs10965228 W3 ACGTTGGATGGTCACTGGGCCTCTATATCA ACGTTGGATGAGTGGCTCACTATTCACATC 100 GGAGGAAATAACATTTTCTGA 
rs10125231 W3 ACGTTGGATGGCATCTCAGTTACCATGAGC ACGTTGGATGAAAATGCAGGGAATTTAAG 99 aTCAGTTACCATGAGCCCAATA 
rs3218009 W3 ACGTTGGATGCCTAAGGGATAAAGCTAGTG ACGTTGGATGCTTACTGAATATCCCTTGTC 95 AAGGGATAAAGCTAGTGTCATAG 
rs2184061 W3 ACGTTGGATGGCATAATCAAAATCAAGCCTG ACGTTGGATGGCACTACTACTTACCTAATG 99 cagCAAAATCAAGCCTGTTAGATA 
rs10811650 W3 ACGTTGGATGTCCTAGGGAATGTGTTACAG ACGTTGGATGTGTTACCCACACCTTTGATG 87 ggaAGATACAGTGAAGAGTACAAA 
rs495490 W3 ACGTTGGATGCAGCACTCCGAACCAAAATG ACGTTGGATGGGTGAGGAACTGCATAAGTG 98 ACCAAAATGATTCTGTAAACAAAAA 
rs7857345 W3 ACGTTGGATGAGTTAGGATGCTTTCAGGTA ACGTTGGATGCCATCAGGAAATAATCCTTAG 100 cctGATGCTTTCAGGTACTTGTAATA 
rs3731239 W3 ACGTTGGATGATCAGTGGAAATCTGTGGTG ACGTTGGATGGCCGCTTCTGAATAATTTCG 94 GTGTATGTTGGAATAAATATCGAATA 
rs7036656 W4 ACGTTGGATGTCCAAAGCCTTTGACACACG ACGTTGGATGCTACCCATCTAAGGGTAGAG 95 TTTGACACACGGTAACA 
rs1547705 W4 ACGTTGGATGGTGCTAGTGGCTCACTATTC ACGTTGGATGGGCCTCTATATCATGATCAAC 98 GGCTCACTATTCACATCA 
rs1333045 W4 ACGTTGGATGCATGTCATCTTAATGAATGC ACGTTGGATGTTATTGTGAGGCCCAAGTGC 96 ATGCTTACTAGATGCCAG 
rs1011970 W4 ACGTTGGATGAGAACTGATAGGGAGCCAGC ACGTTGGATGGAAGATACAGGTGGAACTGG 99 AGAAATATCATGGTCCTCTG 
rs2811712 W4 ACGTTGGATGCTAGGGATAAGGGTAATTGC ACGTTGGATGGAACAGAGAGCTTACTATAT 98 GGAATGCCATCTGAATAAAAG 
rs1801022 W5 ACGTTGGATGAACCTGCGCACCATGTTCTC ACGTTGGATGTGCTCACCTCTGGTGCCAAA 100 TGTTCTCGCCGCCTCCA 
rs3731249 W5 ACGTTGGATGCTCTCAGGGTACAAATTCTC ACGTTGGATGGCAGTAACCATGCCCGCATA 99 ACCTGAGGGACCTTCCG 
rs2811711 W5 ACGTTGGATGCTTAGACATGTGGTTCTCGC ACGTTGGATGTCAGTTTCCCACGATTGAGG 95 cGTGGTTCTCGCAGTACC 
rs3814960 W5 ACGTTGGATGTAATAGCACCTCCTCCGAGC ACGTTGGATGCTCAAATCCTCTGGAGGGAC 99 CCTCCGAGCACTCGCTCAC 
rs3218018 W5 ACGTTGGATGATTCCATCTTGGTTTCCCCC ACGTTGGATGATTCCCCTGCATACTGCAAC 91 CGCTGCCCAATACCTGTTC 
rs36228834 W5 ACGTTGGATGTCCCTATGACACCAAACACC ACGTTGGATGGTTTCCTTCCTCCGCGATAC 88 CCGATTCAATTTGGCAGTT 
rs2518723 W5 ACGTTGGATGACACACCCACCCACTCAGG ACGTTGGATGACCCGGAGCCTGCGGTCT 96 gcGCCCGCGAGGTTTAGGAC 
rs2069418 W5 ACGTTGGATGCCCTTGTGACCGAGAGAAAG ACGTTGGATGCAGAAAGACACATCCAAGAG 94 AGTCATTCAAAATAACTCCGT 
rs3218005 W5 ACGTTGGATGGCCAGGATTGAGAAACAATT ACGTTGGATGTGGTGTTTGCCTCAGTAGTC 100 ggAGGGGTTTTAAACTTGTTG 
rs2383208 W5 ACGTTGGATGTCTTGAAACTAGTAGATGC ACGTTGGATGGCAACTAAAACTGTGACAGG 80 cCTAGTAGATGCTCAATTCATG 
rs3218022 W5 ACGTTGGATGCCCATATTATTGAGGATAATC ACGTTGGATGGCTGTGGAGGTATTTTTTAG 99 TTATTGAGGATAATCTGCTTTT 
rs2891169 W5 ACGTTGGATGGGCCAAGGCAACAGTTTCTT ACGTTGGATGACTCTTTGTTATGAATGTG 83 AGTTTCTTAATGAGAGAGTAGA 
rs10757283 W5 ACGTTGGATGCAGGATGGGGAAGGTTTTTG ACGTTGGATGCCCGACTGGAAAACCTTATA 99 ggTGGGGAAGGTTTTTGACTTTA 
rs10811661 W5 ACGTTGGATGATAAGCGTTCTTGCCCTGTC ACGTTGGATGAGATCAGGAGGGTAATAGAC 99 AGCTCACCTCCAGCTTTAGTTTTC 
rs3731257 W5 ACGTTGGATGCTTGGTTCAGCACTCACTTG ACGTTGGATGAGCTGCCAGAATTGACTTCG 99 agTGGTTGCTGTAAAACTTTCTTA 
rs3218012 W5 ACGTTGGATGGTTTTTTTTAACAGGGGTA ACGTTGGATGTTTTTCTCCCCTATCCCTGC 98 TTTAACAGGGGTAAATAATTTTCT 
rs3218008 W5 ACGTTGGATGCAAAACCCCAAAGTCATAAG ACGTTGGATGCTTTTGACATATATGATC 97 AGATAACATAAGCAAGAATAAAAAA 
rs3218020 W5 ACGTTGGATGAACTGTCACATTATCCCGTC ACGTTGGATGGATCCTCAGAAAACTGAGGG 80 cCACATTATCCCGTCATGCCTGAGGG 
rs2069416 W5 ACGTTGGATGCCTGGCACACATAAGACAAA ACGTTGGATGGATGTTTCATTATTACTGC 98 CACATAAGACAAAAAAAAATTATACT 
      
9p21 genotyping assays for investigation of HWE departure (HTO cohort)   
rs10757278 W6 ACGTTGGATGCAAGTCAGGGTGTGGTCATT ACGTTGGATGGAGAGAGAGAAGGAGAAAC 93 ATTCTGCATCGCTGC 
rs2383206 W6 ACGTTGGATGCTTACTATCCTGGTTGCCCC ACGTTGGATGGGTTCAGGATTCAGGCCATC 100 AGGCCATCTTGCAAA 
rs615552 W6 ACGTTGGATGCAAAAATGTGGCCACACTGC ACGTTGGATGAGACTCTACCCAGTGATGAG 96 TGATGAGGAACGGGA 
rs1333049 W6 ACGTTGGATGCACTACCCTACTGTCATTCC ACGTTGGATGATATCTTGCTTACCTCTGCG 100 GCGAGTGGCTGCTTTT 
rs11790231 W6 ACGTTGGATGGGGAAGAAAGAAAGTGGTAG ACGTTGGATGCTCTCTCTTCCCTTTTCCTC 98 CCCTTTTCCTCCAACTC 
rs564398 W6 ACGTTGGATGTCAGTGGCACATACCACACC ACGTTGGATGAGCTCCTCTCATCTGATCTC 96 CCCCATGACTTTCTTTG 
rs10125231 W6 ACGTTGGATGAAAATGCAGGGAATTTAAG ACGTTGGATGGCATCTCAGTTACCATGAGC 99 GTTACCATGAGCCCAATA 
rs1333040 W6 ACGTTGGATGCTCATATCTGTACCTTCCTC ACGTTGGATGCATTCAAGAGAGACAGGAGG 92 GGGTCAGAGGTAAGAATG 
rs2383207 W6 ACGTTGGATGCAAGACATAACTAATAGCTG ACGTTGGATGGGGACCATTTTTTACTCCTG 99 ggCCTGTTCGGATCCCTTC 
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rs10116277 W6 ACGTTGGATGCCAAATCAGACAAGAGTTCAC ACGTTGGATGCGATTCTTGGGGAGGTTATT 99 cGTGATGGACAGAGTGTAG 
rs10965215 W6 ACGTTGGATGGGATGTTTTGCAGGACTATT ACGTTGGATGGGAATCATCACAGCATGGAC 100 aTTGGAATCCTTTGAAATGT 
rs1063192 W6 ACGTTGGATGAACTTGTGGAATCTTTCCT ACGTTGGATGACTGTGGGATCCACAATAAC 95 TTCTTTAGTTTCCCTTAATATCA 
rs7857345 W6 ACGTTGGATGAGTTAGGATGCTTTCAGGTA ACGTTGGATGCCATCAGGAAATAATCCTTAG 100 ccAGATGCTTTTAGTTGTGTTTT 
rs10757274 W6 ACGTTGGATGCGTGGGTCAAATCTAAGCTG ACGTTGGATGGAATTCCCTACCCCTATCTC 97 CTATCTAGTGAATTTCAATTATGTC 
rs10811650 W6 ACGTTGGATGTGTTACCCACACCTTTGATG ACGTTGGATGTCCTAGGGAATGTGTTACAG 87 ggaaAGATACAGTGAAGAGTACAAA 
rs2184061 W6 ACGTTGGATGGCATAATCAAAATCAAGCCTG ACGTTGGATGGCACTACTACTTACCTAATG 99 tcAGTTGCTATTAATGGATGAATTTT 
rs1333045 W6 ACGTTGGATGCATGTCATCTTAATGAATGC ACGTTGGATGTTATTGTGAGGCCCAAGTGC 96 cctTGCAATAATATATAGTACACTGTG 
      
Congenital heart disease study genotyping assays   
rs564398 W7 ACGTTGGATGAGCTCCTCTCATCTGATCTC ACGTTGGATGTCAGTGGCACATACCACACC 96 ACCACACCCTAACTACC 
rs3218018 W7 ACGTTGGATGATTCCCCTGCATACTGCAAC ACGTTGGATGATTCCATCTTGGTTTCCCCC 91 CTGCCCAATACCTGTTC 
rs1333049 W7 ACGTTGGATGCACTACCCTACTGTCATTCC ACGTTGGATGATATCTTGCTTACCTCTGCG 100 TGCGAGTGGCTGCTTTT 
rs2811708 W7 ACGTTGGATGGAAAAGTGGATAGTTTTGAC ACGTTGGATGCTAAGCCAACATCATTTCCC 98 TTCTACATGTTCTTCTCCC 
rs1547705 W7 ACGTTGGATGGGCCTCTATATCATGATCAAC ACGTTGGATGGTGCTAGTGGCTCACTATTC 98 GTGGCTCACTATTCACATCA 
      
STK39 study genotyping assays (HTO cohort)   
rs3754777 W8 ACGTTGGATGGCCTGAACAAAAATGAGGAC ACGTTGGATGATCTCGCCTGTTTCACCCAC 96 AGGCGTCTCTGGGTCTTTTACT 
rs35929607 W8 ACGTTGGATGCACACTCATGGAATTAAAGG ACGTTGGATGTCAGAGGGCTCACATTTTGG 90 ATGGAATTAAAGGATTATTAGGATACC 
rs6749447 W8 ACGTTGGATGTGGAGTCTGCTAGTACTAGA ACGTTGGATGCAGTTAGGTCACCTCCTTTC 100 GAGTCTGCTAGTACTAGATTAGGA 
rs4977950 W8 ACGTTGGATGCTGAGAACAGTCTTCAACTTG ACGTTGGATGCACTAGACTGGTTGATTGAA 100 CCTGAAGGTTTTTTTTTATATCACTA 
      
STK39 study genotyping assays (SA cohort)   
rs1061471 W9 ACGTTGGATGTTTAGAAGTTACAAATACTC ACGTTGGATGGCTTCTTGCAGTTAATCTCG 93 GAAGTTACAAATACTCCAAAGA 
rs1802105 W9 ACGTTGGATGGAAGGCTAATGGCACTTACC ACGTTGGATGAGAGTACCTGATTGAGAAGC 100 CTTTGGGCTATGTCTGGTG 
rs56031549 W9 ACGTTGGATGGATGAGAAGAGCGAAGAAGG ACGTTGGATGACACAGATTAGCTCATCGTC 100 GCGAAGAAGGGAAAGCA 
rs56048258 W9 ACGTTGGATGATTCAAGCCATGAGTCAGTG ACGTTGGATGGCCAAAGTTCATCTTTGACC 99 ATGAGTCAGTGCAGCCA 
rs56330212 W9 ACGTTGGATGGGCACAAGAAGAAGCTTCTC ACGTTGGATGAACACTGTTTGCTGTTTTC 96 TCTGTAGTCTTCATTAGCATT 
rs56697518 W9 ACGTTGGATGACACAGATTAGCTCATCGTC ACGTTGGATGGATGAGAAGAGCGAAGAAGG 100 CGTCAACGATITCATTTAC 
      
AEI cDNA assays   
rs11515/rs3088440 
CDKN2A exons2-
3 cDNA 
GGAAGGTCCCTCAGACATCC ATTTTCTAAATGAAAACTACGAAAGC 150 
AGGCTCTGAGAAACCTC and 
CGAAGGTCCTACAGGGC 
rs1063192 
CDKN2B1063192 
cDNA 
ACGTTGGATGCATGTTACTTCATTTCTGG ACGTTGGATGACTGTGGGATCCACAATAAC 121 GGAATCTTTCCTAATGACAAC 
rs3217992 
CDKN2B3217992 
cDNA 
ACGTTGGATGGCTGATGAAACAGCTAAACC ACGTTGGATGTGGGTATCAATTACCACCTG 131 TGGCATTGATAAGTTACTATTT 
rs10965215/rs564398 
ANRIL exons1-2 
cDNA 
CGCCGGACTAGGACTATTTG GCACATACCACACCCTAACTACC 150 
TTGGAATCCTTTGAAATGT and 
GCCCCCATGACTTTCTTTG 
rs15735 
MTAP15735 
cDNA 
CCTGAAGAATATGGCCCAGT AGGGGGAGAAGAGAATGGTG 326 GAGAAGAGAATGGTGGG 
rs7023954 
MTAP7023954 
cDNA 
GCCGTGAAGATTGGAATAATTG GACCTTTGAAGGCATGATGG 192 GGAAGATAAAAAATGTTGATTGC 
rs1799977 MLH1 cDNA ACGTTGGATGAGCAAGGAGAGACAGTAGC ACGTTGGATGGTGATGGAATGATAAACCAAG 229 TCTTTGGAAATGCTGTTAG 
rs1061471 STK39 cDNA ACGTTGGATGTTTAGAAGTTACAAATACTC ACGTTGGATGGCTTCTTGCAGTTAATCTCG 93 GAAGTTACAAATACTCCAAAGA 
      
AEI gDNA assays   
rs11515/rs3088440 
CDKN2A exons2-
3 gDNA 
ACGTTGGATGAGACATCCCCGATTGAAAG ACGTTGGATGATTTTCTAAATGAAAACTACGAAAGC 158 
AGGCTCTGAGAAACCTC and 
CGAAGGTCCTACAGGGC 
rs1063192 
CDKN2B1063192 
gDNA 
ACGTTGGATGCATGTTACTTCATTTCTGG ACGTTGGATGACTGTGGGATCCACAATAAC 121 GGAATCTTTCCTAATGACAAC 
rs3217992 
CDKN2B3217992 
gDNA 
ACGTTGGATGGCTGATGAAACAGCTAAACC ACGTTGGATGTGGGTATCAATTACCACCTG 131 TGGCATTGATAAGTTACTATTT 
rs10965215/rs564398 
ANRIL exons1-2 
gDNA 
ACGTTGGATGTCTGAATCTAATCACATAGAGACTTG ACGTTGGATGGCACATACCACACCCTAACTACC 219 
TTGGAATCCTTTGAAATGT and 
GCCCCCATGACTTTCTTTG 
rs15735 
MTAP15735 
gDNA 
TGGCCCAGTTTTCTGTTTTATTAC AGGGGGAGAAGAGAATGGTG 315 GAGAAGAGAATGGTGGG 
rs7023954 
MTAP7023954 
gDNA 
ACGTTGGATGTTTCATTGCATGCAGCCATC ACGTTGGATGTCCTTTAGTAGTAACATCC 134 GGAAGATAAAAAATGTTGATTGC 
rs1799977 MLH1 gDNA acgttggatgGTTTCAGTCTCAGCCATGAGAC acgttggatgAAGCCTGTGTATTTGACTAAAG 174 TCTTTGGAAATGCTGTTAG 
rs1061471 STK39 gDNA ACGTTGGATGTTTAGAAGTTACAAATACTC ACGTTGGATGGCTTCTTGCAGTTAATCTCG 93 GAAGTTACAAATACTCCAAAGA 
 
Table 10.2. Taqman custom gene expression assays. 
Assay PCR primer 1 PCR primer 2 Probe sequence 
CDKN2A_exon1alpha GGCGGCTGCGGAGA CGCCGGCTCCATGCT CTGCCTGCTCTCCC 
CDKN2B GTGGGATGTCCTACTATCACTGAAC GTAGTGAAGTATCAGTTGTTCCAATGATATAATGA CAACCCTGGAAATTAA 
ANRIL_exon13 CCTACGAAGCTGGGTGATAAAAG GGATCCTGGTATAGAATGAAGCTATCTG ACATTGGACAAAAAC 
ANRIL_exon20 TCCCCATGTTACATATGAAGAGACAGA GGTTAGACTGCTTAAGTTCAAATCCCA CACCGCTGGTAATTG 
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Table 10.3. Primers for microsatellite and transcript-specific AEI assays. 
Primer Sequence 
Microsatellite study  
Microsatellite_10583774_F AGCAATAATTCTCCCCAAGG* 
Microsatellite_10583774_R GAAACTGAGGCGAACAGAGC 
  
CDKN2A/ARF transcript-specific 1  
CDKN2A_exon1alphaA_F CTCCGAGCACTCGCTCAC 
ARF_exon1betaA_F GGTTTTCGTGGTTCACATCC 
CDKN2A-ARF_exon3A_R TTTACGGTAGTGGGGGAAGG 
  
CDKN2A/ARF transcript-specific 2  
CDKN2A_exon1alphaB_F CAACGCACCGAATAGTTACG 
CDKN2A_exon3B_R TTTTCTAAATGAAAACTACGAAAGC 
ARF_exon1betaB_F GCCGCTTCCTAGAAGACCAG 
ARF_exon3B_R CCTGTAGGACCTTCGGTGAC 
  
CDKN2A transcript-specific 3  
CDKN2A_exon1alphaA_F CTCCGAGCACTCGCTCAC 
CDKN2A_exon1alphaA_R CTGTCCCTCAAATCCTCTGG 
  
ANRIL transcript-specific  
ANRIL_exon1_F CTCTGACGCGACATCTGG 
ANRIL_exon2_F GTCCATGCTGTGATGATTCC 
ANRIL_exon6_F GGTTCAAGCATCACTGTTAGG 
ANRIL_exon2_R TCAGTGGCACATACCACACC 
ANRIL_exon6_R GCAGTACTGACTCGGGAAAGG 
ANRIL_exon13_R TTTATCACCCAGCTTCGTAGG 
ANRIL_exon19_R CCACAATGTTCAACTTGCTGTC 
ANRIL_exon20_R CACAGCTTTGATCTATATGCTTGG 
MTAP_exon4_F TGCCTTCAAAGGTCAACTACC 
 
Table 10.4. MLPA probes. 
Probe 
Total 
robe 
length 
(bases) 
Left primer oligo sequence Right primer oligo sequence 
9p21_01 92 GGGTTCCCTAAGGGTTGGATGGGTTACTTGTGTCTGTGCTGTTG TTTCCTTAAGGAGGCTGGTGCTGCTTCTAGATTGGATCTTGCTGGCAC 
9p21_02 100 GGGTTCCCTAAGGGTTGGATTTCCACCTGCTAAGCTAGTGTCCCTTCA AACCCTTGTTTCCTGTAGCTCATGAGTCATCTAGATTGGATCTTGCTGGCAC 
9p21_03 104 GGGTTCCCTAAGGGTTGGATCAGTGCTGGGTGACTCTCTCCTGGCATGTT CTGGCAAGACTCTACCTGGTTTGCGTAATCTTCTAGATTGGATCTTGCTGGCAC 
9p21_04 108 GGGTTCCCTAAGGGTTGGATGAATTGCATGGAAGAGGCTGTTCATGGGGTTA GTCTGGCAGATAAGAGGTCTCCACTGGATTTTTTCTAGATTGGATCTTGCTGGCAC 
9p21_05 112 GGGTTCCCTAAGGGTTGGACAATGAACGCCTTCACTGATATCCAAAGCATGAAG GACACACCAGGGAAAAACATAGACCTAACACAGGATCTAGATTGGATCTTGCTGGCAC 
9p21_06 116 GGGTTCCCTAAGGGTTGGAGTATACACACTGGTATAGTCAGATGGCATGAGTACCA AGGTGGAAGTGTGGTGGTCCTAAAGTGGCATTAAGGATCTAGATTGGATCTTGCTGGCAC 
9p21_07 120 GGGTTCCCTAAGGGTTGGAGTAGAGTGGGCTGGGGAGCGACTTTCTTGGGACTATTAT GCTTTTCTTGCACTTTACTAGGTTCCTGTTCTTCCCCACTCTAGATTGGATCTTGCTGGCAC 
9p21_08 124 GGGTTCCCTAAGGGTTGGAGACAGATATCTAAGATAACACGAACACCCAGACGACAACTC AGGCAACCCCAGCACAGTGTTTTGGTATGAGAACAGGAGAATCTAGATTGGATCTTGCTGGCAC 
9p21_09 128 GGGTTCCCTAAGGGTTGGACTAACTAGTCTGTTTCCCTACCCAGGTGGAGAACTTCAGTAGA GGAAGTGGCAGGAATTTGGGAATGAGGAGCACAGTGATTAAACTCTAGATTGGATCTTGCTGGCAC 
9p21_10 132 GGGTTCCCTAAGGGTTGGACATGCAGCCAGCCACTAAGACTACTTCCCACAGGACTGGAAATCT CTACCACCGTACCTCTCCTACATGCTGGGTATAAGAAGTTAAAGGTCTAGATTGGATCTTGCTGGCAC 
9p21_11 136 GGGTTCCCTAAGGGTTGGACTCCCACTGTCACAGCCACTTCTGTCATGACCTAGTTGTTCTCAGAA AGTTCCCTCTTATACCTGGTCAAACTTCTCTTACAATCACCTGTGACTCTAGATTGGATCTTGCTGGCAC 
9p21_12 140 GGGTTCCCTAAGGGTTGGACAGCTAAGTTAGAATGTGATACCATTGTTTACACAAGTGTGGCCTGCCT TCAAGATAGGGTGAGGTGTTTTATGACCACAGGCTTTATGAGTTATAGCTCTAGATTGGATCTTGCTGGCAC 
    
8p23_DEFA3 96 GGGTTCCCTAAGGGTTGGATATTGCAGAATACCAGCGTGCATTGC AGGAGAACGTCGCTATGGAACCTGCATCTCTAGATTGGATCTTGCTGGCAC 
14q11_OR4K2 104 GGGTTCCCTAAGGGTTGGATTCTGTCATTAGTCCCCAGGTGTGTGTTGCT CTCGTGGTGGCTTCCTGGATTATGGGAGTTATCTAGATTGGATCTTGCTGGCAC 
22q11_CLDN5 112 GGGTTCCCTAAGGGTTGGAGCTTTTCTGCAGACTCAGGCTCTTCTCACACACAA TTAATGAGATCCTGCCATTCTTCCCCTGGGAAAGCTCTAGATTGGATCTTGCTGGCAC 
17p11_PMP22 124 GGGTTCCCTAAGGGTTGGAGCTGACTGTAGGTTTGGGAGTTGTCTGTCTCCTTGCTCTAG ATTACAGCTCTGTGTGTTGTGTGGGGTCTCCATGGTTTGCCTCTAGATTGGATCTTGCTGGCAC 
6p25_DUSP22 132 GGGTTCCCTAAGGGTTGGACACTGACCAGCCTCTCCTTACAACTGAAGACTTTTGCAGGACACT CTTCCTAGATGTTGCCTTCATGTTGAGTCCCGGTGTCTGAGCATTTCTAGATTGGATCTTGCTGGCAC 
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10.2 MLPA protocol 
Hybridisation mix preparation 
Hybridisation mix prepared containing 0.5µL of synthetic probemix, 1µL of P200 
probmix and 1.5µL MLPA buffer per sample.  Mixed thoroughly by pipetting. 
DNA denaturation and hybridisation of MLPA probes 
5µL of DNA (50-200ng) added wells of 96-well plate.  Heated on thermocycler at 
98oC for 5 min, followed by 25oC hold.  Whilst still on block, film lid removed and 
3µL hybridisation mix added to each well (using a multichannel pipette from a 
loading plate).  Mixed thoroughly by pipetting.  Sealed with new lid and heated at 
95oC for 1 min, followed by 60oC for 16 (12-24) hours. 
Ligase-65 mix preparation (within 1 hour of use, stored on ice) 
Ligase-65 mix prepared containing 3µL Ligase-65 buffer A, 3µL Ligase-65 buffer B, 
25µL water, 1µL Ligase-65 per sample.  Mixed thoroughly by pipetting. 
Ligation reaction 
Whilst plate still on block, temperature reduced to 54oC.  32µL Ligase-65 mix added 
to each well using multichannel pipette and mixed thoroughly by pipetting.  Then 
heated at 54oC for 15 min, followed by 98oC for 5 min, followed by 4oC hold. 
Polymerase mix prepared 
Polymerase mix prepared containing 1µL SALSA PCR primers, 1µL SALSA enzyme 
dilution buffer, 15.75µL water, 0.25µL SALSA polymerase, 2µL SALSA PCR buffer 
per sample.   
PCR reaction 
20µL of polymerase mix added to wells of a new 96-well PCR plate.  5µL of MLPA 
ligation reaction product added to each well.  Thermocycler heated to 95oC and plate 
put onto block once reached 95oC.  PCR performed using 35 cycles of (95oC for 30 
sec, followed by 60oC for 30 sec, followed by 72oC for 1 min), then 72oC for 20 min, 
then 4oC hold.  Product stored in dark at 4oC until analysis. 
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Analysis  
A master mix was then prepared containing 8.5µL of Hi-Di formamide (Applied 
Biosystems, USA) and 0.3µL of Genescan-500 ROX size standard (Applied 
Biosystems, USA) per sample.  8.8µL of the master mix was added to each well of a 
new 96-well semi-skirted, straight-edge PCR plate (StarLab, Germany), and 1µL of 
the PCR product was transferred to each well of this plate.  The plate was covered in 
foil to prevent photo-degradation, before analysis by capillary electrophoresis on a 
3130xl Genetic Analyzer (Applied Biosystems, USA).  Data were analysed using 
GeneMarker v1.8 software (SoftGenetics, USA).   
  
 
 
Appendix 2 
Published manuscripts 
 
 301 
 
11 Appendix 2: Published manuscripts 
 
 
